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CHAPTER 1 
 
Antibiotics and the Evolution of Resistance 
 
1.1 Introduction 
 One of the most important advances in modern medicine is the discovery and 
development of antibiotics. Antibiotics are loosely defined as molecules with the capacity 
to inhibit the growth of and/or destroy bacteria and other micro-organisms. Their history 
can be traced back to the pioneering work of Paul Ehrlich at the end of the nineteenth 
century (Figure 1.1).1, 2  As a compliment to his work that would come to define what is 
now known as immunology, Ehrlich hypothesized that a pathogen could be treated with 
a chemical substance that had a high affinity and selectivity for the pathogen.3 This idea 
of a “magic bullet” was validated with Ehrlich’s discovery of diamidodioxyarsenobenzol, 
better known as Salvarsan (1.1), as an effective treatment against the causative agent of 
syphilis, Treponema pallidum (Figure 1.2).3, 4  
 
 
Figure 1.1. Timeline of antibiotic discovery. 
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Taking inspiration from the seminal work of Ehrlich, the Friedrich Bayer Company 
began to investigate the possibility that synthetic compounds could be used to treat 
bacterial diseases.2, 5, 6 The targeted hypothesis that dyes could serve as antimicrobial 
agents ultimately lead to the discovery of sulphamido-chrysoidine, better known as 
Prontosil (1.2), in the 1930s as a potent compound for the treatment of streptococcal 
infections (Figure 1.2). Importantly, this discovery, credited to Gerhard Domagk, ushered 
in the development of additional sulfa drugs.  
 
Even though penicillin (1.3) would not find clinical significance until the early 1940s 
(after the introduction of Prontosil), Alexander Fleming’s discovery of penicillin in 1928 is 
largely considered the start of the “antibiotic era” (Figure 1.2).5, 7 Moreover, the discovery 
of penicillin, an antibiotic derived from the fungus originally believed to be Penicillium 
rubrum, served to shift the focus of antibiotic discovery from synthetic small molecules to 
natural products.4, 8 This shift is considered to have paved the way for the so-called 
“golden era” of antibiotic discovery (1945-1960). This era saw the discovery of the 
majority of antibiotic classes now in clinal use and was followed by an era of antibiotic 
medicinal chemistry (1970-1980). The medicinal chemistry era is characterized by 
extensive chemical elaboration of many of the scaffolds originally identified during the 
“golden age” as a means to improve drug pharmacology and avoid antibiotic resistance.  
Figure 1.2. Structures of selected early antibiotics Salvarsan (1.1), Prontosil (1.2), and 
penicillin G (1.3). 
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In contrast to the many highly productive and fruitful decades of antibiotic discovery 
and development of the mid-twentieth century, the last few decades have seen a dramatic 
decrease in the rate of discovery of new and clinically viable antibiotics.4, 9 One 
explanation for this decline is that the antibiotics discovered around the 1950s were 
simply the “low hanging fruit.” Related to this notion is the idea that we may have 
exhausted soil bacteria, which are the source of a significant number of currently used 
antibiotics, as sources of new drugs.  
In addition to these scientific explanations, there are also economic factors that 
have contributed to the antibiotic discovery void. Most pharmaceutical companies have 
limited investments in the development of new antibiotics due in large part to the generally 
poor return on investment seen for antibiotic development.2, 9, 10 Indeed, from a financial 
standpoint, it is more advantageous for companies to invest in drugs for chronic diseases, 
which are taken over long periods of time, than in antibiotics that are taken for only a short 
amount of time. Additionally, the ability of bacteria to develop resistance to antibiotics, 
often within a short window after initial introduction of an antibiotic, increases the risk of 
investing in new antibiotic development.   
Antibiotic resistance is a natural, evolutionary response to the strong selective 
pressure that results from antibiotic exposure (Figure 1.3).9 In this sense, antibiotic 
treatment is a double-edged sword. On the one hand, antibiotics have revolutionized 
medicine by allowing us to treat a host of previously untreatable infections. On the other 
hand, continued exposure of pathogenic species to antibiotics drives the evolutionary 
response that ultimately gives rise to resistant organisms that render antibiotics obsolete. 
Indicative of this reality, since the introduction of penicillin in the clinic in the 1940s, 
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resistance to all classes of antibiotics has emerged (Figure 1.4).9, 11 Moreover, multi-drug 
resistant (MDR) bacterial species are becoming increasingly common.  
 
While antibiotic resistance is not a phenomenon restricted to the 20th and 21st 
centuries, these centuries have seen an increase in the prevalence and diversity of 
resistant organisms.4, 10 This increase is largely attributable to the widespread overuse 
and misuse of antibiotics. Alarmingly, the increasing prevalence of antibiotic resistance 
coupled with a dramatically slowed rate of novel antibiotic discovery has created an 
environment wherein antimicrobial resistance is one of the most serious threats to human 
health. Common illnesses, such as pneumonia, as well as the world’s most prevalent 
infectious diseases—human immunodeficiency virus (HIV), malaria, and tuberculosis—
are  becoming increasingly difficult to treat due to drug resistance. Additionally, infections 
caused by antibiotic-resistant bacteria continue to challenge physicians.  
Antibiotic
Population of mostly 
antibiotic-susceptible 
bacteria
Population of mostly 
antibiotic-resistant 
bacteria
Antibiotic-resistant 
bacteria
Antibiotic-susceptible 
bacteria
Figure 1.3. Selection for antibiotic resistance. Antibiotic exposure eliminates most 
antibiotic-susceptible bacteria, but the antibiotic-resistant bacteria survive. The antibiotic-
resistant bacteria can then proliferate to create a population of mostly resistant bacteria. 
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The extensive problem of resistant infections prompted the World Health 
Organization (WHO) to develop a classification system to rank priority pathogens based 
on the urgency for new treatments (Table 1.1).12 Moreover, there now exists a cohort of 
bacterial pathogens termed the ESKAPE pathogens (see section 1.4), which are 
characterized by their abilities to resist the action of multiple antibiotics.13, 14 These MDR 
bacteria are often referred to colloquially as superbugs, and several of these species are 
effectively untreatable with our current arsenal of antibiotics.4  
In order to develop new techniques to address the growing problem of 
antimicrobial resistance, it is important to understand how this problem first came to be 
and how it evolved into the epidemic it is today. Indeed, gaining a deeper understanding 
of the modes of bacterial resistance as well as the sources of this resistance has already 
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led to the development of several new strategies to combat bacterial pathogens. Many of 
these will be presented later in the chapter. 
 
1.2 Mechanisms of Antibiotic Action 
1.2.1 Introduction 
 Antibiotics can be classified by the cellular component or system they affect and 
whether they induce cell death (bactericidal) or inhibit cell growth (bacteriostatic).9, 15, 16 
Priority Level 1: Critical 
Pathogen Resistance 
Acinetobacter baumannii Carbapenem 
Pseudomonas aeruginosa Carbapenem 
Enterobacteriaceaeb Carbapenem, 3rd gen. Cephalosporin 
Priority 2: High 
Pathogen Resistance 
Enterococcus faecium Vancomycin 
Staphylococcus aureus Methicillin, Vancomycin 
Helicobacter pylori Clarithromycin 
Campylobacter Fluoroquinolone 
Salmonella Fluoroquinolone 
Neisseria gonorrhoeae 3rd gen. Cephalosporin, Fluoroquinolone 
Priority 2: Medium 
Pathogen Resistance 
Streptococcus pneumoniae Penicillin 
Haemophilus influenzae Ampicillin 
Shigella Fluoroquinolone 
aMycobacteria was not included as it is already a globally established priority for which innovative new 
treatments are urgently needed 
bEnterobacteriaceae includes: Klebsiella pneumonia, Escherichia coli, Enterobacter spp., Serratia spp., 
Proteus spp., and Providencia spp, Morganella spp.  
Table 1.1. World Health Organization Priority Pathogen List for R&D of New Antibioticsa 
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In order to affect pathogen death or interrupt pathogen growth, antibiotics target essential 
bacterial machinery. Consistent with this strategy, there are five major targets of 
antibiotics: the cell wall, the cell membrane, protein synthesis, DNA and RNA synthesis, 
and folic acid metabolism (Figure 1.5). Importantly, these targets are either sufficiently 
different or absent from eukaryotic cells (including human cells). For example, although 
cell walls are essential for bacterial survival, these structures are not found in eukaryotic 
cells. Additionally, while both bacterial cells and eukaryotic cells possess ribosomes, the 
structures of the ribosomes are sufficiently different that cross-inhibition is not observed.  
 
 
 
 
 
 
 
 
 
 
1.2.2 Cell Wall-Targeting Antibiotics 
 Bacterial cells are surrounded by a bacterial envelope that serves as protection 
from a hostile environment while also allowing for passage of select nutrients into the 
cell.17 Importantly, the composition of this envelope is what gives rise to the Gram-positive 
versus Gram-negative bacterial classification (Figure 1.6). In Gram-positive bacteria, the 
Figure 1.5. Major classes of antibiotic bacterial cell targets. 
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cell envelope is composed of a thick, outer peptidoglycan (PG) cell wall and an inner 
phospholipid bilayer membrane. While Gram-negative cell envelopes also contain a PG 
cell wall and an inner membrane, the cell wall is significantly thinner than that of Gram-
positive cell envelopes. It is this difference in thickness that allows for experimental 
differentiation between Gram-positive and Gram-negative cells. The Gram stain is a 
crystal violet stain developed by Christian Gram that stains the PG of the bacterial cell 
wall. Because Gram-positive bacteria have a thick PG layer, they are to retain a large 
amount of the Gram stain and thus are distinctly colored purple. Gram-negative bacteria, 
however, with their thin PG layer are not able to retain a large amount of Gram stain and 
can thus be counterstained with safranin or fuchsine to yield pink-colored cells. 
  
In addition to a thinner cell wall, Gram-negative cells are also differentiated from 
Gram-positive cells by the presence of an outer membrane (OM) in their cell envelopes 
(Figure 1.6B). This feature is absent in the Gram-positive cell envelope. The OM is a lipid 
Cell Wall
Inner Membrane
A. B.
Gram-positive cell envelope Gram-negative cell envelope
Cell Wall
Outer Membrane
Inner Membrane
Cytoplasm Cytoplasm
Figure 1.6. General compositional differences between Gram-positive and Gram-
negative bacterial cell envelopes. 
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bilayer composed of glycolipids, most notably lipopolysaccharides (LPSs), that extend 
beyond the outer leaflet of the OM (see section 1.2.3). The OM affords Gram-negative 
bacteria an additional layer of protection compared to Gram-positive species and is 
largely responsible for the increased difficulty of treating Gram-negative bacterial 
infections (see section 1.3.2). 
 
 
 
 
 
 
 
 
 
 
In both Gram-positive and Gram-negative species, the rigid PG cell wall confers 
strength and structural integrity to the cell it surrounds.16, 17 In a similar vein, this layer 
determines cell shape. In terms of general composition, the PG layer is composed of 
linear glycan strands cross-linked by short peptide chains (Figure 1.7).18 The glycan 
strands consist of alternating N-acetylglucosamine (GlcNAc or NAM, 1.4) and N-
acetylmuramic acid (MurAc or NAG, 1.5) residues linked via b1-4 glycosidic bonds. Key 
to the cross-linking of these strands is a short peptide chain that is attached to the lactoyl 
group of the MurAc residues. The composition of this chain is most commonly L-Ala-D-
Figure 1.7. Typical repeating unit of the peptidoglycan bacterial cell wall. 
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Glu-meso-DAP-D-Ala-D-Ala (meso-DAP or meso-A2pm corresponds to D,L-2,6-
diaminopimelic acid) (Figure 1.7). Crosslinking between glycan strands typically occurs 
at the subterminal D-Ala or DAP residues directly or through a short peptide bridge. 
Notably, the higher the degree of cross-linking in the PG, the higher the strength against 
osmotic lysis.16, 19 
 
Penicillin binding proteins (PBPs) are membrane-associated enzymes that are 
responsible for the synthesis and maintenance of the PG.20 Importantly, PBPs are 
bifunctional enzymes possessing both transglycosylase and transpeptidase domains. 
Transglycosylases polymerize the disaccharide pentapeptide monomeric units while 
transpeptidases cross-link the short peptide chains of adjacent PG strands. As evidenced 
by their name, PBPs are the cellular targets of penicillin (1.3), the seminal b-lactam. PBPs 
Figure 1.8. Structures of common b-lactams of the penicillin, carbapenem, and 
cephalosporin sub-classes. 
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are also the cellular targets of other antibiotics of the b-lactam class including other 
penicillins, carbapenems, and cephalosporins (Figure 1.8).16, 19, 20  
b-lactams are bactericidal and exert their antibiotic action by blocking the cross-
linking of PG strands through inhibition of the transpeptidase domain of PBPs (Figure 
1.9).16, 19 As an analog of the terminal D-Ala-D-Ala dipeptide of the PG, b-lactams serve 
as pseudosubstrates and acylate the transpeptidase active site of PBPs to generate a 
ring-opened, penicilloylated PBP (1.11). This intermediate is unable to perform normal 
crosslinking of the PG strands which yields a weakened PG. Importantly, the 
penicilloylated PBP intermediate is hydrolyzed very slowly meaning that transpeptidase 
activity is blocked for prolonged periods.  
 
 
 
 
 
 
  
 
 
 
 
Figure 1.9. Mechanism of penicillin (b-lactam)-mediated inhibition of transpeptidase 
(TPase) action in peptidoglycan (PG) cell wall synthesis. (A) TPase cross-linking of PG 
strands in PG layer biosynthesis. (B) Inhibition of TPase activity by penicillins through 
covalent modification of the TPase active site by penicillin binding. 
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Glycopeptide antibiotics, such as vancomycin (1.12), also target the 
transpeptidase activity of PBPs and are similarly bactericidal.16, 19 However, in contrast to 
b-lactams that interact directly with the PBP to inhibit cross-linking, glycopeptides inhibit 
cross-linking by interacting with the PG units at the terminal D-Ala-D-Ala dipeptide (Figure 
1.10). This interaction, characterized for vancomycin by five hydrogen bonds to the 
terminal D-Ala-D-Ala dipeptide, prevents a PG unit from reacting with either 
transglycosylases of transpeptidases. Again, this serves to reduce the amount of cross-
linking in the PG which leads to a weaker cell that is more prone to lysis. Notably, because 
b-lactams and glycopeptides exert their effects on different aspects of the cross-linking 
reaction (enzyme and substrate, respectively), they have been found to work 
synergistically when used together, i.e. their combined activity is greater than the additive 
activity of each antibiotic when used alone.  
 
 
 
 
 
  
 
 
 
Figure 1.10. Mechanism of vancomycin-mediated inhibition of transpeptidase (TPase) 
and transglycosylase (TGase) action in peptidoglycan (PG) cell wall synthesis. 
Vancomycin forms five hydrogen bonds with the terminal D-Ala-D-Ala dipeptide of a PG 
strand. This steric interference prohibits the dipeptide from reacting with TPases or 
TGases, which inhibits cross-linking of PG strands. 
O
OH
N
CH3
CH3
NHCH3
O
O
N
N
NH2
O
H
N
N
HO
O
O
HO
N
H
O O
O
Cl
Cl
OHHO
OH
O
HO
H3C
NH2
CH3
O
OH
OHHO
O
R N
H
N
O
O
CH3
CH3
H
H O
O
H
HH
R-D-Ala-D-Ala
Vancomycin (1.12)
 13 
 
Antibiotics also exist that inhibit the synthesis or transport of individual PG units, 
like fosfomycin (1.13) and bacitracin (1.14) (Figure 1.11). Fosfomycin and related 
phosphonic acids inhibit the synthesis of PG strands by interfering with the first committed 
step of PG synthesis: the formation of MurAc.21, 22 UDP-N-acetylglucosamine enolpyruvyl 
transferase (MurA) catalyzes the transfer of an enolpyruvyl moiety from 
phosphoenolpyruvate (PEP, 1.15) to the C3’-hydroxyl of UDP-GlcNAc (1.16) to generate 
UDP-GlcNAc enolpyruvate (1.17); UDP-GlcNAc enolpyruvate (1.17) is a precursor for 
UDP-MurAc (Figure 1.12A). Similar to the b-lactams, Fosfomycin covalently modifies the 
active site of its target enzyme (MurA) which consequently inactivates the enzyme 
(Figure 1.12B). Conversely, the polypeptide antibiotic bacitracin exerts its antibiotic 
action by inhibiting the transport of PG units to the cell wall by interfering with the 
dephosphorylation of C55-isoprenyl pyrophosphate; this dephosphorylation is essential to 
regenerate the lipid carrier that transports PG building blocks to the cell wall.16, 23 
 
Figure 1.11. Structures of Fosfomycin (1.13) and Bacitracin (1.14). Fosfomycin and 
Bacitracin inhibit the synthesis and transport of peptidoglycan (PG) units, respectively.  
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1.2.3 Cell Membrane-Targeting Antibiotics 
 As previously mentioned, the bacterial cell membrane differs in composition and 
arrangement of constituent parts from the eukaryotic membrane. One of the most 
important differences is the presence of exposed anionic lipids on the surface of bacterial 
membranes; in eukaryotic membranes, anionic lipids are isolated to the lipid monolayer 
facing the cell interior.24 In Gram-positive bacteria, teichoic and lipoteichoic acids extend 
from the inner membrane and the PG and are ultimately exposed to the extracellular 
environment (Figure 1.13A). In the OM of Gram-negative bacteria, LPS constitutes the 
major lipid component and is critical to the barrier function of the OM (Figure 1.13B).17  
Figure 1.12. Fosfomycin-mediated inhibition of peptidoglycan (PG) strand synthesis. (A) 
The first committed step of PG strand synthesis is the synthesis of MurAc. MurAc 
synthesis begins with MurA-catalyzed transfer of an enolpyruvyl moiety to UDP-GlcNAc 
(1.16). (B) Fosfomycin inhibits the action of MurA through covalent modification of an 
active site cysteine residue. Abbreviations: UDP, uridine diphosphate; PEP, 
phosphoenolpyruvate (1.15); MurA, UDP-N-acetylglucosamine enolpyruvyl transferase. 
O
AcHN
HO
HO
OH
OUDP
O
AcHN
O
HO
OH
OUDP
-O2C
H2C
O
-O2C OPO32-
UDP-GlcNAc (1.16)
PEP (1.15)
UDP-GlcNAc enolpyruvate (1.17)
MurA
+ Pi
O
P CH3O
HO
OH
Fosfomycin (1.13)
HS HO
P CH3O
HO
OH
MurA
S
MurA
A.
B.
 15 
 
 
General architecture of the LPS is shown in Figure 1.13B.25, 26 Lipid A (1.18), a 
glucosamine disaccharide phospholipid (Figure 1.14), is the innermost portion of the LPS 
and serves as a highly hydrophobic anchor of the LPS to the outer monolayer of the 
membrane.17, 25 Covalently attached to the lipid A component is the core oligosaccharide 
component of LPS that can be further broken down into the inner and outer core. The 
inner core is composed of less common sugars such as 2-keto-3-deoxy-D-manno-
octulosonic acid (Kdo, 1.19) and L-glycero-D-manno heptose (hep, 1.20) (Figure 1.14). 
Conversely, the outer core is typically comprised of common hexaose sugars like glucose 
(Glc, 1.21), galactose (Gal, 1.22), GlcNAc (1.4), and N-acetylgalactosamine (GalNAc, 
1.23) (Figure 1.14). Notably, the carbohydrate residues in the inner and outer cores can 
be modified with phosphate- and pyrophosphate-containing functionalities. The binding 
of these negatively-charged functionalities, as well as the negatively-charged phosphate 
groups of lipid A, to Mg2+ or Ca2+ ions helps to facilitate tight packing of LPS molecules. 
Finally, a polymer of repeating saccharide units termed the O-polysaccharide, -chain, or 
-antigen is bound typically to the core oligosaccharide component. Importantly, the 
composition of this polymer varies among bacterial strains. 
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Figure 1.13. Gram-positive and Gram-negative cell envelopes.  
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To take advantage of the unique anionic nature of bacterial cell membranes, many 
antimicrobials are cationic (at physiological pH) as the favorable electrostatic interaction 
between drug and membrane facilitates greater selectivity for the bacterial membrane. 
Notably, cationic antimicrobials are an important form of treatment against Gram-negative 
bacteria. One class of cationic cell membrane-targeting antibiotics is the antimicrobial 
peptide (AMP). AMPs interact with the bacterial cell membrane to produce membrane 
perturbation and/or disintegration.21, 27, 28 For example, AMPs can be inserted into the 
membrane bilayer to form transmembrane pores. Moreover, in some cases, AMPs can 
translocate across the membrane and engage cytoplasmic targets.  
Figure 1.14. Structures of common lipopolysaccharide (LPS) components. (A) Structure 
of lipid A (1.18) as found in E. coli. Structures of common monosaccharides in the outer 
oligosaccharide core. (B) Structures of common monosaccharides in the inner 
oligosaccharide core. 
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Two common AMPs are the cyclopeptide antibiotics polymyxin B (1.24) and colistin 
(polymyxin E, 1.25) (Figure 1.15).21, 29 Polymyxins induce membrane destabilization by 
first displacing Mg2+ and Ca2+ ions and binding to the lipid A component of the LPS. The 
hydrophobic portion of the polymyxin is then inserted into the OM which weakens the tight 
packing between adjacent lipid A molecules.30 Once a sufficient level of OM 
destabilization has been reached, the polymyxin can cross the OM and engage the IM. 
Polymyxin interaction with the IM leads to membrane thinning and eventual lysis and cell 
death. As Gram-positive species lack LPS, polymyxins are typically inactive against this 
class of bacteria.15, 31 
 Daptomycin (DAP, 1.26) is a related lipopolypeptide antibiotic that is effective 
against Gram-positive bacteria but generally ineffective against Gram-negative species 
(Figure 1.16).32, 33 Analogous to the polymyxins that are effective against Gram-negative 
bacteria, DAP binds the Gram-positive membrane which leads to membrane 
destabilization and ultimately cell death. However, rather than targeting lipid A, DAP 
targets the anionic phospholipid phosphatidylglycerol (1.27) of the cell membrane (Figure 
1.16). It has been hypothesized that the limited activity of DAP against Gram-negative 
Figure 1.15. Structures of polymyxins B (1.24) and E (1.25). 
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species is due to a significantly decreased prevalence of phospholipid 
phosphatidylglycerol in Gram-negative membranes. Importantly, prior to engaging 
phospholipid phosphatidylglycerols, DAP first binds Ca2+ ions to form DAP micelles that 
are hypothesized to aid in the delivery of DAP to the membrane. Once it has engaged 
phospholipid phosphatidylglycerols, it is proposed that DAP inserts its lipophilic tail into 
the cell membrane which leads to membrane destabilization and the formation of pore-
like structures. The newly formed pore-like structures then facilitate potassium ion efflux 
which is followed by DNA, RNA, and protein synthesis arrest. 
 
1.2.4 Protein Synthesis-Targeting Antibiotics 
The ribosome, i.e. the protein-synthesizing factory of the cell, is the target of 
numerous classes of antibiotics including the aminoglycosides (AGs), lincosamides, 
macrolides,  oxazolidinones, and tetracyclines (Figure 1.17).  
Figure 1.16. Structures of daptomycin (DAP,1.26) and its bacterial cell membrane target, 
phosphatidylglycerol (1.27). 
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Protein assembly can be divided into four main steps: initiation, elongation, 
termination, and recycling (Figure 1.18).16, 34 Initiation begins with formation of a 70S 
ribosome, composed of the 50S and 30S ribonucleoprotein subunits, in complex with the 
mRNA start codon (typically AUG) and initiator tRNA (usually fMet-tRNA). Once the 
mRNA start codon and initiator tRNA are properly positioned at the ribosomal P-site, 
elongation of the protein can occur. Elongation commences with delivery of an 
aminoacylated tRNA (aa-tRNA) to the A-site (adjacent to the P-site) of the 70S ribosome. 
The amino acid attached to the P-site tRNA is then transferred to the A-site aa-tRNA to 
form a peptide bond. The tRNAs in the A- and P-sites are then translocated to the P- and 
Figure 1.17. Structures of select ribosomal protein synthesis-targeting antibiotics. 
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E-sites to ready the ribosome for additional peptide bond formation. Elongation continues 
until a stop codon is encountered. When a stop codon is reached, the polypeptide chain 
is released from the ribosome (termination). The post-termination complex is then 
disassembled to allow the constituent parts to be recycled for the next round of protein 
translation (recycling). 
 
The majority of known ribosome-targeting antibiotics target the elongation step of 
protein synthesis (Figure 1.19).16, 34 This inhibition can occur via binding of the antibiotic 
to either the 50S or 30S ribosomal subunits. The 30S subunit is the site of base-pairing 
interactions between mRNA codons and aa-tRNA anticodons that facilitate selection of 
the cognate aa-tRNA.35 Conversely, the 50S subunit is the site of peptide bond formation; 
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The initial structural insights into the mechanism of 
antibiotic action on the ribosome were obtained from 
crystal structures of antibiotics in complex with the 
30S subunit of Thermus thermophilus, the 50S subunit 
of Deinococcus radiodurans and the 50S subunit of the 
archaeon Haloarcula marismortui4. However, the recent 
ability to determine the structures of the 70S ribosome 
from T. thermophilus8 and Escherichia coli 9 at high 
resolution has led to a rapid increase in the number of 
structures of 70S–antibiotic complexes over the past 
5–7 years. Crystal structures of almost all of the major 
ribosome-targeting antibiotic classes in complex with 
the ribosome have now been obtained. In this Review, 
I discuss the insights gained from these structures and 
highlight how this information is advancing our under-
standing of the molecular mechanisms underlying 
antibiotic action. In addition, an up-to-date overview 
of the main bacterial resistance mechanisms to riboso-
mal antibiotics is provided, as well as a discussion of the 
ongoing efforts to combat multidrug-resistant bacteria.
Structural basis of antibiotic action
Despite the large size of the ribosome, relatively few 
sites are targeted by our current arsenal of antibiotics. 
On the 30S subunit, the antibiotic binding sites are clus-
tered along the path of the mRNA and tRNAs (FIG. 2a). 
Antibiotics that bind to the 30S subunit, such as edeine 
and kasugamycin, inhibit translation initiation by pre-
venting a stable interaction between the initiator tRNA 
and the start codon at the P-site. The majority of other 
30S-targeting antibiotics inhibit translation elongation 
by interfering with either the delivery of tRNAs to the 
A-site (for example, tetracyclines and streptomycins) 
or the subsequent translocation of the mRNA–tRNA 
Figure 1 | Antibiotic target sites during bacterial protein synthesis. Initiation of protein synthesis involves the 
formation of a 70S ribosome (composed of a 30S and a 50S subunit) with the initiator tRNA and start codon of the mRNA 
positioned at the P-site. This process is inhibited by the antibiotics edeine (Ede), kasugamycin (Ksg), pactamycin (Pct) and 
thermorubin (Thb) on the 30S subunit, and by the orthosomycins avilamycin (Avn) and evernimicin (Evn), as well as 
thiostrepton (Ths) on the 50S subunit. The elongation cycle involves the delivery of the aminoacylated-tRNA (aa-tRNA) 
to the A-site of the ribosome by elongation factor Tu (EF-Tu), which is inhibited by streptomycin (Stp), tetracyclines (Tet) 
and glycylcyclines (tigecycline (Tig)). Peptide-bond formation between the A- and P-site tRNAs is inhibited by blasticidin 
S (Bls), chloramphenicol (Cam), lincosamides (clindamycin (Cln)), oxazolidinones (linezolid (Lnz)), pleuromutilins (Plu), 
puromycin (Pmn), streptogramin A (S
A
) and sparsomycin (Spr). Translocation of the tRNAs is catalysed by EF-G and 
inhibited by the tuberactinomycins capreomycin (Cap) and viomycin (Vio), the aminoglycosides ygromyci  B (HygB), 
neomycin (Neo) and paromomycin (Par), as well as fusidic acid (Fus), spectinomycin (Spt) and Ths. Elongation of the 
nascent chain is inhibited by the macrolides (erythromycin (Ery)), streptogramin B (S
B
) and ketolides (telithromycin (Tel)). 
The fi al phases of termination and recycling lead to release of the polypeptide hain and subsequent diss ciation of  
the 70S ribosome, followed by recycling of the components for the next round of initiation. Termination is inhibited by 
peptidyl-transferase inhibitors, such as Bls, Cam, Pmn and Spr, whereas recycling is inhibited by translocation 
inhibitors, especially Fus.
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Figure 1.18. Steps of ribosomal-protein synthesis (figure adapted from reference 34). 
Abbreviati s: tRNA, transf r ribonucleic cid; mRNA, me senger ribonucleic aci ; EF-
Tu-GTP, elongation factor thermos unstable-guanosine triphosphate; aa-tRNA, 
aminoacyl transfer ribonucleic acid. 
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bond formation occurs in the peptidyl transferase center (PTC) located within the 50S 
subunit.  
 
Tetracyclines bind the 30S subunit at a site that overlaps with the position of the 
anticodon stem loop of the tRNA in the A-site.16, 34 The steric bulk imposed by the bound 
tetracycline blocks the delivery of aa-tRNAs to the A-site, which effectively halts protein 
elongation (Figure 1.19). AGs also interact with the 30S subunit. Importantly, AGs are 
the only ribosome-targeting antibiotic class that are broadly bactericidal. AGs bind the 
16S rRNA (ribosomal ribonucleic acid) of the 30S subunit which induces a conformational 
change. This change subsequently promotes the binding of non-cognate tRNAs to the 
mRNA at the ribosome. This tRNA mismatching (translational misreading) can lead to the 
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The initial structural insights into the mechanism of 
antibiotic action on the ribosome were obtained from 
crystal structures of antibiotics in complex with the 
30S subunit of Thermus thermophilus, the 50S subunit 
of Deinococcus radiodurans and the 50S subunit of the 
archaeon Haloarcula marismortui4. However, the recent 
ability to determine the str ctures of the 70S rib some 
from T. thermophilus8 and Escherichia coli 9 at high 
resolution has led to a rapid increase in the number of 
structures of 70S–antibiotic complexes over the past 
5–7 years. Crystal structures of almost all of the major 
ribosome-targeting antibiotic classes in complex with 
the ribosome have now been obtained. In this Review, 
I discuss the insights gained from these structures and 
highlight how this information is advancing our under-
standing of the molecular mechanisms underlying 
antibiotic action. In addition, an up-to-date overview 
of the main bacterial resistance mechanisms to riboso-
mal antibiotics is provided, as well as a discussion of the 
ongoing efforts to combat multidrug-resistant bacteria.
Structural basis of antibiotic action
Despite the large size of the ribosome, relatively few 
sites are targeted by our current arsenal of antibiotics. 
On the 30S subunit, the antibiotic binding sites are clus-
tered along the path of the mRNA and tRNAs (FIG. 2a). 
Antibiotics that bind to the 30S subunit, such as edeine 
and kasugamycin, inhibit translation initiation by pre-
venting a stable interaction between the initiator tRNA 
and the start codon at the P-site. The majority of other 
30S-targeting antibiotics inhibit translation elongation 
by interfering with either the delivery of tRNAs to the 
A-site (for example, tetracyclines and streptomycins) 
or the subsequent translocation of the mRNA–tRNA 
Figure 1 | Antibiotic target sites during bacterial protein synthesis. Initiation of protein synthesis involves the 
formation of a 70S ribosome (composed of a 30S and a 50S subunit) with the initiator tRNA and start codon of the mRNA 
positioned at the P-site. This process is inhibited by the antibiotics edeine (Ede), kasugamycin (Ksg), pactamycin (Pct) and 
thermorubin (Thb) on the 30S subunit, and by the orthosomycins avilamycin (Avn) and evernimicin (Evn), as well as 
thiostrepton (Ths) on the 50S subunit. The elongation cycle involves the delivery of the aminoacylated-tRNA (aa-tRNA) 
to the A-site of the ribosome by elongation factor Tu (EF-Tu), which is inhibited by streptomycin (Stp), tetracyclines (Tet) 
and glycylcyclines (tigecycline (Tig)). Peptide-bond formation between the A- and P-site tRNAs is inhibited by blasticidin 
S (Bls), chloramphenicol (Cam), lincosamides (clindamycin (Cln)), oxazolidinones (linezolid (Lnz)), pleuromutilins (Plu), 
puromycin (Pmn), streptogramin A (S
A
) and sparsomycin (Spr). Translocation of the tRNAs is catalysed by EF-G and 
inhibited by the tuberactinomycins capreomycin (Cap) and viomycin (Vio), the aminoglycosides hygromycin B (HygB), 
neomycin (Neo) and paromomycin (Par), as well as fusidic acid (Fus), spectinomycin (Spt) and Ths. Elongation of the 
nascent chain is inhibited by the macrolides (erythromycin (Ery)), streptogramin B (S
B
) and ketolides (telithromycin (Tel)). 
The final phases of termination and recycling lead to release of the polypeptide chain and subsequent dissociation of  
the 70S ribosome, followed by recycling of the components for the next round of initiation. Termination is inhibited by 
peptidyl-transferase in ibitors, such as Bls, C m, Pmn and Spr, whereas recycling is in ibited by translocation 
inhibitors, especially Fus.
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Tetracyclines (30S)
Aminoglycosides (30S) 
Lincosamides (50S)
Oxazolidinones (50S)
Macrolides (50S)
Figure 1.19. Protein synthesis target sites of aminoglycosides (AGs), lincosamides, 
macrolides, oxazolidinone , and tetracycline  (figur  ad pted from reference 34). 
Information in parentheses following antibiotic class names corresponds to the ribosomal 
subunit targ t of the antibi tic class. 
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production of faulty proteins that can then be incorporated into the cellular structure. 
Notably, the incorporation of mistranslated proteins into the cell membrane increases cell 
permeability which allows for greater influx of AGs into the intracellular environment.36 
 While lincosamides, macrolides, and oxazolidinones also target the elongation 
step of protein synthesis, they do so by binding the 50S near the PTC rather than binding 
the 30S ribosomal subunit.16, 34 Lincosamides bind the PTC at a site that overlaps with 
aa-tRNA in the A-site. This steric bulk blocks peptide bond formation by blocking delivery 
of aa-tRNAs to the A-site (Figure 1.19). While oxazolidinones also bind the PTC at the 
A-site, their binding is thought to inhibit formation of the initial peptide bond by perturbing 
the position of the initial P-site tRNA.34, 37 This perturbation effectively blocks assembly of 
the 70S, mRNA start codon, and initiator tRNA complex thereby preventing 
commencement of mRNA translation. In contrast to lincosamides and oxazolidinones, 
macrolides bind the 50S subunit within the ribosomal exit tunnel, a site adjacent to the 
PTC; during peptide elongation, the growing peptide chain passes through the ribosomal 
exit tunnel to the cytoplasm where protein folding occurs.34 This binding inhibits 
elongation of short nascent peptide chains which leads to peptidyl-tRNA drop off (release 
of peptidyl-tRNAs from the ribosome) and abortion of translation.34, 38 
Antibiotics that target the remaining steps of protein synthesis (initiation, 
termination, and recycling) as well as those that specifically target the translocation of 
growing peptide chains from the A- to P-sites are reviewed elsewhere.34, 39, 40  
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1.2.5 DNA and RNA-Targeting Antibiotics 
 
 DNA replication is essential for cell survival and has thus become an attractive 
antibiotic target.16, 24, 41 Successful replication requires a multi-protein complex, termed 
the replisome, which is composed of the following proteins: DNA polymerase, processivity 
or sliding clamp, clamp ladder, helicase, primase, and single-stranded DNA-binding (SSB) 
(Figure 1.20).41, 42 In addition to the replisome complex, DNA ligase and the type II 
topoisomerases (Topo IIs) DNA gyrase and topoisomerase IV (Topo IV) are crucial for 
DNA replication (Figure 1.20). For replication to begin, double-stranded DNA must first 
be unwound and the two strands separated at what is termed a replication fork. 
Importantly, ahead of this fork, DNA gyrase introduces negative supercoiling that relaxes 
the DNA helix which allows replication to proceed. Topo IV similarly works to alleviate 
torsional stress in DNA, though it does so by removing knots that accumulate in the 
bacterial chromosome. Additionally, after replication, Topo IV catalyzes decatenation of 
the topoisomerase.10 Novobio in was licensed for tre tment of in-
fections by staphylococci and other susceptible organisms, but the
clinical use of aminocoumarins is very limited due to poor pharma-
cological properties (e.g. poor solubility, poor absorption). Though
improvement of pharmacological propertiesmayyield clinical can-
didates, none has entered trials yet.13
FQs are the most successful class of antimicrobials targeting
DNA replication and among the most widely used antimicrobials
on themarket.2 The FQmode of action is to stabilize cleaved DNA–
topoisomerase II complexes, thereby increasing the number of
double-stranded DNA breaks in the b cter al cell.14,15 Rapid ce l
death induced by FQs is likely the consequence of chromosome
fragmentation, while inhibition of DNA replication results in
reduced cell growth instead of cell death.14Most FQs are able to in-
hibit both gyrase and TopoIVwith different efficiencies, with actual
target preference depending on the specific compound and the
bacterial species againstwhich it is used.14,16–18
A major concern is the rise of FQ-resistant pathogens. FQs are
commonly used to treat infections by Enterobacteriaceae, non-
fermenting Gram-negative bacilli (in particular Pseudomonas
aeruginosa and Acinetobacter baumannii) and Mycobacterium
tuberculosis,19,20 but resistance can also occur when FQs are used
to treat infections with a different pathogen. For instance,
increased use of FQs and simultaneous development of FQ resist-
ance in clinical isolates of C. difficile resulted in the emergence of
the epidemic PCR ribotype 027, as evidenced bywhole-gen me se-
quence data,21,22 even though FQs are not the drug of choice to
treat C. difficile infections. FQ resistance ismainly acquired through
mutations in the so-called quinolone resistance-determining
regions (QRDRs) of the gyrase and/or TopoIV genes.23 In most re-
sistant pathogens the mutations are located in gyrA and/or parC,
and rarely in gyrB or parE. In most Gram-positive bacteria, TopoIV
is the primary target for FQs and resistance mutations arise first in
parC. In contrast, mutations inmost Gram-negative bacteria occur
first in gyrA.24 Single-ste mutations can lead to resis ance and
the C. difficile example illustrates how such a single mutation can
fuel an epidemic with detrimental clinical outcome. FQ resistance
can also be conferred by non-specific efflux systems that can ex-
port quinolones andother antimicrobial agents or by plasmids har-
bouring a quinolone resistance det rmi ant.19
Antimicrobials targeting DNA repli tion
under development
There are many different compoun s that have been identified as
DNA replication inhibitors with potential to be used as an anti-
microbial. These have been comprehensively reviewed else-
where.2,25 Here, we discuss several classes of DNA replication
antimicrobials to highlight the diversity of replication proteins that
can be xploited as targets and indicate some of the new
developments.
Novel bacterial topoisomerase inhibitors (NBTIs)
Increasing FQ resistance has spurred the dev lopment of novel
topoisomerase inhibitors that are active against FQ-resistant
gyrase or TopoIV. Besides modifying existing FQ scaffolds,26 novel
non-quinolone topoisomerase II inhibitors, which are collectively
clamp loader
catalytic subunit of
DNA polymerase
AUs, guanine inhibitors,
non-nucleobase inhibitors
ANCs,
adenosine analogues
Fluoroquinolones,
NBTIs
SSB-PPI
inhibitors
Griselimycins
processivity
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protein
RNA primer
helicase
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5’ 5’
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Figure 1. Schematic representation of the variety of targets of antimicrobials in the bacterial replisome. Indicated is the core of the replisome and
the other proteins that have been targeted by antimicrobial compounds. For simplicity, replication initiation proteins and regulators have been omit-
ted from this figure. Important classes of drugs inhibiting specific proteins are boxed. The activity of all proteins is described in the main text. PPI,
protein–protein interaction.
Review JAC
1277
Figure 1.20. Schematic depiction of bacterial DNA replication (figure adapted from 
reference 41). For simplicity, DNA replication initiation and regulator proteins have been 
omitted. Abbreviations: DNA, deoxyribonucleic acid; SSB, single-stranded DNA-binding. 
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the two DNA molecules; the bacterial chromosome is typically circular, thus replication 
produces two rings that must be separated from one another. While any of the proteins 
involved in DNA replication are theoretically viable and effective drug targets, clinical 
antibiotics have largely been limited to Topo II inhibitors that target DNA gyrase and/or 
Topo IV.16, 41  
Of the Topo II inhibitors, the quinolones are the most successful and widely-used 
class of antibiotic.42 The earliest member of this class, nalidixic acid (1.36), was 
introduced into the clinic in the 1960s (Figure 1.21).43 Since the 1960s, numerous 
second-generation quinolones, such as ciprofloxacin (1.37) and levofloxacin (1.38), have 
been introduced that feature improved efficacy against DNA gyrase, greater cell 
penetration in Gram-positive species, and improved pharmacodynamics and kinetics 
(Figure 1.21). The most notable features of these second-generation compounds are the 
introduction of a fluorine at the C6 position of the quinolone skeleton as well as a ringed 
substituent at the C7 position. Notably, due to the inclusion of a fluorine atom, quinolone 
antibiotics are now often referred to as fluoroquinolones. 
 
 The actions of DNA gyrase and Topo IV require the generation of double-stranded 
breaks in the bacterial chromosome. While these genome fragmentations are necessary, 
quinolone antibiotics exert their action by exploiting Topo II-mediated genome 
Figure 1.21. Structures of select quinolone antibiotics. The accepted numbering scheme 
for positions on the quinolone skeleton are denoted on the structure of nalidixic acid 
(1.36). 
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fragmentation.16, 41, 43 Quinolones bind non-covalently to the Topo II-cleaved DNA 
complex by intercalating into the DNA. This action stabilizes the complex and 
consequently prolongs the lifetime of double-stranded DNA breaks. When the replication 
process encounters quinolone-stabilized gyrase- or Topo IV-DNA cleavage complexes, 
the complexes are converted to permeant chromosomal breaks. If enough breaks are 
created, they can ultimately lead to cell death (Figure 1.22). Because of the ability of 
quinolones to effectively convert Topo II enzymes into cellular toxins, they are often 
referred to as “topoisomerase poisons.” 
 
Much like the inhibition of DNA replication, the inhibition of bacterial transcription 
can have a catastrophic effect on cellular viability. Transcription, i.e. the process by which 
RNA is synthesized from template DNA, is facilitated by RNA polymerase (RNAP) and 
numerous protein transcription factors (Figure 1.23).44, 45  
 
Figure 1. Drug-target interactions and associated cell death mechanisms
a) Quinolone antibiotics interfere with changes in DNA supercoiling by binding to
topoisomerase II or IV. This leads to the formation of double-stranded DNA breaks and cell
death in either a protein synthesis dependent or protein synthesis independent fashion. b) β-
lactams inhibit transpeptidation by binding to PBPs on maturing peptidoglycan strands. The
decrease in peptidoglycan synthesis and increase in autolysins leads to lysis and cell death.
c) Aminoglycosides bind to the 30S subunit of the ribosome and cause misincorporation of
amino acids into elongating peptides. These mistranslated proteins can misfold, and
incorporation of misfolded membrane proteins into the cell envelope leads to increased drug
uptake, which together with an increase in ribosome binding has been associated with cell
death.
Kohanski et al. Page 22
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Figure 1.22. Mechanism of quinolone-mediated cell death (figure adapted from 
reference 16). Quinolones trap Topo II enzymes as a drug-enzyme-DNA complex. When 
this complex is encountered by the replisome, or DNA polymerase complex, lethal, 
double-stranded DNA breaks are released. The release of these strands triggers the 
SOS response and other DNA repair pathways. If strand breaks overwhelm these 
responses, cell death can occur. 
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For transcription to begin, RNAP must first associate with an initiation factor, s , to 
form a complex that is poised to bind DNA at a promoter region.44, 45 Following promoter 
recognition, the double stranded DNA near the transcript start site is unwound to form an 
open promoter complex and initiation of RNA synthesis begins. Once approximately 
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UP elements, and these seem to function simply by
binding to the RNA polymerase αCTDs6. Although
differences in promoter sequence elements provide a
useful way to control a wide range of promoter activities,
these differences provide only static regulation that
cannot normally be modulated according to environ-
mental conditions. So, most adaptative regulation is
due to modulation by trans-acting factors, as discussed
below. An exception could arise from the differential
distribution of RNA polymerase between promoters,
when the free cellular polymerase concentration
varies; some promoters might be more affected by
changes in RNA polymerase concentration than others.
Sigma factors
E. coli has one main σ factor, σ70, which equips RNA
polymerase to recognize most promoters. However, the
E. coli genome also contains six other σ factors that
accumulate in response to specific stresses22. As they
accumulate, these alternative σ factors compete with σ70
for RNA polymerase. They bind a certain number of
RNA polymerase molecules and equip these molecules
to initiate transcription at promoters carrying particular
sequence elements23. Specific examples include σH and
σE, which accumulate in response to heat-shock stress
in the cytoplasm and periplasm, respectively, and
enable the RNA polymerase to recognize promoters that
control genes that assist the cell in coping with elevated
temperatures26,27. Alternative σ factors are widely
distributed in bacteria9, and they all work by binding
RNA polymerase molecules so that the holoenzyme that
is generated is directed to a specific subset of promoters.
Regulation of alternative σ factor activity can be very
complicated, involving transcriptional, translational and
post-translational control. In many cases, the activity of
a σ factor is controlled by an ANTI-SIGMA FACTOR, which
sequesters it away from the RNA polymerase28 (BOX 1).
Small ligands
Small ligands provide an alternative mechanism by
which RNA polymerase can respond quickly and
efficiently to the environment. The best example is
guanosine 3′,5′ bisphosphate (ppGpp), which is synthe-
sized when amino-acid availability is restricted to the
extent that translation is also limited29. ppGpp works
by destabilizing open complexes at promoters that
control synthesis of the machinery for translation30,31.
In fact, although the interaction of ppGpp with RNA
polymerase is not promoter-specific, ppGpp-dependent
inhibition only occurs at promoters that form unstable
open complexes. Such promoters typically have short
runs of GC-rich sequences near position +1, and they
are found to control many of the genes that encode the
products that are needed for translation. Such promoters
are also unable to function well at low concentrations of
the initiating nucleotide, usually ATP32,33. It has been
proposed that ppGpp controls expression of the trans-
lation machinery in response to sudden starvation,
whereas ATP availability controls expression in response
to growth rate34. Many of these promoters recruit
RNA polymerase very effectively and so, potentially,
Promoter sequences
In the bacterial cell, RNA polymerase is faced with
an array of nearly 2,000 promoter sequences25, and
differences between these sequences act as powerful
drivers in the unequal distribution of RNA polymerase
betwee  differen  transcription units. W  know that
promoters with near-consensus sequence elements
function more efficiently. The observation that nearly all
promoters possess non-consensus sequences teaches us
that the activity of each promoter in the cell is balanced
against that of other promoters. Also, it is obvious that
promoters that function sub-optimally are amenable to
upregulation when the appropriate situation arises.
Many of the strongest bacterial promoters have effective
ANTI-SIGMA FACTORS
A negative transcriptional
regulator that acts by binding to
a sigma factor and preventing its
activity. An anti-anti-sigma
factor, in turn, counteracts the
action of an anti-sigma factor.
R + P
Transcribing complex
RPC
RPO
RPINIT
Binding
Isomerization
Initiation
NTP
NTP
σ
Abortive
products
Elongation
Figure 2 | The pathway of transcription initiation at
bacterial promoters. The RNA polymerase (R) interacts with
promoter DNA (P) to form the closed complex (RPC). Dashed
lines show the promoter DNA that is bound by the RNA
polymerase holoenzyme. The duplex DNA around the transcript
start site is unwound (represented by a ‘bubble’ in the DNA that
is bound by the RNA polymerase holoenzyme) to form the open
complex (RPO). The initiating complex (RPINIT) is formed and
synthesis of the DNA-template-directed RNA chain (shown as a
dashed red line) begins with formation of a phosphodiester
bond between the initiating and adjacent phosphodiester
nucleoside triphosphates (NTPs). Elongation is the final stage,
and the RNA chain length increases, shown as a solid red line.
RNAP
s
Figure 1.23. Process of bacterial transcription (figure adapted from reference 44). RNA 
polymerase (RNAP) forms a complex with initiation factor s, and the resulting complex 
binds double-stranded DNA to form a closed co plex (RPC). Dashed lines indicate that 
DNA is bound by RNAP. Duplex DNA is next unwound to form the open complex (RPO). 
The initiation complex (RPINT) is formed as synthesis of the DNA-template-directed RNA 
chain begins. The dashed red line indicates a growing RNA chain bound by RNAP. 
Finally, s is released and RNAP undergoes a conformational c ange to facilit t  
elongation of the RNA chain. The solid red line indicates an elongated RNA chain. 
Abbreviations: NTP, nucleotide triphosphate. 
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twelve nucleotides of RNA have been synthesized, s is released and RNAP undergoes a 
conformational change to form a transcription elongation complex (EC). Elongation of the 
DNA-template-directed RNA chain continues until a transcription termination signal is 
reached. RNAP is then released from the template DNA to allow for initiation of another 
round of transcription. Because RNAP and its associated transcription factors are highly 
conserved across bacterial species, antibiotics that target RNAP have the potential to be 
broad-spectrum drugs. Moreover, because bacterial RNAP and the associated 
transcription factors differ significantly from those of eukaryotes, antibiotics that target 
RNA synthesis have a low potential for cytotoxic effects.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1.24. Structures of select rifamycin antibiotics. 
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Rifamycins were the first RNAP-targeting class of antibiotic discovered, and, today, 
this class is one of only a few approved for clinical use.45 Structurally, rifamycins are part 
of the ansamycin antibiotic family, a family whose structures are defined by an aromatic 
residue bridged at nonadjacent positions by an aliphatic chain (Figure 1.24).46 Derived 
from rifamycin B (1.39), which was isolated from the metabolites of Amycolatopsis 
mediterranei, rifamycin SV (1.40) was the first of its class to be approved for clinical use. 
Subsequent structural modifications to yield compounds like rifampicin (1.41, also known 
as rifampin) and rifaximin (1.42) were made to improve pharmacokinetics and reduce 
affinity for eukaryotic RNAPs rather than to modify the mechanism of antibiotic action. 
 Rifamycins inhibit the initiation phase of transcription by binding DNA-bound, 
actively-transcribing RNAP with high affinity at a site close to the active site.16, 45, 46 
Importantly, the rifamycin binding site is located within the channel formed by the RNAP 
complex through which newly synthesized RNA chains emerge. Thus, the binding of 
rifamycin sterically hinders the growth of RNA. It is important to note, however, that this 
inhibition is unique to the initiation phase. Indeed, once RNA synthesis has progressed 
past an early stage and the growing RNA chain is several nucleotides long, the process 
is no longer sensitive to rifamycin treatment. 
Fidaxomicin (1.43) is another approved RNAP-targeting antibiotic that possess 
selective antibacterial activity against Gram-positive species, especially Clostridium 
difficile (Figure 1.25).45, 47, 48 Like the rifamycins, fidaxomicin inhibits the action of RNAP 
at the initiation phase of transcription. However, fidaxomicin exerts its action earlier in 
transcription than the rifamycins. Fidaxomicin binds the DNA-bound RNAP complex and 
prevents initial separation of DNA strands, i.e. formation of the open complex, by the 
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initiation factor, s. The engagement of fidaxomicin with s is what is hypothesized to 
explain the limited spectrum of fidaxomicin antibacterial activity as s subunits differ across 
bacterial species.48 
 
 
 
 
 
 
 
 
1.2.6 Folate Biosynthesis-Targeting Antibiotics 
 In both prokaryotic and eukaryotic cells, folate cofactors are necessary for the 
biosynthesis of a diverse range of critical cellular components in nucleobases, proteins, 
and other cofactors.49-51 Due to its essential role in nucleic acid synthesis, inhibition of the 
folate biosynthetic pathway prevents cell growth and proliferation. Consequently, folate 
biosynthesis represents another attractive antibiotic cellular target. To make this target 
even more attractive, while bacteria rely on de novo folate biosynthesis, humans lack this 
biosynthetic pathway and instead must obtain folate from their diet (in the form of the 
vitamin B9, folic acid). Thus, antibiotics targeting bacterial folate synthesis act only on the 
desired bacterial target.  
The folate biosynthetic pathway is depicted in Figure 1.26. The pathway begins 
with guanosine triphosphate (GTP, 1.44) which over several steps is converted to 6-
hydroxymethyl-7,8-dihydropterin 1.45.49, 51 6-hydroxymethyl-7,8-dihydropterin 
Figure 1.25. Structure of fidaxomicin (1.43). 
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pyrophosphokinase (HPPK) then catalyzes ATP-dependent phosphorylation of 1.45 to 
yield 6-hydromethyl-7,8-dihydropterin pyrophosphate 1.46. Next, dihydropteroate 
synthase (DHPS) catalyzes the condensation of 1.46 with para-aminobenzoic acid (pABA, 
1.47) to generate 7,8-dihydropteroate 1.48. Intermediate 1.48 is converted to 7,8-
dihydrofolate 1.49 via dihydrofolate synthase (DHFS)-mediated coupling with L-glutamate. 
Finally, 1.49 is reduced by dihydrofolate reductase (DHFR) to afford tetrahydrofolate (THF, 
1.50). THF can then be converted into various cofactors for use in a number of one carbon 
metabolic processes. 
Figure 1.26. Bacterial folate biosynthetic pathway. Abbreviations: HPPK, 6-
hydroxymethyl-7,8-dihydropterin pyrophosphokinase; ATP, adenosine triphosphate; 
AMP, adenosine monophosphate; pABA, para-aminobenzoic acid; DHPS, 
dihydropteroate synthase; PPi, pyrophosphate DHFS, dihydrofolate synthase; L-glu, L-
glutamate; ADP, adenosine diphosphate; Pi, inorganic phosphate; DHFR, dihydrofolate 
reductase; NADPH, reduced nicotinamide adenine dinucleotide phosphate; NADP+, 
oxidized nicotinamide adenine dinucleotide phosphate; THF, tetrahydrofolate. 
NH
N
N
O
NH2N
O
OHOH
OP-O
O
O-
3
guanosine triphosphate (GTP, 1.44)
HN
N N
H
N
H3C
O
OH
1.45
HPPK
ATP AMP
HN
N N
H
N
H3C
O
O
1.46
P O-
O-
O
2
H2N
CO2H
HN
N N
H
N
H3C
O
1.48
pABA (1.47)
N
H
CO2H
DHFS
ADP
Pi
L-Glu
ATP
HN
N N
H
N
H3C
O
1.49
N
H
O
N
H
CO2H
CO2H
NADPH
NADP+
DHFR
HN
N N
H
H
N
H3C
O
tetrahydrofolate (THF, 1.50)
N
H
O
N
H
CO2H
CO2H
DHPS
PPi
 31 
The sulfonamides, the first widely used synthetic antibiotics, target bacterial folate 
biosynthesis.49 Due to their shared structural features (Figure 1.27), sulfonamide 
antibiotics act as mimics of pABA and can serve as alternative substrates for DHPS. By 
serving as an alternative substrate, sulfonamides effectively deplete the folate pool which 
inhibits cellular growth. The related diaminopyrimidine class of antibiotic, including 
trimethoprim (1.51), inhibits folate biosynthesis by inhibiting the action of DHFR.49, 52, 53 It 
is important to note, however, that both bacterial and human cells possess DHFR; in 
humans, DHFR reduces the folic acid obtained through diet to dihydrofolate then to THF. 
Thus, antibiotics targeting DHFR must be selective for the bacterial enzyme. The high 
selectivity of trimethoprim as an inhibitor of bacterial DHFR confers an advantage for this 
antibiotic over methotrexate (1.52), which features lowered selectivity for bacterial DHFR 
over human DHFR.53 
Figure 1.27. Folate synthesis-targeting antibiotics. (A) Structural comparison between 
para-aminobenzoic acid (pABA) and select sulfonamide antibiotics. (B) Structures of the 
diaminopyrimidine antibiotics trimethoprim (1.51) and methotrexate (1.52). 
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1.3 Mechanisms of Antibiotic Resistance 
1.3.1 Introduction 
 Bacterial antibiotic resistance mechanisms can be divided into three general 
categories: prevention of antibiotic target engagement, modification of antibiotic structure, 
and modification or bypass of antibiotic target.9, 54 The first of these mechanistic classes 
results from decreased antibiotic penetration or active antibiotic efflux from the cell. 
Decreased antibiotic penetration, in particular, is an important resistance mechanism for 
Gram-negative pathogens due to their unique OM. For example, vancomycin is not active 
against Gram-negative bacteria due to its inability to traverse the OM to reach its cell wall 
target.54 Examples of other general resistance mechanisms (not including decreased 
antibiotic penetration) for several common antibiotics are provided in Table 1.2.7, 19 
Several of these specific examples will be discussed in more depth below.  
In addition to the various methods bacteria use to resist antibiotic action, there are 
multiple ways bacteria can acquire resistance mechanisms. The first general strategy is 
through vertical transmission of a resistance mechanism from a resistant bacterium to its 
progeny.9 For example, resistance to quinolone antibiotics can be vertically transmitted 
as this resistance arises from point mutations in the genes encoding DNA gyrase and 
Topo IV. The second strategy involves transfer via mobile genetic elements, such as 
plasmids, that carry one or more resistance genes.9, 19 This type of transfer, known as 
horizontal gene transfer (HGT), is capable of transferring resistance mechanisms both 
vertically to bacterial progeny and horizontally to other bacteria. Importantly, HGT is not 
limited to intra-genera transfer. For example, the resistance mechanisms that have 
emerged in clinically relevant pathogenic species parallel the resistance mechanisms 
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found in environmental, antibiotic-producing bacteria and other non-pathogenic soil 
bacteria; the majority of soil bacteria have been found to be MDR as these species have 
had to adapt to life in an environment rich with potentially toxic small bioactive molecules. 
 
Antibiotic 
Class Example Antibiotic Target Bacterial Resistance Mechanism 
b-lactams Penicillin Penicillin-binding proteins (cell wall) 
1. Modification of antibiotic structure 
2. Modification/bypass of antibiotic target 
Antimicrobial 
peptides Polymyxin Cell membrane 
1. Modification/bypass of antibiotic target 
2. Antibiotic efflux 
Aminoglycosides Gentamicin 30S ribosomal subunit (protein synthesis) 
1. Modification of antibiotic structure 
2. Modification/bypass of antibiotic target 
3. Antibiotic efflux 
Glycopeptides Vancomycin 
Terminal D-Ala-D-Ala of 
peptidoglycan and lipid 
II (cell wall) 
1. Modification/bypass of antibiotic target 
Macrolides Erythromycin 50S ribosomal subunit (protein synthesis) 
1. Modification/bypass of antibiotic target 
2. Antibiotic efflux 
Oxazolidinones Linezolid 50S ribosomal subunit (protein synthesis) 
1. Modification/bypass of antibiotic target 
2. Antibiotic efflux 
Quinolines Ciprofloxacin Topoisomerase II (DNA replication) 
1. Modification of antibiotic structure  
2. Modification/bypass of antibiotic target 
3. Antibiotic efflux 
Rifamycins Rifampin RNA polymerase (RNA synthesis) 
1. Modification of antibiotic structure 
2. Modification/bypass of antibiotic target 
3. Antibiotic efflux 
Sulfonamides Prontosil 
Dihydropteroate 
synthase (folate 
biosynthesis) 
1. Modification/bypass of antibiotic target 
2. Antibiotic efflux 
Tetracyclines Minocycline 50S ribosomal subunit (protein synthesis) 
1. Modification/bypass of antibiotic target 
2. Antibiotic efflux 
Table 1.2. General bacterial resistance mechanisms against common classes of 
antibiotics 
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1.3.2 Prevention of Antibiotic Target Engagement 
 
  
 
 
 
 
 
 
 
Bacteria can prevent antibiotics from engaging their intended targets by 
decreasing antibiotic penetration into the intracellular environment, actively pumping 
antibiotics out of the intracellular environment using efflux pumps, or a combination of the 
two (Figure 1.28). As previously mentioned, the first of these mechanisms is 
characteristic of Gram-negative bacteria due to their unique OM. In fact, the only known 
function of this OM is to act as a protective barrier.17 Of the components of the OM, the 
LPS and porin protein channels play particularly critical roles in limiting the penetration of 
toxic compounds like intracellular-targeting antibiotics (see Figure 1.13).  
 The LPS is especially effective at limiting the influx of hydrophobic antibiotics such 
as the macrolides, rifamycins, and AMPs.17, 55 This protection is afforded by the tight 
packing of individual LPS strands. LPS strands can bind tightly due to the majority of their 
acyl chains being saturated. Additionally, avid binding of LPS strands to one another is 
improved in the presence of divalent cations like Mg2+ that can neutralize the negatively-
x
Antibiotic
Increased 
efflux
Decreased
influx
Figure 1.28. Prevention of antibiotic target engagement as a resistance mechanism. 
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charged phosphate groups of the strands. In contrast to the LPS, porins serve to limit the 
influx of small, hydrophilic antibiotics. Porins, the most abundant OM proteins, are open, 
water-filled channels that facilitate the transfer of nutrients to the intracellular 
environment.55, 56 Important in terms of pathogenicity, porins limit the diffusion of small 
molecules to hydrophilic molecules smaller than approximately 700 Daltons.17 As small 
hydrophilic antibiotics such as the b-lactams, tetracyclines, and quinolones are not able 
to diffuse across the hydrophobic LPS, lipid bilayer OM, they rely on porins for passage 
into the cell.55, 56 Given the dependence of hydrophilic antibiotics on porin channels, 
resistant bacteria often downregulate porin expression or alter porin architecture to limit 
the influx of hydrophilic antibiotics. Indeed, these changes have been reported in a variety 
of species including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, 
Pseudomonas aeruginosa, and Neisseria gonorrhoeae.55 
 Efflux pumps are also a common method used by both Gram-positive and Gram-
negative species to limit the ability of intracellular-targeting antibiotics to reach their 
desired targets in concentrations sufficient to inhibit the target’s cellular function.19, 57-60 
These pumps are membrane-associated, active transporter proteins that allow microbes 
to regulate their intracellular environment by expelling toxic substances such as 
antibiotics, heavy metals, detergents, antiseptics, metabolites, etc.59, 60 In this sense, 
efflux pumps are able to expel an antibiotic from the cell faster than the antibiotic is able 
to accumulate intracellularly to reach lethal concentrations.  
Efflux as a mechanism of antibiotic resistance was first described in 1980 by 
McMurry et al. in E. coli as a means to protect against tetracycline.57, 60, 61 While it was 
originally hypothesized that this resistance mechanism was unique to tetracycline 
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antibiotics due to HGT from tetracycline-producing species, it has since been found that 
a single efflux pump can extrude a wide range of antibiotics. These types of efflux pumps 
have appropriately been termed MDR efflux pumps.57, 62 It is important to note, however, 
that there do exist efflux systems that are highly specific for a particular class of antibiotic. 
For example, the TetA efflux pump is highly selective for tetracycline antibiotics. Another 
important finding regarding efflux as a resistance mechanism was the discovery of a 
chromosomally-encoded efflux pump in E. coli, i.e. not obtained via HGT. This 
demonstrated that acquisition of antibiotic efflux pumps was not limited to HGT from 
antibiotic-producing microbes.57, 62 This notion was further supported by the finding that 
synthetic quinolone antibiotics are a favored substrate of bacterial MDR pumps.43, 60  
 
1.3.3 Modification of Antibiotic Structure  
 
   
 
 
 
 
 
 
 
In contrast to the often broadly-applicable influx and efflux resistance mechanisms, 
enzymatic modification of an antibiotic is a highly specific resistance mechanism whose 
goal is to alter the structure of a drug enough to render it inactive (Figure 1.29). A 
Modified antibiotic
xAntibiotic
Target
Figure 1.29. Modification of antibiotic structure as a resistance mechanism.  
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quintessential example of this type of resistance is the production of b-lactamases. These 
enzymes hydrolyze the b-lactam ring of penicillins and other b-lactams. As this ring is the 
antimicrobial warhead of b-lactam antibiotics, its hydrolysis renders these drugs inactive 
(Figure 1.30).  
 
 
 
 
 
b-lactamases were first described by Abraham and Chain in 1940; Abraham and 
Chain identified an enzyme (penicillinase) in E. coli that was capable of destroying 
penicillin (1.3) and that was absent from penicillin-sensitive S. aureus.63, 64 In 1944, Kirby 
published similar reports detailing the presence of a penicillinase in penicillin-resistant 
strains of S. aureus.65-67 By the end of the 1940s, the majority of hospital isolates of S. 
aureus were resistant to penicillin.66 From the hospital, penicillin-resistant S. aureus 
(PRSA) strains spread to the community, and by the 1950s and 1960s, community-
associated PRSA strains had become pandemic.68 Today, over 90% of staphylococcal 
isolates produce b-lactamase and are consequently resistant to penicillin.69  
 Due to the increasing prevalence of b-lactamase-producing isolates, new b-lactam 
antibiotics were developed in an attempt to overcome this resistance. However, bacteria 
have proven to be highly adaptable to these changes. For example, only a few years after 
the discovery of ampicillin (1.6, Figure 1.8) in 1958, plasmid-encoded b-lactamases 
Figure 1.30. Mechanism of b-lactamase-mediated resistance to penicillin (1.3). 
N
S
CH3
CH3
O
OH
HNH
O
O
Penicillin (1.3)
Active form
β-lactamase
HN
S
CH3
CH3
O
OH
HNH
O
O
Inactive form
OH
 38 
capable of hydrolyzing ampicillin were identified in E. coli and K. pneumoniae.70, 71 A 
similar trend is seen with the extended-spectrum cephalosporins, such as cefotaxime 
(1.53, Figure 1.31).  
 
 
 
 
 
The extended-spectrum cephalosporins were developed to combat the increasing 
occurrence of ampicillin-hydrolyzing b-lactamases. However, shortly after these 
antibiotics gained widespread clinical application in the early 1980s, a b-lactamase 
capable of hydrolyzing extended-spectrum cephalosporins was identified in several 
strains of K. pneumoniae.71, 72 Shortly after this initial report, additional b-lactamases were 
discovered that conferred resistance to extended-spectrum cephalosporins. Today, over 
150 extended-spectrum b-lactamases (ESBLs) have been described in species such as 
species of the Enterobacteriaceae family, P. aeruginosa, E.coli, and K. pneumoniae.66, 71 
Notably, resistance to b-lactams in Gram-negative species is most commonly due to 
acquisition of b-lactamases while in Gram-positive species resistance is most commonly 
due to alternations in b-lactam cellular target (see section 1.3.4).66, 73 
 Another well-known example of resistance facilitated by modification of antibiotic 
structure is the resistance conferred against AGs by the production of aminoglycoside 
modifying enzymes (AMEs). AME-mediated modification of AGs is the most common 
mechanism of AG resistance and is used by a wide range of Gram-positive and Gram-
Figure 1.31. Structure of the extended-spectrum cephalosporin cefotaxime (1.53). 
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negative species.36, 54, 74 Importantly, AMEs are highly mobile, i.e. the genes encoding 
these enzymes are found on a variety of transposable genetic elements. Concurrently, 
the majority of pathogenic bacteria acquire AME-mediated resistance via HGT.74 Notably, 
the widespread dissemination of AMEs has rendered AGs like kanamycin (1.54, Figure 
1.32) largely obsolete.34 
 
 
 
 
 
Figure 1.32. Structure of the aminoglycoside antibiotic kanamycin A (1.54). 
Figure 1.33. Mechanisms for structural modification of the aminoglycoside (AG) 
kanamycin A by select AG modifying enzymes (AMEs). Modification sites are denoted 
by the number in parentheses following the AME abbreviation. AG N-
acetyltransferases (AACs) acetylate AG amines; AAC(6’) acetylates the amine at C6’. 
AG O-nucleotidyltransferases/adenylyltransferases (ANTs) adenylates AG alcohols; 
ANT(3’) adenylates the alcohol at C3’. AG O-phosphotransferases (APHs) 
phosphorylate AG alcohols; APH(2’’) phosphorylates the alcohol at C2’’. Abbreviations: 
Ade, adenosine. 
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AMEs are a large family of enzymes consisting of the following subclasses: AG N-
acetyltransferases (AACs), which catalyze acylation of AG amino functionalities; AG O-
nucleotidyltransferases or -adenylyltransferases (ANTs), which catalyze adenylylation of 
AG hydroxyl functionalities; and AG O-phosphotransferases (APHs), which catalyze 
phosphorylation of AG hydroxyl functionalities (Figure 1.33).36, 74, 75 These structural 
modifications introduce unfavorable steric and/or electronic interactions between the drug 
and its ribosomal binding site which greatly reduces AG affinity for its target.  
The prevalence and effectiveness of AMEs has prompted significant efforts to 
modify AG structure in an attempt to protect against the action of AMEs. For example, 
amikacin (1.29) is kanamycin-derived AG that is more resistant to the action of several 
AMEs than its parent kanamycin (1.54) (Figure 1.34).74 This increased resistance is 
attributable to the introduction of a (S)-2-hydroxyaminobiutyric acid (HABA) sidechain, 
which likely sterically shields the AG core structure from modification by certain AMEs.       
 
 
 
 
 
 Several additional classes of antibiotics such as the macrolides, rifamycins, and 
tetracyclines are subject to similar enzyme-mediated structural modifications that render 
the antibiotics inactive (Table 1.3).76 These mechanisms are reviewed elsewhere.34, 76, 77 
 
Figure 1.34. Structures of kanamycin A (1.54) and kanamycin A-derived amikacin 
(1.29). The (S)-2-hydroxyaminobiutyric acid (HABA) sidechain of amikacin is 
highlighted in blue. The kanamycin A core is shown in black.  
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1.3.4 Modification of Antibiotic Target 
 
 
  
 
 
 
 
 
In addition to limiting intracellular concentrations of active antibiotics, bacteria also 
avoid the action of antibiotics by altering antibiotic cellular targets (Figure 1.35). This 
General Modification 
Strategy 
Specific Type of 
Modification 
Antibiotic Classes 
Affected 
Hydrolysis N/A b-lactam Macrolide 
 
Group Transfer Acetylation 
Aminoglycoside 
Fluoroquinolone 
Phosphorylation 
Aminoglycoside 
Macrolide 
Rifamycin 
Peptide 
Thiolation Fosfomycin 
Nucleotidylation Aminoglycoside Lincosamide 
Glycosylation Macrolide Rifamycin 
Other Redox Tetracycline Rifamycin 
x
Modified target
Antibiotic
Target
Figure 1.35. Modification of antibiotic cellular target as a resistance mechanism. 
Table 1.3. Enzymatic Strategies for Antibiotic Structural Modification and Inactivation 
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highly specific strategy can take the form of structural modification(s) to the target itself 
that reduce(s) antibiotic affinity or protection of the target from engagement by an 
antibiotic. Notably, target site modification is one of the most common mechanisms used 
by bacteria to evade the action of antibiotics.54 Common modifications include point 
mutations in genes that encode the antibiotic target site, enzymatic alteration of the target 
site, and replacement/bypass of the original target. Despite the variety of modification 
strategies, each strategy ultimately serves to decrease the affinity of an antibiotic for its 
intended cellular target.  
A well-known example of mutation-mediated resistance is the development of 
rifamycin resistance. As previously described in section 1.2.5, rifamycins inhibit the 
initiation phase of transcription by binding DNA-bound, actively-transcribing RNAP with 
high affinity close to the RNAP active site.44 More specifically, rifamycins bind in a highly 
conserved pocket located within the b subunit of RNAP (encoded by rpoB); the core 
RNAP enzyme has a subunit composition of bb’a2w (Figure 1.36).46, 78 It has been shown 
that high-level rifamycin resistance can result from single amino acid substitutions in 
rpoB.46, 54 Amino acid deletions and insertions have also been reported. Importantly, 
although these modifications successfully reduce the affinity of rifamycins for RNAP, they 
spare RNAP activity and thus allow transcription to proceed.54  
 
 
 
 
 
a1
a2
b
b’
w
Figure 1.36. Bacterial RNA polymerase (RNAP) core enzyme subunit composition. 
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 A similar form of resistance is observed against the quinolone class of antibiotic.43, 
54 As described in section 1.2.5,  quinolones bind non-covalently to Topo II enzymes (DNA 
gyrase and Topo IV) at the DNA cleavage/ligation site. This binding stabilizes the Topo 
II-DNA cleavage complex, which leads to the formation of permanent double-stranded 
DNA breaks that can ultimately lead to cell death. Bacterial resistance to quinolones is 
most commonly associated with point mutations in DNA gyrase and/or Topo IV.43 While 
multiple mutations have been identified, the most commonly mutated amino acid residue 
is the serine that interacts with the water-metal ion bridge that facilitates quinolone binding 
to Topo II enzymes (Figure 1.37). Although the acidic residues that interact with this 
bridge are also commonly mutated, mutations to these residues do result in a reduction 
of Topo II catalytic activity while mutations to the serine residue do not.  
 
 
 
 
 
 
 
 
 
Figure 1.37. Schematic depiction of the water-ion bridge that facilitates quinolone (ex. 
ciprofloxacin (1.37)) binding  to topoisomerase II (Topo II). Ciprofloxacin and its 
interactions with the Mg2+ ion (shown in purple) are shown in black. The participating 
serine and acidic amino acid residues of Topo II are and their interactions with the water 
molecules are shown in red. The water molecules and their interactions with the Mg2+ ion 
are shown in blue.  
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 Methylation of antibiotic-binding site residue(s) is one of the most common 
enzyme-mediated target site modifications.54 This form of resistance is particularly 
relevant for ribosome-targeting antibiotics. Indeed, various methylations of ribosomal 
RNA (rRNA) by rRNA methyltransferases (RMTs) can confer resistance against antibiotic 
classes including aminoglycosides, lincosamides, macrolides, and oxazolidinones.54, 79, 80  
A particularly well-characterized example is the antibiotic resistance that arises 
from mono- or dimethylation of an adenine residue in the 23rRNA of the 50S ribosomal 
subunit. Due to overlapping binding sites, this methylation confers resistance to 
macrolides, lincosamides, and streptogramin B (MLSB) antibiotics. It is thought that 
methylation results in a ribosomal conformational shift that reduces antibiotic binding 
affinity.34, 79 Methylation of the adenine residue is catalyzed by enzymes encoded by the 
erm (erythromycin ribosomal methylation) genes.54 To date, over 30 erm genes have 
been identified. Moreover, likely due to the fact that many of these genes are located on 
mobile genetic elements, erm genes have been found in over 30 different bacterial genera 
including Escherichia, Mycobacterium, Staphylococcus, Streptomyces, and 
Streptococcus.54, 79, 80 It is important to note, however, that there is a fitness cost 
associated with Erm-mediated resistance as the methylation associated with this 
resistance results in less efficient translation compared to wild-type ribosomes.34, 54 Thus, 
most erm genes are not constituently expressed. Instead, their expression is induced 
when an antibiotic is present. Notably, erythromycin is typically the best inducer of erm 
expression. 
In contrast to the fitness cost of Erm-mediated resistance, Cfr-mediated resistance 
has a low fitness cost.34 Cfr monomethylates a different adenine residue of the 23rRNA; 
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erm genes methylate an adenine within the exit tunnel while cfr genes methylate an 
adenine in the PTC. Cfr-mediated methylation confers resistance against the 
oxazolidinone antibiotic linezolid as well as lincosamides and some macrolides. The cfr 
gene was first identified in Staphylococcal species and has since been found in 
Enterococcus species and some Gram-negative species.54, 81 
Another class of RMTs that are gaining clinical significance are those that facilitate 
resistance towards AGs by methylating residues in the 30S ribosomal subunit.36, 74, 82 
These include ArmA and RmtA-D that methylate a guanine residue and NmpA that 
methylates an adenine residue. Each methylation serves to disfavor AG binding by 
introducing unfavorable steric and electronic interactions between the AG and its 
ribosome binding target. While originally an autoprotective mechanism in 
aminoglycoside-producing actinomycetes, this modification strategy has been identified 
in several pathogenic bacterial species such as P. aeruginosa, K. pneumoniae, and A. 
baumannii.82-85  
 The final strategy used by bacteria to directly modify antibiotic targets involves 
replacement or bypass of the original target. One of the most well-known and clinically-
relevant examples of this strategy is the development of methicillin resistance in S. 
aureus.43, 68 In an attempt to combat penicillin resistance due to the production of b-
lactamases, methicillin (1.7, see Figure 1.8) was introduced.64, 66, 68 Methicillin features a 
larger aryl moiety near the b-lactam ring which reduces the drug’s affinity for 
Staphylococcal b-lactamases. However, shortly after methicillin’s introduction, resistance 
to this b-lactam emerged. Contrary to penicillin resistance, the resistance to methicillin 
was not a result of drug inactivation, but rather a result of drug target bypass. Methicillin-
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resistant S. aureus (MRSA) strains expressed an additional PBP known as PBP2a; 
PBP2a is encoded by the mecA gene that is hypothesized to have originated in 
Staphylococcus sciuri.54, 69 PBP2a is a PBP that has low affinity for all b-lactams and 
consequently renders most b-lactams ineffective against MRSA infections. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Another important example of target replacement/bypass is the development of 
vancomycin resistance. While vancomycin-resistant S. aureus (VRSA) strains have 
emerged, vancomycin resistance is particularly relevant in Enterococcus species such as 
E. faecium (VRE: vancomycin-resistant Enterococci).19, 54 Vancomycin resistance results 
from acquisition of genes that are responsible for remodeling PG synthesis. Specifically, 
Figure 1.38. Alterations to terminal D-Ala-D-Ala dipeptide of peptidoglycan (PG) strands 
that confer resistance to vancomycin (1.12).  
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the van gene clusters encode a new pathway of enzymes that change the terminal D-Ala 
to D-Lactate (Lac) (high-level resistance) or D-Ser (low-level resistance) and destroys the 
original D-Ala-D-Ala ending precursors (prevents vancomycin binding to cell wall 
precursors). Exchange of the D-Ala for D-Lac removes a hydrogen bonding interaction 
between vancomycin and the terminal dipeptide of a PG strand (Figure 1.38). While 
exchange of D-Ala for D-Ser does not remove a hydrogen bonding interaction, the 
presence of the serine hydroxyl group nevertheless reduces the affinity of vancomycin for 
its target, albeit to a lesser extent that caused by replacement with D-Lac (Figure 1.38). 
  In addition to target modification that reduces antibiotic affinity, bacteria can also 
prevent antibiotics from engaging their desired targets via factor-associated protection of 
antibiotic cellular targets.9, 34, 54 For example, expression of the Tet(M) and Tet(O) proteins 
confers resistance to tetracycline antibiotics. Tet(M) and Tet(O) bind the ribosome and 
subsequently dislodge tetracyclines from their binding site. This action is facilitated by the 
structural homology of Tem(M) and Tet(O) to the elongation factors (EF-G and EF-Tu) 
used in protein synthesis. Moreover, the binding of these proteins to the ribosome results 
in a ribosomal conformational shift that prevents rebinding of the antibiotic.54 Tem(M) and 
Tet(O), also termed ribosomal protection proteins (RPPs), were first identified in C. jejuni 
and Streptococcal species but are now widely distributed among numerous bacterial 
species.54, 86  
Target protection is also used to hinder the action of quinolone antibiotics.43, 54 This 
form of resistance involves the expression of Qnr (quinolone resistance protein). Qnr acts 
as a DNA mimic that competes for DNA binding to the Topo II enzymes, DNA gyrase and 
Topo IV. It is hypothesized that this competition decreases the interaction of DNA with 
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DNA-gyrase which in turn decreases the opportunity for quinolone antibiotics to form and 
stabilize lethal gyrase-cleaved DNA-quinolone complexes.  
 
1.4 The ESKAPE Pathogens 
 The growing number of antimicrobial-resistant pathogens continues to challenge 
our ability to combat infectious diseases. As mentioned in section 1.1, although 
antimicrobial resistance (AMR) is a natural phenomenon, the modern age has seen an 
increase in the prevalence and diversity of resistant organisms.4, 10 Moreover, we have 
also seen the emergence of MDR pathogens; MDR is defined as resistance to two or 
more antimicrobials of different antimicrobial classes.87 MDR pathogens pose one of the 
most significant threats to human health both in the hospital and the community. Indeed, 
several MDR pathogens are effectively untreatable with our current arsenal of antibiotics.4 
A critically important class of MDR pathogens are the ESKAPE pathogens.  
The ESKAPE pathogens (briefly introduced in section 1.1) are a cohort of 
microorganisms aptly named for their ability to “escape” the action of antibiotics.13, 14, 88, 
89 This cohort consists of the following Gram-positive and Gram-negative species: 
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumannii, Pseudomonas aeruginosa, and Enterobacter species (Table 1.4). Importantly, 
these pathogens are responsible for the majority of nosocomial infections and are 
common causes of life-threatening illnesses among immunocompromised or critically-ill 
patients.14, 89 While these pathogens are characterized by their MDR, exceptionally critical 
antibiotic resistances for each of the ESKAPE pathogens are noted in Table 1.4. 
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E. faecium is a Gram-positive, facultative anaerobe frequently associated with 
hospital-acquired infections (HAI). E. faecium infections are particularly common among 
immunocompromised patients and include bloodstream, surgical site, and urinary tract 
infections.13, 89, 90 Enterococci species, like E. faecium, are also commonly associated 
with infections of indwelling medical devices due to their ability to colonize both skin and 
abiotic surfaces.13 In terms of resistance, there is an high prevalence of E. faecium 
resistance towards b-lactams. While this resistance is problematic, the increasing 
prevalence of vancomycin-resistant E. faecium (VRE) (first identified in the late 1980s) is 
particularly alarming as vancomycin is often an antibiotic of last resort; vancomycin 
resistance in E. faecium is conferred by expression of van gene clusters as described in 
section 1.3.4.13, 90  
S. aureus is a Gram-positive coccal bacterium that commonly colonizes the skin 
and moist areas like the mucous membranes of the nose.13, 89, 90 Indeed, approximately 
60% of individuals are intermittent carriers of S. aureus (harbor the bacterium at irregular 
Pathogen Gram Classification Notable Resistance 
Enterococcus faecium Gram-positive Vancomycin 
Staphylococcus aureus Gram-positive Methicillin 
Klebsiella pneumoniae Gram-negative Carbapenem 
Acinetobacter baumannii Gram-negative MDR; Carbapenem 
Pseudomonas aeruginosa Gram-negative MDR; Quinoline 
Enterobacter species Gram-negative Carbapenem 
Table 1.4. The ESKAPE Pathogens  
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intervals), while approximately 20% of people are persistent carriers (almost always 
colonized with S. aureus). S. aureus is the leading cause of skin and soft tissue infections 
and can also cause severe infections such as sepsis, pneumonia, bone and joint 
infections, and infective endocarditis. An especially important feature of S. aureus in 
terms of pathogenicity is its propensity for biofilm production.13 Biofilm will be discussed 
in more depth in Chapter 3, but briefly, biofilms are organized communities of cells 
surrounded by an extracellular matrix that serves as an extra source of protection against 
antimicrobial action.91-93 Notably, S. aureus biofilms are the most common cause of 
device related infections (DRIs). 
The majority of clinically- and community-acquired S. aureus isolates are resistant 
to penicillin due to the production of b-lactamases.13, 89 As described in section 1.3.4, 
attempts to overcome S. aureus penicillin resistance through the use of methicillin, which 
is resistant to the action of b-lactamases, has been met with the emergence of methicillin-
resistant S. aureus (MRSA). Today, MRSA is a common hospital and community-
acquired infection. For these infections, vancomycin, is generally the antibiotic of choice.13 
However, the increased use of vancomycin to treat these infections has led to the 
emergence of vancomycin-intermediate and vancomycin-resistant S. aureus (VISA and 
VRSA). Importantly, vancomycin resistance in S. aureus has been traced to the 
interspecies transfer of vancomycin resistance determinants in VRE (i.e. van resistance 
genes). 
Klebsiella pneumoniae is a Gram-negative, encapsulated bacillus that is a 
prominent member of the Enterobacteriaceae family.13, 94 K. pneumoniae is an intrinsically 
virulent species from the environment (e.g. soil and water surfaces) that readily colonizes 
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human mucosal surfaces, such as the gastrointestinal tract (GI) and oropharynx, and 
medical devices. From these initial colonization sites, K. pneumoniae gains access to 
other tissues and can cause a wide range of infections such as pneumonia, urinary tract 
infections (UTIs), bloodstream infections (BSIs), and meningitis. Notably, K. pneumoniae 
infections are prevalent in both hospital and community settings.  
 
Another defining feature of this bacterial species is its notorious ability to rapidly 
accumulate and disseminate MDR determinates.13, 95 Indeed, recent times have seen K. 
pneumoniae strains acquire an extensive variety of b-lactamases capable of conferring 
resistance not only to penicillins and cephalosporins but also carbapenems (Figures 1.39 
and 1.8). Moreover, K. pneumoniae is the pathogen most often associated with 
dissemination of ESBLs.95 Because carbapenems are typically reserved for the treatment 
of difficult, persistent Gram-negative infections, the increasing occurrence of 
carbapenem-resistant K. pneumoniae (CRKP) poses a significant challenge.13, 89 To 
Table 1.39. Structure of the common carbapenem core and the carbapenem antibiotics 
imipenem (1.55), doripenem (1.56), and meropenem (1.57). 
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compound this problem, a K. pneumoniae “super enzyme,” metallo-b-lactamade-1 (NDM-
1), has emerged and has led to an increased number of CRKP isolates. Moreover, this 
enzyme is hypothesized to be a possible threat to the effectiveness of other antibiotic 
classes such as the AGs and quinolones. 
 Acinetobacter baumannii is a Gram-negative, opportunistic pathogen that has 
become a major source of nosocomial infections worldwide.13, 89, 96 While other 
Acinetobacter species are widely distributed in the environment (soil, water, and animals) 
A. baumannii is found almost exclusively in the hospital, especially in intensive care units 
(ICUs) and surgical wards.13, 97 Indeed, A. baumannii infection is most commonly 
associated with immunocompromised individuals or those who have undergone major 
surgery. A. baumannii can cause a variety of infections including skin, soft tissue, wound, 
and urinary tract infections. More severely and life-threateningly, A. baumannii can also 
cause ventilator-associated pneumonia and BSIs.97 More recently, A. baumannii gained 
notoriety for its increased association with military personnel in combat regions.96, 97 The 
increasing prevalence of this species in the conflict in Iraq even garnered it colloquial 
names like “Iraquibacter” and “Iraqi-baumannii.” 
A characteristic and notorious feature of A. baumannii is its ability to survive for 
long periods on human hands and hospital equipment.13, 96 This long lifetime is 
hypothesized to contribute to high-rates of cross-contamination in nosocomial infections. 
Another well-known feature of A. baumannii is its high level of MDR. In addition to being 
inherently resistant to numerous antibiotics due to the Gram-negative OM, A. baumannii 
expresses fewer and smaller OM porins compared to other Gram-negative species, which 
further decreases antibiotic penetration.13, 98 Moreover, A. baumannii is capable of 
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widening the periplasmic space in its cell wall in response to environmental conditions. 
An increasingly common resistance mechanism of A. baumannii is the production of b-
lactamases. Perhaps most notably, A. baumannii has acquired numerous 
carbapenemases, such as imipenem metallo-b-lactamases and oxacillinase (OXA) serine 
b-lactamases, that confer widespread resistance to penicillins, cephalosporins, and 
carbapenems. Finally, A. baumannii has also been found to mutate DNA gyrase and Topo 
IV to reduce quinoline binding and to use efflux pumps to protect against the action of 
tetracyclines.99, 100 
Pseudomonas aeruginosa is a Gram-negative, facultative anaerobe that 
preferentially colonizes immunocompromised individuals (i.e. an opportunistic pathogen) 
in nosocomial settings.13, 101 Indicative of this preference, P. aeruginosa is the main 
pathogen associated with respiratory tract infections in cystic fibrosis (CF) patients and is 
also commonly associated with cancer patients and burn victims. Furthermore, due to its 
ability to metabolize a wide range of organic molecules, P. aeruginosa is able to survive 
in extreme environmental conditions.13  
Similar to other Gram-negative pathogens, P. aeruginosa is inherently resistant to 
a range of antimicrobials due to its OM.13, 89 Moreover, most substances pass through the 
P. aeruginosa OM porin protein OprF which limits molecules to 500 Da or less. Antibiotic 
permeability can be further reduced in P. aeruginosa through decreased expression of 
another OM porin, OprD. This porin channel is the main route used by carbapenems to 
enter the cell. Thus, loss of this transmembrane channel confers resistance to several 
carbapenems. Resistance to carbapenems is also afforded by the production of broad-
spectrum ESBLs and carbapenemases. Importantly, P. aeruginosa can simultaneously 
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up-regulate expression of the single efflux pump system MexAB-OprM which can 
increase resistance to a wide range of antibiotics including b-lactams, cephalosporins, 
fluoroquinolones, macrolides, tetracyclines, and sulfonamides.13 Finally, P. aeruginosa is 
also characterized by a resistance to quinolone antibiotics due to target mutations in DNA 
gyrase and/or Topo IV.  
Enterobacter species are also Gram-negative opportunistic pathogens that are 
notorious for causing infections in immunocompromised individuals, particularly in 
hospital settings.13, 89 These species most commonly cause urinary and respiratory tract 
infections but have also been shown to cause BSIs. Enterobacter species are notable for 
their broad MDR mediated by numerous plasmid-encoded ESBLs and carbapenemases. 
Generally, only colistin and tigecycline are effective against Enterobacter species. 
 
1.5 Alternative Approaches to Current Antibiotic Monotherapy 
The increasing prevalence of MDR pathogens like the ESKAPE pathogens 
demonstrates the need for new treatment methods. While developing new antibiotics with 
novel structures and modes of actions is an obvious approach, in the last few decades, 
this approach has been largely unfruitful. Moreover, any new antibiotics that target 
essential cellular function(s) will ultimately be plagued by the development of resistance. 
With this in mind, several alternative approaches have been developed with the objective 
not only to combat infectious diseases but also to limit antibiotic resistance development. 
Examples of these alternative approaches include the use of multi-drug combination 
therapies, antibiotic and antibiotic adjuvant combinations, antibiotics that target virulence 
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factors, and antibiotics with narrow spectrums of activity. These approaches will be 
discussed briefly for the remainder of the chapter. 
 
1.5.1 Multi-Antibiotic Combination Therapies 
  Treatments that rely on the use of two or more antibiotics are becoming 
increasingly common for the treatment of both bacterial and non-bacterial-associated 
diseased states. 102-104 For example, drug combinations are standard for most cancer 
treatments and are routinely used in anti-HIV treatments. In terms of bacterial infections, 
a well-known example of multi-drug therapy is in the treatment of Mycobacterium 
tuberculosis infections.103, 105, 106 These treatments typically use a combination of at least 
four drugs (usually isoniazid (1.58), rifampicin (1.41), ethambutol (1.59), and 
pyrazinamide (1.60); Figure 1.40) and are often used to treat MDR and even extensively 
drug-resistant (XDR) M. tuberculosis infections. Treatments of MDR Gram-negative 
bacterial infections also commonly use a multi-drug approach. These treatments typically 
use colistin (1.25, Figure 1.15), an AMP that targets the Gram-negative OM and 
increases membrane permeability, and another non-OM targeting antibiotic.103 
 
Figure 1.40. Structures of antibiotics typically used in multi-drug therapy for 
Mycobacterium tuberculosis infections.  
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The aforementioned combination therapies for bacterial infections are examples 
of multi-drug therapies that use antibiotics which target different pathways or different 
cellular targets. Another well-known example of this strategy is the combination of b-
lactams, like penicillin and ampicillin (see Figure 1.8), and AGs, like gentamicin (see 
Figure 1.7).8, 107, 108 b-lactams target the cell wall and increase cell permeability which 
subsequently facilitates increased cellular uptake of AGs compared to treatment with AGs 
alone. This combination treatment has been used in the treatment of Enterococci-
associated infections and is a common treatment for early-onset Group B Streptococcus 
disease in infants.108-110 
In addition to combination therapies that use antibiotics which target different 
pathways or cellular targets, combination therapies can also rely on combinations of 
antibiotics that inhibit different targets in the same pathway or the same target in different 
ways. A commonly used example of these first of these strategies is the combination of 
sulfamethoxazole (1.61) and trimethoprim (1.51) (Figure 1.41); this combination is 
marketed as co-trimoxazole.50, 52, 103 Sulfamethoxazole and trimethoprim both target 
folate synthesis (see section 1.2.6), but sulfamethoxazole inhibits dihydropteroate 
synthase (DHPS) while trimethoprim inhibits dihydrofolate reductase (DHFR) (see Figure 
1.26). This antibiotic combination has been used to treat MRSA and E. coli-associated 
UTIs.52  
 
 
 
Figure 1.41. Structures of folate synthesis-targeting antibiotics typically used in 
combination therapies.  
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Combinations of streptogramins are prime examples of treatments using 
antibiotics that inhibit the same target but in different ways.103 Streptogramins are 
depsipeptides that can be divided into two distinct categories: smaller type A 
streptogramins that block translation by binding the ribosomal P-site and the larger type 
B streptogramins that bind the 50S ribosome and block the peptide exit tunnel.111-113 
Importantly, binding by a type A streptogramin induces a ribosomal conformational shift 
that facilitates binding of a type B streptogramin.112 Also importantly, when used alone, 
type A and B streptogramins exert only bacteriostatic effects as opposed to the 
bactericidal effect that results when these types are used in combination.111, 113 Synercid, 
a combination of dalfopristin (1.62, type A streptogramin) and quinupristin (1.63, type B 
streptogramin), has been used to treat MRSA and VRE (Figure 1.42).112, 113  
  
1.5.2 Antibiotic and Antibiotic Adjuvant Combination Therapies 
 A common alternative to using a combination of two antibiotics is to use the 
combination of an antibiotic and an antibiotic adjuvant.103, 110, 114 An antibiotic adjuvant is 
Figure 1.42. Structures of ribosome-targeting streptogramins used together in 
combination therapies.  
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a compound that does not possess antimicrobial activity itself but rather potentiates the 
activity of an antibiotic. Notably, because adjuvants lack antimicrobial activity, it has been 
hypothesized that this antibiotic/adjuvant approach may decrease the development of 
antibiotic resistance.114 Adjuvants commonly potentiate antibiotic action by inhibiting a 
resistance mechanism against the antibiotic. These types of adjuvants are classified as 
class I adjuvants (Figure 1.43).110 Class I adjuvants can be further divided into class IA 
adjuvants that directly inhibit resistance mechanisms (ex. inactivating enzymes) and class 
IB adjuvants that indirectly inhibit resistance mechanisms by circumventing intrinsic 
resistance mechanisms (ex. perturbing proton motive force). In contrast to class I 
adjuvants, class II adjuvants do not directly impact bacteria but rather enhance host 
defense mechanisms (Figure 1.43). 
 
 
 
 
 
 
 
 
 
 
Figure 1.43. Classification of antibiotic adjuvants and corresponding examples from each 
adjuvant class (figure adapted from reference 110). Class I adjuvants potentiate antibiotic 
action by directly inhibiting active (class IA) or passive/intrinsic (class IB) resistance 
mechanisms, while class II potentiate antibiotic action by enhancing host defense 
mechanisms. Abbreviations: A, antibiotic; I, inhibitor; N, non-antibiotic; H, host defense 
mechanism. 
In contrast to antibiotic combinations, antibiotic adjuvants [15,16,18,22] show little or no
antimicrobial activity alone. Instead, when combined with drugs, they enhance antibiotic activity
under speciﬁc conditions. It is useful to classify antibiotic adjuvants into two general classes
based on target proﬁle: Class I adjuvants that work with antibiotics on bacterial targets, and
Class II adjuvants that enhance antibiotic activity in the host (Figure 1). Class I adjuvants can be
further differentiated based on their mechanisms. Class I.A compounds directly inhibit antibiotic
resistance (inactivating enzymes, efﬂux pump systems, or alternate targets) and are the only
adjuvants in current clinical use. Class I.B adjuvants enhance antibiotic activity by circumventing
intrinsic resistance mechanisms including metabolic pathways or physiology other than direct
inhibition of speciﬁc resistance elements. By contrast, Class II adjuvants do not directly impact
bacteria but rather operate on host properties to potentiate antibiotic action. Examples of Class I.
B and Class II adjuvants have yet to be approved by regulatory agencies as formulated drug
combinations with antibiotics, but are being explored in preclinical models.
Mechanisms of Antibiotic Resistance
Resistance to antibiotics occurs through a variety of molecular mechanisms, including
decreased drug permeability, active efﬂux, alteration or bypass of the drug target, production
of antibiotic-modifying enzymes, and physiological states such as bioﬁlms that are less sus-
ceptible to antibiotic activity (Figure 2). All of these mechanisms are susceptible to inhibition by
small molecules and thus are potential targets for antibiotic adjuvants. For the purposes of
targeting resistance with adjuvants, it is useful to classify resistance as either active, that is,
mechanisms that have evolved speciﬁcally to detoxify speciﬁc antibiotics, or passive, mecha-
nisms that are intrinsic to speciﬁc bacteria that have the effect of resistance but are not
necessarily directly targeted to an individual antibiotic. Examples of active resistance include
genes acquired by horizontal and vertical transfer and the upregulation of ‘silent’ chromosomal
elements that can confer drug resistance to otherwise sensitive bacteria. These include most of
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The most well-known and clinically successful examples of antibiotic adjuvants are 
those that inhibit b-lactamase action (class IA adjuvants).103, 110, 114 A classic example is 
the combination drug Augmentin. Augmentin consists of the b-lactam antibiotic amoxicillin 
(1.67) and the b-lactamase inhibitor clavulanic acid (1.64) (Figure 1.44). While clavulanic 
acid alone has poor antimicrobial activity, it does exhibit potent and irreversible 
inactivation of b-lactamases. Thus, when used in combination with amoxicillin, clavulanic 
acid allows amoxicillin to escape the action of b-lactamases and inhibit cell wall 
biosynthesis. Despite the success of Augmentin, many b-lactamases, such as the 
carbapenem hydrolyzing oxacillinases (CHDLs) and the metallo- b-lactamases (MBLs) 
are not inhibited by clavulanic acid. To address the limitations of clavulanic acid, several 
other b-lactamase inhibitors have been developed. These compounds are reviewed 
elsewhere.103, 110 
 
 
 
 
Compounds that inhibit efflux pumps (class IB adjuvants) have also been 
investigated as antibiotic adjuvants.103, 110 For example, Phe-Arg-b-naphthylamine (PAbN) 
was identified as an efflux pump inhibitor against a variety of species, including P. 
aeruginosa, and is able to enhance the activity of several antibiotics from a variety of 
antibiotic classes. As shown in Figure 1.43, loperamide (1.65) is another example of a 
class IB adjuvant. Loperamide operates by decreasing the electrical component of the 
Figure 1.44. Structures of the components of Augmentin, amoxicillin (1.67) and 
clavulanic acid (1.64). 
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proton motive force in Gram-negative bacteria which ultimately results in increased 
uptake of tetracyclines.110 
 For the last class of adjuvant (class II), immunomodulatory peptides (ex. LL-37) 
that enhance that antimicrobial activity of the innate immune system represent attractive 
potential adjuvants.110 As illustrated in Figure 1.43, streptazolin (1.66) represents another 
example of a class II adjuvant. Streptazolin was shown to stimulate macrophage activity 
in vitro to increase bacterial killing.110, 115 
 
1.5.3 Antivirulence Antibiotics 
 Closely related to the development of antibiotic adjuvants is the development of 
antivirulence antibiotics. Unlike traditional antibiotics, antivirulence antibiotics do not 
target essential cellular processes like cell wall synthesis or DNA replication.116, 117 Rather, 
this class of compound targets and neutralizes virulence factors. Virulence factors are 
products produced by bacteria to promote pathogenesis via damaging the host or evading 
host immune system action. Examples of virulence factors include toxins, adhesions, 
siderophores, and factors that promote biofilm formation. Importantly, without these 
factors, bacteria are generally unable to cause infection in a host. Indeed, in the absence 
of virulence factors, the host immune system is more effective against pathogens, and 
commensal species within the host are also more likely to outcompete pathogenic species.  
 The strategy of targeting bacterial virulence factors has several attractive 
features.116, 117 First, because antivirulence agents do not target essential cellular 
processes or machinery, it is hypothesized that their use will be less likely to elicit the 
development of resistant phenotypes. Antivirulence drugs are also hypothesized to curb 
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resistance development due to the largely bacterium-specific nature of virulence factors. 
Thus, should one species develop resistance to an antivirulence drug, horizontal transfer 
of the relevant resistance genes to another species is unlikely to confer resistance to the 
recipient species. Another attractive feature of antivirulence agents is that they are 
unlikely to affect commensal species of the normal human flora as these species 
generally lack virulence factors. Collateral damage to commensal species is a common 
pitfall of typical antibiotic treatment, i.e. treatment with essential cell process-targeting 
antibiotics.117-119 
 Common antivirulence drug targets include but are not limited to bacterial toxins, 
quorum sensing (important for biofilm formation; see section 3.14 of Chapter 3), other 
biofilm-promoting factors, and secretion systems (molecule transport systems).116, 117 
Bacterial toxins are perhaps the most clinically relevant targets as multiple bacterial toxin-
targeting antivirulence drugs have been approved by the FDA.117 For example, 
immunoglobulins purified from donor plasma are used to neutralize botulinum neurotoxins 
(BoNTs) secreted by Clostridium botulinum. Similarly, bezlotoxumab, a human 
monoclonal antibody, targets the TcdB toxin produced by Clostridium difficile and has 
been shown to reduce the recurrence of C. difficile infections (CDIs) in patients at high 
risk of recurrence. Additional approved antivirulence drugs and antivirulence drugs still in 
development are reviewed elsewhere.117, 120 
 
1.5.4 Narrow-Spectrum Antibiotics 
 To date, antibiotic development has largely been focused on uncovering antibiotics 
that feature potent activity against a wide range of bacterial pathogens.118, 121, 122 This is 
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due in large part to the economic benefit associated with developing a drug with wide-
reaching effects. Broad-spectrum antibiotics offer a better return on investment than 
antibiotics that are only effective against a narrow range of bacterial pathogens. While 
narrow-spectrum antibiotics have not been a primary focus of antibiotic development thus 
far, this class of antibiotic may prove key in the fight against antimicrobial resistance. 
Before continuing on in a discussion about narrow-spectrum antibiotics, it is important to 
note that the definition of narrow-spectrum has evolved over time.118 Originally, this term 
was developed to describe antibiotics that were only effective against one type of Gram 
stain group. However, for the present discussion, narrow-spectrum refers to antibiotics 
that are active against only one or a small cohort of bacterial species. 
 While broad-spectrum antibiotics have been and continue to be paramount for the 
treatment of infectious diseases, as previously discussed, their success is also their 
undoing. First, because the cellular targets of broad-spectrum antibiotics are highly 
conserved across bacterial species, continued use of these antibiotics is associated with 
an increased risk of resistance development and dissemination.123-126 Indeed, broad-
spectrum antibiotics impose high selective pressure on numerous bacterial species and 
HGT among different species has contributed significantly to the rise of antibiotic 
resistance. Second, due to their lack of specificity in bacterial species they target, broad-
spectrum antibiotics are prone to adverse effects such as damage to the host 
microbiome.125, 127 Importantly, antibiotic-associated damage to the microbiome can 
persist long after treatment has ceased. Additionally, damage to the normal gut flora can 
increase a patient’s risk of developing secondary infections. For example, CDIs  have 
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been directly linked to prior treatment with broadly-active antibiotics such as 
cephalosporins and quinolones. 118, 127, 128 
 In contrast to broad-spectrum antibiotics, narrow-spectrum antibiotics have been 
postulated to slow resistance development and dissemination, decrease the risk of 
damage to the microbiome, and help control the misuse and overuse of antibiotics129, 130 
Because narrow-spectrum antibiotics fail to elicit the development of cross-resistance in 
pathogenic species not targeted by the antibiotics, this class of antibiotic represents an 
attractive approach to combat MDR bacterial infections. An example of a recently FDA-
approved narrow-spectrum antibiotic is fidaxomicin (14.3, see Figure 1.25). Fidaxomicin 
is a macrolide antibiotic with selective antimicrobial activity against Gram-positive 
anaerobes that has garnered use in the treatment of severe CDI.118, 130, 131 Fidaxomicin 
inhibits spore and toxin formation by C. difficile and has been shown to decrease the 
recurrence of CDI compared to treatment of CDI with vancomycin. The multi-drug 
combination therapy used to treat M. tuberculosis infections is another example of a 
treatment that employs narrow-spectrum drugs.118, 130 Three of the four first-line drugs 
typically used to treat these infections (isoniazid (1.58), ethambutol (1.59), and 
pyrazinamide (1.60); see Figure 1.40) possess little to no activity against non-
mycobacterial species. Additional narrow-spectrum antibiotics are reviewed 
elsewhere.118, 124, 130 
 
1.6 Conclusions and Future Outlook 
 As the occurrence of antibiotic-resistant bacteria continues to rise, new treatments 
are needed to combat infectious diseases, particularly those attributed to Gram-negative 
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pathogens. Without new treatments, we are at risk of returning to a “pre-antibiotic” era 
where infections are no longer treatable. In addition to new treatments, it is also 
imperative that we be more judicious with the use of current drugs so as to minimize the 
development and dissemination of antimicrobial resistance. To address these needs, 
several alternative approaches to treatment with a single, broadly-active antibiotic have 
been developed. These approaches include the use of multi-drug combinations, antibiotic 
adjuvants, antivirulence antibiotics, and narrowly-effective antibiotics that are active 
against only a small group of pathogens. While these approaches have often found 
success, additional work is needed to keep pace with the continued development of 
resistance. 
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CHAPTER 2 
 
Human Milk Oligosaccharides: A Source of Protection Against Infectious 
Diseases  
 
2.1 Infant Feeding: A Brief History 
Throughout history, breastmilk was considered the golden standard for infant 
nutrition.1-3 Moreover, breastfeeding was judged by some to be a religious obligation.2 
While evidence suggests that animal milk was used as far back as ancient times as an 
alternative to human milk, wet nursing, a practice wherein a woman breastfeeds another’s 
child, was long considered the best alternative for infants of mothers who could not 
breastfeed.2, 4 It was not until the 19th century with the introduction of the feeding bottle, 
increased availability of animal milk, and advancements in food preservation that animal 
milk and infant formula became popular alternative feeding methods.2, 4, 5  
As early as the mid 1700s, scientists began comparing the composition of human 
milk to that of animal milk. In 1760, Dr. Jean Charles Desessartz published the Treatise 
of Physical Upbringing of Children in which he concluded that based on their compositions, 
human milk was a superior source of infant nutrition than the milk of other animals 
including cows, goats, and sheep.2 Around a century later, the first modern infant formula, 
composed of cow’s milk, wheat flour, malt flour, and potassium bicarbonate (K2CO3), was 
developed by Justus von Liebig. By the 1880s, there were approximately 30 patented 
brands of infant food consisting of carbohydrates to be added to milk.2, 6  
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Infant formula continued to rise in popularity and, by the 1950s, was considered by 
physicians and consumers alike to be a popular and safe alternative for human milk. 
These sentiments, accompanied by aggressive marking campaigns for formula, 
contributed to a global decline in breastfeeding rates in the 21st century.2, 3 Interestingly, 
declining rates were seen despite several known and acknowledged advantages of 
human milk over formula. For example, formula manufacturers publicly acknowledged 
that human milk remained the ideal form of nourishment for infants. Moreover, there were 
observations dating back as far as the late 19th century that breastfed infants had higher 
survival rates and lower instances of diarrhea than bottle-fed infants.2  
Today, it is well-known that infants who are breastfed experience decreased 
instances of diarrhea, ear and urinary tract infections (UTIs), necrotizing enterocolitis 
(NEC), and sudden infant death syndrome (SIDS) compared to formula-fed infants.1, 7 
Additionally, it is well-known that breastfeeding promotes the development of a healthy 
infant intestinal microbiome as the intestinal microbiome of breastfed infants are 
consistently shown to be dominated to a much greater extent by symbiotes such as 
Bifidobacteria compared to their formula-fed counterparts. In accordance with these 
findings, the World Health Organization (WHO) and the American Academy of Pediatrics 
(AAP) both recommend exclusive breastfeeding for the first 6 months of life followed by 
continued breastfeeding in addition to complementary foods for 1 year or more.8, 9 
While the superiority of human milk for infant development was attributed to 
differences in milk composition over 200 years ago, today we have a much more thorough 
understanding of the molecular components of human milk and the benefits these 
components impart on infant health.1, 7, 10-12  
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2.2 Human Milk Composition 
Human milk, with its numerous nutritive and non-nutritive components, is well-
tailored to promote infant survival and proper development. Indeed, human milk is a 
dynamic mixture whose composition varies over time to meet the evolving needs of an 
infant. For instance, colostrum, the first milk produced, features higher concentrations of 
secretory immunoglobulins and human milk oligosaccharides (HMOs) and lower 
concentrations of lactose and fat compared to mature milk.10, 12 As immunoglobulins and 
HMOs are non-nutritive protective components while lactose and fat are nutritional 
components, the composition of colostrum suggests that its primary role is immunologic 
rather than nutritional.12 Conversely, the milk of mothers who give birth prematurely tends 
towards higher levels of protein and fat as a means to supplement the additional 
nutritional requirements of premature infants. 
Broadly speaking, the macromolecular components of human milk can be broken 
down into three categories: fat, protein, and carbohydrate; the carbohydrate fraction can 
be further broken down into lactose and oligosaccharides. On average, mature milk, i.e. 
milk after 4-6 weeks postpartum, contains 8-12 g/L protein, 32-41 g/L fat, 67-78 g/L 
lactose, and 5-15 g/L oligosaccharides (Figure 2.1).7, 12 In contrast to the shifting 
concentrations of fat, protein, and carbohydrate during the first month of life, after 4-6 
weeks postpartum, human milk composition remains largely consistent with only subtle 
changes observed over the remainder of lactation.12 In addition to macromolecules, 
human milk also contains micronutrients such as vitamins A, B1, B2, B3, B6, B12, C, and 
D as well as iodine. Concentrations of several of these components can, however, vary 
greatly with material diet.12, 13 
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2.2.1 Fats 
Fats, or lipids, are the largest source of energy in human milk. Indeed, this class 
of macromolecule is estimated to account for 40-55% of the total energy derived from 
human milk. Fats also represent the most highly variable macronutrient in human milk. 10, 
14, 15 In addition to varying fat concentrations in preterm, colostrum, transitional, and 
mature milk, fat content can also vary over the course of a single feeding. Indeed, hindmilk, 
i.e. the last milk of a feed, can have two to three times the amount of fat as that of foremilk, 
i.e. the initial milk of a feed.12, 14 In terms of composition, triglycerides comprise the vast 
majority of lipids in human milk and account for around 98% of human milk fat. The 
remainder are predominately diglycerides, monoglycerides, and free fatty acids as well 
as phospholipids and cholesterol.10, 14 Lipid components are presented as milk fat 
globules wherein the nonpolar triglycerides constituent the majority of the core and 
phospholipids constitute the bulk of the outer membrane (Figure 2.2).15 In addition to 
phospholipids, the milk fat globule membrane (MFGM) contains sphingomyelin, 
Figure 2.1. Human milk macromolecular composition. 
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gangliosides, and cholesterol which are important for proper brain and central nervous 
system development.10, 16, 17 
 
 
 
 
 
 
 
 
 
While breast milk contains over 200 different types of fatty acids, oleic, palmitic, 
and linoleic acids are found in the highest concentrations with palmitic acid alone 
accounting for 25% of all milk fatty acids.10, 15 Through the action of gastric or lingual 
lipases, fatty acids are released from the glycerol backbone and can subsequently serve 
as energy sources and/or protective molecules.16 Interestingly, the position of fatty acids 
on the glycerol backbone influences their bioavailability. For example, in human milk, 
palmitic acid is most commonly found at the 2-position (sn-2) of triglycerides as this 
location assists in palmitic acid absorption.10, 12 During digestion, infant lipases primarily 
hydrolyze the fatty acids and the sn-1 and -3 positions while the fatty acid at the sn-2 
position is left as the monoglyceride. While free palmitic acid is poorly water soluble and 
poorly absorbed, palmitoyl-monoglycerol is highly water soluble and consequently more 
readily absorbed.15 In addition to larger fatty acids like oleic, palmitic, and linoleic acids, 
Figure 2.2. Structure and composition of human milk fat globules (figure adapted from 
reference 15). 
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short-chain fatty acids (SCFAs) like acetate, butyrate, and propionate serve as important 
sources of energy. Moreover, SCFAs are important for the development of a healthy 
microbiome.10  
 
2.2.2 Proteins 
 Milk proteins can be divided into three classes: mucin, casein, and whey. Casein 
and whey account for the vast majority of milk proteins while mucins contribute only 
minorly to total milk protein content.10, 18 An important distinguishing factor amongst these 
protein subclasses is the environment in which each protein type is found. Whey proteins 
are soluble and are consequently found in solution whereas casein proteins are not 
soluble and are instead found in casein micelles suspended in solution.10 Mucins, also 
termed MFGM proteins, are found in the outer membrane of milk fat globules (Figure 
2.2).10, 15 
 Generally speaking, protein levels decrease significantly over the first 4 to 6 weeks 
of lactation regardless of timing of delivery (term or preterm) then decrease at a much 
slower rate after that.18, 19 In line with this broad trend, the whey protein portion decreases 
in concentration over time. Conversely, the casein fraction increases over lactation. For 
example, ratios of whey to casein can range from around 80:20 early in lactation to closer 
to 50:50 at the late stages of lactation. Thus, the commonly cited 60:40 ratio of whey to 
casein proteins is simply an approximation or average of the dynamic ratio between these 
protein components. 
 While human milk proteins serve as direct sources of nutrition as they are major 
sources of amino acids, they also serve as nutrient absorption aids.18 For example, bile 
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salt-stimulating lipase (BSSL), which is found in human milk, is an enzyme that aids in 
the break-down of lipids. Importantly, BSSL can digest a wide range of substrates 
including mono-, di-, and triacylglycerols as well as cholesterol esters and 
diacylphosphatidylglycerols. Additionally, BSSL is capable of acting on both micellular 
and water-soluble substrates. Milk also contains several proteins which are important for 
mineral and ion absorption. The highly phosphorylated b-casein complexes Ca2+ ions and 
keeps them in solution (thus increasing their absorption), which likely contributes to the 
elevated bioavailability of calcium in human milk.18 a-lactalbumin, one of the most 
abundant milk proteins, also binds Ca2+ and Zn2+ ions, though to a lesser extent than b-
casein, and is also thought to aid in mineral absorption. It remains, however, that a major 
benefit of a-lactalbumin is derived from its high levels of tryptophan, lysine, and cysteine 
which are released during a-lactalbumin digestion.17, 18 
Another major milk protein known for its absorption properties is lactoferrin. 
Lactoferrin accounts for around 15% of total protein content and is an iron-binding protein 
that facilitates iron uptake by intestinal cells.17, 18 Importantly, lactoferrin’s ability to bind 
ferric iron also helps to protect infants from infection as it sequesters iron from iron-
requiring bacteria. Interestingly, it has also been shown that lactoferrin possess strong 
bactericidal activity against numerous pathogens and that this activity is not dependent 
on the level of iron saturation of lactoferrin.18 Moreover, lactoferrin has been found to work 
synergistically with lysozyme, a major component of the whey fraction of human milk, to 
kill Gram-negative bacteria. Lysozyme is an enzyme that can degrade bacterial cell walls 
by hydrolyzing the b-1,4 linkages between N-acetylmuramic acid and N-
acetylglucosamine in the peptidoglycan layer. Against Gram-negative bacteria, lactoferrin 
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first binds to and removes the lipopolysaccharide (LPS) outer layer. This then allows 
lysozyme to access and subsequently break down the peptidoglycan layer of the cell wall 
which leads to cell death.18 Lastly, lactoferrin has also been shown to promote the 
production and release of the pro-inflammatory cytokines interleukin (IL)-1b, IL-8, and 
tumor necrosis factor (TNF)-a as well as transforming growth factor (TGF)-b. These 
actions promote immune system development and cell development and proliferation, 
respectively.17, 18  
Impressively, human milk is enriched with numerous immune factors including 
immune cells, cytokines, chemokines, and antibodies.12  For example, macrophages, T 
cells, stem cells, and lymphocytes have all been found in human milk. Macrophages 
represent the largest cellular component in early milk with around 80% of cells being 
macrophages. These cells can then go on to differentiate into dendritic cells capable of 
stimulating T-cell activity. In terms of cytokine composition, TGF-b is the most abundant 
cytokine in human milk and is important for inflammation regulation and wound repair as 
well as the prevention of allergic diseases. While human milk also contains TNF-a, IL-6, 
IL-8, and interferon gamma (INFg) cytokines, these are generally found at low levels and 
decrease in concentration over the course of lactation.  
Maternal antibodies are extremely important for the proper development of an 
infant’s immune system. 10 As infants are born with immature acquired immunity, they are 
largely reliant on antibodies from their mother to protect them from infection. In light of 
this reality, it is unsurprising that antibodies, or immunoglobulins, are found in particularly 
high concentrations early in lactation. The most predominant of the human milk 
immunoglobulins is secretory IgA (SIgA). In colostrum, SIgA is generally found at 
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concentrations around 12 mg/mL as opposed to around 1 mg/mL in mature milk.10, 20 SIgA 
protects against mucosal pathogens by immobilizing them and consequently preventing 
their adherence to epithelial cell surfaces. Moreover, SIgA can neutralize toxins and 
virulence factors of these pathogens. In accordance with these findings, SIgA antibodies 
are found in high concentrations in mucous membranes.10, 20 Additionally, human milk 
contains SIgA antibodies against a number of enteric and respiratory pathogens such as 
Vibrio cholerae, Campylobacter, and Shingella. Also important is the increased resistance 
of SIgA towards proteolysis compared to other immunoglobulins. This allows SIgA to 
function in the gastrointestinal (GI) tract. Given the diverse array of protection it affords, 
SIgA is hypothesized to serve as the primary protective agent of human milk. 
In addition to SIgA, human milk also contains IgM and IgG though to a lesser extent 
than SIgA.12 IgM is the type of antibody that appears when an individual is exposed to a 
particular antigen for the first time and characteristically possesses lower antigen 
specificity and thus lower potency in defeating an infection.21 IgG on the other hand is 
involved in antigen uptake and is present in all body fluids. While SIgA and IgM are found 
in higher concentrations early in lactation, IgG is found in higher abundances in mature 
milk. Given the roles of SIgA and IgG, it is thought that the transition from higher SIgA 
levels to higher IgG levels as milk matures is suggestive of shift in milk function from 
directly protecting against pathogens via the action of maternal SIgA to indirectly aiding 
in the development of an infant’s immune system via increased antigen intake through 
the action of IgG.22 
As previously mentioned, while whey and casein represent the largest protein 
classes in human milk, human milk also contains proteins that are integral components 
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of the outer membrane of fat globules called MFGM proteins.16 This class of proteins 
include mucin (MUC1), lactadherin, and lactoferrin. Many of these outer membrane 
integrated proteins serve as antimicrobial agents.17 For example, MUC1, a highly 
glycosylated glycoprotein, binds fimbriated Escherichia coli while lactadherin, also 
referred to as milk fat globule epidermal growth factor VIII (MFGE8), is a glycoprotein that 
protects against rotavirus, which is a major cause of diarrheal disease in infants. As is the 
general trend with many immunomodulatory and antimicrobial proteins in human milk, 
concentrations of MFGM proteins like MUC1 and lactadherin are highest earlier in 
lactation.  
As a final note on human milk protein composition, human milk also contains 
several growth factors such as epidermal growth factor (EGF), vascular endothelial 
growth factor (VEGF), brain-derived neurotrophic factor (BDNF), insulin-like growth factor 
(IGF), erythropoietin (Epo), and adiponectin.12  Many of these growth factors, such as 
EGF, are present in higher concentrations in early milk and decrease over the course of 
lactation. Epo in particular is found in significant quantities in milk. It is the primary 
hormone responsible for increasing the concentration of red blood cells (RBCs). Epo is 
also an important trophic factor (helps neurons to develop and maintain connections with 
surrounding neurons). Additionally, Epo tightens intestinal junctions and some evidence 
suggests it may help to reduce the risk of NEC as well as the transfer of human 
immunodeficiency virus (HIV) from mother to infant. EGF is vital to the maturation and 
healing of intestinal mucosa as it plays a role in stimulating cell division, absorption of 
glucose and water, and protein synthesis. Finally, adiponectin is important for the 
regulation of infant metabolism. Because levels of this growth factor are inversely 
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correlated with infant weight and BMI when an infant is exclusively breastfed, it is 
hypothesized that adiponectin may reduce the incidence of obesity later in life.  
 
2.2.3 Carbohydrates 
The carbohydrate portion of human milk is composed primarily of lactose. Lactose 
(2.1) is a disaccharide featuring a b-1,4 linkage between galactose (1.22) and glucose 
(1.21), wherein glucose is at the reducing end (Figure 2.3). For a more detailed 
description of carbohydrate structure and nomenclature, see section 4.3.1 of Chapter 3. 
Interestingly, human milk features some of the highest concentrations of lactose when 
compared to the milk of other species.10 Additionally, lactose concentrations in human 
milk are the least variable of all the macronutrient concentrations, though it has been 
found that mothers who produce larger quantities of milk have milk with higher lactose 
concentrations.12  
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Structure of lactose (2.1). (A) Hydrolysis of the b1-4 glycosidic linkage of 
lactose yields the monosaccharides galactose (1.22), and glucose (1.21). (B) The 
reducing end of lactose is highlighted in blue. The reducing end of any carbohydrate is 
the end that possesses a reducible aldehyde functionality when the carbohydrate 
converts from the closed-chain to open-chain form. 
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The primary function of human milk lactose is a nutritive one.23 Most lactose is 
digested in the small intestine, and this digestion provides around 4 kcal/g of energy. If, 
however, lactose escapes digestion in the small intestine, it can be fermented by 
saccharolytic colonic bacteria into SCFAs which yields around 2 kcal/g of energy.23, 24 It 
is important to note that lactose itself cannot be directly absorbed in the small intestine. 
Rather, lactose must first be broken down into its monosaccharide constituents, galactose 
and glucose by b-galactosidase (b-Gal) (Scheme 2.1).25-28  
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.1. Enzymatic hydrolysis of lactose into glucose and galactose by b-
galactosidase (b-Gal). Human b-Gal is a retaining glycosidase (stereochemistry of the 
starting material is retained in the product) that hydrolyzes the b-glycosidic bond of 
lactose via a double-displacement reaction mechanism. First, an acidic amino acid 
residue protonates the glycosidic oxygen and a nucleophilic, basic amino acid residue 
attacks the anomeric center to facilitate departure of glucose. The resulting galactosyl-
enzyme construct is hydrolyzed by a water molecule, with the aid of a basic amino acid 
residue, to yield galactose and to regenerate the original acidic and basic amino acid 
residues. 
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After hydrolysis of the glycosidic bond, glucose enters into circulation where it can 
be used as an energy source.29 Conversely, galactose must first be converted to glucose 
in the liver before it can serve as a source of energy. Interestingly, lactose has also been 
shown to enhance calcium, magnesium, and manganese absorption and retention when 
compared to other carbohydrate sources such as sucrose, corn starch hydrolysate, and 
glucose polymers.30-32 
Oligosaccharides constitute the other significant carbohydrate component of milk. 
While the biosynthesis of human milk oligosaccharides (HMOs) will be discussed in depth 
in section 2.4, a brief description is provided here (Figure 2.4).  
 
Figure 2.4. HMO structure and biosynthesis. (A) General HMO biosynthetic blueprint. (B) 
Structures of fucose (Fuc, 2.6) and sialic acid (Sia, 2.7). The growing HMO chains 
illustrated in (A) can be fucosylated and/or sialylated to yield additional HMOs. 
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All HMOs feature lactose at the reducing end. Lactose (Lac, 2.1) can be elongated 
with lacto-N-biose (LNB, 2.2) or N-acetyllactosamine (LacNAc, 2.3) via b1-3 linear or          
b1-6 branched linkages. Elongation via a b1-3 linkage with one LNB residue yields lacto-
N-tetraose (LNT, 2.4), while elongation via a b1-3 linkage with one LacNAc residue yields 
lacto-N-neotetraose (LNnT, 2.5). HMO chains can continue to be elongated with LacNAc 
residues until they are eventually terminated with an LNB residue. Finally, fucose (2.6) 
and/or sialic acid (2.7) can be added to the growing HMO chain to generate additional 
compounds (Figure 2.4). 
 
 
Although oligosaccharides are the third largest macromolecular component of 
human milk, they are largely absent from bovine milk (Figure 2.5).7, 33, 34 The comparison 
between HMOs and bovine milk oligosaccharides (BMOs) is an important one to make 
as bovine milk serves as the basis for most types of infant formula. In addition to 
differences in concentration, HMOs and BMOs are significantly different in composition. 
For instance, while the majority of HMOs and are fucosylated (50-80%) and the minority 
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Figure 2.5. Human milk versus bovine milk macromolecular compositions. 
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sialylated (10-20%), this trend is reversed for BMOs; around 70% of BMOs are sialylated 
while only around 1% are fucosylated. Moreover, in contrast to the more than 200 different 
HMOs that have been identified, only around 40 BMOs have been identified. While HMOs 
are the focus of this dissertation and will be discussed in depth in the remaining sections 
of this chapter, a brief introduction is provided here.  
HMOs are typically found in mature milk between 5 and 15 g/L. In colostrum, HMO 
concentration is typically higher at around 20-25 g/L.7, 35, 36 As mentioned, over 200 HMOs 
have been identified in milk, and the prevalence of specific compounds has been found 
to vary over the course of lactation. For example, fucosylated HMOs are typically found 
in higher concentrations in colostrum.37 HMO composition is also known to vary from 
mother to mother on the basis of maternal blood type. Moreover, HMOs differ in 
composition from those of any other mammal.12  
Unlike lactose, HMOs cannot be digested by the infant.1, 38 Rather, HMOs reach 
the small intestine intact where they can be broken down into SCFA by saccharolytic 
colonic bacteria. This accounts for the prebiotic activity of HMOs; a prebiotic is a 
nondigestible compound in food that promotes the growth or activity of beneficial 
microorganisms in the intestines. In addition to serving as important prebiotics, HMOs are 
known for their ability to serve as antiadhesive antimicrobials by serving as soluble decoy 
receptors for pathogens or pathogenic virulence agents (ex. toxins). This ability is made 
possible by the resemblance of HMOs to various cell surface glycan receptors. Finally, 
HMOs have also been shown to modulate host immune and intestinal epithelial cell 
responses, protect against necrotizing enterocolitis (NEC), and serve as important brain 
development nutrients. A more detailed explanation of the health benefits of HMOs will 
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be provided in the proceeding sections of this chapter. As a final note, the numerous 
health benefits attributed to HMOs coupled with the general lack of analogous BMOs has 
led to the development of numerous carbohydrate infant formula additives.23 These 
additives are designed to mimic the protective properties of HMOs and thus confer similar 
protections to formula-fed infants as are afforded to breastfed infants. 
 
2.3 Human Milk Oligosaccharides: Discovery and Early Research 
 In his Treatise of Physical Upbringing of Children published in 1760, Desessartz 
offered some of the first analyses of human milk composition.2 In this work, Desessartz 
compared the composition of human milk to that of cow, goat, sheep, ass, and mare and 
subsequently concluded that human milk was the best source of infant nutrition. In light 
of the proposed superiority of human milk, many scientists began trying to develop animal 
milk-based infant formulas that more closely resembled human milk. By 1883, there were 
27 patented brands of infant food.4 Despite these attempts, at the end of the 19th century 
when infant first-year mortality rates reached as high as 30%, it was observed that 
breastfed infants had significantly lower mortality rates and incidences of diarrhea and 
other infections than their formula-fed counterparts.6, 7 Indeed, breastfed infants were 
reported to have mortality rates up to 7 times lower than formula-fed infants.6 
 Around this time, Theodor Escherich, a respected pediatrician and microbiologist 
in Europe, discovered a relationship between intestinal bacteria and the physiology of 
digestion in infants.6, 39 Inspired by this finding as well as the observation that breastfed 
infants had higher survival rates, in 1900, Ernst Moro, a former student of Escherich’s, 
discovered that fecal bacterial composition varied between breastfed and formula-fed 
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infants. At the same time and independent of Moro’s studies, Henry Tissier, a graduate 
student at the University of Paris, noted similar compositional differences and is credited 
with the first isolation of bifidobacteria from the feces of breastfed infants (termed by 
Tissier in 1899 as Bacillus bifidus).7 After this discovery, Tissier went on to suggest that 
the increased levels of bifidobacteria in the feces of breastfed infants was likely the reason 
for the lower incidences of diarrhea seen in these infants.40 It would not be until the 
collaborative efforts of Paul György, a pediatrician and former student of Moro’s, and 
Richard Kuhn, an accomplished chemist, in the 1950’s, however, that HMOs would be 
identified as the milk component responsible for determining bacterial composition in the 
infant gut and, by extension, infant feces. 
 While HMOs would not begin to be isolated cleanly and described clearly until the 
1950s, in 1888, the chemist Eschbach noted that human milk contained a “different type 
of lactose” than bovine milk. Shortly after this assertion, another chemist, Deniges, found 
that human milk did not in fact contain a “different type of lactose” but rather possessed 
an additional unknown carbohydrate component.6, 7 However, the composition of this non-
lactose carbohydrate component remained uncharacterized until the work of Michel 
Polonowski and Albert Lespagnol in the 1930s. Polonowski and Lespagnol established a 
method to characterize the carbohydrate fraction they termed “gynolactose.” They noted 
that the “gynolactose” component, which was weakly soluble in methanol, was not 
homogenous but rather consisted of numerous components that contained nitrogen and 
hexosamines.41-44 Around 20 years later in 1954, Polonowski and Jean Montreuil, a 
pioneer in the field of carbohydrates and glycoconjugates, applied 2-dimensional paper 
chromatography to separate “gynolactose” into individual compounds.45 This work 
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resulted in isolation of the first individual HMOs, 2’-fucosyllactose (2’-FL, 2.8) and 3-
fucosyllactose (3-FL, 2.9), though the exact structures and potential functions of these 
HMOs were unknown at the time of initial discovery (Figure 2.6).6, 7 
  
 
 
 
 
 
In the years following the initial finding by Moro and Tissier that the feces of 
breastfed infants featured unique bacterial compositions, there was an intense drive to 
identify the growth factors in human milk that were responsible. Due to the unique 
prominence of bifidobacteria in the feces of breastfed infants, the elusive growth factor 
was termed simply as the “bifidus factor.” In 1926, Herbert Schönfeld made a significant 
contribution to the search when he reported that the growth-promoting factor for 
Bifidobacterium bifidus (classified as Lactobacillus bifidus at the time of Schönfeld’s 
discovery) was in the nonprotein fraction of milk and was thermoresistant.6, 46 While 
Schönfeld hypothesized that the bifidus factor was a vitamin, less than 30 years later, 
György and Kuhn provided proof that HMOs were the true bifidus factors.6, 47-51 
Specifically, they showed that the growth-promoting abilities were unique to the N-
acetylglucosamine-containing carbohydrate fraction; the nitrogen-free carbohydrate 
fraction had no bifidogenic effect and neither did the carbohydrates wherein the amine of 
the N-acetylglucosamine component had been liberated via treatment with barium 
hydroxide.50 
Figure 2.6. Structures of 2’-fucosyllactose (2’-FL, 2.8) and 3-fucosyllactose (3-FL, 2.9). 
O O
OH OH
HO
OH
O
OH
OH
OH
O
3-fucosyllactose (3-FL, 2.9)
O
HO
OH
OH
O O
OH OH
HO
O
O
OH
OH
OH
HO
2’-fucosyllactose (2’-FL, 2.8)
O
HO
OH
OH
 94 
In the years following György and Kuhn’s groundbreaking studies, numerous 
individual HMOs were discovered and characterized by the groups of Kuhn and 
Montreuil52, 53 including 2’-FL (previously isolated by Polonowski and Montreuil without 
accompanying structural characterization),54 lacto-N-tetraose (LNT, 2.4)55,  lacto-N-
fucopentaose I (LNFP I, 2.10),56 lacto-N-fucopentaose II (LNFP II, 2.11),57 and 
difucosyllactose (DFL, 2.12) (also referred to as lacto-difucosyltetraose: LDFH) (Figure 
2.7).58 
 
Figure 2.7. Selected HMO structures. Dates in parenthesis indicate year of isolation and 
characterization. 
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 Shortly after, Akria Kobata and Victor Ginsburg developed a new method to 
determine oligosaccharide patterns in milk which involved a combination of Sephadex gel 
filtration and paper chromatography. Using this method in combination with various 
structural elucidation techniques, Akria and Ginsburg would go on to discover and 
characterize several new HMOs including lacto-N-fucopentaose III (LNFP III, 2.13),59 
lacto-N-neohexaose (LNnH, 2.14),60 lacto-N-hexaose (LNH, 2.15),61 and 6’-
galactosyllactose (6’-GL, 2.16) (Figure 2.7).62 
Importantly, Kobata and Ginsburg’s work towards the elucidation of additional 
HMO structures was driven by previous work from the Ginsburg laboratory that detailed 
the relationship between oligosaccharide patterns in milk and human blood groups. 
Throughout the 1960’s, Winfred Watkins worked to elucidate the structures of the blood 
group determinants in the ABO, Lewis (Le), and Secretor (Se) genetic systems;63 see 
section 2.4 for a more detailed description of these blood group determinants and 
accompanying structures. Armed with the knowledge of specific structures, Ginsburg and 
his colleagues demonstrated that oligosaccharide patterns in milk varied with maternal 
blood type because the enzymes involved in the synthesis of blood group determinants 
were also involved in the synthesis of HMOs.64, 65 For instance, Grollman and Ginsburg 
reported that while the presence of 2’-FL was independent of the ABO blood group system, 
there was a direct correlation between the presence of 2’-FL in a particular sample and 
the Se status of the mother; no 2’-FL was found in the milk or colostrum of non-
Secretors.66  
At the time of this discovery, the structural determinants for other blood types such 
as M, N, P, and Rh were not as well understood as those for the ABO and Lewis groups.64, 
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67 There was, however, some evidence that carbohydrates were related to specificities 
for the M, N, P, and Rh blood groups. As a result, Ginsburg and colleagues hypothesized 
that the presence or absence of certain HMOs might be related to these blood types.64 
Thus, elucidation of new HMO structures could provide information regarding the 
structural determinants of additional blood groups. This prospect ultimately led Ginsburg’s 
group to develop new methods to discover previously uncharacterized HMOs. 
To date, more than 200 HMO structures have been identified.34, 68 Moreover, 
detailed descriptions of the relative concentrations of a long list of HMOs over the course 
of lactation are now available.33, 34, 69 This extensive characterization would not have been 
possible without the development of numerous, more advanced methods for HMO 
characterization than those used in the 1960s. Some of the first major advances in HMO 
characterization came courtesy of Heinz Egge, one of Richard Kuhn’s former students. 
Egge was one of the first to use field desorption or fast atom bombardment (FAB)-mass 
spectrometry (MS) to characterize HMO structure.6, 70 This technique proved highly 
reliable and allowed for exact determination of molecular composition. Moreover, it 
facilitated analyses of oligosaccharide mixtures that were not resolved purely by 
chromatographic methods.6  
Additional techniques that have been used for structural characterization and 
quantitation include high performance liquid chromatography (HPLC), high pH anion-
exchange chromatography (HPEAC), capillary electrophoresis (CE), nuclear magnetic 
resonance (NMR), and additional MS techniques including matrix-assisted laser 
desorption/ionization MS (MALDI-MS).71-74 Indeed, MALDI-MS has greatly increased the 
utility of MS analysis of HMOs.33, 75 Nevertheless, even with advanced characterization 
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techniques, it remains that analysis of HMO composition is challenging due to the number 
and complexity of HMO structures as well as the variations in HMO patterns seen from 
mother to mother and over the course of lactation. 
 
2.4 Human Milk Oligosaccharides: Structure and Biosynthesis 
 
 Despite the vast array of HMO structures, all HMOs are composed of just five 
monosaccharide building blocks: glucose (Glc), galactose (Gal), N-acetylglucosamine 
(GlcNAc), fucose (Fuc), and N-acetylneuraminic acid (Neu5Ac) (Table 2.1).7, 34, 76 
Neu5Ac is a form of sialic acid (Sia) and is thus far the only form to have been identified 
in HMOs. Thus, when describing HMO structure, Neu5Ac residues are termed Sia for 
simplicity. In addition to the simplicity of the building blocks, while HMOs can range 
Table 2.1. HMO Monosaccharide Building Blocks 
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anywhere in size from 3 to 50 monosaccharide residues, all HMO biosyntheses follow the 
same basic blueprint (Figure 2.4 and 2.8). 
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Figure 2.8. HMO biosynthetic blueprint and selected HMO structures. (A) General 
blueprint for HMO biosynthesis (monosaccharides are designated as specified in Table 
2.1). Lactose can be elongated with lacto-N-biose (LNB) or N-acetyllactosamine 
(LacNAc) via a b1-3 linkage to yield type I and II chains, respectively. Alternatively, 
lactose can be elongated with LNB or LacNAc via a b1-6 linkage to introduce branching. 
Lactose or the growing HMO chain can be fucosylated via a1-2, 3, or 4 linkages or 
sialylated via a2-3 or 6 linkages. (B) Selected fucosylated or sialylated lactose HMOs. 
(C) Selected HMO chain structures. (D) Selected fucosylated type I and II chains. (E) 
Selected sialylated type I and II chains. 
 
can be elongated with lacto-N-biose (LNB) or N-acetyllactosamine (LacNAc), and 
lactose or the growing HMO chain can fucosylated or sialylated. (B) Selected HMO chain  
 
Elongation with LNB and LacNAc through a b1-3 glycosidic linkage yields type I and II 
chains, respectively. Lactose can also be elongated with LNB or LacNAc through a b1-
6 linkage to produce a branching point. (B) Cartoon representation of the process shown 
in (A). (C)  
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First, all HMOs contain lactose (Lac, Galb1-4Glc, 2.1) at the reducing end. Lactose 
can then be elongated with either lacto-N-biose (LNB, Galb1-3GlcNAc, 2.2) or N-
acetyllactosamine (LacNAc, Galb1-4GlcNAc, 2.3) via a linear b1-3 glycosidic linkage to 
yield type I and II chains, respectively. Alternatively, lactose can be elongated with LNB 
or LacNAc via a b1-6 linkage which introduces chain branching. Linear chains are termed 
para-HMOs while branched structures are termed iso-HMOs. While lactose can be 
elongated with multiple LacNAc residues, incorporation of an LNB residue appears to 
terminate the chain (Figure 2.8A and C). 
Lactose and/or an elongated oligosaccharide chain can be further elaborated via 
fucosylation or sialylation (Figure 2.8B, D, and E). Specifically, fucose (2.6) can be 
incorporated via a1-2, a1-3, or a1-4 linkages while sialic acid (2.7) can be incorporated 
via a2-3 or a2-6 linkages. Due to the various potential sites for fucosylation and sialylation, 
some HMOs exist in multiple isomeric forms. For example, lacto-N-fucopentaose (LNFP) 
exists in three forms: LNFP I , II, and III. Similarly, sialyllacto-N-tetraose (LST) exists in 
two forms: LST a and LST b.  
While the general blueprints for HMO biosynthesis are known, our understanding 
of the exact biomechanical machinery involved in HMO biosynthesis remains limited. 7, 77 
Additionally, the order of operations is not clearly understood. As all HMOs feature lactose 
at the reducing end, it is hypothesized that HMO biosynthesis is simply an extension of 
lactose biosynthesis catalyzed by glycosyltransferases in the mammary gland. However, 
most of the proposed glycosyltransferases have yet to be identified.77  
Lactose itself is synthesized in the mammary gland by the lactose synthase 
complex through the transfer of uridine 5’-diphosphate galactose (UDP-Gal, 2.17) to 
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glucose (1.21) (Scheme 2.2A).23, 78 While plasma glucose is the main carbon source for 
lactose biosynthesis, glucose and galactose can also be synthesized in the mammary 
gland through a process known as hexoneogenesis. In this process, glycerol serves as a 
precursor for a large amount of galactose and a minor amount of glucose.79, 80 Other 
studies have shown by orally administering 13C-labeled galactose to lactating mothers 
that a portion of dietary galactose may be used directly in lactose biosynthesis.81  
 
UDP-galactose can be synthesized directly from galactose in two steps: 
phosphorylation of galactose (1.22) by galactokinase to yield galactose 1-phosphate 
Scheme 2.2. Lactose biosynthesis. (A) Lactose biosynthesis from UDP-Gal and glucose. 
(B) Generation of uridine 5’-diphosphate galactose (UDP-Gal) starting from galactose 
and glucose. Abbreviations: ATP, adenosine triphosphate; ADP, adenosine diphosphate; 
UTP, uridine triphosphate; UDP, uridine diphosphate; PPi, pyrophosphate. 
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(2.18) followed by transfer of uridine 5’-monophosphate (UMP) from UDP-glucose (2.19) 
by galactose 1-phosphate uridylyltransferase.23, 78 Alternatively, UDP-galactose can be 
synthesized from glucose in three steps: phosphorylation of glucose by glucokinase to 
yield glucose 1-phosphate (2.20), conversion of glucose 1-phosphate to UDP-glucose 
(2.19) by UDP-glucose pyrophosphorylase, and epimerization of the C4 center of UDP-
glucose by UDP-glucose 4-epimerase (Scheme 2.2B).23, 78   
The lactose synthase complex consists of two proteins: galactosyltransferase and 
a-lactalbumin. Although galactosyltransferase is found outside the mammary gland, a-
lactalbumin is expressed solely in the mammary gland and is key to lactose production.82, 
83 Specifically, a-lactalbumin, whose expression is controlled by lactation hormones, 
promotes the preferential selection of glucose by galactosyltransferase.7, 23 In the 
absence of a-lactalbumin, glucose is a poor substrate, and galactosyltransferase will 
instead catalyze the transfer of UDP-galactose to GlcNAc. In the presence of a-
lactalbumin, however, the Km of galactosyltransferase for glucose is reduced by three 
orders of magnitude which resultantly allows for lactose synthesis at physiological 
glucose concentrations.23, 83 
While lactose synthesis is fairly well understood, the ways in which lactose is 
elongated is much less understood.7 This lack of understanding is at least partly 
attributable to the vastly different oligosaccharide compositions and concentrations in 
human milk versus animal milk. Indeed, these differences complicate any attempt to study 
HMO biosynthesis in animal models. For example, while mice models would be readily 
available, mice only produce 3’- and 6’-sialyllactose (3’-SL and 6’-SL, respectively) and 
thus are not suitable to study the biosynthesis of elongated or fucosylated 
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oligosaccharides.84 Another roadblock is the limited success researchers have had using 
immortalized or transformed human mammary gland epithelial cells to study HMO 
biosynthesis.7  
In contrast to lactose elongation, HMO fucosylation is a fairly well-understood 
process due to its direct link to maternal Secretor (Se) and Lewis (Le) blood groupings.7 
To understand this linkage, it is important to digress momentarily into a discussion of 
ABO(H), Secretor, and Lewis blood group antigen determinants. The ABO system is 
characterized by the presence or absence of the A, B, and/or H antigens (2.21, 2.22, and 
2.23, respectively) on red blood cell membranes (Figure 2.9).  
 
Figure 2.9. Structures of blood group antigens. (A) Structures of the A, B, and H 
antigens of the ABO blood group. (B) Structures of the Lewis a (Lea) and Lewis b (Leb) 
antigens of the Lewis (Le) blood group. Antigens are bound to various carbohydrate 
cores of glycoproteins and glycolipids that are not characteristic of a specific blood 
group. 
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Type A blood has only A antigens on red blood cells, type B has only B antigens, 
and type AB has both antigens. Type O blood is characterized by the absence of both the 
A and B antigens and the presence of the H antigen; the H antigen is a truncated form of 
the A and B antigens. In addition to expressing A, B, and/or H antigens on the surfaces 
of red blood cells, Secretors express these antigens in exocrine secretions corresponding 
to their individual blood type. Conversely, non-Secretors only express these antigens on 
red blood cell membranes. Finally, Lewis blood types are defined by the presence or 
absence of the Lea and Leb antigens (2.24 and 2.25, respectively) (Figure 2.9); Le(a +) 
blood types have only the Lea antigen, Le(b +) have only the Leb antigen, and Le(a-b-) 
have neither antigen.  
 
Scheme 2.3. Activity of a hypothesized H gene-encoded fucosyltransferase (FUT). 
Watkins and Morgan hypothesized that an H gene encoded a FUT that was responsible 
for formation of the Fuca1-2Gal bonds in the H and Leb blood group antigens. The added 
fucose residue is highlighted in blue. Abbreviations: GDP-Fuc, guanosine 5’-diphospho-
fucose. 
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Given these antigen determinant structures, it was proposed by Watkins and 
Morgan that variations in blood groups resulted from a genetically determined presence 
or absence of particular glycosyltransferases.85, 86 They hypothesized that the “H gene” 
was responsible for the fucosyltransferase (FUT) that catalyzes, one, the addition of 
fucose to galactose via an a1-2 glycosidic linkage to generate the H antigen, and, two, 
the addition of fucose to the Lea antigen, again via a1-2 glycosidic linkage, to generate 
the Leb antigen (Scheme 2.3). Furthermore, they noted that absence of this H gene-
encoded FUT in the secretory organs of non-Secretors would result in the inability of non-
Secretors to synthesize A, B, or H antigens; they could, however, still secrete the Lea 
antigen as this antigen lacks the Fuca1-2Gal moiety. They thus also hypothesized that 
expression of the H gene in secretory organs would be controlled by the Se gene. 
 
These hypotheses were supported by Grollman and Ginsburg when they found 
that 2’-FL, an HMO that contains a Fuca1-2Gal linkage, was found only in the milk of 
Secretors (Figure 2.10).66 This suggested that the FUT involved in the synthesis of 2’-FL 
was also involved in the synthesis of secreted blood group antigens, and that the 
presence or absence of this FUT determined maternal Secretor status.87 Because FUTs 
Figure 2.10. Structural similarities between blood group antigens H (2.23) and Leb (2.25) 
and human milk-derived oligosaccharide 2’-fucosyllactose (2’-FL, 2.8). The Fuca1-2Gal 
linkage moiety common to all structures is highlighted in blue. 
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are found in human milk in soluble form, Grollman and Ginsburg were able to confirm a 
relationship between this FUT and Secretor status by comparing the ability of milk 
samples from Secretors and non-Secretors to transfer fucose, derived from GDP-fucose 
(guanosine 5’-phosphate fucose), to the C2-position of galactose. Only the milk of 
Secretors was able to catalyze this transfer. Importantly, this suggested that as originally 
hypothesized by Watkins and Morgan, Secretor status was characterized by the presence 
or absence of a specific FUT termed by Ginsburg and colleagues as GDP-L-fucose: b-D-
galactosylsaccharide a-2-L-fucosyltransferase.87 
In addition to an H gene-encoded FUT, Watkins and Morgan also proposed that 
the Le gene encoded for a FUT that catalyzed the addition of fucose to GlcNAc via an 
a1-4 linkage in the synthesis of the Lea and Leb antigens (Scheme 2.4).86 Thus, 
individuals lacking this enzyme would not be able to synthesize either antigen, and their 
blood type would resultantly be Le(a-b-). Based on their earlier work which demonstrated 
that the Fuca1-2Gal linkages of HMOs and blood group antigens were formed by the 
same FUT, Ginsburg and colleagues hypothesized that the Fuca1-4Gal linkages of 
HMOs and the Lewis antigens were similarly formed by the same FUT.  
Scheme 2.4. Activity of a hypothesized Le gene-encoded fucosyltransferase (FUT). 
Watkins and Morgan hypothesized that an Le gene encoded a FUT that was responsible 
for formation of the Fuca1-4GlcNAc bonds in the Lea and, by extension, the Leb blood 
group antigens. The added fucose residue is highlighted in red. Abbreviations: GDP-Fuc, 
guanosine 5’-diphospho-fucose. 
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At the time of their hypothesis, two HMOs were known which featured Fuca1-
4GlcNAc linkages: LNFP II (2.11) and LNDFH I (2.26) (Figure 2.11). If their hypothesis 
was correct, these HMOs should be present in the milk of Le(a+) and Le(b+) mothers but 
absent in Le(a-b-) mothers. Indeed, this is precisely what they observed.65 Moreover, they 
found heightened levels of LNFP I (2.10, Figure 2.11), the precursor to LNDFH I, in the 
milk of Le(a-b-) mothers compared to the milk of Le(b+) mothers. To further support these 
findings, Ginsburg et al. also tested milk samples from the three Lewis blood types for the 
ability to catalyze the transfer of fucose from GDP-fucose to LNFP I to form LNDFH I. 
Consistent with previous results, only the milk from Le(a+) and Le(b+) mothers possessed 
the enzyme capable of completing this transformation.  
  
Figure 2.11. Experimental evidence that the fucosyltransferase (FUT) responsible for 
formation of the Fuca1-4GlcNAc bond of Lewis blood group antigens is also responsible 
for formation of the Fuca1-4GlcNAc bond of HMOs like LNFP II (2.11) and LNDFH I (2.26). 
Milk of Lewis negative mothers did not have LNFP II or LNDFH I, but did have heightened 
levels of LNFP I (2.10), the precursor to LNDFH I. The Fuca1-4GlcNAc moiety common 
to the Lewis blood group antigens, LNFP II, and LNDFH I is highlighted in red. 
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In a separate study which detailed the isolation and characterization of LNFP III 
(2.13, Figure 2.12), Kobata and Ginsburg provided evidence that the Le gene-encoded 
FUT might also be responsible for adding fucose to GlcNAc of type II chains and the 
glucose moiety of lactose via a1-3 linkages (Scheme 2.5).59  
 
In the course of their characterizations, Kobata and Ginsburg found that LNFP III 
was present in 3 out of 4 milk samples from Le(a-b-) donors.59 Importantly, the sample 
that lacked LNFP III also lacked all HMOs with Fuca1-3Glc linkages, such as 3-FL and 
DFL (Figure 2.12). Based on this result, they hypothesized that the FUT responsible for 
formation of the Fuca1-3GlcNAc bond in LNFP III was also responsible for formation of 
the Fuca1-3Glc bond in other oligosaccharides like 3-FL and DFL.  
 
Scheme 2.5. Additional hypothesized activity of an Le gene-encoded fucosyltransferase 
(FUT). Kobata and Ginsburg hypothesized that the Le gene-encoded FUT was also 
responsible for formation of the Fuca1-3Glc bond of fucosylated lactose derivatives as 
well as the Fuca1-3GlcNAc bond in type II oligosaccharide chains. The added fucose 
residue is highlighted in purple. Abbreviations: GDP-Fuc, guanosine 5’-diphospho-fucose. 
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In a later report by Watkins et al. investigating the occurrence of FUT activity in the 
saliva of individuals of differing Lewis blood types, it was observed that Fuca1-3GlcNAc 
FUT activity was independent of Lewis blood group while Fuca1-3Glc FUT activity was 
unique to donors expressing the Le gene.88 Indeed, only the FUT dependent on Le gene 
expression was able to catalyze the transfer of fucose to the C3 position of glucose. This 
work demonstrated that the Le gene-encoded FUT was indeed an a1-3/4 FUT, not just 
an a1-3 FUT. However, there have been conflicting reports about the ability of this FUT 
to also catalyze the transfer of fucose to the C3 position of GlcNAc in type II chains.89-91  
Figure 2.12. Experimental evidence that the fucosyltransferase (FUT) responsible for 
formation of the Fuca1-4GlcNAc bond of Lewis blood group antigens might also 
responsible for formation of the Fuca1-3GlcNAc bond of HMOs like DFL (2.12), 3-FL (2.9), 
and LNDP III (2.12). The milk of a Lewis negative mother did not have DFL, 3-FL, or LNFP 
III all of which possess a Fuca1-3GlcNAc bond. The common Fuca1-3GlcNAc moiety is 
highlighted in purple. 
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Today, the Le gene-encoded enzyme is referred to as the a1-3/4 
fucosyltransferase FUT3.7 The enzyme originally termed by Ginsburg et al. as GDP-L-
fucose: b-D-galactosylsaccharide a-2-L-fucosyltransferase is known today as the Se 
gene-encoded a1-2 fucosyltransferase FUT2 (Table 2.2). Contrary to the original 
hypothesis of Watkins, however, is has been demonstrated that the Se gene does not 
regulate expression of the H gene, and by extension the a1-2 FUT that synthesizes the 
blood group H antigen, in secretory tissues.86, 92 Indeed, it was found that the H and Se 
genes are both structural genes that encode distinct FUTs in different tissues (FUT1 and 
FUT2 for the H and Se genes, respectively).92, 93 
 
Gene Fucosyltransferase (FUT) Encoded 
HMO Glycosidic Bond 
Formed 
Se (Secretor) FUT2 Fuca1-2Gal 
Le (Lewis) FUT3 Fuca1-3GlcNAc 
 
Based on the expression of FUT3 and FUT2 (corresponding to Le and Se blood 
types, respectively), human milk can be divided into four groups with each group 
corresponding to a particular Lewis blood group: Le-positive Secretors (Se+Le+), Le-
positive non-Secretors (Se-Le+), Le-negative Secretors (Se+Le-), and Le-negative non-
Secretors (Se-Le-).7 A schematic showing the HMO fucosylation patterns characteristic 
of these four groups is provided (Figure 2.13). It is important to note, however, that this 
classification system is an oversimplification of HMO expression. For example, in one 
study, Newburg and colleagues found a1-2 fucosylated HMOs in the milk of both 
Secretors and non-Secretors, though these HMOs were not found in the milk of non-
Table 2.2. Le and Se Gene-Encoded Fucosyltransferases 
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Secretors until late in lactation.94 Additionally, it has also been found that the milk of Le 
negative non-Secretors, i.e. mothers who lack both FUT2 and FUT3, is not completely 
devoid of fucosylated HMOs like 3-FL and LNFP III.7  
 
Deviations from “typical” HMO fucosylation patterns based on Se and Le blood 
groups suggest the involvement of additional FUTs not expressed by either the Se or Le 
genes. To date, thirteen FUTs have been identified in the human genome.93 Of these, 
FUT1 is an a1-2 FUT and has been postulated to be involved in the production of a1-2 
fucosylated HMOs at certain stages in lactation. FUT4-7 and 9 are FUTs belonging to the 
a1-3 FUT family and have been suggested to be involved in the synthesis of a1-3 
fucosylated HMOs.93-95 
Unlike HMO fucosylation, HMO sialylation is not well-understood. To date, twenty 
human sialyltransferases (ST) have been identified, and these enzymes are responsible 
b1-
R
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b1-
R
b1-3
FUT3 (Le)
a1-4
a1-2
b1-
R
b1-3
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FUT2 (Se)
b1-
R
b1-3 FUT3 (Le)
a1-4 b1-
R
b1-3
Lewis a (Lea) (X)
X
Milk group: Lewis-positive non-Secretor (Se-Le+)
Lewis blood group: Le(a+b-)
b1-
R
b1-3 FUT2 (Se)
a1-2
b1-
R
b1-3
FUT3 (Le)X
Milk group: Lewis-negative Secretor (Se+Le-)
Lewis blood group: Le(a-b-)
b1-
R
b1-3 FUT2 (Se) FUT3 (Le)X X
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Figure 2.13. Human milk groups based on HMO fucosylation patterns. HMO fucosylation 
patterns are highly dependent on maternal Se- and Le-blood group status: the Se gene 
encodes FUT2 which adds Fuc to terminal Gal residues via an a1-2 linkage; the Le gene 
encodes FUT3 which adds Fuc to subterminal GlcNAc residues of type I HMO chains 
via an a1-4 linkage. When both FUT2 and FUT3 are both expressed, milk contains HMOs 
with the Leb antigen moiety. When only FUT3 is expressed, milk contains HMOs with the 
Lea antigen moiety. When FUT3 is not expressed, milk does not contain HMOs with the 
Lea or Leb antigen moieties.  
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for the transfer of sialic acid from cytidine 5’-monophospho-N-acetylneuraminic acid 
(CMP-Neu5Ac) to oligosaccharide chains of glycoproteins and glycolipids.96 STs can add 
sialic acid via a2-3 or -6 linkages to galactose, an a2-6 linkage to N-acetylgalactosamine 
(GalNAc, 1.23) or GlcNAc, or an a2-8 linkage to another sialic acid residue (polysialic 
acid) (Scheme 2.6). Based on these regioselectivities and acceptor specificities, human 
STs can be grouped into four subfamilies: ST3Gal (1-6), ST6Gal (1 and 2), ST6GalNAc 
(1-6), and ST8Sia(1-6).97, 98  
 
 
 
Of the twenty human STs, ST3Gal4 and ST6Gal1, which add sialic acid via a2-3 
and -6 linkages to galactose, respectively, are thought to be involved in HMO sialylation. 
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Scheme 2.6. Patterns of sialyltransferase (ST)-catalyzed addition of N-acetylneuraminic 
acid (Neu5Ac) to oligosaccharide chains. Abbreviations: CMP-Neu5Ac, cytidine 5’-
monophono-N-acetylneuraminic acid. 
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Using a mouse model, Fuhrer et al. discovered that these STs had heightened expression 
levels and were two of the three most abundant ST transcripts in the lactating mammary 
gland.84  The involvement of ST3Gal4 and ST6Gal1 in milk oligosaccharide biosynthesis 
was then confirmed by analyzing milk oligosaccharide content of St3gal4  and St6gal1 
knockout mice; the milk of St3gal4 knockout mice showed significant decreases in 3’-SL 
concentrations, and the milk of St6gal1 knockout mice was devoid of 6’-SL. Nevertheless, 
it remains unknown if these STs are able to sialylate the terminal galactose residues of 
more structurally complex HMOs. A more recent study using recombinant human 
ST3Gal4 and ST6Gal1 (expressed in Escherichia coli) provided additional evidence that 
ST3Gal4 and ST6Gal1 are at least partly responsible for the sialylation of lactose to yield 
3’- and 6’-SL, respectively.98 
Interestingly, although HMOs contain Siaa2-6GlcNAc linkages, to date, no 
ST6GlcNAc sialyltransferases have been found in humans. Conversely, six ST6GalNAc 
human sialyltransferases have been identified.96, 99 There is some evidence that 
ST6GalNAc5 could be partially involved in HMO biosynthesis. In certain colon cancer 
lines, ST6GalNAc5 was found to add sialic acid to subterminal GlcNAc residues through 
an a2-6 linkage to yield disialyl lactotetraosylceramide (disialyl Lc4). Sialylation of the 
terminal galactose residue of disialyl Lc4 through an a2-3 linkage was, however, found to 
be a prerequisite for this enzymatic action.100 Given this requirement, ST6GalNAc5 could 
potentially be involved in the synthesis of HMOs like DSLNT (see Figure 2.7E) which 
feature both terminal Siaa2-3Gal and subterminal Siaa2-6GlcNAc moieties.  
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2.5 Human Milk Oligosaccharides: Health Benefits 
Since their debut in the mid-20th century as the Bifidobacterium bifidus growth-
promoting factor of human milk (i.e. the “bifidus factor”), the benefits of HMOs have been 
shown to extend well beyond this prebiotic function. Indeed, it well-established that 
breastfed infants experience decreased instances of diarrhea, respiratory infection, 
urinary tract infection, ear infection, necrotizing enterocolitis (NEC), and sudden infant 
death syndrome (SIDS).1 While the prebiotic role of HMOs can help to protect infants 
against disease (discussed in more detail below), protection from disease is largely 
attributable to the ability of HMOs to serve as antiadhesive antimicrobials. Due to their 
importance in the HMO-fostered protection against infectious disease, the prebiotic and 
antiadhesive roles of HMOs will be discussed in further detail in the remainder of this 
chapter. While the following functions will not be discussed in further detail, it is important 
to note that HMOs also serve as modulators of intestinal epithelial cell responses, 
modulators of immune responses, and brain development nutrients.7, 69, 76, 77 
 
2.5.1 Prebiotics 
 A prebiotic is broadly-defined as a non-digestible food substance that, when 
consumed, selectively stimulates the growth of colonic bacteria to improve host health.101 
For the first of these criteria, i.e. non-digestible, a compound must resist gastric acidity, 
hydrolysis by host enzymes, and intestinal absorption. HMOs fulfill these criteria as the 
overwhelming majority reach the distal intestine in-tact; only ~1% are absorbed into 
circulation.1, 102, 103 Moreover, a portion of HMOs pass through the distal intestine in-tact 
and are excreted in urine and feces.7, 77, 104, 105 
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It is well-established that HMOs also fulfill the second criteria of a prebiotic. As 
previously described, HMOs were first touted for their ability to promote the growth of the 
symbiotic colonic bacterial species Bifidobacterium bifidus back in the 1950s.47-50 Since 
the 1950s, HMOs have also been shown to promote the growth of other bifidobacteria 
species including B. longum subsp. infantis and B. longum subsp. longum.1 Moreover, 
the growth of several species of Bacteroides, another class of intestinal symbiote, have 
been found to be promoted by HMOs such as 2’-FL, 3-FL, 3’-SL, and 6’-SL (Figure 2.14). 
Unlike bifidobacteria and Bacteroides, lactobacilli, a third class of intestinal symbiote, are 
largely unable to catabolize HMOs.1, 106, 107 A summary of HMO prebiotic activity is 
provided in Table 2.3.1  
 
 
While various species of Bacteroides and Lactobacillus exist in the infant gut, 
bifidobacteria constitute the vast majority of the gut microbiota, particularly in breastfed 
infants. Indeed, bifidobacteria are often found to comprise over 75% of the gut microbiota 
in breastfed infants with B. breve, B. longum subsp. infantis, and B. longum subsp. 
Figure 2.14. Structures of selected HMOs previously shown to promote the growth of 
several species of Bacteroides. 
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longum being among the most common species. Conversely, bifidobacteria are 
significantly less dominant in the guts of formula-fed infants. As a result, the gut microbiota 
of formula-fed infants features a more diverse array of species compared to breastfed 
infants.1, 38, 107, 108 Due to the prominence of bifidobacteria in the guts of breastfed infants, 
HMO utilization by this class of commensal will be discussed in more detail. 
 
It has consistently been found that different species of infant-associated 
bifidobacteria possess varying levels of HMO metabolism.107, 113-115 For instance, B. 
longum subsp. infantis and B. bifidum have been shown to grow better with HMOs as the 
sole carbon source than B. longum subsp. longum and B. breve.107, 116-119 Concurrent with 
this variation, different species have also been found to possess different preferences for 
the HMO structures they consume.107, 113-115 For example, B. longum subsp. infantis has 
been found to consume preferentially HMOs containing eight or fewer monosaccharides, 
Symbiote Action Ref. 
B. bifidum, B. longum 
Major strains found in breastfed infant feces 
Can grow using HMOs as the sole carbon source 
Metabolize “small” oligosaccharides in human milk 
106 
B. breve, B. adolescentis Major strains associated with adult gut flora Do not grow efficiently on HMOs 
106 
B. fragilis, B. thetaiotaomicron HMO use coupled to up-regulation of mucin degradation pathways 
109, 
110 
B. ovatus, B. stericoris Do not exhibit growth in the presence of HMO 
109, 
110 
L. plantarum, L. acidophilus 
Do not digest complex HMOs 
Metabolize neutral HMOs 
Ferment Lac, Glc, GlcNAc, and Fuc 
111, 
112 
L. reuteri, L. fermentum,  
L.mesenteroides subsp. cremoris  
and S. thermophilus 
Do not metabolize HMOs 
111, 
112 
Table 2.3. HMO-Promoted Growth of Symbiotic Bacteria 
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corresponding to a degree of polymerization (DP) of ≥8, with a mass of <1400 Da.107, 114, 
117 Examples of HMOs that are consumed by B. longum subsp. infantis include LNT, 
LNnH, isomeric fucosylated LNH, and DFL. While not preferred, it is important to note 
that this bifidobacterial species is capable of metabolizing other classes of HMOs.117 
In contrast to B. longum subsp. infantis, B. longum subsp. longum and B. breve 
have been found to metabolize preferentially LNT and LNnT.7, 114, 117 Indeed, these strains 
were found to be devoid of fucosidase activity and possess lower sialidase activity than 
B. longum subsp. infantis.117 B. breve is, however, able to metabolize smaller HMO 
components including fucose, isomeric fucosyllactose, LNB, and sialic acid, all of which 
are released through the extracellular hydrolysis of larger HMOs by other species of 
bifidobacteria. B. bifidum, for example, is capable of degrading HMOs, but it often leaves 
behind portions of the hydrolyzed product which can subsequently be taken up by the 
scavenging B. breve.7, 114, 120 
While HMOs have long been deemed the “bifidus factor,” the unique molecular 
mechanisms that allow bifidobacteria to metabolize HMOs have only recently been 
described.118 Investigations into bifidobacteria genomes have not only revealed how this 
class of symbiote are able to use HMOs, it has also revealed reasons for variations in 
HMO metabolism seen among different bifidobacteria species. B. longum subsp. infantis, 
considered to be the archetypical HMO consumer, has been shown to possess a unique 
43-kb gene cluster dedicated to HMO import into cells and subsequent degradation and 
processing (Figure 2.15).  
Within this cluster are four glycosidases (b-galactosidase, fucosidase, sialidase, 
and b-hexosaminidase; Figure 2.16) multiple ABC transporters, and several extracellular 
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soluble binding proteins (SBP) that are predicted to bind oligosaccharides and facilitate 
their cellular uptake.115, 118 Importantly, these glycosidases have been found to be 
intracellular based on their lack of secretion signals. 
 
 
 
 
 
 
 
 
This finding highlights the importance of the ABC transporters in HMO utilization 
and may explain the preference of B. longum subsp. infantis for small-mass HMOs; 
Figure 2.15. Glycosidases and transport-related genes located in the HMO utilization 
cluster (figure from reference 118). The 43 kbp HMO cluster possesses four glycosidases 
which are active on HMO glycosidic linkages. Family 1 (oligosaccharide-binding) solute 
binding proteins (SBP) associated with ABC transporters are found in high density in the 
cluster. HMO cluster sequence depth in JCM1272 and JCM11346 is normalized to 
Bifidobacterium longum subsp. infantis ATCC15697 in arbitrary units. With the exception 
of the IS3 insertion sequence, the entire locus is found to be present in both B. longum 
subsp. infantis genomes. Transport-related genes are denoted as M: major facilitator 
superfamily, P: ABC transporter permease component, and A: ABC transporter ATPase 
subunit. 
Figure 2.16. Example cleavage sites of the glycosidases in the HMO utilization gene 
cluster of Bifidobacterium longum subsp. infantis on the HMO sialylfucosyllacto-N-
tetraose (S-LNF II or F-LST a, 2.29). 
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transporter specificity or steric constraints may limit the transfer of larger HMOs through 
the transporters and into the cell.113, 115 Although it possesses different molecular 
machinery, HMO degradation in B. breve follows the same general pattern as B. longum 
subsp. infantis; B. breve uses ABC transporters to get LNT and LNnT into cells where 
they are then degraded through intracellular processes.114  
In contrast to the intracellular glycosidases of B. longum subsp. infantis and B. 
breve, B. bifidum possesses extracellular fucosidases and sialidases as well as a 
membrane-anchored lacto-N-biosidase which liberate fucose, sialic acid, and LNB, 
respectively. The simplified LNB is then transported into the cell by an ABC transporter in 
association with an LNB-specific SBP.113, 115, 120 While type I oligosaccharide chains 
predominate in human milk,  B. bifidum is also equipped to degrade type II chains 
extracellularly which ultimately results in the formation of GlcNAc, Gal, and Glc. These 
monosaccharides can then be transferred into the cell and subsequently metabolized.114 
It is hypothesized that the extracellular HMO degradation strategy used by B. bifidum 
allows it to use a wide range of HMO structures thus conferring a competitive advantage 
for this species.113, 115, 120 The differences between B. longum subsp. infantis and B. 
bifidum HMO metabolic pathways are depicted in Figure 2.17.  
Despite numerous genetic differences among the various infant-associated 
bifidobacteria species, there is an HMO catabolic pathway that is conserved across B. 
bifidum, B. breve, B. longum subsp. infantis, and B. longum subsp. longum: the LNB/ 
GNB pathway for the catabolism of LNB. The LNB/GNB gene cluster encodes for an ABC 
transporter responsible for the import of LNB and GNB (galacto-N-biose, the building 
block of mucin sugars), an LNB phosphorylase that cleaves LNB, and two enzymes of 
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the Leloir pathway to further metabolize the liberated galactose.107, 115, 118 Consistent with 
its inability to use HMOs, the adult-associated B. adolescentis lacks this LNB/GNB gene 
cluster.118 
 
Once HMOs have been broken down into their constituent monosaccharides, the 
monosaccharides can be further degraded by the appropriate catabolic pathways all of 
which feed into the bifid shunt. The bifid shunt is a Bifidobacteriaceae-specific metabolic 
pathway for the fermentation of hexaoses.118, 121 Ultimately, this pathway generates 1.5 
and 1 mole of acetate and lactate, respectively, for every mole of hexose that enters the 
pathway.118 The acetate can subsequently be secreted or incorporated into de novo fatty 
acid synthesis (Figure 2.18). Importantly, the secreted acetate and lactate are beneficial 
Figure 2.17. HMO metabolic pathways in B. longum subsp. infantis and B. bifidum. (A)  
In B. longum subsp. infantis, intact HMOs and LNB traverse the cell membrane through 
an HMO ABC transporter and an LNB/GNB ABC transporter, respectively. Once in the 
cell, HMOs are hydrolyzed by various cytoplasmic glycosidases to yield the constituent 
monosaccharides. (B) In B. bifidum, HMOs are hydrolyzed extracellularly by various cell 
membrane-bound glycosidases to generate LNB. LNB then traverses the cell membrane 
through the LNB/GNB ABC transporter. Once in the cell, LNB is further degraded by LNB 
phosphorylase to yield the constituent monosaccharides. Abbreviations: ABC, ATP-
dependent binding cassette; ATP, adenosine triphosphate; ADP, adenosine diphosphate; 
HMO, human milk oligosaccharide; LNB, lacto-N-biose; GNB, galacto-N-biose. 
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for the host. These SCFAs prevent the growth of pathogenic bacteria by lowering 
intestinal pH, serve as an energy source for intestinal epithelial cells, and modulate 
intestinal immune and inflammatory responses through G-protein-coupled receptors.118, 
121 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.18. The bifid shunt hexose fermentative pathway. Bifidobacteria ferment 
carbohydrates through the bifid shunt pathway. Monosaccharides are degraded through 
this pathway to yield 3 acetate, 2 lactate, and 2 ATP per 2 glucose. The acetate produced 
through this pathway can be secreted into the extracellular environment or incorporated 
into de novo fatty acid synthesis. The lactate produced through this pathway is secreted 
into the extracellular environment. Abbreviations: ATP, adenosine triphosphate; ADP, 
adenosine diphosphate; P, phosphate; Pi, inorganic phosphate; NAD+, oxidized 
nicotinamide adenine dinucleotide; NADH, reduced nicotinamide adenine dinucleotide. 
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The prebiotic capacities of HMOs serve as a key source of indirect protection from 
pathogens. Not only does the selective metabolism of HMOs by infant-associated gut 
symbiotes like bifidobacteria confer a competitive growth advantage for these species 
over pathogenic species, the final products of HMO catabolism lower the pH of the gut 
which creates an environment which is further prohibitive of pathogenic growth. In 
contrast to this indirect form of protection, HMOs can also serve as direct sources of 
protection via their roles as antiadhesive antimicrobials.  
 
2.5.2 Antiadhesive Antimicrobials  
Central to the infectious disease process is the sequential invasion, colonization, 
and proliferation of a pathogen inside a host organism.122, 123 Initial host-pathogen 
interactions occur through pathogen adherence to an epithelial surface. The pathogen 
then colonizes the contact surface and surrounding tissues to establish a site of infection. 
Once a site of infection has been successfully established, the pathogen can spread and 
proliferate in other parts of the body and cause disease. Concurrent with this road to 
infection, the ability to inhibit initial binding of a pathogen to an epithelial surface effectively 
halts infection before it begins. Impressively, HMOs are well-known to prevent this initial 
attachment by serving as soluble decoy receptors for pathogens or pathogenic virulence 
agents such as toxins. An example of this mode of inhibition is illustrated in Figure 2.19. 
In this regard, HMOs serve as antiadhesive antimicrobials. A summary of HMO 
antiadhesive antimicrobial activities is provided in Table 2.4. 
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Bacterial 
Species Action HMOs Ref. 
Campylobacter 
jejuni 
Inhibition of adhesion to epithelial cells  
Inhibition of inflammatory signaling 
2’-FL  
Other a1-2 fucosylated 
oligosaccharides 
124-126 
Candida  
albicans 
Inhibition of adhesion to epithelial cells 
Interference with hyphal 
morphogenesis 
Pooled HMOs 127 
Clostridium  
difficile 
Binding to exotoxins A (TcdA) and B 
(TcdB) (prevents interactions of toxin 
with cellular receptors) 
Fucosylated HMOs (e.g. LNFP I, 
LNFP III) 
Acidic HMOs (e.g. LST b and c) 
LNT, LNnH 
128, 
129 
Enterococcus 
faecium 
Faster vancomycin-resistant E. 
faecium (VRE) colonization reduction 
compared to non-HMO treatment 
Mixtures of fucosylated HMOs 130 
Escherichia  
coli 
Interference with intracellular signals 
used by UPEC to cause cell damage 
Inhibition of UPEC adhesion to 
epithelial cells 
Inhibition of EPEC adhesion to 
epithelial cells 
Binding to heat-labile enterotoxin type 
1 (HLT) 
Acidic and neutral HMO mixtures 
Neutral and acidic HMOs (e.g. 2’-
FL, 6’-SL, LNFP I and II) 
131-135 
Haemophilus 
influenzae Inhibition of adhesion to epithelial cells 
High molecular weight fraction of 
milk  
136 
Helicobacter  
pylori Inhibition of adhesion to epithelial cells 
Acidic HMOs (e.g. 3’-SL and 6’-
SL) 
137 
Pseudomonas 
aeruginosa 
Inhibition of adhesion to epithelial cells 
Reduction of adhesion to and 
internalization in pneumocytes 
2’-FL and 3-FL 
3’-SL and 6’-SL 
138, 
139 
Streptococcus 
pneumoniae Inhibition of adhesion to epithelial cells 
Low and high molecular weight 
milk fractions  
LNT 
136 
Shigella 
dysenteriae 
Binding to Shiga toxins Stx2 and 
Stx1B5 
Acidic and neutral HMOs (e.g. 2’-
FL, 6’-SL, LNDFH I, LNFP III) 
135 
Salmonella 
fyris Inhibition of adhesion to epithelial cells 
Acidic and neutral low molecular 
weight HMOs (e.g. 3-FL and 6’-
FL) 
132 
Noroviruses 
and 
Rotaviruses 
Inhibition of binding to HBGAs 
(Norovirus) 
Inhibition of adhesion to epithelial cells 
(Rotavirus) 
2’-FL and 3-FL 
Sialylated HMOs (e.g. 3’-SL and 
6’-FL) 
140-142 
Table 2.4. Protection Against Infectious Disease Derived from Antiadhesive 
Antimicrobial Functions of HMOs 
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The propensity of HMOs to serve as decoy receptors for pathogens is made 
possible by their resemblance to various cell surface glycan receptors. For instance, the 
potential of HMOs to protect against norovirus infection is hypothesized to be due to 
commonalities between HMO and histo-blood group antigen (HBGA) fucosylation 
patterns (see Figures 2.9 and 2.13).140, 141 These structural similarities allow HMOs to act 
as natural decoys for the HBGA binding pocket of noroviruses. Noroviruses are a group 
of related viruses that are highly contagious and are collectively one of the dominant 
causes of gastroenteritis; gastroenteritis, also known as the stomach flu or stomach bug, 
is an intestinal infection characterized by stomach pain, nausea, vomiting, and 
diarrhea.141  
 
Fucosylated HMOs, namely a-1,2 fucosylated HMOs like 2’-FL, have also been 
shown to prevent the binding of Campylobacter jejuni to host cell receptors.124-126 In a 
H-2 
antigen
H-2 
antigen
2’-FL
2’-FL
A. B.
Figure 2.19. Antiadhesive antimicrobial activity of 2’-fucosyllactose (2’-FL) against 
Campylobacter jejuni. (A) C. jejuni binds the H-2 antigen on cell surfaces to initiate 
infection. (B) The binding of C. jejuni to its target H-2 cell surface antigen is inhibited in 
the presence of 2’-FL via competitive binding. C. jejuni is depicted in red. 
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study by Ruiz-Palacios, Newburg, et al. C. jejuni was first found to bind cells expressing 
the H-2 antigen, i.e. the H antigen (Figure 2.9) presented on a type II oligosaccharide 
chain. It was subsequently shown that this binding was inhibited by the addition of soluble 
a-1,2 fucosylated HMOs (Figure 2.19).126 Like noroviruses, C. jejuni is leading cause of 
intestinal infection, and is the most common cause of bacterial diarrhea. As diarrheal 
disease is one of the most common causes of infant mortality, protection against 
pathogens such as the noroviruses and C. jejuni is extremely important to infant health 
and well-being.124, 126, 143 In addition to being directly relevant to infant health, this study 
also provided information about the host cell receptors for C. jejuni as our knowledge 
about these receptors and mechanisms for the entry of this pathogen into cells remains 
limited.126, 144, 145 
In addition to serving as antiadhesive antimicrobials against intestinal (enteric) 
infections, HMOs have also been shown to similarly protect against upper respiratory 
infections caused by pathogens such as Pseudomonas aeruginosa, Streptococcus 
pneumoniae, and Haemophilus influenzae. A summary of these protections is provided 
in Table 2.4.1 HMOs can come into direct contact with mucosal pathogens as human milk 
often covers the mucosal surfaces of an infant’s nasopharynx (upper part of the pharynx 
that connects the pharynx to the nasal cavity) and can also reach parts of the upper 
respiratory tract during bouts of aspiration.7 It is hypothesized that the presence of human 
milk in the naso- and oropharynx may similarly protect infants from infections caused by 
Streptococcus agalactiae (Group B Streptococcus, GBS); GBS is a leading cause of 
neonatal morbidity and mortality and will be discussed in detail in Chapter 3. GBS is 
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thought to initially colonize an infant’s oropharyngeal mucosa through contact of this 
region with vaginal secretions during birth.20 
Finally, HMOs have also been shown to prevent the binding of uropathogenic 
Escherichia coli (UPEC); UPEC is a major cause of urinary tract infections (UTIs) (Table 
2.4).131, 134 As previously discussed, HMOs are not metabolized by the infant and a portion 
pass intact through the colon and are excreted in feces and urine.7, 77, 104, 105 This source 
of HMO/pathogen contact helps to explain how HMOs may also help to lessen the 
occurrence of UTIs in infants. 
 
2.6 Conclusion and Future Outlook 
 Human milk is uniquely tailored to promote infant health and well-being. Even 
under the harshest of scenarios and even when the mother’s own nutrition is 
compromised, human milk provides infants will all the necessary nutrients, vitamins, and  
protective bioactive macromolecules that are essential to proper growth and development. 
Moreover, human milk composition changes over the course of lactation to adapt to the 
developing needs of a child. While human milk contains a plethora of protective 
immunogenic components such as immune cells, cytokines, chemokines, and antibodies, 
HMOs represent a unique and important source of protection against infectious agents. 
This class of structurally complex and diverse carbohydrates, which are absent from 
bovine milk and by extension absent from formula, are key to the lowered incidences of 
diarrhea, respiratory infection, urinary tract infection, ear infection, necrotizing 
enterocolitis (NEC), and sudden infant death syndrome (SIDS) seen in breastfed infants 
compared to their formula-
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and antiadhesive antimicrobials to promote the growth of important intestinal symbiotes, 
including numerous bifidobacteria species, and to protect infants from colonization by 
infectious agents such as Escherichia coli, Clostridium difficile, and Campylobacter 
jejuni.1  
 Although numerous prebiotic HMO mimics have been developed as formula 
additives, these compounds lack the structural complexity and diversity of HMOs and thus 
are not able to offer a comparable range of infant benefits.23 Additionally, this class of 
additive does not address the antiadhesive antimicrobial properties of HMOs. While 2’-
fucosyllactose, an important antiadhesive antimicrobial HMO, has more recently been 
developed as a formula additive, this single HMO is unlikely to yield comparable benefits 
to the actions of heterogenous HMO extracts. Thus, it is important to identity additional 
single-entity HMOs that are key to infection prevention. Closely related to this need is the 
need to continue to elucidate the protections HMOs afford against infectious disease, i.e. 
expanding our knowledge about the specific pathogens that HMOs protect against and 
the mechanisms by which these protections occur. 
 The greatest barrier to HMO research is the limited availability of these compounds. 
At a basic level, there is a limited supply of donor milk accessible to researchers as donor 
milk is rightfully prioritized for sick neonates who are most likely to benefit from exclusive 
consumption of human milk. Even if researchers have access to donor milk, however, the 
high variation in HMO composition and the difficulties associated with isolating 
homogeneous HMOs from heterogenous extracts makes determining specific HMO 
structure activity relationships difficult. To compound this problem, single-entity HMOs 
are by in large cost and/or synthetically prohibitive.1 Regardless of the challenges, 
 127 
continued research on the biological impact of HMOs, particularly with regard to infectious 
disease prevention, is paramount to human health.  
 In line with this need, the focus of my doctoral work was to investigate the extent 
to which HMOs can serve as sources of protection against infectious disease. The work 
completed in this regard is detailed in subsequent chapters and begins with a description 
of our investigations into the antibacterial properties of heterogenous HMOs against 
several clinically relevant pathogens (Chapter 3). Guided by these findings, we next 
moved to evaluate the antibacterial properties of single-entity compounds. As previously 
mentioned, single-entity HMOs are prohibitively expensive. Thus, I developed a scalable 
chemical synthesis of the ubiquitous HMO lacto-N-tetraose (LNT) (Chapter 4). In the final 
chapter of this dissertation, the antibacterial properties of LNT as well as several 
additional homogenous HMOs are presented (Chapter 5).  
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CHAPTER 3 
 
Evaluation of the Antibacterial Properties of Heterogenous Human Milk 
Oligosaccharides Against Streptococcus agalactiae, Staphylococcus aureus, and 
Acinetobacter baumannii 
 
3.1 Group B Streptococcus 
3.1.1 Group B Streptococcus: An Introduction 
 Streptococcus agalactiae (Group B Streptococcus, Group B Strep, GBS) is an 
encapsulated Gram-positive diplococcus that colonizes the gastrointestinal (GI) and 
genital tracts of around 50% of women at some point during their pregnancy.1, 2 While 
GBS colonization is typically asymptomatic in healthy adults, it can pose a real threat to 
elderly, infant, and/or immunocompromised populations. Indicative of this reality, since 
the 1970s, GBS has been a leading cause of neonatal morbidity and mortality. 1, 2 3  
 
3.1.2 Clinical Manifestations and Modes of Transmission 
Neonatal GBS infections most commonly present as pneumonia, sepsis, and 
meningitis.1, 2, 4, 5 Importantly, GBS is one of the most common causes of neonatal sepsis 
and is responsible for around 12% of stillbirths worldwide.6, 7 Though less frequently, GBS 
can also present as cellulitis, septic arthritis, adenitis, and osteomyelitis.1, 2  
GBS is most commonly transmitted from a GBS-colonized mother to her infant 
during labor and delivery as the infant passes through a colonized birth canal or in utero 
via bacterial ascension into the amniotic sac.1 These modes of transmission are known 
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as vertical transmission. In women, the primary reservoirs for GBS are the GI and genital 
tracts. In infants, while the GI tract is similarly a frequent site of colonization, the throat is 
also a common GBS reservoir; the throats of infants are more commonly colonized than 
the throats of adults.1, 3, 8 It has been hypothesized that GBS initially colonizes the infant 
throat when it comes into contact with vaginal secretions during an infant’s passage 
through the birth canal.3 Though much less common, GBS can also colonize infants via 
horizontal transmission from hospital or community sources; this transmission is likely 
fecal to oral.1 
 In addition to these modes of transmission, there is also evidence that GBS may 
be transmitted through infected breastmilk. It is well-known that breastmilk is not sterile 
but rather contains hundreds of bacterial species.9-11 Furthermore, it has been shown that 
the milk of healthy women contains around 103-104 cfu/mL of bacteria. The prevalence 
and diversity of bacteria in human milk has given rise to the term “the human milk 
microbiome” Some of the most commonly isolated species from breastmilk include 
various Bifidobacterium, Lactobacillus, Staphylococcus, and Streptococcus species.10 
 Despite the clear potential for the transmission of bacteria through breastmilk, 
studies detailing the prevalence of GBS in breastmilk are few in number and the methods 
for identification of GBS in these studies can be highly variable.3 Regardless, while 
numerous studies have found GBS in breastmilk, the manner in which breastmilk 
becomes colonized remains unclear.3, 10, 12-14 One proposed mechanism is through 
retrograde transmission from the infant. In this mode of transmission, GBS found in the 
throat and oral cavity of an infant who became colonized with GBS during labor and 
delivery contaminates the mother’s milk ducts due to retrograde flow of milk during 
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suckling. Once introduced into the mammary ducts, GBS can then multiply and 
persistently infect the mother and infant.3, 10, 13 This can occur with or without mastitis.3 
 Another potential mechanism by which breastmilk may become contaminated is 
via translocation of GBS from the maternal gut and GI through lymphatics to the mammary 
glands.3, 13 However, the exact manner in which bacteria could cross the intestinal 
epithelium and reach the mammary gland whilst evading the immune system remains 
unknown.10 Regardless, there are several discoveries which lend credence to this 
mechanism of transmission. First, the presence of strict anaerobes like bifidobacteria in 
breastmilk suggests that there is mechanism of transmission other than via infant mouth 
to maternal skin. Second, bacteria can be isolated from colostrum even prior to an infant’s 
birth.10 Third, the presence of orally administered bacteria, such as lactobacilli, in 
breastmilk suggests that bacteria from the maternal gut can in fact colonize the mammary 
gland and, by extension, breastmilk.3, 10 
 As a final note, even in the absence of preventative treatments to stop vertical GBS 
transmission, not all infants born to GBS colonized mothers will be colonized with GBS 
themselves.1, 3, 7 Indeed, only around 50% of infants born to GBS colonized mothers will 
be colonized with GBS at birth, and only around 1-2% of these infants will go on to develop 
invasive GBS disease.  
 
3.1.3 Types of GBS Disease and Methods for Prevention and Treatment 
 There are two main types of GBS disease: early-onset disease (EOD) and late-
onset disease (LOD) (Table 3.1). EOD accounts for around 70% of all GBS cases and 
typically occurs within the first 24 hours of life.1, 3 EOD can also occur up to one week 
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after delivery and can present as a range of illnesses including asymptomatic bacteremia 
and septic shock. While maternal GBS colonization status is the most significant risk 
factor for EOD, other common risk factors include maternal intrapartum fever (>99 oF; 38 
oC), prolonged rupture of membranes (>18 h before delivery), chorioamnionitis, and 
having had a previous infant with invasive GBS disease. 1, 7  
 LOD is less common than EOD and occurs after the first week of life and up to the 
first three months of life, though most cases of LOD present within the first month to month 
and a half after birth.1 Similar to EOD, bacteremia without a defined focus is an 
exceedingly common manifestation of LOD. Meningitis is, however, more common in 
LOD than EOD.1, 3 Other manifestations of LOD include pneumonia, cellulitis, and 
osteoarticular infections.1 Furthermore, up to 50% of infants who survive LOD suffer from 
severe neurological sequelae.3 Unlike EOD, LOD usually occurs with a lack of maternal 
obstetric and/or nursery complications.1 Additionally, the risk factors for LOD are different 
than those for EOD. LOD can result from late onset presentation following early GBS 
colonization of the infant or from horizontal transmission. Importantly, horizontal 
transmission is a more common mode of acquisition for LOD than EOD. Moreover, 
reports of infants infected with GBS due to contaminated breast milk are generally 
associated with LOD.3, 13 
 The last type of GBS disease is late-late onset disease, though this type of invasive 
disease is much less common than EOD or LOD (Table 3.1).1 Late-late-onset infection 
occurs after the first three months. This type of infection most commonly presents as 
bacteremia without a focus and most commonly occurs in infants who were born before 
35 weeks gestation who had prolonged stays in neonatal hospital units.  
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Table 3.1. Types of GBS Disease 
 
 In the United States alone, a 2014 report from the Centers for Disease Control 
(CDC) estimated that EOD and LOD affected around 1 in 4000 and 1 in 3000 newborns, 
respectively.15 Importantly, while the rates of EOD have decreased dramatically since the 
1990s, the rates of LOD have remained largely stagnant in that time frame. The drop in 
EOD rates is attributed mainly to the introduction and implementation of intrapartum 
antibiotic prophylaxis (IAP). In the 1980s and ‘90s, studies emerged that demonstrated 
the ability of antenatal GBS screening combined with administration of IAP for GBS 
positive mothers to prevent EOD.16-18 As a result, in 1996, the CDC introduced the first 
 Early-Onset  Late-Onset  Late-Late-Onset 
% of GBS 
Cases ~70% <30% Rare 
Time Frame 1st week of life 1st week – 3 months After 3 months 
Common 
Mode of  
Transmission  
Vertical from GBS 
positive mother 
Late presentation of 
early colonization; 
horizontal from 
community; 
contaminated breast 
milk 
Horizontal; common 
in premature babies 
with prolonged stay 
in neonatal units 
Typical 
Presentation 
Asymptomatic 
bacteremia 
Bacteremia without a 
focus; meningitis 
Bacteremia without a 
focus 
Preventative 
Treatment 
Intrapartum 
antibiotic 
prophylaxis (IAP) 
None None 
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guidelines for the prevention of GBS disease which included GBS screening and IAP 
administration.1, 7  
Current CDC guidelines (also recommended by the American Academy of 
Pediatrics, AAP) recommend universal culture-based screening late in a woman’s third 
trimester (between 35 and 37 weeks gestation) and implementation of IAP for mothers 
who test positive for GBS; screening late in pregnancy is recommended because GBS 
colonization status can vary over the course of pregnancy, so colonization status early in 
pregnancy is not a predictive factor for EOD.18 For the implementation of IAP, the CDC 
guidelines include a recommended regimen for antibiotic selection (Figure 3.1).  
 
Broadly speaking, GBS is susceptible to penicillins, extended-spectrum penicillins, 
cephalosporins, and vancomycin.18 However, because penicillin has a narrow spectrum 
of antimicrobial activity and a well-understood safety profile for both mother and child, 
penicillin is the first antibiotic recommended for IAP with ampicillin being considered as 
Patient allergic to penicillin?
Penicillin
or
Ampicillin
Patient at high risk for 
anaphylaxis due to penicillin or 
cephalosporin administration? 
No Yes
GBS isolate susceptible to 
clindamycin?
Cefazolin
ClindamycinVancomycin
YesNo
No Yes
Figure 3.1. Current CDC antibiotic selection guidelines for intrapartum antibiotic 
prophylaxis (IAP) against early-onset GBS disease (EOD). 
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an acceptable alternative; b-lactam antibiotics for prophylaxis are typically administered 
every 4 hours until delivery. Unfortunately, maternal b-lactam allergies preclude the use 
of penicillin or ampicillin. Thus, for b-lactam allergic mothers, appropriate alternatives 
must be identified.  
For women who do not have a history of anaphylaxis, angioedema, respiratory 
distress, or urticaria following administration of a b-lactam or cephalosporin, cefazolin is 
the recommended antibiotic.18 For women who do have a history of these reactions to b-
lactams or cephalosporins and are at a high risk for anaphylaxis, GBS antimicrobial 
susceptibility testing is ordered to determine susceptibility of the GBS isolate to 
clindamycin. Earlier versions of guidelines instructed that susceptibility of GBS to 
erythromycin be tested. Due to increasing instances of GBS resistance to erythromycin 
(ca. 30% of isolates are erythromycin-resistant), however, erythromycin is no longer 
recommended as a potential antibiotic for IAP. Thus, if a woman is at high risk for b-
lactam-induced anaphylaxis and her GBS isolate is sensitive to clindamycin, clindamycin 
is the recommended antibiotic. If her isolate is resistant to clindamycin, vancomycin is 
recommended.  
While IAP has been largely effective at preventing EOD, it is not an effective 
preventative measure for LOD.18 It is important to note, however, that the antibiotics used 
for IAP are appropriate for treating LOD once it has manifested. The ineffectiveness of 
IAP and the current lack of any alternative preventative treatment for LOD is responsible 
for the multi-decade long stagnation in LOD rates. Moreover, IAP is also ineffective 
against prenatal-onset disease (includes stillbirths and miscarriages). It is also important 
to note that rates of GBS infections in developing and resource-poor settings have been 
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shown to be higher than those reported for the United States.19 This, at least with regard 
to EOD, is likely due in part to a lack of adequate facilities and resources for GBS 
screening and IAP administration.  
As a final note, while IAP has dramatically reduced the GBS disease burden, 
concerns remain about the effects of antibiotic treatment on the developing flora of the 
infant and the established flora of the mother. Indeed, collateral damage to host 
symbiotes is a common problem with antibiotic treatments, and the extent of this damage 
due to IAP is currently unclear.2, 13, 20, 21 Additionally, continued antibiotic usage is most 
often accompanied with concerns about increasing antibiotic resistance. The reality that 
ca. 30% of clinical GBS isolates are resistant to erythromycin and around 20% are 
resistant to clindamycin highlights the validity of this concern with respect to IAP.18 
 
3.1.4 GBS Virulence Factors 
 GBS is an opportunistic pathogen that employs numerous virulence factors to help 
it persist in a hostile host environment and cause disease.22 These include factors to 
promote entry into host cells, intracellular survival and systemic circulation, immune 
evasion, resistance to host antimicrobial peptides (AMPs), and adherence and 
subsequent invasion of host-cell surfaces.  For example, GBS produces pore-forming 
toxins that facilitate entry into host cells and possesses cell-surface pili which facilitate 
adherence and attachment to host cells. Moreover, GBS can decrease the net negative 
charge on its cell surface to decrease its affinity towards positively charged AMPs.22  
One GBS virulence factor that has been extensively studied and well-characterized 
are the capsular polysaccharides (CPS). These oligosaccharides are particularly 
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important for evasion of detection by the host immune system.22-32 Based on their 
structures, GBS CPS can be divided into ten serotypes (Ia, Ib, II-IX) (Figure 3.2).25, 33  
 
 
 
Figure 3.2. Structures of the repeating units of the Group B Streptococcus (GBS) 
capsular polysaccharides (CPS) for serotypes Ia, Ib, and II-XI. 
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Serotypes Ia, Ib, II, III, and IV account for over 85% of the global invasive GBS 
disease burden with serotype III alone accounting for around 25%.34, 35 Despite their 
structural differences, all GBS CPS repeating units feature a terminal sialic acid residue 
(the Neu5Ac form of sialic acid). 25, 28, 35  This shared feature has been shown to be critical 
to GBS virulence. As glycoconjugates terminated with Neu5Ac are common host antigens, 
the terminal Neu5Ac moiety of GBS CPS is an example of molecular mimicry. 22, 27, 32 As 
a result of this mimicry, the host fails to recognize GBS as a foreign antigen and thus 
does not initiate the necessary immune response.22, 26, 30 
Another method GBS uses to increase its pathogenicity is biofilm formation. To 
understand the relationship between biofilm production and GBS pathogenicity, it is 
important to digress briefly into a general description about biofilm production, structure, 
and function. Biofilms are structured, organized communities of cells encapsulated by a 
self-produced extracellular polymeric matrix (EPS) which can adhere to biotic or abiotic 
surfaces.36-38 The EPS consists primarily of oligosaccharides, DNA, and proteins and is 
important both to the structural integrity of the biofilm matrix and the ability of bacteria to 
adhere to and communicate with one another.39 Importantly, within the matrix are open 
water channels to facilitate nutrient delivery and waste removal.37 The stages of biofilm 
production are illustrated in Figure 3.3.38 Following initial attachment (initiation), bacteria 
begin to multiply and excrete EPS (maturation). Once the biofilm has reached a mature 
stage, bacterial cells can be liberated from the biofilm matrix (detachment) and spread to 
new locations to form new biofilm communities.  
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 For several species including Pseudomonas aeruginosa, Staphylococcus aureus, 
and Streptococcus mutans, it has been shown that quorum sensing (QS), a method of 
intercellular signaling and communication, is an important factor in the maturation and/or 
dissolution of biofilm bacterial communities.40-43 QS is a method of cell-to-cell 
communication that allows bacterial cells to evaluate their surrounding population density 
and respond accordingly with changes in gene expression once a threshold number of 
cells, also known as a “quorum,” has been reached.43-45 As cells within a biofilm encounter 
much higher local cell densities than planktonic, free-floating cells, it has been argued 
that biofilms represent a particularly environmentally relevant context for this intercellular 
communication.40 
 QS is facilitated by the production of diffusible, low-molecular weight signaling 
molecules known as autoinducers (AIs); AI concentration in the local environment is 
proportional to cell density.44, 45 AIs differ among species with Gram-positive species 
typically using peptide signaling molecules, Gram-negative typically using N-acyl L-
homoserine lactone (AHL) derivatives, and numerous Gram-positive and Gram-negative 
Dissemination
Colonization
Attachment Maturation Detachment
The Biofilm Life Cycle
Figure 3.3. The biofilm life cycle. 
 151 
species using the interspecies signal AI-2. Once a sufficient amount of environmental AI 
has accumulated signaling that a “quorum” of cells has been reached, the AI is able to 
bind its target receptor (intracellular or membrane-bound) and initiate changes in gene 
expression required for the QS phenotype. For example, in S. aureus, when a quorum is 
reached and the autoinducing peptide (AIP) binds its target receptor, this binding 
activates a regulatory cascade that leads to increased expression of invasive factors such 
as toxins, hemolysins, proteases, and other tissue-degrading enzymes.42, 46 Moreover, 
these factors alter the metabolic status of the bacteria which subsequently changes their 
biofilm-forming capacity. 
A notable feature of bacteria in a biofilm matrix is the significantly higher resistance 
to environmental stressors seen for this population compared to their planktonic 
counterparts.38 Indeed, bacteria growing in the biofilm have increased tolerance toward 
antibiotics and disinfectants as well as toward the actions of the host immune response. 
For example, the minimum inhibitory concentration (MIC) of antibiotics against biofilm-
dwelling bacteria can be up to 1000-fold higher than that of planktonic bacteria.36, 37, 47 
The observation that the ESKAPE pathogens (discussed in Chapter 1), which are 
notorious for their abilities to evade antimicrobial action, are also prolific biofilm producers 
speaks to the protective nature of biofilms.48 Moreover, the reality that biofilms are 
involved in an estimated 80% of microbial infections in the body highlights the importance 
of biofilm production to bacterial pathogenesis.37 
 The unique protection the biofilm matrix affords bacteria is multi-faceted. Perhaps 
the most obvious protection afforded by the biofilm is a physical one. The EPS creates a 
physical barrier between bacterial cells and the hostile host environment. This added 
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barrier can make it increasingly difficult for antimicrobial agents and host defense 
mechanisms to fully penetrate the biofilm.36, 38, 49 Perhaps paradoxically, while the EPS 
shields bacteria from harsh external conditions, bacteria within the EPS actual encounter 
harsh internal conditions including, but not limited to, decreased oxygen and nutrient 
levels.36, 37, 50, 51 51 
 As a result of the harsh conditions inside the biofilm, it is largely accepted that 
some cells in the biofilm, particularly those deep within the matrix, exist in a slow-growing 
state.38 This decreased metabolic growth rate is also postulated to play a critical role in 
the ability of bacteria in the biofilm to resist the action of antibiotics that target-specific 
growth factors. For example, b-lactams, which target cell wall synthesis, are ineffective 
against non-dividing cells.36, 37, 47, 49 Moreover, these persistent cells, i.e. dormant versions 
of regularly growing cells, are critical to the restoration of biofilm communities following 
antimicrobial treatment.49 In sum, the physical barrier the biofilm provides as well as the 
phenotypic shift in metabolic rates and gene expression it causes for the bacteria 
enclosed within the matrix account for the increased resistance of bacteria in the biofilm 
state. 
 The first evidence that GBS could form biofilms came from a study by Marrie and 
Costerton wherein they isolated GBS from biofilms on intrauterine devices.52 Importantly, 
the isolated GBS strains were found in association with other known biofilm formers like 
S. aureus. Since this initial study, additional studies have demonstrated the ability of GBS 
to form biofilms on biotic and abiotic surfaces.5, 53-56 These studies have also shown that 
GBS pili and CPS are key to biofilm formation.53, 56, 57 Moreover, it has been found that 
environmental conditions including pH and media nutrient levels can have a strong 
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influence on biofilm formation.5, 55, 58 For example, it has been reported that acidic pH 
stimulates the production of biofilm in GBS. This finding subsequently led to the 
hypothesis that the acidic environment of the vagina signals the bacteria to produce 
biofilm thus allowing them to persist in a hostile environment.55, 58 While it has been shown 
that GBS can persist in the female genital tract, it is not yet well-understood how the 
bacteria accomplish this long-term.55, 59 Similarly, while there is evidence of the 
importance of biofilm formation to GBS survival, more research is needed to confirm the 
relevance of GBS biofilm formation in vivo.55 
 
3.1.5 Maternal-Derived Sources of Protection Against GBS 
 As noted earlier, of the infants born to GBS colonized mothers, only around 50% 
will become colonized with GBS themselves. Of that population, approximately 1-2% will 
develop invasive GBS disease. This apparent disconnect between maternal GBS 
colonization and infant GBS disease development led researchers to investigate potential 
maternal-derived sources of protection against GBS. Thus far, two major sources of 
protection have been identified: maternal antibodies and human milk oligosaccharides 
(HMOs). 
 As discussed in Chapter 2, human milk contains numerous immune-modulating 
components, such as SIgA, that serve to protect infants from infection. Indeed, high levels 
of breast milk SIgA could prevent the carbohydrate-mediated attachment of GBS to the 
epithelial cells of the nose and throat thus protecting infants from developing invasive 
GBS disease.3 The association between maternal type-specific anti-CPS antibody 
concentrations and the occurrence of GBS disease in newborns was initially reported by 
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Baker and Kasper in the late 1970s. In the original study, Baker and Kaper identified an 
antibody in maternal serum which bound a purified polysaccharide antigen extracted from 
a type III serotype GBS strain.60 Moreover, they found that women who were deficient in 
this antibody were more likely to give birth to infants who developed invasive GBS disease. 
The presence of type III CPS-specific antibodies is also notable as type III serotype GBS 
strains are responsible for the majority of LOD cases. Subsequent studies reaffirmed an 
association between low maternal serotype-specific antibodies against type III CPS 
antigens and an increased risk of newborns developing invasive GBS disease.61-64 
Additional studies have also shown the presence of type Ia, II, and V CPS-specific 
antibodies in maternal serum and their link to lowered incidences of invasive GBS 
disease.3, 62, 64, 65 
 In addition to antibodies, HMOs have shown to be important sources of protection 
for infants against several pathogens. While a more exhaustive description of these 
protections is provided in Chapter 2, briefly, HMOs offer direct protection against 
pathogens by serving as antiadhesive antimicrobials. By resembling glycan cell surface 
receptors, HMOs can serve as decoy receptors to prevent the adhesion of pathogens, 
such as C. jejuni and E. coli, to epithelial cells; adhesion is the first step in a pathogen’s 
progression towards invasive disease.9 These results demonstrate the possibility that 
HMOs offer protection against GBS through a similar mechanism. Additionally, the 
structural similarities between HMOs and GBS CPS (see Figure 3.2), especially the 
serotype Ia and Ib, creates a unique link between HMOs and GBS. Indeed, murine 
monoclonal antibodies to type Ib GBS CPS have been shown to also bind to LST a (3.1) 
and LNT (2.4) (Figure 3.4).66 
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3.1.6 HMOs as a Source of Protection Against GBS: Previous Work 
 Recently, researchers began to investigate the roles HMOs have in GBS disease 
prevention. In a study from 2016 by Le Doare and coworkers, it was found that infants 
born to Lewis-positive mothers were significantly less likely to be colonized with GBS 
themselves at birth and were also more likely to clear colonization within ninety days than 
infants born to Lewis-negative mothers.4 There was, however, no association found 
between Secretor status and GBS colonization levels. Finally, they found that the 
presence of LNDFH I (2.26, see Figure 2.10 in Chapter 2) and other similarly branched 
HMOs in milk was associated with significantly reduced levels of GBS growth.  
 In 2017, the Bode laboratory published a report that similarly demonstrated the 
ability of HMOs to inhibit GBS growth.67 Using pooled HMO extracts (pHMO), Bode et al. 
found that HMOs possessed dose-dependent bacteriostatic activity against GBS strains 
of serotypes Ia, III, and V. Additionally, they showed that this activity did not extend to 
uropathogenic E. coli (UPEC), P. aerugeniosa, or S. aureus. In an attempt to more 
narrowly define the active HMOs, they next separated pHMOs into sialylated, acidic 
HMOs (aHMOs) and non-sialylated, neutral HMOs (nHMOs). This separation facilitated 
Figure 3.4. Structures of LS-tetrasaccharide a (LST a, 3.31) and lacto-N-tetraose 
(LNT, 2.4). 
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the discovery that the acidic fraction of HMOs did not inhibit GBS growth. Armed with the 
knowledge that the neutral portion of pHMOs were more active, Bode and coworkers next 
tested various single-entity neutral, fucosylated and non-fucosylated HMOs for activity 
against GBS. At 5 mg/mL, they found that LNT (2.4) and its fucosylated variant LNFP I 
(2.10, see Figure 2.10 in Chapter 2) possessed the strongest antimicrobial activity.  
 Intrigued by these studies as well as the potential link between breastfeeding and 
GBS transmission, especially with regard to LOD, the Townsend lab began a program 
aimed at identifying and describing the protective effects of HMOs against GBS. To test 
the original hypothesis that HMOs possess antimicrobial and antivirulence activities, 
Townsend et al. assessed the antimicrobial and antibiofilm activities of whole HMO 
extracts from five different donors against a serotype V GBS strain (CNCTC 10/84).68 
Importantly, prior to biological evaluation, the Secretor and Lewis blood group status of 
each sample was determined using a high throughput mass spectrometry technique 
developed by Kunz and coworkers. This technique uses matrix assisted laser desorption 
ionization-time of flight (MALDI-TOF) MS and MS/MS to produce a mass fingerprint 
whose MS and MS/MS fragmentation peaks and intensities can be used to characterize 
fucosyl linkages in the HMOs present.69 Due to the relationship between HMO 
fucosylation patterns and blood group status (detailed in Chapter 2), the corresponding 
Secretor and Lewis blood groups can be assigned based on HMO fucosylation patterns. 
The results of these experiments are summarized in Table 3.2; donor numbers 
correspond to the numbers previously assigned to each donor by the Vanderbilt 
Department of Pediatrics. 
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 Following blood group assignments, HMO extracts were tested for their ability to 
alter GBS growth and viability over 24 h using a plate-based assay (Figures 3.5 and 
3.6).68 These evaluations were performed in both Todd-Hewitt Broth (THB) and THB 
supplemented with 1% glucose with HMOs dosed at 5 mg/mL.  
 
 
 
 
 
 
 
 
Donor Lewis Blood Group Milk Group 
43 a+b- Se-Le+ 
42 a-b+ Se+Le+ 
38 a-b- Se+Le- 
20 a-b+ Se+Le+ 
16 a-b- Se+Le- 
Table 3.2. Secretor and Lewis Blood Group Assignments of Five Donor Milk Samples 
Figure 3.5. Effect of heterogeneous HMOs dosed at ca. 5 mg/mL on viability of GBS 
CNCTC 10/84 in THB. Enumeration of CFU/mL was performed at 0, 2, 4, 6, 8, 10, 12, 
22, and 24 h. Mean log10CFU/mL for each HMO source and time point is indicated by 
the respective symbols. Data displayed represent the mean log10CFU/mL ± SEM, of 
three independent experiments each with three technical replicates. * represents p < 
0.05, ** represents p < 0.01, *** represents p < 0.001, and **** represents p < 0.0001 by 
two -way ANOVA with posthoc Dunnett’s multiple comparison test comparing the viability 
of GBS CNCTC 10/84 in each HMO supplementation condition to the viability of GBS 
CNCTC 10/84 in media alone. 
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In both growth conditions, HMOs from Donor 43 demonstrated significant 
antimicrobial activity; GBS growth was decreased by around 40%. It is important to note 
though, that GBS growth did begin to rebound before the end of the 24 h growth period. 
This demonstrates the bacteriostatic rather than bactericidal activity of HMOs, which 
agreed with previous studies.67, 70  In THB, HMOs from Donor 38 also showed significant 
antimicrobial activity though to a lesser extent than those from Donor 43. In THB + 1% 
glucose, however, HMOs from Donor 38 did not cause any significant alternations to GBS 
growth. HMOs from the remaining donors showed no significant antimicrobial activity in 
either growth condition.  
 
Figure 3.6. Effect of heterogeneous HMOs dosed at ca. 5 mg/mL on viability of GBS 
CNCTC 10/84 in THB + 1% glucose (glc). Enumeration of CFU/mL was performed at 
0, 2, 4, 6, 8, 10, 12, 22, and 24 h. Mean log10CFU/mL for each HMO source and time 
point is indicated by the respective symbols. Data displayed represent the mean 
log10CFU/mL ± SEM, of three independent experiments each with three technical 
replicates. * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, and 
**** represents p < 0.0001 by two -way ANOVA with posthoc Dunnett’s multiple 
comparison test comparing the viability of GBS CNCTC 10/84 in each HMO 
supplementation condition to the viability of GBS CNCTC 10/84 in media alone. 
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Using the same-plate based assay, antibiofilm activity of the HMO extracts at 5 
mg/mL was evaluated at 24 h of growth (Figure 3.7).68 To account for any accompanying 
antimicrobial activity, the biofilm results were expressed as a ratio of biofilm produced to 
the number of bacterial cells present (biomass); this essentially provides a measurement 
of biofilm produced per bacterial cell. While in THB no HMO extracts inhibited biofilm 
Figure 3.7. Effects of heterogeneous HMOs dosed at ca. 5 mg/mL on GBS CNCTC 10/84 
biofilm production after 24 h of growth. (A) Biofilm production in THB, denoted by the ratio 
of biofilm/biomass (OD560/OD600), in the presence of heterogenous HMOs relative to 
biofilm production in media alone. Data displayed represent the relative mean 
biofilm/biomass ratio ± SEM of at least three independent experiments, each with 3 
technical replicates, wherein biofilm production in media alone is assigned a value of 
100%. *** represents p = 0.0008 by one-way ANOVA, F = 23.35 with posthoc Dunnett’s 
multiple comparison test comparing biofilm production in the presence of HMOs to biofilm 
production in media alone.  (B) Biofilm production in THB + 1% glc, denoted by the ratio 
of biofilm/biomass (OD560/OD600), in the presence of heterogeneous HMOs relative to 
biofilm production in media alone. Data displayed represent the relative mean 
biofilm/biomass ratio ± SEM of at least three independent experiments, each with 3 
technical replicates, wherein biofilm production in media alone is assigned a value of 
100%. ** represents p = 0.0018 by one-way ANOVA, F = 3.449 with posthoc Dunnett’s 
multiple comparison test comparing biofilm production in the presence of HMOs to biofilm 
production in media alone. Mean GBS biofilm production levels in media alone are 
marked with a dotted line.  
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formation, in THB + 1% glucose (which has been shown to promote biofilm production),55 
HMOs from Donor 38 did significantly decrease biofilm formation. 
 
As a final evaluation of HMO antibiofilm activity, Townsend et al. used scanning 
electron microscopy (SEM) and confocal laser scanning microscopy (CSLM) to evaluate 
the qualitative effects of HMOs on GBS biofilm formation (ex. alterations in biofilm 
structure and architecture) (Figure 3.8).68 Interestingly, treatment with HMOs from Donor 
43 resulted in biofilms that were smaller and less diffuse. Moreover, HMOs from Donor 
43 caused changes in GBS chaining morphology. As opposed to the typical long, 
organized chains of GBS, in the presence of Donor 43 HMOs, GBS organized into 
truncated chains that were more densely packed compared to the control grown in the 
absence of HMOs. Additionally, GBS grown in the presence of HMOs from Donors 38 
and 16 appeared to have less prominent nutrient channels in the biofilm. HMOs from 
Figure 3.8. SEM micrographs of GBS CNCTC 10/84 biofilm formation after 24 h. GBS 
CNCTC 10/84 was cultured in THB + 1% glucose supplemented with HMOs from 
individual donor samples for 24 h at 37 oC. Images are shown at 1000x magnification. 
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Donor 38 were also shown using CSLM to decrease the overall thickness of GBS biofilm 
(results not shown). Moreover, carbohydrates were shown to be concentrated at the tops 
of the biofilm. 
 Encouragingly, the results of this preliminary study demonstrated that HMOs 
possess both antimicrobial (bacteriostatic) and antibiofilm activities against GBS. 
Additionally, this study represented the first report of HMOs serving as antibiofilm agents. 
While encouraging, this probing study was nevertheless somewhat narrow in scope using 
HMOs from only five donors and testing against only one GBS strain. To address these 
limitations, an accompanying study was completed that not only expanded the number of 
donors but also expanded the number of GBS strains tested from one to three. We 
hypothesized that this expanded study would allow for, one, investigation of a potential 
relationship between Lewis and Secretor status and HMO biological activity, and, two, 
determination of whether HMO biological activity against GBS was species- or strain-
specific. The results of this work are presented herein. 
 
3.2 Evaluation of Antimicrobial and Antibiofilm Properties of Heterogenous HMOs71 
 The work described herein was enabled by the generous donation of human milk 
from a number of women from across the United States. Milk samples were obtained 
through Dr. Jörn-Hendrik Weitkamp of the Vanderbilt Department of Pediatrics as well as 
Medolac. Evaluation of heterogenous HMO antibacterial activity against GBS was 
completed in partnership with Dr. Dorothy L. Ackerman.  
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3.2.1 HMO Isolation and Blood Group Characterization 
 
 
HMOs from fourteen new donors were isolated using the four-step procedure 
illustrated in Figure 3.9. Briefly, fats are first removed via centrifugation. Proteins are then 
precipitated with ethanol and removed via centrifugation. Finally, HMOs can be de-salted 
(purified) using size exclusion chromatography. Following HMO isolation, the Lewis and 
Secretor status of each donor were assigned using the high throughput HMO mass 
fingerprinting technique developed by Kunz and co-workers (described previously); again, 
donor sample numbers correspond to the numbers previously assigned to each donor by 
the Vanderbilt Department of Pediatrics (Table 3.3). In total, blood groups for nineteen 
donors (five from previous study and fourteen from the presently described study) were 
then
centrifuge
+ EtOH
Concentrate 
supernatant
Centrifuge
Size exclusion 
chromotography
then
concentrate
Whole milk
HMOs + 
lactose
+≡
HMOs
ProteinFat
Figure 3.9. Isolation of HMOs from whole milk workflow. 
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assigned. Importantly, the distribution of Lewis blood groups for these nineteen donors 
tracks well with distributions reported previously for larger populations (Table 3.4).72-74 
 
 
 
 
 
 
3.2.2 Evaluation of Antimicrobial and Antibiofilm Activities of HMOs Against GBS71 
 After assigning blood groups to each HMO sample, we moved to test the 
antimicrobial and antibiofilm activities of HMOs from the fourteen new donors. To 
determine whether any observed activity was strain- or species-specific, we expanded 
the number of GBS strains from one to three. In addition to assaying against strain 
Donor Lewis Blood Group Milk Group 
0 a-b+ Se+Le+ 
5 a-b+ Se+Le+ 
7 a-b+ Se+Le+ 
8 a-b+ Se+Le+ 
14 a-b+ Se+Le+ 
17 a+b- Se-Le+ 
18 a+b- Se-Le+ 
19 a-b+ Se+Le+ 
24 a-b+ Se+Le+ 
29 a+b- Se-Le+ 
31 a+b- Se-Le+ 
32 a-b+ Se+Le+ 
34 a-b+ Se+Le+ 
37 a-b+ Se+Le+ 
Lewis Blood Group Distribution 
a-b+ 63% 
a-b- 22% 
a+b- 26% 
Table 3.4. Lewis Blood Group Distribution for Nineteen Donor Milk Samples  
Table 3.3. Secretor and Lewis Blood Group Assignments of Fourteen Donor Milk Samples 
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CNCTC 10/84, we also assayed against the clinical isolate strains GB590 and GB2. 
Importantly, these strains are each of a differing serotype. CNCTC 10/84, GB590, and 
GB2 are serotypes V, III, and Ia strains, respectively. These particular strains and 
serotypes were chosen due to their relevance to the global GBS burden; of the ten 
identified serotypes, Ia, Ib, II, III, and V account for over 85% of cases of invasive GBS 
disease.34, 56, 75 Moreover, type III serotype strains are the most prevalent isolates 
associated with neonatal disease in the developed world.34, 76 
 In addition to screening against multiple strains of GBS, we also elected to screen 
in two different media sources. For each HMO sample, activity was evaluated in both THB 
and THB + 1% glucose as supplementation with 1% glucose has been shown to increase 
bacterial biofilm production.53, 55 Finally, HMOs were screened for activity at a 
concentration of ca. 5 mg/mL as this concentration is at the low end of physiological levels; 
HMOs are typically found in milk at 5-25 mg/mL depending on the stage of lactation.77 
 Antimicrobial and antibiofilm activity were assessed at 24 h of growth using a plate-
based biofilm assay which allows for spectrophotometric quantification of both bacterial 
growth and biofilm formation. Growth (biomass) was first quantitated via 
spectrophotometric readings at an optical density of 600 nm (OD600). Following the initial 
biomass reading, free-floating bacteria were gently removed and the remaining, adherent 
bacteria (i.e. bacteria in the biofilm) were stained with crystal violet. Bacteria in the biofilm 
could then be quantitated via spectrophotometric readings at OD560. To account for any 
accompanying antimicrobial activity, biofilm results are expressed as a ratio of total biofilm 
produced (OD560 value) to the number of bacterial cells present (biomass, OD600 value). 
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This method allows for analysis of changes in biofilm production relative to the number of 
bacterial cells present.  
   
 
Change in biomass from control (%) ± SEM 
S. agalactiae 
CNCTC 10/84 
S. agalactiae 
GB590 
S. agalactiae 
GB2 
Lewis 
blood 
group 
Donor THB THB + 1% glc THB 
THB + 
1% glc THB 
THB + 
1% glc 
a-b+ 
 
0 -4 ± 2 +11 ± 2 +14 ± 3 +11 ± 3 +5 ± 2 +9 ± 2 
5 -26 ± 1 -12 ± 2 -31 ± 6 -9 ± 2 -22 ± 1 -5 ± 1 
7 -3 ± 1 +13 ± 4 +6 ± 3 +8 ± 2 -1 ± 2 -3 ± 2 
8 -80 ± 6 -5 ± 2 -75 ± 9 -8 ± 5 -89 ± 4 -6 ± 2 
14 +3 ± 1 +43 ± 1 +8 ± 4 +50 ± 2 +14 ± 2 +57 ± 1 
19 -8 ± 2 +7 ± 3 +13 ± 1 +28 ± 2 +11 ± 2 +14 ± 3 
24 -11 ± 3 +8 ± 1 +11 ± 3 +20 ± 2 +9 ± 3 -3 ± 1 
32 -14 ± 1 -16 ± 1 +10 ± 2 +15 ± 3 +14 ± 2 +6 ± 2 
34 +2 ± 1 +2 ± 3 +21 ± 3 +25 ± 4 +15 ± 2 +19 ± 5 
37 -1 ± 2 -17 ± 3 +23 ± 3 +24 ± 3 0 ± 2 +19 ± 3 
a+b- 
 
17 -2 ± 1 +4 ± 4 +7 ± 2 +17 ± 3 +7 ± 2 +17 ± 4 
18 -13 ± 3 +11 ± 1 -11 ± 3 +14 ± 2 -1 ± 2 -6 ± 2 
29 -42 ± 1 -17 ± 2 -35 ± 11 -22 ± 6 -15 ± 1 -6 ± 1 
31 -6 ± 2 +18 ± 2 +3 ± 2 +33 ± 4 +7 ± 2 +24 ± 3 
 asignificant growth inhibition (p ≤ 0.05, one-way ANOVA) compared to control is bolded and highlighted in 
blue. 
Table 3.5. Antimicrobial Activity of Heterogeneous HMO Extracts Against Three Strains 
of S. agalactiae (GBS)a 
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 To evaluate antimicrobial activity, we compared the biomass of bacteria grown in 
the presence of HMOs to that of bacteria grown in the absence of HMOs. Using this 
standard, several HMO samples were found to significantly inhibit bacterial growth for 
multiple GBS strains and both growth conditions (p ≤ 0.05 by one-way ANOVA with 
posthoc Dunnett’s multiple comparison test) (Table 3.5). The results presented in Table 
3.5 are shown as the average percent change ± standard error of the mean (SEM) from 
the control (bacteria grown in media without HMOs) where negative numbers represent 
an overall decrease in growth and positive numbers represent an overall increase in 
growth. 
The effects of HMOs from Donor 8 on GBS growth are particularly noteworthy. In 
THB, HMOs from Donor 8 decreased growth by more than 70% for all GBS strains. 
However, when 1% glucose was added to the growth medium, a drastic decrease in 
activity for Donor 8’s HMOs was observed; in THB + 1% glucose, HMOs from Donor 8 
decreased GBS growth by less than 10% for all three strains. It is possible that the 
profound antimicrobial activity of this sample, especially when compared to the activity of 
the other donors tested, may, in part, be a result of when in the lactation period the sample 
was collected. The time of collection can be important as HMO concentration and 
expression change of over the course of lactation (detailed in Chapter 2). For example, 
HMO concentrations are highest early in lactation and numerous studies have reported 
higher concentrations of a1-2 fucosylated HMOs, including 2’-FL, in early milk.78-80 
Moreover, it has been suggested based on milk composition that the primary purpose of 
colostrum (the earliest milk) is protective rather than nutritive (see Chapter 2).81 Thus, it 
is possible that milk from Donor 8 was collected at a significantly earlier point in lactation  
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than the other samples and thus has larger quantities of HMOs that are especially 
protective against GBS. Due to milk sample deidentification, however, it is difficult to 
confidently assign an explanation for the marked activity of Donor 8.  
To evaluate antibiofilm activity, we compared the biofilm/biomass ratios of bacteria 
grown in the presence of HMOs to bacteria grown in the absence of HMOs. Using this 
standard, all HMO samples were found to significantly reduce biofilm formation of at least 
one GBS strain (p ≤ 0.05 by one-way ANOVA with posthoc Dunnett’s multiple comparison 
test) (Table 3.6). In numerous cases, biofilm production was reduced by over 80% relative 
to the control. It is important to note that in order to determine significant reductions in 
GBS biofilm production in THB, the results from Donor 8 were omitted from analysis; 
results from Donor 8 were confirmed to be outliers by both ROUT (Q = 1%) and Grubbs 
(a = 0.05) outlier tests. It is likely that the exceptionally high biofilm/biomass ratios seen 
for Donor 8’s HMOs are due to their extreme antimicrobial activity in THB (growth 
reductions were over 75% for each GBS strain). With the less dramatic antimicrobial 
activity seen for this sample in THB + 1% glucose, the biofilm/biomass ratios return to 
more reasonable, non-outlying values. 
Overall, HMO antibiofilm activity appeared to be strongest against GB2 as eleven 
out of fourteen samples significantly reduced biofilm formation in at least one growth 
medium. While there also appeared to be strong antibiofilm activity against GB590, large 
fluctuations were observed in biofilm measurements for this strain, presumably due to 
variations in plate workup, and this variation precluded significant antibiofilm activity 
assignments for all HMOs. Interestingly, GB2 and GB590 were overall less susceptible 
than CNCTC 10/84 to growth reductions caused by HMO supplementation. The varying 
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susceptibilities of each strain to HMO supplementation demonstrated that HMO 
antimicrobial and antibiofilm activity can indeed be strain- rather than species-specific. 
 
Change in biofilm/biomass from control (%) ± SEM 
S. agalactiae 
CNCTC 10/84 
S. agalactiae 
GB590 
S. agalactiae 
GB2 
Lewis 
blood 
group 
Donor THB THB + 1% glc THB 
THB + 
1% glc THB 
THB + 
1% glc 
a-b+ 
 
0 -67 ± 11b -32 ± 13 -40 ± 28 -26 ± 6 -28 ± 14b -45 ± 3 
5 -80 ± 7 -1 ± 8 -17 ± 35 -19 ± 8 -51 ± 6b -45 ± 3 
7 -33 ± 13 -36 ± 11 -23 ± 22 -24 ± 5 +10 ± 37 -6 ± 4 
8 +346 ± 229 -5 ± 17 
+178 ± 
115 -21 ± 7 
+273 ± 
71 -49 ± 5 
14 -63 ± 13b -38 ± 11 -46 ± 18 -58 ± 5 -93 ± 4b -83 ± 1 
19 -71 ± 7b -23 ± 16 -10 ± 54 -28 ± 5 -40 ± 10b -51 ± 2 
24 -70 ± 8b -81 ± 3 0 ± 46 -42 ± 10 -70 ± 9b -33 ± 4 
32 -79 ± 6b -21 ± 12 -13 ± 44 -20 ± 6 +31 ± 25 -6 ± 3 
34 -37 ± 16 -20 ± 8 11 ± 32 5 ± 7 +8 ± 24 -13 ± 3 
37 -53 ± 11b +34 ± 14 22 ± 35 -5 ± 3 +39 ± 28 -10 ± 3 
a+b- 
 
17 -65 ± 7b -20 ± 8 -35 ± 17 -11 ± 3 +11 ± 24 -19 ± 3 
18 -38 ± 18 -40 ± 12 -18 ± 40 -18 ± 3 -53 ± 21b +7 ± 5 
29 -60 ± 8b -27 ± 12 -3 ± 52 +80 ± 31 -37 ± 12b -23 ± 5 
31 -33 ± 15 -43 ± 9 -23 ± 25 -54 ± 5 -43 ± 10b -69 ± 2 
asignificant biofilm inhibition (p ≤ 0.05, one-way ANOVA) compared to control is bolded and highlighted in 
blue. bstatistically significant activity when results from Donor 8 were omitted; Donor 8 was determined 
to be an outlier by both ROUT and Grubbs tests. 
Table 3.6. Antibiofilm Activity of Heterogeneous HMO Extracts Against Three Strains of 
S. agalactiae (GBS)a 
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As mentioned previously, another goal of the present study was to determine if 
there is a relationship between HMO activity and Lewis blood and Secretor status of the 
donor. Interestingly, the data presented herein (Tables 3.5 and 3.6) did not reveal any 
such relationship. Indeed, the data suggests that HMOs from Secretors and non-
Secretors generally demonstrate comparable levels of biological activity.  
 
3.2.3 Evaluation of Antimicrobial and Antibiofilm Activities of HMOs Against 
Staphylococcus aureus and Acinetobacter baumannii71 
Encouraged by the strong antimicrobial and antibiofilm activities observed for 
HMOs against GBS, we next set out to determine if similar activities would be observed 
against other Gram-positive species. Moreover, we were interested to see if HMOs also 
possessed activity against a Gram-negative species. Ultimately, we elected to screen 
against two of the ESKAPE pathogens: Staphylococcus aureus (Gram-positive) and 
Acinetobacter baumannii (Gram-negative).  
While the ESKAPE pathogens were discussed in detail in Chapter 1, briefly, the 
pathogens in this group (Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter 
species) are the leading causes of multidrug resistant (MDR) nosocomial infections 
worldwide and are characterized by their high levels of antimicrobial resistance.48, 82-84 
While each ESKAPE pathogen is highly clinically relevant, S. aureus and A. baumannii 
were selected specifically due to their relevance to pediatric populations and the 
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corresponding urgent need to develop therapeutics to protect pediatric populations from 
infectious diseases (Table 3.7).85-88  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age Common Pathogens 
< 2 days Group B Streptococcus 
2 days to 2 weeks Group B Streptococcus 
14 days to 60 days 
Group B Streptococcus 
Staphylococcus aureus 
Escherichia coli 
Klebsiella pneumonia 
Enterobacteriaceae 
Listeria monocytogenes 
2 months to 5 years 
Group B Streptococcus 
Streptococcus pneumoniae 
Staphylococcus aureus 
Staphylococcus epidermidis 
Candida albicans 
Haemophilus influenza 
Enterobacteriaceae 
Acinetobacter baumannii 
60 days to 5 years 
Haemophilus influenza 
Streptococcus pneumonia 
Acinetobacter baumannii 
5 years to 10 years 
Group A Streptococcus 
Streptococcus pneumoniae 
Acinetobacter baumannii 
10 years to 21 years 
Group A Streptococcus 
Haemophilus influenza 
Streptococcus pneumonia 
Mycoplasma pneumoniae 
Chlamydia pneumonia 
Table 3.7. Important Pathogens Responsible for Infection During Pediatric Age Period 
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Change in biomass from control (%) ± SEM 
S. aureus 
USA300 
A. baumannii 
ATCC 19606 
Lewis 
blood 
group 
Donor THB THB + 1% glc THB 
THB + 
1% glc 
a-b+ 
0 +8 ± 2 +6 ± 3 +4 ± 2 -1 ±2 
5 +9 ± 2 +44 ± 2 +5 ± 2 1 ±1 
7 -2 ± 2 +0 ± 3 0 ± 2 -4 ±1 
8 +2 ± 3 +22 ± 1 -5 ± 1 -10 ± 2 
14 +1 ± 2 -7 ± 2 +6 ± 4 -2 ±2 
19 +10 ± 2 +11 ± 4 +2 ± 2 0 ±1 
24 +4 ± 2 -3 ± 4 +2 ± 2 -6 ± 2 
32 +3 ± 2 -4 ± 4 +7 ± 1 0 ±1 
34 +6 ± 2 +1 ± 3 +8 ± 2 +4 ±2 
37 +8 ± 2 +5 ± 3 +8 ± 2 +2 ±1 
a+b- 
17 +4 ± 2 -2 ± 3 +8 ± 2 1 ±1 
18 -2 ± 2 -8 ± 5 -2 ± 2 -5 ±1 
29 +5 ± 2 +12 ± 3 -7 ± 2 -11 ± 2 
31 +3 ± 3 -5 ± 3 -2 ± 1 -6 ± 1 
asignificant growth inhibition (p ≤ 0.05, one-way ANOVA) compared to control is 
bolded and highlighted in blue. 
Table 3.8. Antimicrobial Activity of Heterogeneous HMO Extracts Against S. aureus and 
A. baumanniia 
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Employing the previously described plate-based assay, the antimicrobial and 
antibiofilm activities of HMOs against S. aureus strain USA300 and A. baumannii strain 
ATCC 19606 were evaluated at 24 h of growth. Once again, for all screens, HMOs were 
dosed at ca. 5 mg/mL and activity was assessed in both THB and THB + 1% glucose. 
The results of these screens are shown in Tables 3.8 and 3.9. While no HMOs were 
found to inhibit S. aureus growth, HMOs from four samples (samples from both Secretor 
and non-Secretor donors) did significantly decrease the growth of A. baumannii in THB + 
1% glucose with reductions ranging from 6-11%; in THB, no growth inhibition was seen 
against either pathogen. Intriguingly, this result reverses the trend observed for HMO 
antimicrobial activity against GBS. Against GBS, greater antimicrobial activity was seen 
in THB, whereas against A. baumannii, greater activity is seen in THB + 1% glucose 
(Table 3.8). 
 Carbohydrate catabolism has been implicated as a critical step in the pathogenesis 
of streptococcal disease as a number of mechanisms (ex. initiation of virulence factor 
production) are closely associated with the ability of streptococci to use glucose.89 For 
example, it was shown by Manettii et al. that glucose supplementation enhanced biofilm 
production in Streptococcus pyogenes and that this enhancement was a direct result of 
environment acidification due to metabolism of glucose into organic acids.55, 90 Work from 
D’Urzo et al. provided evidence that this finding is also extendable to GBS biofilm 
formation. Concurrent with these reports, we hypothesize that, in the case of GBS, 
glucose supplementation assists the bacteria in averting exposure to HMOs.55, 58 
Conversely, A. baumannii is a member of the glucose non-fermenting class of 
bacteria which are not able to catabolize glucose and thus cannot use glucose 
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oxidatively.91 Although glucose catabolism is not possible, glucose does enhance A. 
baumannii anabolism. Interestingly, it has been demonstrated that glucose availability 
enhances lipopolysaccharide (LPS) production in A. baumannii.92 Theoretically, as LPS 
is a major component of the outer membrane of Gram-negative pathogens, one would 
anticipate the presence of glucose would enhance A. baumannii growth. Thus, more 
research is need to explain the observed reversal in selectivity.   
 While the limited antimicrobial activity of HMOs against the Gram-negative A. 
baumannii was not surprising, we were intrigued by the lack of activity seen against the 
Gram-positive S. aureus. It was also intriguing that not only did HMO supplementation 
not significantly decrease S. aureus growth, it also did not increase growth. Indeed, the 
HMOs appeared to have no effect on S. aureus growth. This led to the hypothesis that S. 
aureus does not, or perhaps cannot, catabolize HMOs. This hypothesis was supported 
by work from the McGuire and Bode laboratories which demonstrated that although HMO 
extracts stimulated the growth of S. aureus (isolated from human milk) over a 24 h period, 
this growth stimulation was not attributable to bacterial HMO catabolism.93 Additionally, 
they found that the extent of HMO-fostered growth stimulation was dependent on the 
nutritional components of the growth medium. 
 In contrast to a lack of antimicrobial activity against S. aureus, HMOs from 
numerous donors did exhibit significant antibiofilm activity against S. aureus with 
reductions in biofilm production ranging from 30-60% (Table 3.9). This antibiofilm activity 
was, however, unique to the THB + 1% glucose growth condition and also to the         
Le(a+b-) blood group (Lewis positive Secretor milk group). Against A. baumannii, HMO 
supplementation led only to increases in biofilm formation (Table 3.9). 
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Change in biofilm/biomass from control (%) ± SEM 
S. aureus 
USA300 
A. baumannii 
ATCC 19606 
Lewis 
blood 
group 
Donor THB THB + 1% glc THB 
THB + 
1% glc 
a-b+ 
 
0 +40 ± 7 -46 ± 7 +82 ± 8 +58 ± 12 
5 +446 ± 119 -25 ± 6 +197 ± 37 +79 ± 17 
7 +90 ± 19 -21 ± 11 +87 ± 51 +114 ± 20 
8 +325 ± 169 -33 ± 8 +153 ± 71 +117 ± 19 
14 +215 ± 81 -39 ± 9 +128 ± 6 +48 ± 7 
19 +59 ± 39 -40 ± 9 +96 ± 54 +83 ± 29 
24 +89 ± 56 -60 ± 11 +72 ± 55 +56 ± 14 
32 +113 ± 56 -22 ± 12 +111 ± 58 +73 ± 33 
34 +104 ± 57 -23 ± 12 +26 ± 33 +48 ± 23 
37 +80 ± 51 -35 ± 10 +80 ± 48 +71 ± 32 
a+b- 
17 +126 ± 51 -20 ± 11 +71 ± 48 +70 ± 22 
18 +160 ± 69 -8 ± 17 +90± 55 +95 ± 21 
29 +342 ± 139 5 ± 12 +321 ± 24 +114 ± 41 
31 +68 ± 42 -25 ± 9 +198 ± 29 +62 ± 21 
asignificant biofilm inhibition (p ≤ 0.05, one-way ANOVA) compared to control is bolded and 
highlighted in blue. 
Table 3.9. Antibiofilm Activity of Heterogeneous HMO Extracts Against S. aureus and   
A. baumanniia 
 
 175 
In addition to the lack of antimicrobial activity observed against S. aureus, the 
differing effects of HMOs on S. aureus biofilm production in THB versus THB + 1% 
glucose were striking. Moreover, the increase in biofilm production but not biomass due 
to HMO supplementation in glucose-free THB was particularly interesting. The potential 
of HMOs to serve as either stimulants or inhibitors of S. aureus biofilm formation 
depending on the nutritional content of growth medium was not, however, addressed in 
the McGuire and Bode study. As a result, we elected to investigate the effects of HMOs  
on S. aureus growth and biofilm production when the bacteria were exposed to a co-
treatment of HMOs and a known S. aureus biofilm-inhibitor, N-acetylcysteine (Ac-CYS-
OH; NAC).94-96  
Initial screens were performed to determine the MIC of NAC against S. aureus as 
well as patterns of biofilm formation in the presence of sub-MIC concentrations of NAC. 
In both THB and THB + 1% glucose, the MIC was found to be 8 mg/mL (Figure 3.10A 
and C). For biofilm production in THB, the only significant effect was seen at 2 mg/mL 
NAC. Despite being a reported biofilm inhibitor, at this concentration (4-fold below the 
MIC), NAC was found to significantly increase biofilm production (Figure 3.10B). This 
result was not wholly surprising though as several reports have found increased biofilm 
production levels for bacterial species, including as S. aureus, when grown in the 
presence of sub-MIC antimicrobial compound concentrations.97-99 In contrast, no 
concentration of NAC was found to significantly increase biofilm production when THB + 
1% glucose was used. Furthermore, at 4 mg/mL, NAC significantly decreased biofilm 
formation without completely inhibiting bacterial growth (Figure 3.10D).  
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 For the combined NAC and HMO treatment, we elected to assay HMOs from four 
different sources. The first two sources were samples from Donors 5 and 7. These 
samples were chosen due to their contrasting effects on S. aureus biofilm formation in 
THB (Table 3.9). For the remaining two samples, HMO cocktails were created based on 
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Figure 3.10. Effects of various concentrations of N-acetylcysteine (NAC) on S. aureus 
strain USA300 growth and biofilm formation after 24 h of growth. (A) Biomass in THB 
alone or in the presence of varying concentrations of NAC. (B) Biofilm to biomass ratio 
in THB alone or in the presence of varying concentrations of NAC. (C) Biomass in THB 
+ 1% glucose (glc) alone or in the presence of varying concentrations of NAC. (D) 
Biofilm to biomass ratio in THB + 1% glucose (glc) alone or in the presence of varying 
concentrations of NAC. All data are expressed as mean biomass (OD600) or 
biofilm/biomass (OD560/OD600) measurements ± SEM of 3 separate experiments, each 
with 3 technical replicates. **** represents p < 0.0001 by one-way ANOVA with posthoc 
Dunnett’s multiple comparison test comparing biomass or biofilm/biomass at each NAC 
concentration to biomass and biofilm/biomass in media alone. 
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antimicrobial and antibiofilm activities against GBS. Pulling from the pool of nineteen 
donors, the antimicrobial cocktail (am-cocktail) consisted of five samples that most 
consistently exhibited significant antimicrobial activity but limited antibiofilm activity, and 
the antibiofilm cocktail (ab-cocktail) consisted of seven samples that consistently 
exhibited significant antibiofilm activity but limited antimicrobial activity. The am-cocktail 
was composed of equal contributions from Donors 5, 8, 32, 43; the ab-cocktail was 
composed of equal contributions from Donors 0, 7, 14, 18, 19, 24, and 31. 
We observed that the combined treatment of HMOs (dosed at ca. 5 mg/mL) and 
NAC (dosed at various concentrations) generally did not result in greater growth inhibition 
than treatment with NAC alone for either growth condition (Figure 3.11). In THB, the 
combinations of 2 mg/mL NAC and HMOs from Donor 5, Donor 7, or the ab-cocktail 
resulted in a modestly significant reduction in bacterial growth compared to treatment with 
NAC alone (Figure 3.11A). However, no growth inhibition was observed for any other 
combination of HMO and NAC in either growth condition. Furthermore, several 
combinations actually increased growth compared to treatment with NAC alone (Figure 
3.11). 
For biofilm production at sub-MIC concentrations of NAC, only the combination of 
2 mg/mL NAC and the am-cocktail in THB + 1% glucose caused a significant reduction 
in biofilm production compared to treatment with NAC alone (Figure 3.12B). Interestingly, 
this combined treatment did not reduce biofilm production levels to a greater extent than 
treatment with the am-cocktail alone. Moreover, multiple HMO samples were actually 
found to increase biofilm production relative to treatment with NAC alone in either THB or 
THB + 1% glucose (Figures 3.12). Taken together, the results of these combination 
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studies appear to further demonstrate that HMOs have the potential to act as both growth 
and biofilm production stimulants for S. aureus.  
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Figure 3.11. Effect of co-treatment of HMOs and varying concentrations of N-
acetylcysteine (NAC) on S. aureus strain USA300 growth after 24 h. (A) Biomass in THB 
alone or in the presence of HMOs from various samples, varying concentrations of NAC, 
or combinations of NAC at various concentrations at ca. 5 mg/mL HMO. (B) Biomass in 
THB + 1% glucose (glc) alone or in the presence of HMOs from various samples, varying 
concentrations of NAC, or combinations of NAC at various concentrations at ca. 5 mg/mL 
HMO. Data are expressed as mean biomass measurements (OD600) ± SEM of 3 separate 
experiments, each with 3 technical replicates. ** represents p = 0.0028 and **** 
represents p < 0.0001 by two-way ANOVA with posthoc Dunnett’s multiple comparison 
test comparing each NAC and HMO concentration at a given NAC concentration to NAC 
alone at the same NAC concentration. When NAC concentration is 0 mg/mL, growth in 
media alone is compared to growth in the presence of HMOs.  
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Figure 3.12. Effect of co-treatment of HMOs and varying concentrations of N-
acetylcysteine (NAC) on S. aureus strain USA300 biofilm formation after 24 h. (A) Biofilm 
to biomass ratio in THB alone or in the presence of HMOs from various samples, varying 
concentrations of NAC, or combinations of NAC at various concentrations at ca. 5 mg/mL 
HMO. (B) Biofilm to biomass ratio in THB + 1% glucose (glc) alone or in the presence of 
HMOs from various samples, varying concentrations of NAC, or combinations of NAC at 
various concentrations at ca. 5 mg/mL HMO. Data are expressed as mean biofilm to 
biomass measurements (OD560/OD600) ± SEM of 3 separate experiments, each with 3 
technical replicates. **** represents p < 0.0001 by two-way ANOVA with posthoc 
Dunnett’s multiple comparison test comparing each NAC and HMO concentration at a 
given NAC concentration to NAC alone at the same NAC concentration. When NAC 
concentration is 0 mg/mL, growth in media alone is compared to growth in the presence 
of HMOs.  
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In summary, while HMOs did not possess significant antimicrobial activity against 
S. aureus, they were active against A. baumannii which demonstrates that HMO 
antimicrobial  activity is not limited to GBS or Gram-positive pathogens. That said, due to 
the severely lessened levels of antimicrobial activity seen for HMOs against A. baumannii 
compared to GBS, it does appear as though HMOs generally possess narrow-spectrum 
antimicrobial activity against GBS. In terms of antibiofilm activity, HMOs may possess 
broader-spectrum antibiofilm activity across Gram-positive species. Indeed, we observed 
maximum biofilm inhibitions of 93% and 60% compared to bacteria grown in the absence 
of HMOs for GBS and S. aureus, respectively. Although significant biofilm inhibition was 
observed against S. aureus, this was found to be dependent on the nutritional 
composition of the growth medium. Thus, the ability of HMOs to serves as antibiofilm 
agents as opposed to biofilm production stimulants for S. aureus will require further study.  
While the results of this study support the therapeutic potential of HMOs in disease 
intervention, they did not reveal a mechanism behind the observed antimicrobial and 
antibiofilm activities and, concurrently, the cellular target(s) remained unknown. In the 
following study, we aimed to expand upon the therapeutic potential of HMOs while 
simultaneously providing evidence for a potential mechanism of action behind the 
observed HMO antibacterial activities. The results of this study are presented herein. 
 
3.3 Investigation of HMO Antimicrobial Mechanism of Action100 
3.3.1 Evaluation of Heterogeneous HMOs in Antibiotic Combination Therapies 
 On the basis of our previous studies, we hypothesized that HMOs could sensitize 
GBS to small molecule antibiotics. Importantly, testing this hypothesis would not only 
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potentially broaden the therapeutic utility of HMOs but also assist in deciphering the 
mechanism(s) of action underlying HMO antibacterial activity. For the present study, we 
once again elected to use heterogenous HMO extracts as opposed to single compounds. 
Our reasoning was two-fold. First, the majority of single compounds are prohibitively 
expensive in the amounts required for this study. Second, several labs, including the 
Townsend lab, have shown that while there are several pharmacophoric units in human 
milk, individual HMOs are less effective against bacterial pathogens than heterogeneous 
mixtures. Indeed, studies from the Bode and Chen laboratories have found that while 
various disialylated HMOs can prevent necrotizing enterocolitis (NEC) in a neonatal rat 
model, these compounds are less effective than heterogenous HMO extracts.101, 102  
 Unlike the previously described study, for the present study, lactose was rigorously 
removed from the heterogenous HMO extracts. As pathogens are largely capable of 
catabolizing lactose but not HMOs, we hypothesized that rigorous removal of lactose 
would furnish a more potent carbohydrate mixture and would result in more accurate 
HMO concentrations for biological assays. The second-generation workflow for HMO 
isolation is presented in Figure 3.13.  
 Briefly, fats and proteins are removed in an analogous fashion to that shown in 
Figure 3.9. After protein removal, rather than directly subjecting the carbohydrate fraction 
to size exclusion chromatography, this fraction is first treated with b-galactosidase (from 
Kluveromyces lactis). b-galactosidase hydrolyses lactose into its constituent 
monosaccharide components, glucose and galactose, but is not able to hydrolyze the 
glycosidic bonds of HMOs. Thus, b-galactosidase treatment results in the formation of a 
new carbohydrate extract consisting of glucose, galactose, and HMOs. This mixture is 
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more desirable compared to a mixture of lactose and HMOs as the next purification step 
is size exclusion chromatography; the increased mass difference between the desired 
and undesired carbohydrate components greatly facilitates isolation of pure HMO 
fractions.   
 
 Another deviation from the previously described study was our decision in the 
present study to pool HMO extracts from different donors to create one HMO cocktail. 
Again, our reasoning was two-fold. First, pooling samples from different donors helped to 
account for variations in HMO composition seen from mother to mother; variations in 
activity among donors was not a focus of our work moving forward and was thus a variable 
we wished to eliminate. Second, the mechanistic studies we wanted to undertake required 
Figure 3.13. Second-generation isolation of HMOs from whole milk workflow. 
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significantly more material than could be obtained from a single donor. Thus, pooling 
samples was a necessity. 
 Related to the need for more material, two additional donors were added to the 
donor pool for the present study. Donors are denoted with either the sample label/number 
or the sample label/number and collection date (month/year) assigned to them by the 
providing company, Medolac. HMOs from these donors were isolated with rigorous 
removal of lactose, and the HMO extracts were subsequently evaluated for antimicrobial 
and antibiofilm activity against GBS strains  CNCTC 10/84, GB590, and GB2 (Tables  
3.10 and 3.11, respectively); again, HMOs were dosed at 5 mg/mL. It is important to note 
that while there are three HMO sources presented in Tables 3.10 and 3.11, two of these 
are derived from the same donor (RGB) at different points. Interestingly, the two RGB 
samples, collected three months apart, possessed varying levels of activity. However, as 
HMO composition is known to change over the course of lactation, this result was not 
wholly unexpected. 
 
Change in biomass from control (%) ± SEM 
S. agalactiae 
CNCTC 10/84 
S. agalactiae 
GB590 
S. agalactiae 
GB2 
Donor THB THB + 1% glc THB 
THB + 
1% glc THB 
THB + 
1% glc 
1049 -64 ± 5 -15 ± 5 -24 ± 9 +34 ± 14 -56 ± 7 -56 ± 2 
RGB 2/14 -12 ± 3  -35 ± 3 -12 ± 4 -11 ± 5 -11 ± 2 -17 ± 6 
RGB 5/14 +20 ± 6 +30 ± 6 +34 ± 5 +42 ± 7 +44 ± 2 +11 ± 4 
asignificant growth inhibition (p ≤ 0.05, one-way ANOVA) compared to control is bolded and 
highlighted in blue. 
Table 3.10. Antimicrobial Activity of Three Additional Heterogeneous HMO Extracts 
Against Three Strains of S. agalactiae (GBS)a 
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 With HMO cocktail in hand, we once again elected to screen against three strains 
of GBS of varying serotypes to determine whether any HMO-fostered antibiotic 
potentiation was strain- or species- specific. As before, we selected GBS strains CNCTC 
10/84 (serotype V), GB590 (serotype III), and GB2 (serotype Ia). For our antibiotic 
selection, the following antibiotics were selected due to their relevance to GBS prevention 
and treatment, i.e. the antibiotics suggested for IAP (Figure 3.1): penicillin (b-lactam), 
ampicillin (b-lactam), cefazolin (cephalosporin), clindamycin (lincosamide), and 
vancomycin (glycopeptide). We also elected to test erythromycin (macrolide), gentamicin 
(aminoglycoside), minocycline (tetracycline), and linezolid (oxazolidinone). Erythromycin, 
gentamicin, and minocycline, while not used for GBS treatments, were selected due to 
an increasing prevalence of GBS resistance to these antibiotics.103-105 Moreover, we 
hypothesized that their inclusion would assist in analyzing HMO mechanisms of action. 
Finally, linezolid was selected due to its overarching relevance to infectious disease 
 
Change in biofilm/biomass from control (%) ± SEM 
S. agalactiae 
CNCTC 10/84 
S. agalactiae 
GB590 
S. agalactiae 
GB2 
Donor  THB THB + 1% glc THB 
THB + 
1% glc THB 
THB + 
1% glc 
1049 -2 ± 2 +7 ± 14 -45 ± 22 -36 ± 7 -63 ± 15 -50 ± 19 
RGB 2/14 +16 ± 9  +174 ± 22 +44 ± 11 +43 ± 9 -25 ± 2 0 ± 7 
RGB 5/14 +53 ± 9 34 ± 6 +13 ± 14 +4 ± 5 -53 ± 2 -8 ± 3 
asignificant biofilm inhibition (p ≤ 0.05, one-way ANOVA) compared to control is bolded and 
highlighted in blue. 
Table 3.11. Antibiofilm Activity of Three Additional Heterogeneous HMO Extracts 
Against Three Strains of S. agalactiae (GBS)a 
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prevention; linezolid was included in the World Health Organization’s (WHO) list of 
essential medicines in 2017.106  
 To begin our studies, we determined MICs for the HMO cocktail and each antibiotic 
in both THB and THB + 1% glucose using a microbroth dilution assay. Bacterial growth 
was assessed after 24 h via spectrophotometric reading at OD600, and the MIC was 
assigned at the concentration where no bacterial growth was detected. In all cases, the 
HMO cocktail MIC was 10.25 mg/mL. Strain- and media-specific HMO IC50 concentrations 
(half maximal inhibitory concentrations) are provided in Table 3.12. Interestingly, at 
concentrations below 5 mg/mL (the low end of physiological concentration), HMOs were 
generally observed to promote bacterial growth (Figure 3.14).  
 
 
 
 
 
 
 For the combination treatments, HMOs were dosed at their IC50 values except for 
treatments against CNCTC 10/84 and GB590 in THB. For these trials, HMOs were dosed 
instead at 5 mg/mL as the HMO IC50 curves for these strains in THB were not reflective 
of the biomass data (Figure 3.14A and C). Regardless, is important to note that for all 
trials, HMOs were used at the low end of their typical physiological concentrations (5-25 
mg/mL). Antibiotic MICs are provided in Tables 3.13 and 3.14. With the solo MIC values 
determined, we moved to test the effects of HMO and antibiotic combined treatments. 
 S. agalactiae CNCTC 10/84 
S. agalactiae 
GB590 
S. agalactiae  
GB2 
THB 7.25 7.24 5.04 
THB + 1% glc 5.83 5.51 4.45 
aAll IC50 values are given in mg/mL. 
Table 3.12. HMO IC50 Values Against Three Strains of S. agalactiae (GBS)a 
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Figure 3.14. IC50 curves for HMO cocktail against three GBS strains in THB (A, C, E) 
and THB + 1% glucose (glc) (B, D, F). Bacterial growth (OD600) was recorded after 24 h 
of HMO treatment at 20.5; 10.25; 5.12; 2.56; 1.28; 0.64; 0.32; and 0 mg/mL. (A) HMO 
IC50 curve against CNCTC 10/84 in THB. (B) HMO IC50 curve against CNCTC 10/84 in 
THB + 1% glc. (C) HMO IC50 curve against GB590 in THB. (D) HMO IC50 curve against 
GB590 in THB + 1% glc. (E) HMO IC50 curve against GB2 in THB. (F) HMO IC50 curve 
against GB2 in THB + 1% glc. Data displayed represent the mean normalized growth 
(OD600) ± SEM	 of at least three independent experiments, each with 3 technical 
replicates. Mean normalized growth (OD600) for each time point is indicated by the 
respective symbols. 
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 S. agalactiae CNCTC 10/84 S. agalactiae GB590 S. agalactiae GB2 
Antibiotic 
MIC 
without 
HMO 
MIC 
with 
HMOc 
F.R.d 
MIC 
without 
HMO 
MIC 
with 
HMOc 
F.R.d 
MIC 
without 
HMO 
MIC 
with 
HMOc 
F.R.d 
Penicillin 0.03 0.12 0 0.03 0.06 0 0.03 0.06 0 
Ampicillin 0.125 0.125 0 0.0625 0.125 0 0.0625 0.125 0 
Cefazolin 0.125 0.125 0 0.125 0.125 0 0.125 0.125 0 
Clindamycin 0.0625 0.004 16 0.0625 0.0156 4 0.0312 0.0156 2 
Gentamicin 32 2 16 32 4 8 32 16 2 
Erythromycin 0.0312 0.0078 4 0.125 0.0156 8 0.0312 0.0156 2 
Linezolid 2 1 2 2 1 2 2 2 0 
Minocycline 0.03125 0.0156 2 4 1 4 0.25 0.125 2 
aall MIC values are given in µg/mL. bsignificant MIC fold reductions are bolded and highlighted in blue. cHMOs were dosed 
against CNCTC 10/84, GB590, and GB2 at 5.8; 5.5; and 4.5 mg/mL, respectively. dF.R. denotes MIC fold reduction.  
 S. agalactiae CNCTC 10/84 S. agalactiae GB590 S. agalactiae GB2 
Antibiotic 
MIC 
without 
HMO 
MIC 
with 
HMOc 
F.R.d 
MIC 
without 
HMO 
MIC 
with 
HMOc 
F.R.d 
MIC 
without 
HMO 
MIC 
with 
HMOc 
F.R.d 
Penicillin 0.03 0.015 2 0.03 0.03 0 0.03 0.015 2 
Ampicillin 0.0625 0.0312 2 0.0625 0.0625 0 0.125 0.0625 2 
Cefazolin 0.125 0.0625 2 0.125 0.0625 2 0.125 0.0625 0 
Vancomycin 2 1 2 1 0.5 2 1 0.5 2 
Clindamycin 0.0325 0.0156 2 0.0312 0.0156 2 0.0312 0.0078 4 
Gentamicin 16 2 8 16 1 16 16 2 8 
Erythromycin 0.0156 0.002 8 0.0312 0.001 32 0.0156 0.001 16 
Linezolid 2 1 2 2 1 2 2 1 2 
Minocycline 0.0625 0.0019 32 4 0.5 8 2 0.25 8 
aall MIC values are given in µg/mL. bSignificant MIC fold reductions are bolded and highlighted in blue. cHMOs were dosed 
against CNCTC 10/84, GB590, and GB2 at 5 mg/mL. dF.R. denotes MIC fold reduction. 
Table 3.13. Antibiotic Sensitization Data for HMOs Against Three Strains of S. agalactiae 
(GBS) in THBa,b  
Table 3.14. Antibiotic Sensitization Data for HMOs Against Three Strains of S. agalactiae 
(GBS) in THB + 1% Glucosea,b  
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 While the extent of antibiotic activity potentiation in co-treatments varied among 
strains and growth conditions, overarching patterns of activity potentiation did emerge. 
First, no potentiation was observed against any strain in either growth condition for the   
b-lactams (including cephalosporins) or vancomycin (Tables 3.13 and 3.14). Second, 
aside from linezolid, which saw no significant MIC fold reduction in either growth condition, 
all other ribosome-targeting antibiotics saw significant fold reductions against at least one 
GBS strain; MIC fold reductions of 4 or higher were deemed significant. Most notable 
were gentamicin and erythromycin. These antibiotics saw the most consistent activity 
potentiation and the largest MIC reductions, which reached as high as 32-fold. 
 Strain-specific GBS susceptibility was found to be dependent on the nutritional 
content of the growth medium. For example, while GB2 was the strain most globally 
affected by HMO supplementation in THB, in THB + 1% glucose, HMO supplementation 
had no effect on the activity of any antibiotic against GB2. While HMOs sensitized CNCTC 
10/84 and GB590 to a similar list of antibiotics as GB2, the magnitudes of the MIC fold 
reductions were highly variable. Perhaps the most striking example of this observation is 
clindamycin against CNCTC 10/84. In THB, HMO supplementation resulted in only a 2-
fold reduction while in THB + 1% glucose, HMO supplementation caused a 16-fold 
reduction. 
 Encouraged by these results, we next investigated whether the patterns of 
antibiotic potentiation against GBS were extendable to S. aureus (another Gram-positive 
pathogen). For antibiotic sensitization trials against S. aureus, HMOs were dosed at ca. 
5 mg/mL; the HMO cocktail did not completely inhibit bacterial growth even at 20 mg/mL 
(at the higher end of physiological concentration), so no IC50 values could be determined. 
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Initial screens in THB and THB + 1% glucose revealed that the only significant antibiotic 
MIC fold reduction was for gentamicin in THB + 1% glucose (Table 3.15 and Appendix 
A1). Additional trials confirmed an 8-fold reduction for gentamicin when dosed in 
combination with HMOs in THB + 1% glucose.  
 
  
 
 
  
 
 
 As a final point of study, we investigated whether HMOs could also sensitive A. 
baumannii (a Gram-negative pathogen) to small molecule antibiotics. The following 
antibiotics were used in combination treatments against A. baumannii: amikacin 
(aminoglycoside), tobramycin (aminoglycoside), minocycline (tetracycline), tigecycline 
(glycylcycline), and doripenem (b-lactam). An initial screen revealed similar patterns of 
antibiotic potentiation as were seen with the Gram-positive pathogens. Similar to GBS 
and S. aureus, no antibiotic activity potentiation was seen for antibiotics that inhibit cell 
wall synthesis (Table 3.16 and Appendix A1). Furthermore, as with S. aureus, the only 
significant antibiotic MIC fold reductions against A. baumannii were seen with the 
aminoglycosides. Additional trials corroborated 4-fold reductions for amikacin and 
Antibiotic MIC without HMO MIC with HMOc F.R.d 
Cefazolin 8 8 0 
Vancomycin 8 8 0 
Clindamycin 0.25 0.25 0 
Gentamicin 4 0.5 8 
Erythromycin 32 32 0 
Linezolid 1.7 3.4 0 
aall MIC values are given in µg/mL. bsignificant MIC fold reductions are bolded and 
highlighted in blue. cHMOs were dosed at 5 mg/mL. dF.R. denotes MIC fold reduction. 
Table 3.15. Antibiotic Sensitization Data for HMOs Against S. aureus in THB + 1% 
Glucosea,b  
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tobramycin in THB. No significant fold reductions were seen for any antibiotic in THB + 
1% glucose (see Appendix A1). 
 
 
 
 
 
 
 
 
 In summary, we observed that HMOs potentiate the activity of four classes of 
antibiotics with intracellular targets (aminoglycosides, lincosamides, macrolides, and 
tetracyclines) across multiple bacterial strains but do not potentiate the activity of cell wall- 
targeting antibiotics (b-lactams, cephalosporins, glycopeptides, and carbapenems). This 
result is particularly noteworthy as HMOs have been shown to act as bacteriostatic agents, 
yet bacteriostatic agents are often observed to antagonize the actions of bactericidal 
antibiotics. Against GBS, HMO combination treatments resulted in up to a 16-fold MIC 
reduction for clindamycin and gentamicin and up to a 32-fold reduction for erythromycin 
and minocycline. Furthermore, HMO supplementation significantly reduced the MICs of 
aminoglycosides against two of the ESKAPE pathogens.  
 The consistent aminoglycoside activity potentiation seen across both Gram-
positive and -negative species is particularly notable. While aminoglycosides are effective 
antibiotics and are classified by the WHO as a critically important class of antimicrobial, 
Antibiotic MIC without HMO MIC with HMOc F.R.d 
Amikacin 16 4 4 
Tobramycin 8 2 4 
Imipenem 0.5 1 0 
Meropenem 1 1 0 
Minocycline 0.31 0.31 0 
Tigecycline 0.0625 0.125 0 
Doripenem 0.5 1 0 
aall MIC values are given in µg/mL. bsignificant MIC fold reductions are bolded and 
highlighted in blue. cHMOs were dosed at 5 mg/mL. dF.R. denotes MIC fold reduction. 
Table 3.16. Antibiotic Sensitization Data for HMOs Against A. baumannii in THBa,b 
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the nephrotoxicity of this class limits their utility.107-110 Thus, the ability of HMOs, which 
are nontoxic at any concentration, to lower the effective dosage of aminoglycosides holds 
real therapeutic promise. Furthermore, while HMOs generally potentiated clindamycin, 
gentamicin, erythromycin, and minocycline activity across multiple strains, it is important 
to highlight that in the context of GBS, activity potentiation was strain-specific. This result 
provides support for the potential of developing narrow-spectrum strain-specific 
chemotherapeutic regimens. 
 The HMO-fostered activity potentiation observed for clindamycin and erythromycin 
is especially promising for the prevention of GBS transmission as these two drugs remain 
relevant to IAP despite the fact that they continue to become less effective due to 
resistance development. Our findings, however, demonstrate the feasibility of sensitizing 
GBS to antibiotics that have failed or are struggling in the clinic thus offering new insights 
into the battle against antimicrobial resistance.111 
 A final point of emphasis is that all HMO concentrations used in the combination 
treatments were at the low end of physiological concentrations. Additionally, while the 
millimolar HMO cocktail IC50 values may appear high in comparison to typical micromolar 
antibiotic dosages, it is important to remember that HMOs are delivered to infants in 
multigram doses per day. Given this context, the millimolar HMO dosages used in this 
study are impressive, as is the fact that these molecules are themselves bactericidal at 
the high end of physiological concentration.68 
 Finally, based on the observed patterns of antibiotic activity potentiation, we 
hypothesized that HMOs act by increasing bacterial membrane permeability. Notably, this 
mode of action is characteristic of the role of b-lactams in combination therapies with 
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aminoglycosides. This hypothesis was further supported by a previous study by 
Townsend et al. wherein it was demonstrated that HMOs could potentiate the activity of 
polymyxin B against GBS.68 Polymyxins are antimicrobial peptides (AMPs) that are used 
in the treatment of Gram-negative bacterial infections but are generally inactive against 
Gram-positive species like GBS.112-115 Mechanistically, polymyxins are believed to target 
bacterial cellular membranes.116 In Gram-negative bacteria, the cell membrane is the 
outermost layer. In Gram-positive bacteria, however, the cell membrane is protected by 
a thick peptidoglycan layer. Thus, if HMOs damage the peptidoglycan layer, this action 
would theoretically provide greater access to the cellular membrane and account for the 
potentiation of polymyxin B activity.  
 
3.3.2 Evaluation of HMO Antimicrobial Mechanism of Action100 
To determine if HMO inhibition of bacterial growth and viability was associated with 
cognate changes in bacterial cell membrane integrity, the LIVE/DEAD BacLight assay 
(Invitrogen, ThermoFisher) was used. Briefly, this assay employs two stains: SYTO 9, 
which passes through intact membranes to stain cells green, and propidium iodide (PI), 
which is a larger molecule that can only pass through membranes with breached integrity 
to stain cells red (associated with dead cells). As PI can quench the signal of SYTO 9, 
the ratio of SYTO to PI signal yields a measurement of live to dead cells or intact to 
nonintact cell membranes.  
 As expected, when grown in THB alone, GB590 exhibited a LIVE/DEAD cell ratio 
of 100 ± SEM 2.2. Gratifyingly, exposure to 2.56 mg/mL HMO resulted in a 33% decrease 
in the LIVE/DEAD cell ratio (P = 0.00168) (Figure 3.17 and Appendix A1). Moreover, 
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exposure to 5.125 mg/mL HMO resulted in a 27% decrease, and exposure to 10.25 
mg/mL and 20.5 mg/mL resulted in 28% decreases in the LIVE/DEAD cell ratio (P = 
0.0011 and P = 0.00044, respectively). Similar results were observed with strains CNCTC 
10/84 and GB2 as these strains also exhibited significant decreases in membrane 
integrity at 2.56; 5.125; 10.25; and 20.5 mg/mL HMO (P  < 0.05). The addition of glucose 
to the growth medium inhibited this phenotype at 2.56 mg/mL HMO for all strains, but 
membrane integrity was significantly perturbed in THB + 1% glucose at 10.25 mg/mL 
HMO and higher (P  < 0.05). These resulted indicated that HMOs are in fact altering GBS 
cell membrane integrity in a dose-dependent fashion and could be altering downstream 
processes such as proton motive force. 
 
Figure 3.15. LIVE/DEAD BacLight assay to evaluate bacterial cell membrane integrity. 
Assay reveals that exposure to increasing concentrations of HMOs results in decreased 
cell integrity as determined by the ratio of green fluorescence (SYTO 9 stain of intact 
cells) to red fluorescence (PI stain of nonintact cells). * represents P < 0.05, Student’s t 
test, N = 3 replicates. 
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 It is noteworthy that the results of the BacLight assay compliment results presented 
in a previous study by Bode et al.67 In this study, Bode and co-workers identified a GBS 
serotype III mutant that exhibited normal growth despite exposure to an HMO mixture. 
The observed resistance was attributed to inactivation of the gene gbs0738 which 
encodes a glycosyltransferase (GT) of the carbohydrate-active enzymes (CAZY) GT-8 
family that is conserved across numerous GBS subspecies of varying serotypes. They 
subsequently hypothesized that this GT could promiscuously incorporate HMOs into 
either the capsular polysaccharide structure or the peptidoglycan/glycan-binding proteins 
of the cell wall. The first of these hypotheses, however, was disproved when they 
observed that a GBS serotype III capsule-deficient mutant remained susceptible to HMO 
exposure. Thus, the results of their study in conjunction with the results of our study 
provide compelling evidence that HMOs are affecting cell wall integrity. 
 
3.4 Conclusions and Future Outlook 
 The work with heterogenous HMO extracts discussed in this chapter demonstrates 
the protective potential of HMOs against the important neonate pathogen Group B 
Streptococcus (Streptococcus agalactiae, GBS) as well as the broadly clinically relevant 
ESKAPE pathogens Staphylococcus aureus and Acinetobacter baumannii. HMO extracts 
were shown to possess strong antimicrobial and antibiofilm activities against GBS, strong 
(albeit variably so) antibiofilm activity against S. aureus, and weak antimicrobial activity 
against A. baumannii. Importantly, both antimicrobial and antibiofilm activity against GBS 
were found to be largely strain-specific. This finding provides support for the development 
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of narrow-spectrum antimicrobials. Finally, HMO extracts from Secretors and non-
Secretors were found to possess similar levels of antibacterial activity. 
 In addition to uncovering antibacterial properties of HMOs against various 
pathogens, we also demonstrated the therapeutic potential of HMOs in antibiotic 
combination therapies. HMOs were found to potentiate the function of aminoglycosides, 
lincosamides, macrolides, and tetracyclines against GBS, as well as aminoglycosides 
against S. aureus and A. baumannii, but not b-lactams or glycopeptides that inhibit cell 
wall synthesis. This pattern of activity potentiation led us to hypothesize that HMOs were 
increasing membrane permeability. This hypothesis was subsequently validated using a 
bacterial membrane permeability assay which revealed that HMOs increase membrane 
permeability toward propidium iodide.  
 Although these studies collectively show that HMOs possess antibacterial activity 
and that this activity results from alteration of bacterial membrane permeability, we still 
lacked knowledge about the activities of individual HMOs. Moreover, although a 
mechanism of action was identified, the specific cellular targets of HMOs remained 
unknown. To address these gaps in our understanding, subsequent studies relied on the 
use of single entity HMOs.  
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3.5 Experimental Methods 
3.5.1 General Methods and Materials71, 100 
Bacterial Strains and Culture Conditions 
  
Bacterial strains are shown in Table 3.17. All strains were grown on tryptic soy agar plates 
supplemented with 5% sheep blood (blood agar plates) at 37 °C in ambient air overnight. 
Strains were subcultured from blood agar plates into 5 mL of Todd-Hewitt broth (THB) 
and incubated under shaking conditions at 180 rpm at 37 °C in ambient air overnight. 
Following overnight incubation, bacterial density was quantified through absorbance 
readings at 600 nm (OD600) using a Promega GloMax-Multi Detection System plate 
reader. Bacterial numbers were determined using the predetermined coefficient of 1 
OD600 = 109 CFU/mL (colony forming units/mL). 
 
 
 
Bacterial strains Source 
S. agalactiae strain CNCTC 10/84 ATCC 
S. agalactiae strain GB590 Clinical isolate, Shannon Manning, Michigan State 
S. agalactiae strain GB2 Clinical isolate, Shannon Manning, Michigan State 
S. aureus strain USA300 
The S. aureus strain used was USA300 
JE2,117 a laboratory-adapted strain derived 
from the parental USA300 strain isolated 
from a skin and soft tissue infection118 
A. baumannii strain 19606 ATCC 
Table 3.17. Bacterial Strains 
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3.5.2 Evaluation of Antimicrobial and Antibiofilm Activities of HMOs Against GBS, 
Staphylococcus aureus, and Acinetobacter baumannii71 
HMO Isolation 
Human milk samples were obtained from 14 healthy, lactating women between 3 days 
and 3 months postnatal under a collection protocol approved by the Vanderbilt University 
Institutional Review Board (IRB#100897)and were stored at −20 °C. The deidentified milk 
was provided by Dr. J.-H. Weitkamp from the Vanderbilt Department of Pediatrics under 
a collection protocol approved by the Vanderbilt University Institutional Review Board 
(IRB#100897). Milk samples were first thawed then centrifuged for 30 min at 4 °C. 
Following centrifugation, the resultant top lipid layer was removed. The proteins were then 
removed by diluting the remaining sample with roughly 1:1 v/v 180 or 200 proof ethanol 
and centrifuging the samples for 30 min at 4 °C followed by removal of the resulting HMO- 
containing supernatant. The supernatant was then concentrated in vacuo, and the 
remaining salts were removed by P-2 Gel (H2O elutant). The oligosaccharides were then 
dried by lyophilization. 
 
MS and MS/MS Analysis of HMO Samples 
Dried HMO samples were prepared and processed for evaluation by reconstitution in 
water to approximately 1 mg/mL. These solutions were deposited on a matrix-assisted 
laser desorption/ionization (MALDI) target plate as follows: 1 μL of HMO was spotted 
followed by 0.2 μL of 10 mM NaCl and 1 μL of DHB matrix (60 mg/mL in 50% methanol). 
The spots were allowed to air-dry and then were analyzed in positive ion mode on a 9.4T 
Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer (MS) (Bruker 
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Solarix). Mass spectra were acquired in positive ion mode from m/z 300 to 2500. Sodium 
ion adducts of HMOs were detected with a mass accuracy of >2 ppm. MS/MS analysis 
was performed for selected ions with a linear ion trap mass spectrometer equipped with 
a MALDI source (LTQ XL, Thermo Scientific). Selected sodium adduct ions of interest 
were isolated with a 1 amu window and fragmented via CID using a collision energy of 35 
eV.119   
 
HMO Bacterial Biofilm Assays 
All bacterial strains were grown overnight as described above and used to inoculate fresh 
THB or THB + 1% glucose at a multiplicity of infection (MOI) of 106 colony forming units 
per 200 μL of growth medium in 96 well tissue culture treated, sterile polystyrene plates. 
HMOs isolated from the 14 human milk samples were then added to achieve a final 
carbohydrate concentration of ca. 5 mg/mL. Bacteria grown in THB or THB + 1% glucose 
in the absence of any HMOs served as the controls. Biofilm assays were conducted as 
previously described. Briefly, cultures were incubated under static conditions at 37 °C in 
ambient air for 24 h. Bacterial growth was quantified through absorbance readings at an 
optical density of 600 nm (OD600). Results were analyzed compared to controls in the 
absence of HMOs and were expressed as the percent change in biomass with negative 
numbers indicating a net decrease in biomass and positive numbers indicating a net 
increase in biomass. Culture medium was then removed, and wells were washed gently 
with phosphate buffered saline (PBS, pH 7.4) to remove non-adherent cells; the 
remaining biofilms were stained with a 10% crystal violet solution for 5−10 min for Gram-
positive bacteria and 15−20 min for Gram-negative bacteria. Following staining, wells 
 199 
were washed with PBS and allowed to dry at room temperature for at least 30 min. After 
drying, the remaining crystal violet stain was solubilized via addition of 200 μL of 80% 
ethanol/20% acetone solution. Biofilm formation was quantified through absorbance 
readings (OD560). Results were analyzed compared to controls in the absence of HMOs 
and expressed as the percent change in biofilm/biomass ratio with negative numbers 
indicating a net decrease in biofilm production and positive numbers indicating a net 
increase in biofilm production.   
 
Broth Microdilution Method for Determination of Minimum Inhibitory Concentrations and 
Biofilm Production Patterns of NAC Treatment Against S. aureus 
S. aureus cultures were grown overnight as described above and used to inoculate fresh 
THB or THB + 1% glucose to achieve 5 × 105 CFU/mL. To 96 well tissue culture treated, 
sterile polystyrene plates was added the inoculated media in the presence of increasing 
concentrations of N-acetylcysteine (NAC) to achieve a final volume of 100 μL per well. 
Bacteria grown in THB or THB + 1% glucose in the absence of NAC served as the controls. 
The plates were incubated under static conditions at 37 °C in ambient air for 24 h. 
Bacterial growth was quantified through absorbance readings (OD600). The minimum 
inhibitory concentrations (MICs) were assigned at the lowest concentration of compound 
at which no visible growth of bacteria was observed. Biofilm production patterns were 
then determined using the procedure described above with the exception that the final 
step of solubilizing the remaining crystal violet stain was done via addition of 100 μL of 
80% ethanol/20% acetone.  
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HMO and NAC Combined Bacterial Biofilm Assays 
S. aureus cultures were grown overnight as described above and used to inoculate fresh 
THB or THB + 1% glucose to achieve 5 × 105 CFU/mL. To the inoculated media was 
added HMOs from Donor 5, Donor 7, am-HMO cocktail, or ab-HMO cocktail to achieve 
an HMO concentration of ca. 5 mg/mL. To 96 well tissue culture treated, sterile 
polystyrene plates was added the HMO-containing inoculated media in the presence of 
increasing concentrations of N-acetylcysteine (NAC) to achieve a final volume of 100 μL 
per well. MICs and biofilm production patterns were determined as previously described.  
 
Statistical Analysis 
The data shown represent at least 3 independent experiments. Data are expressed as 
the mean of three technical replicates ± SEM. Statistical analyses were performed in 
GraphPad Prism Software v. 7.0c. Statistical significance for the individual HMO sample 
assays and the NAC treatment assays was determined using one-way ANOVA with 
posthoc Dunnett’s multiple comparison test comparing growth and/or biofilm production 
in the presence of HMOs or NAC to growth and/or biofilm production in media alone. 
Statistical significance for the combined NAC and HMO treatment assays was determined 
using two-way ANOVA with posthoc Dunnett’s multiple comparison test comparing 
growth and/or biofilm production for each NAC and HMO combination at a given NAC 
concentration to treatment with NAC alone at the same NAC concentration.  
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3.5.3 Investigation of HMO Antimicrobial Mechanism of Action100 
HMO Isolation 
Human milk was obtained from 21 healthy, lactating women between 3 days and 3 
months postnatal and stored between −80 and −20 °C. Deidentified milk was provided by 
Dr. Jörn-Hendrik Weitkamp from the Vanderbilt Department of Pediatrics, under a 
collection protocol approved by the Vanderbilt University Institutional Review Board 
(IRB#100897), and Medolac. Milk samples were thawed then centrifuged for 45 min. 
Following centrifugation, the resultant top lipid layer was removed. The proteins were then 
removed by diluting the remaining sample with roughly 1:1 v/v 180 or 200 proof ethanol, 
chilling the sample briefly, and centrifuging for 45 min followed by removal of the resulting 
HMO- containing supernatant. Following concentration of the supernatant in vacuo, the 
HMO-containing extract was dissolved in phosphate buffer (pH 6.5, 0.2 M) and heated to 
37 °C. β-galactosidase from Kluveromyces lactis was added, and the reaction was stirred 
until lactose hydrolysis was complete.120, 121 The reaction mixture was diluted with roughly 
1:0.5 v/v 180 or 200 proof ethanol, chilled briefly, then centrifuged for 30 min. The 
supernatant was removed and concentrated in vacuo, and the remaining salts, glucose, 
and galactose were separated from the oligosaccharides using P-2 Gel (H2O elutant). 
The oligosaccharides were then dried by lyophilization.  
 
HMO Bacterial Biofilm Assays 
HMO antimicrobial and antibiofilm activities for three new donor samples were determined 
as previously described in section 3.6.2 of this chapter.  
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Broth Microdilution Method for Determination of Minimum Inhibitory Concentrations of 
HMO Cocktail and Antibiotics 
All strains were grown overnight as described in section 3.6.1 of this chapter and used to 
inoculate fresh THB or THB + 1% glucose to achieve 5 × 105 CFU/mL. To 96 well tissue-
culture- treated, sterile polystyrene plates was added the inoculated media in the 
presence of increasing concentrations of antibiotic or HMO cocktail to achieve a final 
volume of 100 μL per well. Bacteria grown in media in the absence of any compounds 
served as the control. The plates were incubated under static conditions at 37 °C in 
ambient air for 24 h. Bacterial growth was quantified through absorbance readings 
(OD600). The minimum inhibitory concentrations (MICs) were assigned at the lowest 
concentration of compound at which no bacterial growth was observed.  
 
Broth Microdilution Method for Antibiotic Sensitization 
All strains were grown overnight as described previously and the subcultures used to 
inoculate fresh THB or THB + 1% glucose to achieve 5 × 105 CFU/mL. The freshly 
inoculated media was then supplemented with HMOs. To 96 well tissue-culture-treated, 
sterile polystyrene plates was added the inoculated media supplemented with HMOs in 
the presence of increasing concentrations of antibiotic. Bacteria grown in media in the 
absence of any compounds served as one control. Bacteria grown in media 
supplemented with HMOs in the absence of any antibiotic served as a second control. 
MICs were determined as described in section 3.6.2 of this chapter.  
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Bacterial Membrane Permeabilization Assay  
In order to assess bacterial cell membrane integrity after exposure to HMOs, a 
LIVE/DEAD BacLight assay (Invitrogen, ThermoFisher) was employed. All strains were 
grown overnight as described above and used to inoculate fresh THB or THB + 1% 
glucose to achieve 5 × 105 CFU/mL. To 96 well tissue-culture-treated, sterile polystyrene 
plates was added the inoculated media in the presence of the following HMO 
concentrations: 0, 0.32, 0.64, 1.28, 2.56, 5.125, 10.25, and 20.5 mg/mL. Following 
incubation under static conditions at 37 °C in ambient air for 24 h, cells were stained with 
propidium iodide (PI) and SYTO 9 (8 μL/mL) for 15 min prior to reading with a Promega 
Glomax-Multi Detection System plate reader for excitation/emission 525 nm/580−640 nm 
(green, SYTO 9) and 625 nm/660−720 nm (red, PI). The percent ratio of green to red 
fluorescence was calculated (ratiogreen/red × 100). Three biological replicates were used, 
and statistical significance was calculated using a Student’s t test comparison to bacteria 
grown in medium alone (*P < 0.05).  
 
Statistical Analysis 
The data for the HMO antimicrobial and antibiofilm screens represents three independent 
experiments each with three technical replicates. Data are expressed as the mean 
biomass and/or biofilm/biomass ratio ± SEM. Statistical analyses were performed in 
GraphPad Prism Software v. 7.0c. Statistical significance was determined using one-way 
ANOVA with a posthoc Dunnett’s multiple comparison test comparing growth and/or 
biofilm production in the presence of ca. 5 mg/mL HMOs to growth and/or biofilm 
production in media alone. All antibiotic-only and all antibiotic + HMO antibiotic MIC 
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values against GBS represent at least three independent trials each with three technical 
replicates. HMO IC50 curves were generated in GraphPad Prism Software v. 7.0c. using 
an inhibition dose−response nonlinear regression curve fit for log(inhibitor) vs normalized 
response with a variable slope. All antibiotic-only MIC values against S. aureus and A. 
baumannii represent at least three independent trials each with three technical replicates. 
For S. aureus, the following antibiotic + HMO antibiotic MIC values represent one trial 
with three technical replicates: cefazolin, vancomycin, clindamycin, erythromycin, and 
linezolid. The gentamicin + HMO antibiotic MIC value represents at least three 
independent trials each with three technical replicates. For A. baumannii, the following 
antibiotic + HMO antibiotic MIC values represent one trial with three technical replicates: 
imipenem, meropenem, minocycline, tigecycline, and doripenem. The amikacin and 
tobramycin + HMO antibiotic MIC values represent at least three independent trials each 
with three technical replicates. Statistical analysis for the BacLight assay was performed 
in GraphPad Prism Software v. 7.0c. Statistical significance was determined using 
Student’s t test, N = 3 replicates, comparing the LIVE/DEAD ratio of an HMO treatment 
at a given concentration to the LIVE/DEAD ratio of bacteria grown in media alone. 
 
3.6 References 
1. Sass, L., Group B Streptococcal Infections. Pediatr. Rev. 2012, 33 (5). 
 
2. Gibbs, R. S.;  Schrag, S.; Schuchat, A., Perinatal infections due to group B 
streptococci. Obstet. Gynecol. 2004, 104 (5 Pt 1), 1062-76. 
 
3. Le Doare, K.; Kampmann, B., Breast milk and Group B streptococcal infection: vector 
of transmission or vehicle for protection? Vaccine 2014, 32 (26), 3128-32. 
 205 
4. Andreas, N. J.;  Al-Khalidi, A.;  Jaiteh, M.;  Clarke, E.;  Hyde, M. J.;  Modi, N.;  Holmes, 
E.;  Kampmann, B.; Mehring Le Doare, K., Role of human milk oligosaccharides in 
Group B Streptococcus colonisation. Clin. Transl. Immunology. 2016, 5 (8), e99. 
 
5. Borges, S.;  Silva, J.; Teixeira, P., Survival and biofilm formation by Group B 
streptococci in simulated vaginal fluid at different pHs. Antonie Van Leeuwenhoek 
2012, 101 (3), 677-82. 
 
6. Nan, C.;  Dangor, Z.;  Cutland, C. L.;  Edwards, M. S.;  Madhi, S. A.; Cunnington, M. 
C., Maternal group B Streptococcus-related stillbirth: a systematic review. BJOG 
2015, 122 (11), 1437-45. 
 
7. Pupolo, K. M., Epidemiology of Neonatal Early-onset Sepsis. NeoReviews 2008, 9 
(12), e571-579. 
 
8. Butter, M. N. W.; De Moor, C. E., Streptococcus agalactiae as a cause of meningitis 
in the newborn, and of bacteraemia in adults. Antonie van Leeuwenhoek 1967, 33, 
439-450. 
 
9. Craft, K. M.; Townsend, S. D., The Human Milk Glycome as a Defense Against 
Infectious Diseases: Rationale, Challenges, and Opportunities. ACS Infect. Dis. 2017, 
4 (2), 77-83. 
 
10. Jeurink, P. V.;  van Bergenhenegouwen, J.;  Jimenez, E.;  Knippels, L. M.;  
Fernandez, L.;  Garssen, J.;  Knol, J.;  Rodriguez, J. M.; Martin, R., Human milk: a 
source of more life than we imagine. Benef. Microbes 2013, 4 (1), 17-30. 
 
11. Cabrera-Rubio, R.;  Collado, M. C.;  Laitinen, K.;  Salminen, S.;  Isolauri, E.; Mira, A., 
The human milk microbiome changes over lactation and is shaped by maternal 
weight and mode of delivery. Am. J. Clin. Nutr. 2012, 96 (3), 544-51. 
 
12. Bingen, E.;  Denamur, E.;  Lambert-Zechovsky, N.;  Aujard, Y.;  Brahimi, N.;  Geslin, 
P.; Elion, J., Analysis of DNA restriction fragment length polymorphism extends the 
evidence for breast milk transmission in Streptococcus agalactiae late-onset neonatal 
infection. J. Infect. Dis. 1992, 165 (3), 569-73. 
 
13. Zimmermann, P.;  Gwee, A.; Curtis, N., The controversial role of breast milk in GBS 
late-onset disease. J. Infect. 2017, 74 Suppl 1, S34-S40. 
 206 
14. Burianova, I.;  Paulova, M.;  Cermak, P.; Janota, J., Group B streptococcus 
colonization of breast milk of group B streptococcus positive mothers. J. Hum. Lact. 
2013, 29 (4), 586-90. 
 
15. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, 
Group B Streptococcus, 2014. Centers for Disease Control and Prevention. 2014. 
 
16. Boyer, K. M.; Gotoff, S. P., Prevention of early-onset neonatal group B streptococcal 
disease with selective intrapartum chemoprophylaxis. N. Engl. J. Med. 1986, 314 
(26), 1665-9. 
 
17. Schrag, S. J.;  Zell, E. R.;  Lynfield, R.;  Roome, A.;  Arnold, K. E.;  Craig, A. S.;  
Harrison, L. H.;  Reingold, A.;  Stefonek, K.;  Smith, G.;  Gamble, M.;  Schuchat, A.; 
Active Bacterial Core Surveillance, T., A population-based comparison of strategies 
to prevent early-onset group B streptococcal disease in neonates. N. Engl. J. Med. 
2002, 347 (4), 233-9. 
 
18. Cagno, C. K.;  Pettit, J. M.; Weiss, B. D., Prevention of Perinatal Group B 
Streptococcal Disease Revised Guidelines from CDC, 2010. Am. Fam. Physician 
2010, 86, 59-65. 
 
19. Dagnew, A. F.;  Cunnington, M. C.;  Dube, Q.;  Edwards, M. S.;  French, N.;  
Heyderman, R. S.;  Madhi, S. A.;  Slobod, K.; Clemens, S. A., Variation in reported 
neonatal group B streptococcal disease incidence in developing countries. Clin. 
Infect. Dis. 2012, 55 (1), 91-102. 
 
20. Bizzarro, M. J.;  Dembry, L. M.;  Baltimore, R. S.; Gallagher, P. G., Changing patterns 
in neonatal Escherichia coli sepsis and ampicillin resistance in the era of intrapartum 
antibiotic prophylaxis. Pediatrics 2008, 121 (4), 689-96. 
 
21. Phares, C. R.;  Lynfield, R.;  Farley, M. M.;  Mohle-Boetani, J.;  Harrison, L. H.;  Petit, 
S.;  Craig, A. S.;  Schaffner, W.;  Zansky, S. M.;  Gershman, K.;  Stefonek, K. R.;  
Albanese, B. A.;  Zell, E. R.;  Schuchat, A.;  Schrag, S. J.; Active Bacterial Core 
surveillance/Emerging Infections Program, N., Epidemiology of invasive group B 
streptococcal disease in the United States, 1999-2005. JAMA 2008, 299 (17), 2056-
65. 
 
22. Rajagopal, L., Understanding the regulation of Group B Streptococcal virulence 
factors. Future Microbiol. 2009, 4 (2), 201-21. 
 207 
23. Chang, Y. C.;  Olson, J.;  Beasley, F. C.;  Tung, C.;  Zhang, J.;  Crocker, P. R.;  Varki, 
A.; Nizet, V., Group B Streptococcus engages an inhibitory Siglec through sialic acid 
mimicry to blunt innate immune and inflammatory responses in vivo. PLoS Pathog. 
2014, 10 (1), e1003846. 
 
24. Almeida, A.;  Rosinski-Chupin, I.;  Plainvert, C.;  Douarre, P. E.;  Borrego, M. J.;  
Poyart, C.; Glaser, P., Parallel Evolution of Group B Streptococcus Hypervirulent 
Clonal Complex 17 Unveils New Pathoadaptive Mutations. mSystems 2017, 2 (5), 
e00074-17. 
 
25. Cieslewicz, M. J.;  Chaffin, D.;  Glusman, G.;  Kasper, D.;  Madan, A.;  Rodrigues, S.;  
Fahey, J.;  Wessels, M. R.; Rubens, C. E., Structural and genetic diversity of group 
B streptococcus capsular polysaccharides. Infect. Immun. 2005, 73 (5), 3096-103. 
 
26. Marques, M. B.;  Kasper, D. L.;  Pangburn, M. K.; Wessels, M. R., Prevention of C3 
Deposition by Capsular Polysaccharide Is a Virulence Mechanism of Type I Group B 
Streptococci. Infect. Immun. 1992, 60 (10), 3986-3993. 
 
27. Rubens, C. E.;  Wessels, M. R.;  Heggen, L. M.; kasper, D. L., Transposon 
mutagenesis of type III group B Streptococcus—Correlation of capsule expression 
with virulence. PNAS 1987, 84, 7208-7212. 
 
28. Slotved, H. C.;  Kong, F.;  Lambertsen, L.;  Sauer, S.; Gilbert, G. L., Serotype IX, a 
Proposed New Streptococcus agalactiae Serotype. J. Clin. Microbiol. 2007, 45 (9), 
2929-36. 
 
29. Sorensen, U. B.;  Poulsen, K.;  Ghezzo, C.;  Margarit, I.; Kilian, M., Emergence and 
global dissemination of host-specific Streptococcus agalactiae clones. MBio. 2010, 1 
(3), e00178-10. 
 
30. Takahashi, S.;  Aoyagi, Y.;  Adderson, E. E.;  Okuwaki, Y.; Bohnsack, J. F., Capsular 
sialic acid limits C5a production on type III group B streptococci. Infect. Immun. 1999, 
67 (4), 1866-70. 
 
31. Teatero, S.;  Ferrieri, P.;  Martin, I.;  Demczuk, W.;  McGeer, A.; Fittipaldi, N., Serotype 
Distribution, Population Structure, and Antimicrobial Resistance of Group B 
Streptococcus Strains Recovered from Colonized Pregnant Women. J. Clin. 
Microbiol. 2017, 55 (2), 412-422. 
 208 
32. Wessels, M. R.;  Rubens, C. E.;  Benedi, V. J.; Kasper, D. L., Definition of a bacterial 
virulence factor: sialylation of the group B streptococcal capsule. PNAS 1989, 86 
(22), 8983-7. 
 
33. Berti, F.;  Campisi, E.;  Toniolo, C.;  Morelli, L.;  Crotti, S.;  Rosini, R.;  Romano, M. 
R.;  Pinto, V.;  Brogioni, B.;  Torricelli, G.;  Janulczyk, R.;  Grandi, G.; Margarit, I., 
Structure of the type IX group B Streptococcus capsular polysaccharide and its 
evolutionary relationship with types V and VII. J. Biol. Chem. 2014, 289 (34), 23437-
48. 
 
34. Melin, P.; Efstratiou, A., Group B streptococcal epidemiology and vaccine needs in 
developed countries. Vaccine 2013, 31 Suppl 4, D31-42. 
 
35. Russell, N. J.;  Seale, A. C.;  O'Driscoll, M.;  O'Sullivan, C.;  Bianchi-Jassir, F.;  
Gonzalez-Guarin, J.;  Lawn, J. E.;  Baker, C. J.;  Bartlett, L.;  Cutland, C.;  Gravett, 
M. G.;  Heath, P. T.;  Le Doare, K.;  Madhi, S. A.;  Rubens, C. E.;  Schrag, S.;  
Sobanjo-Ter Meulen, A.;  Vekemans, J.;  Saha, S. K.;  Ip, M.; Group, G. B. S. M. C. 
I., Maternal Colonization With Group B Streptococcus and Serotype Distribution 
Worldwide: Systematic Review and Meta-analyses. Clin. Infect. Dis. 2017, 65 (Suppl 
2), S100-S111. 
 
36. Costerton, J. W.;  Stewart, P. S.; Greenberg, E. P., Bacterial biofilms: a common 
cause of persistent infections. Science 1999, 284 (5418), 1318-22. 
 
37. Davies, D., Understanding biofilm resistance to antibacterial agents. Nat. Rev. Drug 
Discov. 2003, 2 (2), 114-22. 
 
38. Craft, K. M.;  Nguyen, J. M.;  Berg, L. J.; Townsend, S. D., Methicillin-Resistant 
Staphylococcus aureus (MRSA): Antibiotic Resistance and the Biofilm Phenotype. 
Medchemcomm 2019, Ahead of print. 
 
39. Flemming, H.-C.; Wingender, J., The biofilm matrix. Nat. Rev. Microbiol. 2010, 8 (9), 
623-633. 
 
40. Parsek, M. R.; Greenberg, E. P., Sociomicrobiology: the connections between 
quorum sensing and biofilms. Trends Microbiol. 2005, 13 (1), 27-33. 
 
41. Sauer, K.;  Camper, A. K.;  Ehrlich, G. D.;  Costerton, J. W.; Davies, D. G., 
Pseudomonas aeruginosa Displays Multiple Phenotypes during Development as a 
Biofilm. J. Bacteriol. 2002, 184 (4), 1140-1154. 
 209 
42. Yarwood, J. M.;  Bartels, D. J.;  Volper, E. M.; Greenberg, E. P., Quorum Sensing in 
Staphylococcus aureus Biofilms. J. Bacteriol. 2004, 186 (6), 1838-1850. 
 
43. Fux, C. A.;  Costerton, J. W.;  Stewart, P. S.; Stoodley, P., Survival strategies of 
infectious biofilms. Trends Microbiol. 2005, 13 (1), 34-40. 
 
44. Welsh, M. A.; Blackwell, H. E., Chemical probes of quorum sensing: from compound 
development to biological discovery. FEMS Microbiol. Rev. 2016, 40 (5), 774-94. 
 
45. Praneenararat, T.;  Palmer, A. G.; Blackwell, H. E., Chemical methods to interrogate 
bacterial quorum sensing pathways. Org. Biomol. Chem. 2012, 10 (41), 8189-99. 
 
46. Kong, K. F.;  Vuong, C.; Otto, M., Staphylococcus quorum sensing in biofilm formation 
and infection. Int. J. Med. Microbiol. 2006, 296 (2-3), 133-9. 
 
47. Hoiby, N.;  Ciofu, O.;  Johansen, H. K.;  Song, Z. J.;  Moser, C.;  Jensen, P. O.;  Molin, 
S.;  Givskov, M.;  Tolker-Nielsen, T.; Bjarnsholt, T., The clinical impact of bacterial 
biofilms. Int. J. Oral. Sci. 2011, 3 (2), 55-65. 
 
48. Santajit, S.; Indrawattana, N., Mechanisms of Antimicrobial Resistance in ESKAPE 
Pathogens. Biomed. Res. Int. 2016, 2016, 2475067. 
 
49. Hall-Stoodley, L.;  Costerton, J. W.; Stoodley, P., Bacterial biofilms: from the natural 
environment to infectious diseases. Nat. Rev. Microbiol. 2004, 2 (2), 95-108. 
 
50. de Beer, D.;  Stoodley, P.;  Roe, F.; Lewandowski, Z., Effects of biofilm structures on 
oxygen distribution and mass transport. Biotechnol. Bioeng. 1994, 43 (11), 1131-8. 
 
51. Stewart, P. S.; Costerton, J. W., Antibiotic resistance of bacteria in biofilms. Lancet 
2001, 358 (9276), 135-8. 
 
52. Marrie, T. J.; Costerton, J. W., A scanning and transmission electron microscopic 
study of the surfaces of intrauterine contraceptive devices. Am. J. Obstet. Gynecol. 
1983, 146 (4), 384-94. 
 
53. Rinaudo, C. D.;  Rosini, R.;  Galeotti, C. L.;  Berti, F.;  Necchi, F.;  Reguzzi, V.;  
Ghezzo, C.;  Telford, J. L.;  Grandi, G.; Maione, D., Specific involvement of pilus type 
2a in biofilm formation in group B Streptococcus. PLoS One 2010, 5 (2), e9216. 
 
 210 
54. Kaur, H.;  Kumar, P.;  Ray, P.;  Kaur, J.; Chakraborti, A., Biofilm formation in clinical 
isolates of group B streptococci from north India. Microb. Pathog. 2009, 46 (6), 321-
7. 
 
55. Rosini, R.; Margarit, I., Biofilm formation by Streptococcus agalactiae: influence of 
environmental conditions and implicated virulence factors. Front Cell. Infect. 
Microbiol. 2015, 5, 6. 
 
56. Xia, F. D.;  Mallet, A.;  Caliot, E.;  Gao, C.;  Trieu-Cuot, P.; Dramsi, S., Capsular 
polysaccharide of Group B Streptococcus mediates biofilm formation in the presence 
of human plasma. Microbes Infect. 2015, 17 (1), 71-6. 
 
57. Konto-Ghiorghi, Y.;  Mairey, E.;  Mallet, A.;  Dumenil, G.;  Caliot, E.;  Trieu-Cuot, P.; 
Dramsi, S., Dual role for pilus in adherence to epithelial cells and biofilm formation in 
Streptococcus agalactiae. PLoS Pathog. 2009, 5 (5), e1000422. 
 
58. D'Urzo, N.;  Martinelli, M.;  Pezzicoli, A.;  De Cesare, V.;  Pinto, V.;  Margarit, I.;  
Telford, J. L.;  Maione, D.; Members of the, D. S. G., Acidic pH strongly enhances in 
vitro biofilm formation by a subset of hypervirulent ST-17 Streptococcus agalactiae 
strains. Appl. Environ. Microbiol. 2014, 80 (7), 2176-85. 
 
59. Carey, A. J.;  Tan, C. K.;  Mirza, S.;  Irving-Rodgers, H.;  Webb, R. I.;  Lam, A.; Ulett, 
G. C., Infection and cellular defense dynamics in a novel 17beta-estradiol murine 
model of chronic human group B streptococcus genital tract colonization reveal a role 
for hemolysin in persistence and neutrophil accumulation. J. Immunol. 2014, 192 (4), 
1718-31. 
 
60. Baker, C. J.; Kasper, D. L., Correlation of Maternal Antibody Deficiency with 
Suseptibility to Neonatal Group B Streptococcal Infection. N. Engl. J. Med. 1976, 294, 
753-756. 
 
61. Baker, C. J.;  Edwards, M. S.; Kasper, D. L., Role of antibody to native type III 
polysaccharide of group B Streptococcus in infant infection. Pediatrics 1981, 68 (4), 
544-9. 
 
62. Kwatra, G.;  Adrian, P. V.;  Shiri, T.;  Buchmann, E. J.;  Cutland, C. L.; Madhi, S. A., 
Natural acquired humoral immunity against serotype-specific group B Streptococcus 
rectovaginal colonization acquisition in pregnant women. Clin. Microbiol. Infect. 2015, 
21 (6), 568 e13-21. 
 211 
63. Beachler, C. W.;  Baker, C. J.;  Kasper, D. L.;  Fleming, D. K.;  Webb, B. J.; Yow, M. 
D., Group B streptococcal colonization and antibody status in lower socioeconomic 
parturient women. Am. J. Obstet. Gynecol. 1979, 133 (2), 171-3. 
 
64. Baker, C. J.;  Carey, V. J.;  Rench, M. A.;  Edwards, M. S.;  Hillier, S. L.;  Kasper, D. 
L.; Platt, R., Maternal antibody at delivery protects neonates from early onset group 
B streptococcal disease. J. Infect. Dis. 2014, 209 (5), 781-8. 
 
65. Heath, P. T.;  Culley, F. J.;  Jones, C. E.;  Kampmann, B.;  Le Doare, K.;  Nunes, M. 
C.;  Sadarangani, M.;  Chaudhry, Z.;  Baker, C. J.; Openshaw, P. J. M., Group B 
streptococcus and respiratory syncytial virus immunisation during pregnancy: a 
landscape analysis. Lancet Infect. Dis. 2017, 17 (7), e223-e234. 
 
66. Pritchard, D. G., Gray, B.M. Egan, M.L. , Murine Monoclonal Antibodies to Type lb 
Polysaccharide of Group B Streptococci Bind to Human Milk Oligosaccharides. 
Infect. Immun. 1992, 60 (4), 1598-1602. 
 
67. Lin, A. E.;  Autran, C. A.;  Szyszka, A.;  Escajadillo, T.;  Huang, M.;  Godula, K.;  
Prudden, A. R.;  Boons, G. J.;  Lewis, A. L.;  Doran, K. S.;  Nizet, V.; Bode, L., Human 
milk oligosaccharides inhibit growth of group B Streptococcus. J. Biol. Chem. 2017, 
292 (27), 11243-11249. 
 
68. Ackerman, D. L.;  Doster, R. S.;  Weitkamp, J. H.;  Aronoff, D. M.;  Gaddy, J. A.; 
Townsend, S. D., Human Milk Oligosaccharides Exhibit Antimicrobial and Antibiofilm 
Properties against Group B Streptococcus. ACS Infect. Dis. 2017, 3 (8), 595-605. 
 
69. Blank, D.;  Gebhardt, S.;  Maass, K.;  Lochnit, G.;  Dotz, V.;  Blank, J.;  Geyer, R.; 
Kunz, C., High-throughput mass finger printing and Lewis blood group assignment of 
human milk oligosaccharides. Anal. Bioanal. Chem. 2011, 401 (8), 2495-510. 
 
70. Bode, L., The functional biology of human milk oligosaccharides. Early Hum. Dev. 
2015, 91 (11), 619-22. 
 
71. Ackerman, D. L.;  Craft, K. M.;  Doster, R. S.;  Weitkamp, J. H.;  Aronoff, D. M.;  
Gaddy, J. A.; Townsend, S. D., Antimicrobial and Antibiofilm Activity of Human Milk 
Oligosaccharides against Streptococcus agalactiae, Staphylococcus aureus, and 
Acinetobacter baumannii. ACS Infect. Dis. 2018, 4 (3), 315-324. 
 
72. Arifuzzaman, M.;  Ahmed, T.;  Rahman, M. A.;  Chowdhury, F.;  Rashu, R.;  Khan, A. 
I.;  LaRocque, R. C.;  Harris, J. B.;  Bhuiyan, T. R.;  Ryan, E. T.;  Calderwood, S. B.; 
 212 
Qadri, F., Individuals with Le(a+b-) blood group have increased susceptibility to 
symptomatic vibrio cholerae O1 infection. PLoS Negl. Trop. Dis. 2011, 5 (12), e1413. 
 
73. Jaff, M. S., Higher frequency of secretor phenotype in O blood group - its benefits in 
prevention and/or treatment of some diseases. Int. J. Nanomedicine 2010, 5, 901-5. 
 
74. Vague, P.;  Melis, C.;  Mercier, P.;  Vialettes, B.; Lassmann, V., The increased 
frequency of the Lewis negative blood group in a diabetic population. Diabetologia 
1978, 15 (1), 33-6. 
 
75. Lin, F. Y.;  Clemens, J. D.;  Azimi, P. H.;  Regan, J. A.;  Weisman, L. E.;  Philips, J. 
B., 3rd;  Rhoads, G. G.;  Clark, P.;  Brenner, R. A.; Ferrieri, P., Capsular 
polysaccharide types of group B streptococcal isolates from neonates with early-
onset systemic infection. J. Infect. Dis. 1998, 177 (3), 790-2. 
 
76. Johri, A. K.;  Lata, H.;  Yadav, P.;  Dua, M.;  Yang, Y.;  Xu, X.;  Homma, A.;  Barocchi, 
M. A.;  Bottomley, M. J.;  Saul, A.;  Klugman, K. P.; Black, S., Epidemiology of Group 
B Streptococcus in developing countries. Vaccine 2013, 31 Suppl 4, D43-5. 
 
77. Bode, L., Human milk oligosaccharides: every baby needs a sugar mama. 
Glycobiology 2012, 22 (9), 1147-62. 
 
78. Asakuma, S.;  Urashima, T.;  Akahori, M.;  Obayashi, H.;  Nakamura, T.;  Kimura, K.;  
Watanabe, Y.;  Arai, I.; Sanai, Y., Variation of major neutral oligosaccharides levels 
in human colostrum. Eur. J. Clin. Nutr. 2008, 62 (4), 488-94. 
 
79. Urashima, T.;  Asakuma, S.;  Leo, F.;  Fukuda, K.;  Messer, M.; Oftedal, O. T., The 
predominance of type I oligosaccharides is a feature specific to human breast milk. 
Adv. Nutr. 2012, 3 (3), 473S-82S. 
 
80. Kunz, C.;  Meyer, C.;  Collado, M. C.;  Geiger, L.;  Garcia-Mantrana, I.;  Bertua-Rios, 
B.;  Martinez-Costa, C.;  Borsch, C.; Rudloff, S., Influence of Gestational Age, 
Secretor, and Lewis Blood Group Status on the Oligosaccharide Content of Human 
Milk. J. Pediatr. Gastroenterol. Nutr. 2017, 64 (5), 789-798. 
 
81. Ballard, O.; Morrow, A. L., Human milk composition: nutrients and bioactive factors. 
Pediatr. Clin. North Am. 2013, 60 (1), 49-74. 
 
82. Bassetti, M.; Merelli, M.; Temperoni, C.; Astilean, A. New antibiotics for bad bugs: 
where are we? Ann. Clin. Microbiol. Antimicrob. 2013, 12 (22). 
 213 
83. Boucher, H. W.;  Talbot, G. H.;  Bradley, J. S.;  Edwards, J. E.;  Gilbert, D.;  Rice, L. 
B.;  Scheld, M.;  Spellberg, B.; Bartlett, J., Bad bugs, no drugs: no ESKAPE! An 
update from the Infectious Diseases Society of America. Clin. Infect. Dis. 2009, 48 
(1), 1-12. 
 
84. Pendleton, J. N.;  Gorman, S. P.; Gilmore, B. F., Clinical relevance of the ESKAPE 
pathogens. Expert Rev. Anti. Infect. Ther. 2013, 11 (3), 297-308. 
 
85. Alter, S. J.;  Vidwan, N. K.;  Sobande, P. O.;  Omoloja, A.; Bennett, J. S., Common 
childhood bacterial infections. Curr. Probl. Pediatr. Adolesc. Health Care 2011, 41 
(10), 256-83. 
 
86. Van den Bruel, A.;  Bruyninckx, R.;  Vermeire, E.;  Aerssens, P.;  Aertgeerts, B.; 
Buntinx, F., Signs and symptoms in children with a serious infection: a qualitative 
study. BMC Fam. Pract. 2005, 6, 36. 
 
87. Rajaratnam, J. K.;  Marcus, J. R.;  Flaxman, A. D.;  Wang, H.;  Levin-Rector, A.;  
Dwyer, L.;  Costa, M.;  Lopez, A. D.; Murray, C. J., Neonatal, postneonatal, childhood, 
and under-5 mortality for 187 countries, 1970-2010: a systematic analysis of progress 
towards Millennium Development Goal 4. Lancet 2010, 375 (9730), 1988-2008. 
 
88. Galetto-Lacour, A.; Gervaix, A., Identifying severe bacterial infection in children with 
fever without source. Expert Rev. Anti. Infect. Ther. 2010, 8 (11), 1231-7. 
 
89. Almengor, A. C.;  Kinkel, T. L.;  Day, S. J.; McIver, K. S., The catabolite control protein 
CcpA binds to Pmga and influences expression of the virulence regulator Mga in the 
Group A streptococcus. J. Bacteriol. 2007, 189 (23), 8405-16. 
 
90. Manetti, A. G.;  Zingaretti, C.;  Falugi, F.;  Capo, S.;  Bombaci, M.;  Bagnoli, F.;  
Gambellini, G.;  Bensi, G.;  Mora, M.;  Edwards, A. M.;  Musser, J. M.;  Graviss, E. 
A.;  Telford, J. L.;  Grandi, G.; Margarit, I., Streptococcus pyogenes pili promote 
pharyngeal cell adhesion and biofilm formation. Mol. Microbiol. 2007, 64 (4), 968-83. 
 
91. Winn W Jr, A. S., Janda W, Koneman E, Procop G, Schreckenberger P, et al., editors, 
Nonfermenting Gram negative bacilli. Koneman's Color Atlas and Textbook of 
Diagnostic Microbiology, 6th ed. 2006, 305-91. 
 
92. Rossi, E.;  Longo, F.;  Barbagallo, M.;  Peano, C.;  Consolandi, C.;  Pietrelli, A.;  
Jaillon, S.;  Garlanda, C.; Landini, P., Glucose availability enhances 
 214 
lipopolysaccharide production and immunogenicity in the opportunistic pathogen 
Acinetobacter baumannii. Future Microbiol. 2016, 11 (3), 335-49. 
 
93. Hunt, K. M.;  Preuss, J.;  Nissan, C.;  Davlin, C. A.;  Williams, J. E.;  Shafii, B.;  
Richardson, A. D.;  McGuire, M. K.;  Bode, L.; McGuire, M. A., Human milk 
oligosaccharides promote the growth of staphylococci. Appl. Environ. Microbiol. 
2012, 78 (14), 4763-70. 
 
94. Perez-Giraldo, C.;  Rodriguez-Benito, A.;  Moran, F. J.;  Hurtado, C.;  Blanco, M. T.; 
Gomez-Garcia, A. C., Influence of N-acetylcysteine on the formation of biofilm by 
Staphylococcus epidermidis. J. Antimicrob. Chemother. 1997, 39 (5), 643-6. 
 
95. Leite, B.;  Gomes, F.;  Melo, P.;  Souza, C.;  Teixeira, P.;  Oliveira, R.; Pizzolitto, E., 
N-acetylcysteine and vancomycin alone and in combination against staphylococci 
biofilm. Rev. Bras. Eng. Bioméd. 2013, 29 (2), 184-192. 
 
96. Aslam, S.;  Trautner, B. W.;  Ramanathan, V.; Darouiche, R. O., Combination of 
tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular 
catheters. Antimicrob. Agents. Chemother. 2007, 51 (4), 1556-8. 
 
97. Charlebois, A.;  Jacques, M.; Archambault, M., Bioﬁlm formation of Clostridium 
perfringens and its exposure to low-dose antimicrobials. Front Microbiol. 2014, 5. 
 
98. Kaplan, J. B., Antibiotic-induced biofilm formation. Int. J. Artif. Organs 2011, 34 (9), 
737-51. 
 
99. Lazaro-Diez, M.;  Remuzgo-Martinez, S.;  Rodriguez-Mirones, C.;  Acosta, F.;  Icardo, 
J. M.;  Martinez-Martinez, L.; Ramos-Vivas, J., Effects of Subinhibitory 
Concentrations of Ceftaroline on Methicillin-Resistant Staphylococcus aureus 
(MRSA) Biofilms. PLoS One 2016, 11 (1), e0147569. 
 
100. Craft, K. M.;  Gaddy, J. A.; Townsend, S. D., Human Milk Oligosaccharides (HMOs) 
Sensitize Group B Streptococcus to Clindamycin, Erythromycin, Gentamicin, and 
Minocycline on a Strain Specific Basis. ACS Chem. Biol. 2018, 13 (8), 2020-2026. 
 
101. Jantscher-Krenn, E.;  Zherebtsov, M.;  Nissan, C.;  Goth, K.;  Guner, Y. S.;  Naidu, 
N.;  Choudhury, B.;  Grishin, A. V.;  Ford, H. R.; Bode, L., The human milk 
oligosaccharide disialyllacto-N-tetraose prevents necrotising enterocolitis in 
neonatal rats. Gut 2012, 61 (10), 1417-25. 
 215 
102. Autran, C. A.;  Schoterman, M. H.;  Jantscher-Krenn, E.;  Kamerling, J. P.; Bode, 
L., Sialylated galacto-oligosaccharides and 2'-fucosyllactose reduce necrotising 
enterocolitis in neonatal rats. Br. J. Nutr. 2016, 116 (2), 294-9. 
 
103. Shivekar, S.; Menon, T., Molecular Basis for Erythromycin Resistance in Group A 
Streptococcus Isolated From Skin and Soft Tissue Infections. J. Clin. Diagn. Res. 
2015, 9 (11), DC21-3. 
 
104. Lo, H. H.;  Nien, H. H.;  Cheng, Y. Y.; Su, F. Y., Antibiotic susceptibility pattern and 
erythromycin resistance mechanisms in beta-hemolytic group G Streptococcus 
dysgalactiae subspecies equisimilis isolates from central Taiwan. J. Microbiol. 
Immunol. Infect. 2015, 48 (6), 613-7. 
 
105. Yook, J. H.;  Kim, M. Y.;  Kim, E. J.;  Yang, J. H.;  Ryu, H. M.;  Oh, K. Y.;  Shin, J. 
H.;  Foxman, B.; Ki, M., Risk factors associated with group B streptococcus resistant 
to clindamycin and erythromycin in pregnant korean women. Infect. Chemother. 
2013, 45 (3), 299-307. 
 
106. World Healh Organization Model List of Essential Medicines, 2017. 2017. 
 
107. Begg, E. J.; Barclay, M. L., Aminoglycosides - 50 Years On. Brit. J. Clin. Pharmaco. 
1995, 39 (6), 597-603. 
 
108. World Health Organization List of Critically Important Antimicrobials for Human 
Medicine (WHO CIA list). 2017. 
 
109. Mingeot-Leclercq, M. P.;  Glupczynski, Y.; Tulkens, P. M., Aminoglycosides: activity 
and resistance. Antimicrob. Agents Chemother. 1999, 43 (4), 727-37. 
 
110. Mingeot-Leclercq, M. P.; Tulkens, P. M., Aminoglycosides: nephrotoxicity. 
Antimicrob. Agents Chemother. 1999, 43 (5), 1003-12. 
 
111. Melander, R. J.; Melander, C., The Challenge of Overcoming Antibiotic Resistance: 
An Adjuvant Approach? ACS Infect. Dis. 2017, 3 (8), 559-563. 
 
112. Srinivas, P.; Rivard, K., Polymyxin Resistance in Gram-negative Pathogens. Curr. 
Infect. Dis. Rep. 2017, 19 (11), 38. 
 
113. Garg, S. K.;  Singh, O.;  Juneja, D.;  Tyagi, N.;  Khurana, A. S.;  Qamra, A.;  
Motlekar, S.; Barkate, H., Resurgence of Polymyxin B for MDR/XDR Gram-
 216 
Negative Infections: An Overview of Current Evidence. Crit. Care Res. Pract. 2017, 
2017, 3635609. 
 
114. Olaitan, A. O.; Li, J., Emergence of polymyxin resistance in Gram-negative bacteria. 
Int. J. Antimicrob. Agents 2016, 48 (6), 581-582. 
 
115. Harm, S.;  Gabor, F.; Hartmann, J., Low-dose polymyxin: an option for therapy of 
Gram-negative sepsis. Innate Immun. 2016, 22 (4), 274-83. 
 
116. HsuChen, C. C.; Feingold, D. S., The mechanism of polymyxin B action and 
selectivity toward biologic membranes. Biochemistry 1973, 12 (11), 2105-11. 
 
117. Fey, P. D.;  Endres, J. L.;  Yajjala, V. K.;  Widhelm, T. J.;  Boissy, R. J.;  Bose, J. 
L.; Bayles, K. W., A genetic resource for rapid and comprehensive phenotype 
screening of nonessential Staphylococcus aureus genes. MBio. 2013, 4 (1), 
e00537-12. 
 
118. Voyich, J. M.;  Braughton, K. R.;  Sturdevant, D. E.;  Whitney, A. R.;  Said-Salim, 
B.;  Porcella, S. F.;  Long, R. D.;  Dorward, D. W.;  Gardner, D. J.;  Kreiswirth, B. 
N.;  Musser, J. M.; DeLeo, F. R., Insights into Mechanisms Used by Staphylococcus 
aureus to Avoid Destruction by Human Neutrophils. J. Immunol. 2005, 175 (6), 
3907-3919. 
 
119. Ackerman, D. L.;  Craft, K. M.; Townsend, S. D., Infant food applications of complex 
carbohydrates: Structure, synthesis, and function. Carbohydr. Res. 2017, 437, 16-
27. 
 
120. Ramirez-Macias, D.;  Shaw, K.;  Ward, R.;  Galvan-Magana, F.; Vazquez-Juarez, 
R., Isolation and characterization of microsatellite loci in the whale shark 
(Rhincodon typus). Mol. Ecol. Resour. 2009, 9 (3), 798-800. 
 
121. Santibáñez, L.;  Fernández-Arrojo, L.;  Guerrero, C.;  Plou, F. J.; Illanes, A., 
Removal of lactose in crude galacto-oligosaccharides by β-galactosidase from 
Kluyveromyces lactis. J. Mol. Cat. B: Enzym. 2016, 133, 85-91. 
 
122. Kjelleberg, S.; Molin, S., Is there a role for quorum sensing signals in bacterial 
biofilms? Curr. Opin. Microbiol. 2002, 5 (3), 254-258. 
 
  
 217 
Appendix A1:  
 
Data and Spectra Relevant to Chapter 3 
  
 218 
 
 
 
 
Figure A1.1. 1H NMR (400 MHz, D2O) and 13C NMR (100 MHz, D2O) spectra of HMOs 
isolated from Donor 14. The absence of saturated alkyl chain peaks characteristic of lipids 
in the lower ppm region of the 1H NMR spectrum and the absence of amide bond peaks 
characteristic of proteins in the upper ppm region of the 13C NMR preclude the presence 
of fat or protein in the sample. The peaks observed are characteristic of carbohydrates.  
 
	
	1H	(400	mHz)	and	13C	(100	mHz)	Spectra	for	HMOs	isolated	from	donor	14.	
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Figure A1.2. Matrix-assisted laser desorption/ionization (MALDI) full size MS spectra for 
HMO mixtures isolated from Donors 0, 5, 7, 8,14, 17, and 18. Sample labels are listed to 
the left of each spectrum with a D# designation such that D0 corresponds to Donor 0, and 
so on. Samples were analyzed in positive ion mode on a 9.4T Fourier transform ion 
cyclotron resonance (FT-ICR) mass spectrometer (MS) (Bruker Solarix). Mass spectra 
were acquired in positive ion mode from m/z 300-2500. Sodium ion adducts of HMOs 
were detected with a mass accuracy of >2 ppm. 
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Figure A1.3. Matrix-assisted laser desorption/ionization (MALDI) full size MS spectra for 
HMO mixtures isolated from Donors 19, 24, 29, 31,32, 34, and 37. Sample labels are 
listed to the left of each spectrum with a D# designation such that D19 corresponds to 
Donor 19, and so on. Samples were analyzed in positive ion mode on a 9.4T Fourier 
transform ion cyclotron resonance (FT-ICR) mass spectrometer (MS) (Bruker Solarix). 
Mass spectra were acquired in positive ion mode from m/z 300-2500. Sodium ion adducts 
of HMOs were detected with a mass accuracy of >2 ppm. 
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Figure A1.4. Matrix-assisted laser desorption/ionization (MALDI) partial MS spectra from 
m/z 630-730 for HMO mixtures isolated from Donors 0, 5, 7, 8, 14, 17, and 18. Sample 
labels are listed to the left of each spectrum with a D# designation such that D0 
corresponds to Donor 0, and so on. Samples were analyzed in positive ion mode on a 
9.4T Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer (MS) 
(Bruker Solarix). Mass spectra were acquired in positive ion mode from m/z 300-2500. 
Sodium ion adducts of HMOs were detected with a mass accuracy of >2 ppm. 
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Figure A1.5. Matrix-assisted laser desorption/ionization (MALDI) partial MS spectra from 
m/z 630-730 for HMO mixtures isolated from Donors 19, 24, 29, 31, 32, 34, and 37. 
Sample labels are listed to the left of each spectrum with a D# designation such that D19 
corresponds to Donor 19, and so on. Samples were analyzed in positive ion mode on a 
9.4T Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer (MS) 
(Bruker Solarix). Mass spectra were acquired in positive ion mode from m/z 300-2500. 
Sodium ion adducts of HMOs were detected with a mass accuracy of >2 ppm. 
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Figure A1.6. Matrix-assisted laser desorption/ionization (MALDI) partial MS spectra from 
m/z 1010-1060 for HMO mixtures isolated from Donors 0, 5, 7, 8, 14, 17, and 18. Sample 
labels are listed to the left of each spectrum with a D# designation such that D0 
corresponds to Donor 0, and so on. Samples were analyzed in positive ion mode on a 
9.4T Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer (MS) 
(Bruker Solarix). Mass spectra were acquired in positive ion mode from m/z 300-2500. 
Sodium ion adducts of HMOs were detected with a mass accuracy of >2 ppm. 
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Figure A1.7. Matrix-assisted laser desorption/ionization (MALDI) partial MS spectra from 
m/z 1010-1060 for HMO mixtures isolated from Donors 19, 24, 29, 31, 32, 34, and 37. 
Sample labels are listed to the left of each spectrum with a D# designation such that D19 
corresponds to Donor 19, and so on. Samples were analyzed in positive ion mode on a 
9.4T Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer (MS) 
(Bruker Solarix). Mass spectra were acquired in positive ion mode from m/z 300-2500. 
Sodium ion adducts of HMOs were detected with a mass accuracy of >2 ppm. 
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Figure A1.8. Matrix-assisted laser desorption/ionization (MALDI) MS/MS spectra of 
selected m/z 657.2 ion for HMO mixtures isolated from Donors 0, 5, 7, 8, 14, 17, and 18. 
Sample labels are listed to the left of each spectrum with a D# designation such that D0 
corresponds to Donor 0, and so on. MS/MS analysis was performed with a linear ion trap 
mass spectrometer equipped with a MALDI source (LTQ XL, Thermo Scientific). Selected 
sodium adduct ions of interest were isolated with a 1 amu window and fragmented via 
CID using a collision energy of 35 eV. Ions circled in red are deterministic for Lewis blood 
group and secretor status assignment.  
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Figure A1.9. Matrix-assisted laser desorption/ionization (MALDI) MS/MS spectra of 
selected m/z 657.2 ion for HMO mixtures isolated from Donors 19, 24, 29, 31, 32, 34, and 
37. Sample labels are listed to the left of each spectrum with a D# designation such that 
D19 corresponds to Donor 19, and so on. MS/MS analysis was performed with a linear 
ion trap mass spectrometer equipped with a MALDI source (LTQ XL, Thermo Scientific). 
Selected sodium adduct ions of interest were isolated with a 1 amu window and 
fragmented via CID using a collision energy of 35 eV. Ions circled in red are deterministic 
for Lewis blood group and secretor status assignment.  
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Figure A1.10. Matrix-assisted laser desorption/ionization (MALDI) MS/MS spectra of 
selected m/z 1022.2 ion for HMO mixtures isolated from Donors 0, 5, 7, 8, 14, 17, and 18. 
Sample labels are listed to the left of each spectrum with a D# designation such that D0 
corresponds to Donor 0, and so on. MS/MS analysis was performed with a linear ion trap 
mass spectrometer equipped with a MALDI source (LTQ XL, Thermo Scientific). Selected 
sodium adduct ions of interest were isolated with a 1 amu window and fragmented via 
CID using a collision energy of 35 eV. Ions circled in red are deterministic for Lewis blood 
group and secretor status assignment.  
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Figure A1.11. Matrix-assisted laser desorption/ionization (MALDI) MS/MS partial spectra 
of selected m/z 1022.2 ion (from m/z 700-900) for HMO mixtures isolated from Donors 0, 
5, 7, 8, 14, 17, and 18. Sample labels are listed to the left of each spectrum with a D# 
designation such that D0 corresponds to Donor 0, and so on. MS/MS analysis was 
performed with a linear ion trap mass spectrometer equipped with a MALDI source (LTQ 
XL, Thermo Scientific). Selected sodium adduct ions of interest were isolated with a 1 
amu window and fragmented via CID using a collision energy of 35 eV. Ions circled in red 
are deterministic for Lewis blood group and secretor status assignment.  
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Figure A1.12. Matrix-assisted laser desorption/ionization (MALDI) MS/MS spectra of 
selected m/z 1022.2 ion for HMO mixtures isolated from Donors 19, 24, 29, 31, 32, 34, 
and 37. Sample labels are listed to the left of each spectrum with a D# designation such 
that D19 corresponds to Donor 19, and so on. MS/MS analysis was performed with a 
linear ion trap mass spectrometer equipped with a MALDI source (LTQ XL, Thermo 
Scientific). Selected sodium adduct ions of interest were isolated with a 1 amu window 
and fragmented via CID using a collision energy of 35 eV. Ions circled in red are 
deterministic for Lewis blood group and secretor status assignment.  
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Figure A1.13. Matrix-assisted laser desorption/ionization (MALDI) MS/MS partial spectra 
of selected m/z 1022.2 ion (from m/z 700-900) for HMO mixtures isolated from Donors 
19, 24, 29, 31, 32, 34, and 37. Sample labels are listed to the left of each spectrum with 
a D# designation such that D19 corresponds to Donor 19, and so on. MS/MS analysis 
was performed with a linear ion trap mass spectrometer equipped with a MALDI source 
(LTQ XL, Thermo Scientific). Selected sodium adduct ions of interest were isolated with 
a 1 amu window and fragmented via CID using a collision energy of 35 eV. Ions circled 
in red are deterministic for Lewis blood group and secretor status assignment.  
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T: ITMS + p MALDI Full ms2 1022.20@cid40.00 
[280.00-1200.00] 
NL: 7.08E1
30-d29 msms 1022_a10#1-10  RT: 0.00-0.70  AV: 10 
T: ITMS + p MALDI Full ms2 1022.20@cid40.00 
[280.00-1200.00] 
NL: 6.24E1
31-d31 msms 1022_a11#1-10  RT: 0.00-0.67  AV: 10 
T: ITMS + p MALDI Full ms2 1022.20@cid40.00 
[280.00-1200.00] 
NL: 1.09E4
32-d32 msms 1022_a12#1-10  RT: 0.00-0.50  AV: 10 
T: ITMS + p MALDI Full ms2 1022.20@cid40.00 
[280.00-1200.00] 
NL: 3.69E3
33-d34 msms 1022_a13#1-10  RT: 0.00-0.77  AV: 10 
T: ITMS + p MALDI Full ms2 1022.20@cid40.00 
[280.00-1200.00] 
NL: 5.46E3
34-d37 msms 1022_a14#1-10  RT: 0.00-0.54  AV: 10 
T: ITMS + p MALDI Full ms2 1022.20@cid40.00 
[280.00-1200.00] 
x2
MS/MS	of	m/z	1022.2	® [fragments	from	m/z	700-900]
D19
D24
D29
D31
D32
D34
D37
730.3
730.3
730.3
730.3
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Figure A1.14. General HMO composition of two distinct donors. (A) Matrix-assisted laser 
desorption/ionization (MALDI) MS spectra for HMO mixtures isolated from two distinct 
donor samples. Samples were analyzed in positive ion mode on a 9.4T Fourier transform 
ion cyclotron resonance (FT-ICR) mass spectrometer (MS) (Bruker Solarix). Mass 
spectra were acquired in positive ion mode from m/z 300-2500. Sodium ion adducts of 
HMOs were detected with a mass accuracy of >2 ppm. (B) Generic structural descriptions 
for the molecular ions observed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.   B.  
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Figure A1.15. Biofilm formation for S. agalactiae strain CNCTC 10/84 after 24 H of growth 
in THB media alone or in the presence of ca. 5 mg/mL HMOs from various donors. Data 
expressed as mean biofilm measurements (OD560) ± SEM of 3 separate experiments, 
each with 3 technical replicates. **** represents p<0.0001 by one-way ANOVA, F=3.843 
with posthoc Dunnett’s multiple comparison test comparing each HMO sample against 
the control sample without HMOs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.16. Biomass for S. agalactiae strain CNCTC 10/84 after 24 H of growth in THB 
media alone or in the presence of ca. 5 mg/mL HMOs from various donors. Data 
expressed as mean biomass measurements (OD600) ± SEM of 3 separate experiments, 
each with 3 technical replicates. **** represents p<0.0001 by one-way ANOVA, F=88.34 
with posthoc Dunnett’s multiple comparison test comparing each HMO sample against 
the control sample without HMOs. 
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Figure A1.17. Biofilm to biomass ratio of S. agalactiae strain CNCTC 10/84 after 24 H of 
growth in THB media alone or in the presence of ca. 5 mg/mL HMOs from various donors. 
Data expressed as mean biofilm/biomass ratio measurements (OD560/OD600) ± SEM of 3 
separate experiments, each with 3 technical replicates. *** represents p=0.0001 by one-
way ANOVA, F=3.351 with posthoc Dunnett’s multiple comparison test comparing each 
HMO sample against the control sample without HMOs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.18. Biofilm to biomass ratio of S. agalactiae strain CNCTC 10/84 after 24 H of 
growth in THB media alone or in the presence of ca. 5 mg/mL HMOs from various donors 
excluding Donor 8. Data expressed as mean biofilm/biomass ratio measurements 
(OD560/OD600) ± SEM of 3 separate experiments, each with 3 technical replicates. **** 
represents p<0.0001 by one-way ANOVA, F=4.065 with posthoc Dunnett’s multiple 
comparison test comparing each HMO sample against the control sample without HMOs. 
Results from Donor 8 were determined to be outliers using ROUT (Q=1) and Grubbs 
(alpha=0.05) outlier tests. 
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Figure A1.19. Biofilm for S. agalactiae strain CNCTC 10/84 after 24 H of growth in THB 
+ 1% glucose media alone or in the presence of ca. 5 mg/mL HMOs from various donors. 
Data expressed as mean biofilm measurements (OD560) ± SEM of 3 separate 
experiments, each with 3 technical replicates. **** represents p<0.0001 by one-way 
ANOVA, F=6.057 with posthoc Dunnett’s multiple comparison test comparing each HMO 
sample against the control sample without HMOs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.20. Biomass for S. agalactiae strain CNCTC 10/84 after 24 H of growth in THB 
+ 1% glucose media alone or in the presence of ca. 5 mg/mL HMOs from various donors. 
Data expressed as mean biomass measurements (OD600) ± SEM of 3 separate 
experiments, each with 3 technical replicates. **** represents p=<0.0001 by one-way 
ANOVA, F=43.21 with posthoc Dunnett’s multiple comparison test comparing each HMO 
sample against the control sample without HMOs. 
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Figure A1.21. Biofilm to biomass ratio of S. agalactiae strain CNCTC 10/84 after 24 H of 
growth in THB + 1% glucose media alone or in the presence of ca. 5 mg/mL HMOs from 
various donors. Data expressed as mean biofilm/biomass ratio measurements 
(OD560/OD600) ± SEM of 3 separate experiments, each with 3 technical replicates. **** 
represents p<0.0001 by one-way ANOVA, F=7.579 with posthoc Dunnett’s multiple 
comparison test comparing each HMO sample against the control sample without HMOs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.22. Biofilm for S. agalactiae strain GB590 after 24 H of growth in THB media 
alone or in the presence of ca. 5 mg/mL HMOs from various donors. Data expressed as 
mean biofilm measurements (OD560) ± SEM of 3 separate experiments, each with 3 
technical replicates. No results were found to be significant by one-way ANOVA, F=1.197 
with posthoc Dunnett’s multiple comparison test comparing each HMO sample against 
the control sample without HMOs. 
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Figure A1.23. Biomass for S. agalactiae strain GB590 after 24 H of growth in THB media 
alone or in the presence of ca. 5 mg/mL HMOs from various donors. Data expressed as 
mean biomass measurements (OD600) ± SEM of 3 separate experiments, each with 3 
technical replicates. **** represents p<0.0001  by one-way ANOVA, F=19.55  with 
posthoc Dunnett’s multiple comparison test comparing each HMO sample against the 
control sample without HMOs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.24. Biofilm to biomass ratio of S. agalactiae strain GB590 after 24 H of growth 
in THB media alone or in the presence of ca. 5 mg/mL HMOs from various donors. Data 
expressed as mean biofilm/biomass ratio measurements (OD560/OD600) ± SEM of 3 
separate experiments, each with 3 technical replicates. ** represents p=0.0064  by one-
way ANOVA, F=2.354  with posthoc Dunnett’s multiple comparison test comparing each 
HMO sample against the control sample without HMOs.  
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Figure A1.25. Biofilm to biomass ratio for S. agalactiae strain GB590 after 24 H of growth 
in THB media alone or in the presence of ca. 5 mg/mL HMOs from various donors 
excluding Donor 8. Data expressed as mean biofilm/biomass ratio measurements 
(OD560/OD600) ± SEM of 3 separate experiments, each with 3 technical replicates. No 
results were found to be significant by one-way ANOVA, F=1.061 with posthoc Dunnett’s 
multiple comparison test comparing each HMO sample against the control sample without 
HMOs. Results from Donor 8 were determined to be outliers using ROUT (Q=1) and 
Grubbs (alpha=0.05) outlier tests.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.26. Biofilm for S. agalactiae strain GB590 after 24 H of growth in THB + 1% 
glucose media alone or in the presence of ca. 5 mg/mL HMOs from various donors. Data 
expressed as mean biofilm  measurements (OD560) ± SEM of 3 separate experiments, 
each with 3 technical replicates. No results were found to be significant by one-way 
ANOVA, F=1.961 with posthoc Dunnett’s multiple comparison test comparing each HMO 
sample against the control sample without HMOs. 
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Figure A1.27. Biomass for S. agalactiae strain GB590 after 24 H of growth in THB + 1% 
glucose media alone or in the presence of ca. 5 mg/mL HMOs from various donors. Data 
expressed as mean biomass measurements (OD600) ± SEM of 3 separate experiments, 
each with 3 technical replicates. **** represents p<0.0001 by one-way ANOVA, F=10.93 
with posthoc Dunnett’s multiple comparison test comparing each HMO sample against 
the control sample without HMOs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.28. Biofilm to biomass ratio of S. agalactiae strain GB590 after 24 H of growth 
in THB + 1% glucose media alone or in the presence of ca. 5 mg/mL HMOs from various 
donors. Data expressed as mean biofilm/biomass ratio measurements (OD560/OD600) ± 
SEM of 3 separate experiments, each with 3 technical replicates. **** represents 
p<0.0001 by one-way ANOVA, F=6.423 with posthoc Dunnett’s multiple comparison test 
comparing each HMO sample against the control sample without HMOs. 
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Figure A1.29. Biofilm for S. agalactiae strain GB2 after 24 H of growth in THB media 
alone or in the presence of ca. 5 mg/mL HMOs from various donors. Data expressed as 
mean biofilm measurements (OD560) ± SEM of 3 separate experiments, each with 3 
technical replicates. **** represents p<0.0001 by one-way ANOVA, F=12.85 with posthoc 
Dunnett’s multiple comparison test comparing each HMO sample against the control 
sample without HMOs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.30. Biomass for S. agalactiae strain GB2 after 24 H of growth in THB media 
alone or in the presence of ca. 5 mg/mL HMOs from various donors. Data expressed as 
mean biomass measurements (OD600) ± SEM of 3 separate experiments, each with 3 
technical replicates. **** represents p<0.001  by one-way ANOVA, F=132.3 with posthoc 
Dunnett’s multiple comparison test comparing each HMO sample against the control 
sample without HMOs. 
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Figure A1.31. Biofilm to biomass ratio of S. agalactiae strain GB2 after 24 H of growth in 
THB media alone or in the presence of ca. 5 mg/mL HMOs from various donors. Data 
expressed as mean biofilm/biomass ratio measurements (OD560/OD600) ± SEM of 3 
separate experiments, each with 3 technical replicates. * represents p=0.0382  by one-
way ANOVA, F=1.855  with posthoc Dunnett’s multiple comparison test comparing each 
HMO sample against the control sample without HMOs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.32. Biofilm to biomass ratio for S. agalactiae strain CNCTC 10/84 after 24 H 
of growth in THB media alone or in the presence of ca. 5 mg/mL HMOs from various 
donors excluding Donor 8. Data expressed as mean biofilm/biomass ratio measurements 
(OD560/od600) ± SEM of 3 separate experiments, each with 3 technical replicates. **** 
represents p<0.0001 by one-way ANOVA, F=9.692 with posthoc Dunnett’s multiple 
comparison test comparing each HMO sample against the control sample without HMOs. 
Results from Donor 8 were determined to be outliers using ROUT (Q=1) and Grubbs 
(alpha=0.05) outlier tests. 
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Figure A1.33. Biofilm for S. agalactiae strain GB2 after 24 H of growth in THB + 1% 
glucose media alone or in the presence of ca. 5 mg/mL HMOs from various donors. Data 
expressed as mean biofilm measurements (OD560) ± SEM of 3 separate experiments, 
each with 3 technical replicates. **** represents p<0.0001 by one-way ANOVA, F=99.11 
with posthoc Dunnett’s multiple comparison test comparing each HMO sample against 
the control sample without HMOs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.34. Biomass for S. agalactiae strain GB2 after 24 H of growth in THB + 1% 
glucose media alone or in the presence of ca. 5 mg/mL HMOs from various donors. Data 
expressed as mean biomass measurements (OD600) ± SEM of 3 separate experiments, 
each with 3 technical replicates. **** represents p<0.0001  by one-way ANOVA, F=58.52  
with posthoc Dunnett’s multiple comparison test comparing each HMO sample against 
the control sample without HMOs. 
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Figure A1.35. Biofilm to biomass ratio of S. agalactiae strain GB2 after 24 H of growth in 
THB + 1% glucose media alone or in the presence of ca. 5 mg/mL HMOs from various 
donors. Data expressed as mean biofilm/biomass ratio measurements (OD560/OD600) ± 
SEM of 3 separate experiments, each with 3 technical replicates. **** represents 
p<0.0001  by one-way ANOVA, F=8.55  with posthoc Dunnett’s multiple comparison test 
comparing each HMO sample against the control sample without HMOs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.36. Biofilm formation for S. aureus USA300 after 24 H of growth in THB media 
alone or in the presence of ca. 5 mg/mL HMOs from various donors. Data expressed as 
mean biofilm measurements (OD560) ± SEM of 3 separate experiments, each with 3 
technical replicates. **** represents p<0.0001 by one-way ANOVA, F=4.364 with posthoc 
Dunnett’s multiple comparison test comparing each HMO sample against the control 
sample without HMOs. 
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Figure A1.37. Biomass for S. aureus strain USA300 after 24 H of growth in THB media 
alone or in the presence of ca. 5 mg/mL HMOs from various donors. Data expressed as 
mean biomass measurements (OD600) ± SEM of 3 separate experiments, each with 3 
technical replicates. *** represents p=0.0001 by one-way ANOVA, F=1.884 with posthoc 
Dunnett’s multiple comparison test comparing each HMO sample against the control 
sample without HMOs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.38. Biofilm to biomass ratio of S. aureus strain USA300 after 24 H of growth 
in THB media alone or in the presence of ca. 5 mg/mL HMOs from various donors. Data 
expressed as mean biofilm/biomass ratio measurements (OD560/OD600) ± SEM of 3 
separate experiments, each with 3 technical replicates. *** represents p=0.0001 by one-
way ANOVA, F=3.384 with posthoc Dunnett’s multiple comparison test comparing each 
HMO sample against the control sample without HMOs. 
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Figure A1.39. Biofilm formation for S. aureus strain USA300 after 24 H of growth in THB 
+ 1% glucose media alone or in the presence of ca. 5 mg/mL HMOs from various donors. 
Data expressed as mean biofilm measurements (OD560) ± SEM of 3 separate 
experiments, each with 3 technical replicates. **** represents p<0.0001 by one-way 
ANOVA, F=8.034 with posthoc Dunnett’s multiple comparison test comparing each HMO 
sample against the control sample without HMOs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.40. Biomass for S. aureus strain USA300 after 24 H of growth in THB + 1% 
glucose media alone or in the presence of ca. 5 mg/mL HMOs from various donors. Data 
expressed as mean biomass measurements (OD600) ± SEM of 3 separate experiments, 
each with 3 technical replicates. **** represents p<0.0001 by one-way ANOVA, F=17.12 
with posthoc Dunnett’s multiple comparison test comparing each HMO sample against 
the control sample without HMOs. 
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Figure A1.41. Biofilm to biomass ratio of S. aureus strain USA300 after 24 H of growth 
in THB + 1% glucose media alone or in the presence of ca. 5 mg/mL HMOs from various 
donors. Data expressed as mean biofilm/biomass ratio measurements (OD560/OD600) ± 
SEM of 3 separate experiments, each with 3 technical replicates. **** represents 
p<0.0001 by one-way ANOVA, F=4.694 with posthoc Dunnett’s multiple comparison test 
comparing each HMO sample against the control sample without HMOs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.42. Biofilm formation for A. baumannii strain ATCC 19606 after 24 H of growth 
in THB media alone or in the presence of ca. 5 mg/mL HMOs from various donors. Data 
expressed as mean biofilm measurements (OD560) ± SEM of 2 separate experiments, 
each with 3 technical replicates. * represents p=0.0347 by one-way ANOVA, F=1.943 
with posthoc Dunnett’s multiple comparison test comparing each HMO sample against 
the control sample without HMOs. 
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Figure A1.43. Biomass for A. baumannii strain ATCC 19606 after 24 H of growth in THB 
media alone or in the presence of ca. 5 mg/mL HMOs from various donors. Data 
expressed as mean biomass measurements (OD600) ± SEM of 3 separate experiments, 
each with 3 technical replicates. **** represents p<0.0001 by one-way ANOVA, F=7.17 
with posthoc Dunnett’s multiple comparison test comparing each HMO sample against 
the control sample without HMOs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.44. Biofilm to biomass ratio of A. baumannii strain ATCC 19606 after 24 H of 
growth in media alone or in the presence of ca. 5 mg/mL HMOs from various donors. 
Data expressed as mean biofilm/biomass ratio measurements (OD560/OD600) ± SEM of 2 
separate experiments, each with 3 technical replicates. ** represents p=0.0088 by one-
way ANOVA, F=2.369 with posthoc Dunnett’s multiple comparison test comparing each 
HMO sample against the control sample without HMOs. 
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Figure A1.45. Biofilm formation for A. baumannii strain ATCC 19606 after 24 H of growth 
in THB + 1% glucose media alone or in the presence of ca. 5 mg/mL HMOs from various 
donors. Data expressed as mean biofilm measurements (OD560) ± SEM of 2 separate 
experiments, each with 3 technical replicates. **** represents p<0.0001 by one-way 
ANOVA, F=4.853 with posthoc Dunnett’s multiple comparison test comparing each HMO 
sample against the control sample without HMOs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.46. Biomass for A. baumannii strain ATCC 19606 after 24 H of growth in THB 
+ 1% glucose media alone or in the presence of ca. 5 mg/mL HMOs from various donors. 
Data expressed as mean biomass measurements (OD600) ± SEM of 3 separate 
experiments, each with 3 technical replicates. **** represents p<0.0001 by one-way 
ANOVA, F=11.23 with posthoc Dunnett’s multiple comparison test comparing each HMO 
sample against the control sample without HMOs. 
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Figure A1.47. Biofilm to biomass ratio of A. baumannii strain ATCC 19606 after 24 H of 
growth in THB + 1% glucose media alone or in the presence of ca. 5 mg/mL HMOs from 
various donors. Data expressed as mean biofilm/biomass ratio measurements 
(OD560/OD600) ± SEM of 2 separate experiments, each with 3 technical replicates. **** 
represents p<0.0088 by one-way ANOVA, F=7.029 with posthoc Dunnett’s multiple 
comparison test comparing each HMO sample against the control sample without HMOs. 
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Table A1.1. Antibiotic sensitization data for HMOs against S. aureus in THBa,b 
 
Antibiotics MIC without HMO MIC with HMO Fold Reduction 
Cefazolin 8 8 0 
Vancomycin 8 8 0 
Clindamycin 0.125 0.125 0 
Gentamicin 1 1 0 
Erythromycin 16 16 0 
Linezolid 1.7 1.7 0 
aall MIC values given in µg/mL. bHMOs were dosed at ca. 5 mg/mL. 
 
 
 
 
 
 
 
Antibiotic MIC without HMO MIC with HMO Fold Reduction 
Amikacin 16 16 0 
Tobramycin 16 8 2 
Imipenem 0.25 1 0 
Meropenem 0.5 0.5 0 
Minocycline 0.0156 0.0312 0 
Tigecycline 0.125 0.25 0 
Doripenem 0.5 0.5 0 
aall MIC values given in µg/mL. bHMOs were dosed at ca. 5 mg/mL.40-46, 122 
 
 
 
 
 
 
 
Table A1.2. Antibiotic sensitization data for HMOs against A. baumannii in THB 
+ 1% glucosea,b 
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Table A1.3. Results of LIVE/DEAD BacLight Assay for Treatment of Three Strains of 
GBS with Heterogenous HMO Extractsa, b, c 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 THB THB + 1% glc 
 GB590 CNCTC 10/84 GB2 GB590 
CNCTC 
10/84 GB2 
HMO 
Concentration 
(mg/mL) 
Difference in LIVE/DEAD Ratio from control (%) ± SEM 
0 (control) 0.00 ± 2.23 0.00 ± 2.96 0.00 ± 2.78 0.00 ± 14.14 0.00 ± 1.56 0.00 ± 6.52 
0.32 -0.72 ± 3.80 -4.23 ± 5.77 -4.57 ± 4.94 4.22 ±10.57 -4.62 ± 2.32 -3.81 ± 4.89 
0.64 -7.94 ± 1.63 -12.66 ± 3.18 -23.87 ± 1.58 -3.95 ± 9.69 -6.79 ± 1.86 
-18.66 ± 
3.79 
1.28 -21.79 ± 3.23 -9.00 ± 5.01 -40.16 ± 1.85 -17.35 ± 8.33 -6.02 ± 2.73 
-28.19 ± 
3.33 
2.56 -32.70 ± 2.68 -20.34 ± 3.83 -49.94 ± 1.46 -18.36 ± 9.71 -7.98 ± 2.04 
-34.76 ± 
3.08 
5.12 -27.00 ± 2.18 -35.81 ± 3.17 -15.53 ± 3.29 -18.62 ±8.16 
-13.09 ± 
10.02 
-16.75 ± 
4.14 
10.25 -28.20 ± 2.57 -20.61 ± 2.18 -20.37 ± 2.46 -21.22 ± 7.94 -23.13 ± 0.96 
-23.46 ± 
3.60 
20.5 -28.59 ± 1.35 -18.25 ± 2.48 -23.46 ± 3.60 -27.99 ± 7.58 -20.37 ± 2.46 
-26.40 ± 
3.43 
ameasurements taken at 24 h of growth. bHMOs dosed at ca. 5 mg/mL. csignificantly decreased LIVE/DEAD ratios 
are bolded and highlighted in blue (P < 0.05 by Student’s t test, N = 3 replicates). 
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CHAPTER 4 
 
Synthesis of Lacto-N-Tetraose 
 
4.1 Rationale for the Synthesis of Lacto-N-Tetraose  
  Having described the antibacterial activities of heterogenous HMO extracts 
against various bacterial pathogens, our next aim was to more narrowly-define these 
activities, i.e. to uncover single compounds with biological activity. However, as there 
have been over 200 distinct HMOs recognized, identifying active single compounds is no 
trivial task.1 First, it is essential to narrow down the list of possible active compounds as 
it is impractical to randomly select HMOs to evaluate. This research strategy is made 
even more impractical when one considers the nature of the compounds to be tested. As 
described in Chapter 2, HMOs vary in size and complexity from simple fucosylated 
lactose trisaccharides to HMOs that incorporate over 30 monosaccharide residues. While 
some of the simpler, smaller HMOs are commercially available, the vast majority are 
either not commercially available or are too costly to purchase in sufficient amounts.1  
 In addition to the infeasibility of purchasing most HMOs in the quantities needed 
for thorough biological testing, it is also infeasible to isolate single compounds from 
human milk in purities and quantities sufficient for testing. Thus, in order to evaluate 
individual compounds, it becomes necessary for researchers to synthesize, chemically or 
enzymatically, the desired HMOs.1, 2 While synthesis is a viable route, it remains that 
carbohydrate synthesis is known for being time-consuming and challenging. Due to the 
need to dedicate significant time and resources for the synthesis of each compound, it 
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becomes even more imperative that researchers be judicious with their choice of synthetic 
target(s). 
 When selecting an HMO target, we considered the following criteria: 
concentrations in individual samples, prevalence across different samples, synthetic 
feasibility, and synthetic utility. Ultimately, we wanted to target a ubiquitous HMO that was 
one, at the time largely inaccessible to researchers, and, two, whose synthesis would 
yield not only a potentially active compound but also a compound whose synthesis could 
be easily altered to provide access to additional molecules. Given these criteria, lacto-N-
tetraose (LNT, 2.4) (Figure 4.1) stood out as an attractive target.  
 
 
 
 
 First and foremost, LNT is present in high concentrations in human milk and is 
common across donor samples regardless of donor blood group.3-6 Second, although 
several groups had previously completed chemical or enzymatic syntheses of LNT or 
LNT-derivatives,7-13 it remains that LNT is not currently available at large scale through 
chemical or enzymatic synthesis. Third, as described in Chapter 2, LNT serves as a core 
tetrasaccharide in type I chains which predominate over type II chains in human milk.5 
Indeed, LNT is significantly more common in human milk than its type II chain isomer 
lacto-N-neotetraose (LNnT, 2.5).5, 14 Thus, we envisioned that developing a scalable route 
to LNT would allow access both to large quantities of an important and ubiquitous HMO 
and to a number of additional HMOs with minimal effort. Access to larger quantities of 
Figure 4.1. Structure of lacto-N-tetraose (LNT, 2.4). 
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HMOs would then allow for studies aimed at investigating the biological importance of 
single-entity compounds.    
 
4.2 Methods for Oligosaccharide Synthesis 
 It is well-known that oligosaccharide synthesis is a challenging endeavor and one 
that is significantly more complicated than the synthesis of other biopolymers like nucleic 
acids and proteins. Simply put, the increased difficultly results from a greater number of 
possible combinations of polymeric building blocks, i.e. monosaccharides. First, there 
exist a vast array of monosaccharides which can vary in ring size, substitution pattern, 
modifications such as sulfonation and phosphorylation, and so on. Second, in contrast to 
amide and phosphodiester linkages, linkages between monosaccharide residues (a 
glycosidic bond) generates a new stereocenter (a or b linkages). Third, the location of the 
glycosidic bond can vary. For example, LNT and LNnT feature the same monosaccharide 
building blocks that are connected similarly through b-oriented glycosidic bonds, yet these 
structures differ in the location of glycosidic bonds: LNT features a b1-3 bond between 
Gal and GlcNAc while LNnT features a b1-4 bond. Thus, synthetic efforts must not only 
yield the correct building blocks, they must also link these building blocks together in a 
stereoselective and regioselective fashion.  
 Due to the complexity and diversity inherent to oligosaccharide synthesis, a variety 
of methods have been developed for the synthesis of this class of compound. These 
methods can be broadly classified as chemical or enzymatic, or a combination of the two. 
In the next section, the methods for and attributes of chemical carbohydrate synthesis will 
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be discussed. The corresponding information for enzymatic carbohydrate synthesis is 
reviewed elsewhere.15-19 
 
4.3 Chemical Approaches for Oligosaccharide Synthesis 
4.3.1 Glycoside Bond Formation: The Glycosylation Reaction20-22 
  
 At the heart of oligosaccharide synthesis is the glycosylation reaction. This reaction 
links building blocks and must be done with both regio- and stereoselectivity. Generally 
speaking, this reaction is characterized by the union of a suitably protected acceptor 
bearing a free alcohol at the position of the desired glycosidic bond and a suitably 
protected donor bearing a latent leaving group at the anomeric position (Scheme 4.1).   
When a new glycosidic bond is formed, it can have either an a or b orientation. 
Carbohydrate a/b configuration is determined by the orientation of the non-hydrogen 
substituent at C1 in relation to the non-hydrogen substituent at C6.  An a glycoside is one 
in which these substituents are trans to one another. In contrast, a b glycoside is one in 
which these substituents are cis to one another. In the case of a 6-deoxy sugar, such as 
fucose, a/b is determined by the orientation of the C1 substituent in relation to the C5 
substituent. Additionally, glycosidic bonds can be termed 1,2-cis or 1,2-trans linkages; in 
Scheme 4.1. The chemical glycosylation reaction. A latent leaving group, X, at the anomeric 
center of a glycosyl donor is activated with a promoter in the presence of a protected glycosyl 
acceptor bearing a free alcohol. The alcohol of the acceptor effectively replaces the latent 
leaving group of the donor and “accepts” the “donor” monosaccharide to form a glycosidic 
bond. The newly formed bond can have an a or b orientation. Abbreviations: P, protecting 
group; X, latent leaving group. 
O
XPO
Glycosyl Donor
HO
O
OP
Glycosyl Acceptor
Promoter+ O OPO
O
OP
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an 1,2-cis linkage, the C1 and C2 substituents are cis whereas in a 1,2-trans linkage 
these groups will be trans to one another (Figure 4.2). 
By conventional carbohydrate carbon numbering, ring carbons of a 
monosaccharide are labeled clockwise in numerical order beginning with the anomeric 
carbon which is labeled C1; the anomeric center is the ring carbon directly adjacent to the 
in-ring oxygen (endocyclic) when moving around the ring in a clockwise fashion. With a 
disaccharide, the carbons in the ring furthest from the reducing end are still labeled 
clockwise in numerical order, but they are denoted with a prime, i.e. C1’. Additional rings 
are labeled as double prime and so on. Finally, when denoting a glycosidic bond, the 
designation of a/b is followed by the numbers of the ring carbons that are connected by 
the bond (Figure 4.2).  
 
 While the glycosylation reaction may seem straight-forward, the mechanism of 
nucleophilic displacement at the sp3 anomeric carbon can vary greatly from reaction to 
reaction. Indeed, the outcome of a glycosylation reaction can be affected by solvent, 
protecting group strategies, donor type, promoter systems, temperature, etc. Based on 
reaction conditions, glycosylation reaction mechanisms can span from a unimolecular, 
dissociative SN1 process that proceeds through an oxocarbenium intermediate to a 
biomolecular associate SN2 process that proceeds in a single step.22, 23 Consequently, 
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Figure 4.2. Conventional carbohydrate carbon numbering and a/b and cis/trans 
designations for monosaccharides (A) and larger (B). 
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the glycosylation reaction mechanism is generally considered to be a continuum between 
purely SN1 and purely SN2. Between these two ends of the mechanistic spectrum are ion-
associated mechanisms where contact ion pair (CIP) mechanisms are more SN2-like and 
solvent-separated ion pair (SSIP) mechanisms are more SN1-like. Generally speaking, 
polar solvents will better stabilize a SSIP and consequently promote more SN1-type 
reactions while non-polar solvents are not as capable of stabilizing a SSIP and thus 
promote more SN2-type reactions proceeding through CIP (Scheme 4.2).  
 
4.3.2 The Anomeric Effect20, 24 
 Important to understanding any glycosylation mechanism is understanding the 
anomeric effect (Scheme 4.3). The anomeric effect, first described by Edward and later 
named by Lemieux and Chü, refers to the preferential axial orientation of electronegative 
substituents (halides, alkoxy groups, triflates, etc.) at the anomeric carbon.25-27 This 
Scheme 4.2. Mechanistic continuum for a glycosylation reaction. Abbreviations: P, 
protecting group; X, latent leaving group; X’, activated leaving group.  
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preference is attributed to stabilization that occurs through delocalization of a lone pair of 
electrons from the endocyclic oxygen to the periplanar antibonding s orbital of the 
anomeric carbon to electronegative anomeric substituent bond (C-X bond). Indeed, this 
interaction is not possible in the non-periplanar C-X bond of the b-anomer. The 
stabilization uniquely experienced by the a-anomer is estimated to be around 1.5 kcal/mol.  
 While stabilization via hyperconjugation is not the only proposed explanation of the 
anomeric effect, it is the only one that explains the shortening of the C-X bond of the a-
anomer compared to the b-anomer. Indeed, although reduction of unfavorable dipole-
dipole or electron-pair-electron-pair interactions have similarly been offered as an 
explanation for the axial preference, these explanations do not explain the shorter bond 
length. As a final note, generally speaking, the stronger the electronegativity of an 
anomeric substituent, the stronger the axial preference. Moreover, in the case of alkoxy 
substituents, electronics dominate the orientation preference; the size of the alkoxy group 
has little effect.  
 
 
 
 
 
 
4.3.3 Protecting Groups20, 28 
 As previously mentioned, there are several factors that can influence the outcome 
of a glycosylation. One of the most important is the protecting group strategy used, 
Scheme 4.3. The anomeric effect. Electrons in a non-bonding orbital of the endocyclic 
oxygen (noxygen) can interact with the antibonding sigma orbital of an a-oriented anomeric 
C-X bond (s*C-X). This interaction (n® s*) imparts additional stabilization for the a anomer 
as this interaction is not possible with the b anomer. 
O
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especially that used on the glycosyl donor. A list of commonly employed O- and N- 
protecting groups is provided in Figure 4.3. Protecting groups can influence the 
stereoselectivity of a glycosylation and can also tune donor reactivity. While the effects of 
protecting groups can be far reaching and can take many forms, two of the most well 
know effects are neighboring group participation (NGP) and donor arming/disarming.   
 
 NGP, also termed anchimeric assistance, refers to the capability of 2-O- or -N-acyl 
protecting groups to generate 1,2-trans glycosides through their interaction with the 
Figure 4.3. Common oxygen and nitrogen protecting groups in carbohydrate chemistry. 
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oxocarbenium ion intermediate. Indeed, this strategy is one of the most common and 
reliable methods for generating 1,2-trans glycosides. Briefly, a latent leaving group on a 
glycosyl donor is activated by a promoter to facilitate its departure. The departure of the 
leaving group generates an oxocarbenium intermediate which can interact with a C2 acyl 
substituent to generate a more stable acetoxonium ion (the positive charge is shared 
across two oxygen atoms as opposed isolated to one). Subsequent nucleophilic attack at 
the anomeric center will result in the 1,2-trans glycoside (Scheme 4.4). In the absence of 
a C2 participating group, nucleophilic attack at the anomeric center can occur from either 
face of the ring resulting in a mixture of a/b glycosides. Importantly, nucleophilic attack 
can also occur at the C2 position of the dioxolane ring of the acetoxonium ion to generate 
an undesired 1,2-orthoacetate (Scheme 4.4). While often unstable, these orthoacetates 
can sometimes rearrange to give the desired 1,2-trans product or even the 1,2-cis product. 
Generally, use of a bulky C2-acyl protecting group like a benzoyl or pivaloyl group 
disfavors formation of the orthoacetate. 
Scheme 4.4. Neighboring group participation (NGP). C2-O-acetyl groups can participate 
in glycosylations by stabilizing the oxocarbenium ion intermediate that results from 
departure of an activated leaving group. The resulting acetoxonium ion facilitates 
formation of the 1,2-trans product.  
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 The “armed/disarmed” effect, originally introduced by Fraser-Reid, refers to the 
ability of protecting groups to influence donor reactivity.21, 29-31 Specifically, donors 
protected with acyl groups are less reactive (“disarmed”) than donors protected with ether 
groups (“armed”) (Figure 4.4). While this effect was initially applied only to the protecting 
group at C2, the electronics of protecting groups at other positions have similarly been 
shown to affect donor reactivity.21, 32  The lessened reactivity of disarmed donors is due 
to the strong electron-withdrawing nature of the ester protecting groups. This serves not 
only to decrease the nucleophilicity of the latent leaving group but also to destabilize the 
oxocarbenium ion intermediate that forms in concert with the departure of this group. 
Contrarily, electron-donating ether groups increase nucleophilicity and stabilize the 
oxocarbenium ion intermediate which consequently increases reaction rate. 
In addition to strongly electron-withdrawing substituents, cyclic protecting groups, 
such as a benzylidene acetal, can also create “disarmed” donors (Figure 4.4).33, 34 Rather 
than an electronic effect, these protecting groups disarm donors through torsional effects. 
More specifically, cyclic protecting groups constrict ring flexibility and effectively “lock” 
pyranoses into a chair confirmation. This imposed rigidity creates a higher energy 
oxocarbenium ion intermediate; the ideal C5O5-C1C2 dihedral angle (w) of 0 oC for the 
oxocarbenium ion cannot be obtained with a cyclic protecting group.33 
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X
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X
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Figure 4.4. Arming and disarming effects of protecting groups. 
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4.3.4 Solvent Effects20-22, 35, 36 
 In addition to protecting group strategies, solvent can also have a significant effect 
on the outcome of a glycosylation. This effect is even greater when the glycosyl donor 
lacks a C2 participating group. For example, formation of 1,2-cis glycosides requires a 
non-participating C2 protecting group. Thus, solvent choice can be particularly important 
in the formation of this class of glycoside.36 Generally speaking, solvents of low polarity 
are hypothesized to increase a-selectivity due to a combination of suppressing 
oxocarbenium ion formation and promoting in situ anomerization to the more reactive b-
oriented leaving group (more reactive because less stabilized due to the anomeric 
effect).20, 22 The reaction then proceeds through a more SN2-like mechanism to yield an 
a-glycoside. In contrast, solvents of moderate polarity are hypothesized to stable a 
positively charged oxocarbenium or acetoxonium intermediate. While useful when a 
glycosyl donor has a C2 participating group, in the absence of a C2 participating group, 
solvents of moderate stability are unlikely by themselves to yield highly stereoselective 
glycosylations. 
 Solvents can also influence stereoselectivity by forming complexes with the 
oxocarbenium ion intermediate.20, 22 For example, ethereal solvents, most commonly 
diethyl ether, are known to increase a selectivity (Scheme 4.5A). The increased a 
selectivity is best explained by preferential formation of a b-oriented diethyl oxonium ion 
followed by an SN2-like displacement to yield the a glycoside. The b configuration of this 
intermediate is favored due to the reverse anomeric effect; the reverse anomeric effect 
refers to the preference of positively charged-electronegative substituents to adopt an 
equatorial, b orientation.  
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Scheme 4.5. Solvent participation in glycosylation reactions. (A) Ethereal solvents, such 
as diethyl ether, increase a selectivity. (B) Acetonitrile increases b selectivity.  
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 Contrarily, acetonitrile has been shown to lead preferentially to equatorial, b-linked 
glycosides (Scheme 4.5B).20, 37 This result is best explained by formation of an a-nitrilium 
ion followed by SN2-like displacement to yield the b glycoside. While this result contrasts 
that predicted by the reverse anomeric effect, experimental evidence does support its 
existence. Through the combined efforts of Pougny and Sinjaÿ (1976) and Fraser-Reid 
and Ratcliffe (1990), it was shown that trapping of the intermediate nitrilium ion with 2-
chlorobenzoic acid affords the corresponding a-imide, thus confirming existence of the a-
nitrilium intermediate (Scheme 4.6A). Importantly, this outcome agreed with the 
explanation from Schmidt that fast a-nitrilium-nitrile-complex formation precedes 
formation of a more thermodynamically stable b-nitrilium-nitrile-complex (Scheme 4.6B). 
 
4.3.5 Glycosyl Donors20, 36, 38 
 
 
 
 
 
 
Another key factor for a glycosylation reaction is the type of donor employed. A list 
of commonly used donor types is provided in Figure 4.5. Glycosyl chlorides and bromides, 
introduced in 1901 by Koenigs and Knörr, served as the original glycosyl donors.20, 39 
These donors, typically found as the a anomer due to the anomeric effect, can be 
Figure 4.5. Common classes of glycosyl donor. 
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activated with heavy metal salts, mainly silver or mercury salts (Scheme 4.7A). Glycosyl 
bromides are commonly prepared via treatment of a per-O-acetylated glycoside with HBr 
in acetic acid (Scheme 4.7B). While glycosyl chlorides can similarly be prepared from a 
per-O-acetylated glycoside using aluminum chloride (AlCl3) or phosphorus pentachloride 
(PCl5), a milder method to generate the anomeric chloride is via treatment of a lactol with 
the Vilsmeier-Haack reagent (Scheme 4.7B). 
 
Scheme 4.7. Preparation and use of glycosyl bromides and chlorides. (A) Activation of 
glycosyl bromides. (B) Common methods to prepare glycosyl bromides and chlorides. 
(C) Method for in situ anomerization of glycosyl bromides for formation of a-glycosides. 
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 Depending on the promoter system, glycosyl halides can be used to generate a- 
or b-glycosides selectively via direct displacement of the anomeric halide.20 Synthesis of 
an a-glycoside requires in situ anomerization of the more stable a-halide to the much 
more reactive b-halide. In this procedure, developed by Lemieux and coworkers, tetra-n-
butylammonium bromide (TBAB) is added to promote anomerization to the b-halide which 
subsequently undergoes nucleophilic attack in an SN2 fashion to yield the a-glycoside; to 
facilitate SN2-type displacement, solvents of low polarity must be used to suppress 
formation of the oxocarbenium ion intermediate (Scheme 4.7C).40, 41 Conversely, to 
generate a b-glycoside, in situ anomerization to the b-halide must be suppressed. This 
can be achieved using an insoluble silver salt which sequesters halide nucleophiles from 
the reaction mixture.  
 Often more stable alternatives to glycosyl bromides are glycosyl fluorides. While 
these types of halide donors were originally believed to be too stable and unreactive, in 
1981 Mukaiyama and co-workers found that glycosyl fluorides could be activated using 
AgClO4/SnCl2.42 Since this initial report, additional fluoride promoter systems have been 
developed such as Cp2HfCl2-AgClO4, Cp2ZrCl2-AgClO4, and Cp2HfCl2-AgOTf.20, 35 
Glycosyl fluorides are most commonly prepared from a thioglycoside via treatment with 
N-bromosuccinimide (NBS) and (diethylamino)sulfur trifluoride (DAST) or from a lactol via 
treatment with DAST. Similarly, fluorides can be generated from the corresponding 
thioglycoside via treatment with NBS and hydrofluoric acid (HF) (Scheme 4.8). Due to 
the high stability of anomeric a-fluorides (arising from the anomeric effect), for 
glycosylation to proceed with this class of donor, in situ anomerization to the more reactive 
b-fluoride must occur. Direct displacement of the b-fluoride yields the a-glycoside (see 
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Scheme 4.7C for more detail). Consequently, glycosyl fluorides are particularly well-
known for their highly a-selective glycosylations.20, 35, 36, 42 
  
 
 
 
 
 
 
 
 
 In contrast to glycosyl fluorides, trichloroacetimidates are highly reactive and easily 
activated donors. Moreover, this class of donor does not require heavy metal salts for 
activation. Introduced by Schmidt and Michel in 1980, glycosyl trichloroacetimidates, also 
known as Schmidt imidates, have become the most widely used class of donor. 36, 43 Their 
widespread use arises from their ease of preparation, high reactivity, methods for catalytic 
activation, and utility in forming a- or b-glycosides. As trichloroacetimidates were used 
extensively as glycosyl donors in our synthesis of LNT (see section 4.5 of this chapter), 
this class of donor will be discussed in more detail.  
 Trichloroacetimidates can be prepared readily via treatment of a lactol with base 
and trichloroacetonitrile.20, 23, 43, 44 Judicious choice of base and reaction time allows for 
selective generation of either the a- or b- imidate. For example, use of a mild base like 
potassium carbonate (K2CO3) and short reaction times yields the kinetic b-
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Scheme 4.8. Common methods for the synthesis of glycosyl fluorides. 
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trichloroacetimidate product. More specifically, using these conditions, the more reactive 
b-alkoxide is formed preferentially, and this alkoxide subsequently attacks the 
trichloroacetonitrile. Conversely, use of a strong base like sodium hydride (NaH) or 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) yields the thermodynamic a-trichloroacetimidate 
product. Strong bases facilitate alkoxide equilibration to the more stable a-alkoxide which 
subsequently attacks trichloroacetonitrile to yield the a-trichloroacetimidate (Scheme 4.9).  
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 In addition to their ease of preparation, trichloroacetimidates are readily activated 
via treatment with catalytic amounts of acid (Scheme 4.10A). The most commonly 
employed Lewis acids are trimethylsilyl trifluoromethanesulfonate/triflate (TMSOTf) and 
boron trifluoride diethyl etherate (BF3•OEt2) while trifluoromethanesulfonic acid (triflic acid, 
TfOH) is a commonly employed Brønsted acid.20, 23 In glycosylations where the 
trichloroacetimidate donor lacks a C2 participating group, the choice of acid promoter, as 
well as the starting trichloroacetimidate anomeric configuration and reaction solvent, can 
greatly influence the a/b ratio of the glycosylation product. For instance, use of strong 
catalysts like TMSOTf and TfOH with b-trichloroacetimidates has been shown to favor 
formation of the thermodynamic a-glycosides.23, 36 This preference can be enhanced by 
using ethereal solvents which, as previously described, promote a-glycoside formation. 
 In glycosylations using a donor with a C2 participating group, trichloroacetimidate 
donors generally yield the b-glycoside selectively and cleanly regardless of the starting 
donor anomeric configuration.23 However, acyl protection does decrease donor reactivity 
(disarmed donors). Thus, for extensively acyl protected donors, strong catalysts like 
TMSOTf and TfOH are generally preferred over more mild catalysts like BF3•OEt2.23 
Interestingly, it has been observed that glycosylations with BF3•OEt2 and disarmed 
trichloroacetimidate donors can lead to formation of the corresponding glycosyl fluoride.45 
 Although the reactive nature of trichloroacetimidates is often advantageous in 
glycosylations, this reactivity does restrict their formation to the last step in a donor’s 
synthesis.20, 23 Additionally, trichloroacetimidates can undergo internal rearrangement to 
the corresponding trichloroacetamide, termed a Chapman rearrangement, especially 
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when activated in the presence of an unreactive acceptor; the trichloroacetamide is an 
unreactive intermediate (Scheme 4.10B).  
 
  
 
 
 
 
 
 Thioglycosides, aryl or alkyl, are another common donor type.20, 36, 46 Unlike 
trichloroacetimidates, anomeric thiols have excellent stability and are consequently 
compatible with a wide range of reaction conditions typically used in carbohydrate 
chemistry. Thus, in addition to ultimately serving as a donor, thiols can be used as a 
temporary protecting group for an anomeric center. Another attractive feature of the 
thioglycoside donor is its general ease of preparation; alkyl and aryl thioglycosides can 
be prepared by Lewis-acid mediated reaction of an anomeric acetate with the appropriate 
starting thiol (Figure 4.11A). In a similar vein, thioglycosides can be converted readily 
into a number of different donor types (Figure 4.11B).  
 Thioglycosides can be selectively activated by fairly mild, soft electrophiles. Some 
of the most commonly used activators are N-iodosuccinimide/triflic acid (NIS/TfOH), 
methyl triflate (MeOTf), dimethyl(methylthio) sulfonium triflate (DMTST), iodonium 
dicollidine perchlorate (IDCP), and benzenesulfenyl triflate (PhSOTf) and related 
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Scheme 4.10. Reactions of trichloroacetimidates. (A) Acid-mediated activation of 
trichloroacetimidate glycosyl donors. (B) Intramolecular Chapman rearrangement of 
trichloroacetimidate to the corresponding trichloroacetamide. 
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variants.20 Moreover, judicious selection of activator coupled with proper tuning of the 
electron-donating or -withdrawing nature of the anomeric thiol can allow for selective 
activation of one thioglycoside over another.47 This approach is referred to as a “one-pot 
sequential glycosylation.” 
 
 
 
 
 
 
 
 
 Detailed descriptions of the remaining donor types presented in Figure 4.5 as well 
as additional donor types not included in this figure are reviewed elsewhere.20, 36, 38, 44 
 
4.4 Previous Syntheses of Lacto-N-Tetraose and Derivatives 
4.4.1 Introduction 
 LNT serves as a core structure not only for type I HMOs but also for numerous 
glycolipids, such as the lacto-series glycosphingolipids (GSLs) and sialylated 
lipooligosaccharide (LOS) structures of bacterial outer membranes. Due to its relevance 
as a core carbohydrate structure, LNT and LNT-derivatives featuring an anomeric amino 
linker have been the focus of numerous synthetic efforts. These efforts have ranged from 
Scheme 4.11. Thioglycoside preparation and donor interconversion. (A) Preparation of 
thioglycosides. (B) Methods for conversion of thioglycoside to other donor types. 
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purely chemical7-11, 13 to purely enzymatic48, 49 to a combination of the two.12 Several of 
these syntheses will now be presented.  
 
4.4.2 Tejima et al. LNT Synthesis (Chemical)9 
 
 
 
 
 
 
 
 
 
 
 
 As part of a campaign to synthesize various oligosaccharides found in human milk, 
in 1980, Tejima and coworkers described the first reported synthesis of LNT (2.4). Their 
synthetic route relied on the union of known acetylated oxazoline lacto-N-biose (LNB) 
donor 4.1 with selectively benzylated lactose acceptor 4.2;50 LNB derivative 4.1 could be 
accessed from peracetylated galactosyl bromide 4.3 and orthogonally-protected 
glucosamine acceptor 4.4 (Scheme 4.12).  
 As described by Augé and Veyriéres, mercuric cyanide-promoted glycosylation of 
galactosyl bromide 4.3 and glucosamine acceptor 4.4 furnished disaccharide 4.5 in 78% 
yield (Scheme 4.13). Subsequent acid-mediated hydrolysis of the benzylidene acetal and 
Scheme 4.12. Tejima’s retrosynthetic analysis of LNT. 
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acetylation of the resulting diol followed by hydrogenation of the anomeric benzyl ether 
yielded lactol 4.6. Acetylation of 4.6 followed by treatment of the a-acetate with acetyl 
chloride and dry HCl furnished the anomeric chloride, which was subsequently treated 
with tetraethylammonium chloride (TEAC) to yield oxazoline donor 4.1 in 60% yield. 
 
  
 
 
Scheme 4.13. Augé and Veyriéres’ synthesis of oxazoline LNB donor 4.1. 
Scheme 4.14. Tejima’s synthesis of LNT (2.4). (A) Synthesis of lactose acceptor 4.2.                   
(B) Synthesis of LNT (2.4). 
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 Synthesis of lactose acceptor 4.2 began with partial tosylation of known 1,6-
anhydro-4’, 6’-benzylidene lactose derivative 4.7, accessible in three steps from lactose 
octaacetate (LOA) 4.8, to yield 3’-tosylate 4.9 in 15% yield (Scheme 4.14).51-54 
Benzylation of 4.9 followed by tosyl group removal gave lactose acceptor 4.2 in 51% over 
two steps. Protected LNT derivative 4.10 was then synthesized via para-toluenesulfonic 
acid (pTsOH)-mediated glycosylation of 4.1 and 4.2 in 79% yield. Notably, this 
glycosylation required two days of stirring at 60 oC and upwards of three equivalents of 
oxazoline donor 4.1. A three step deprotection sequence then gave LNT (2.4). 
 
4.4.3 Schmidt et al. LNT Synthesis (Chemical)7 
 In 1998, the Schmidt laboratory introduced the dimethylmaleoyl (DMM) group as a 
novel amino protecting group for glucosamine (Scheme 4.15); while the DMM group had 
been reported previously, it had not yet been used in the protection of amino sugars.55 
Importantly, it was hypothesized that this new protecting group would increase donor 
reactivity compared to glucosamine donors wherein the amine was protected as the 
acetamide; the 1,3 oxazolinium intermediate (see Scheme 4.4) derived from neighboring 
group participation from the C2 acetamide possesses weak donor properties. 
 In their initial report, Schmidt and coworkers demonstrated that DMM-protected 
glucosamine, accessible via treatment of glucosamine hydrochloride (4.11) with dimethyl 
maleoyl anhydride (DMMA), could be transformed into numerous glycosyl donors and 
acceptors. This served to showcase the protecting group’s stability toward acid and non-
nucleophilic bases. Next, using TMSOTf as a promoter, various DMM-protected 
glucosamine trichloroacetimidate donors and DMM-protected glucosamine acceptors 
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were glycosylated to yield b-glycosides in generally high yields. Finally, it was found that 
cleavage of the DMM and conversion to the acetamide worked reliably and in good yields 
(Scheme 4.15).55 
  
 To further demonstrate the utility of this new amino sugar protecting group, 
Schmidt et al. developed a synthesis of LNT (as well as LNnT) featuring a DMM-protected 
glucosamine derivative (Scheme 4.16).  
 
 
 
 
 
 
 
 
 
 
Scheme 4.15. Selected example of dimethylmaleoyl (DMM) amino protecting group in 
carbohydrate synthesis. 
Scheme 4.16. Schmidt’s retrosynthetic analysis of LNT (2.4). 
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 Similar to Tejima’s synthesis, the Schmidt synthesis relied on union of an LNB 
donor, 4.17 (accessed via union of galactose donor 4.1856 and glucosamine acceptor 
4.19)55 and a lactose acceptor, 4.20;57 importantly, galactose donor 4.18, glucosamine 
acceptor 4.19, and lactose acceptor 4.20 had all been previously synthesized in the 
Schmidt laboratory. 
 
 Galactose donor 4.18 was prepared in one step from known acetylated galactosyl 
lactol 4.21 (Scheme 4.17A).58 Glucosamine acceptor 4.19 was prepared beginning from 
known peracetylated, DMM-protected glucosamine derivative 4.12 (Scheme 4.17B). 
Selective anomeric deacetylation with hydrazine acetate furnished the lactol which was 
subsequently converted to anomeric tert-butyldimethyl silyl ether 4.22 in 90% yield. 
Scheme 4.17. LNT building block synthesis. (A) Synthesis of galactosyl imidate donor 
4.18. (B) Synthesis of DMM-protected glucosamine acceptor 4.19. (C) Synthesis of 
benzylated lactose acceptor 4.20.  
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Deacetylation of 4.22 followed by treatment with benzaldehyde dimethyl acetal (BDMA) 
yielded the 4,6-benzylidene acetal glucosamine acceptor 4.19.55 Lactose acceptor 4.20 
was synthesized starting with a Koeings-Knorr glycosylation of known peracetylated 
lactosyl bromide 4.23, synthesized via treatment of LOA with HBr in acetic acid,59 with 
benzyl alcohol to yield the b-benzyl lactoside (not pictured) in 58% yield. The benzyl 
lactoside was then deacetylated to yield polyol 4.24 (Scheme 4.17C). Treatment of polyol 
4.24 with dibutyltin oxide furnished the stannylene complex which facilitated 
regioselective allylation of the C3’ alcohol to yield 4.25. Finally, perbenzylation of allyl 
ether 4.25 followed by tris(triphenylphosphine)rhodium(I) chloride-mediated cleavage of 
the allyl group furnished lactose acceptor 4.20.57  
  
  
 As described in an earlier report by Schmidt et al., TMSOTf-promoted glycosylation 
of galactosyl trichloroacetimidate donor 4.18 and DMM-protected glucosamine acceptor 
4.19 yielded disaccharide 4.26 in 89% yield (Scheme 4.18).55 Treatment of 4.26 with 
tetra-n-butylammonium fluoride (TBAF) and acetic acid followed by treatment of the 
resulting lactol with DBU and trichloroacetonitrile gave LNB donor 4.17. A second 
Scheme 4.18. Schmidt’s synthesis of LNT (2.4). 
CH2Cl2, -30oC
TMSOTf
(89%)
O
AcO
AcO
OAc
OAc
O
NDMM
OO
OPh
4.26
OTBDMS+4.18 4.19
1) TBAF, AcOH (83%)
2) Cl3CCN, DBU
    CH2Cl2 (79%)
O
AcO
AcO
OAc
OAc
O
DMMN
OO
OPh
4.17
O
CCl3
NH
CH2Cl2, -30oC
TMSOTf
(76%)
O
AcO
AcO
OAc
OAc
O
NDMM
OO
OPh
4.27
O O
BnO OBn
O
OBn
O
OBn
OBn
OBn
BnO
+ 4.20
1) pTsOH, EtSH,
    CH2Cl2 (75%)
2) i.NaOH, aq. dioxane
    ii. HCl, pH 5
    iii. Ac2O, pyr (76%)
O
AcO
AcO
OAc
OAc
O
NHAc
O
AcO
OAc
4.28
O O
AcO OBn
O
OBn
O
OBn
OBn
OBn
BnO
1) Pd/C, H2, AcOH
    MeOH/dioxane
2) Ac2O, pyr 
    (2 steps, 86%)
3) NaOMe, aq. MeOH
(78%)
(2.4)
 277 
TMSOTf-promoted glycosylation between LNB trichloroacetimidate donor 4.17 and 
lactose acceptor 4.20 furnished fully protected LNT derivative 4.27.7 A five-step 
deprotection sequence then afforded LNT (2.4). 
   
4.4.4 Chen et al. LNT-ProN3 Synthesis (Chemical)11 
 In 2011, the Chen group reported the chemoenzymatic syntheses of numerous 
a2-3 sialylated carbohydrate epitopes. Importantly, each sialoside featured an anomeric 
propyl azide (ProN3) functionality so that they could be used as probes to investigate the 
biological importance of this class of sialylated compound. To access the a2-3 sialylated 
carbohydrates, neutral core carbohydrate structures with the ProN3 feature, including 
LNT-Pro3 4.29 (Scheme 4.19), were chemically synthesized. The sialic acid moieties 
were then added enzymatically using a one-pot, three enzyme approach including an        
a2-3 sialyltransferase from Pasteurella multocida.  
 
 
 
 
 
 
 
 
 
 Scheme 4.19. Chen’s retrosynthetic analysis of LNT-ProN3 4.29. 
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 LNT-Pro3 4.29 was synthesized using a two-glycosylation approach with known 
galactose donor 4.18,56 glucosamine acceptor 4.30, and benzoylated lactose acceptor 
4.31 (Scheme 4.19). In contrast to previously described syntheses, the present synthesis 
relied heavily on thioglycoside donors and featured a benzoylated rather than benzylated 
lactose acceptor. The later was selected due to the increased ease of selective benzoyl 
deprotection compared to selective benzyl deprotection in the presence of an azide.  
 Glucosamine acceptor 4.30 was readily synthesized in 83% yield over 2 steps from 
known glucosamine thioglycoside 4.33 (Scheme 4.20A);60 thioglycoside 4.33 can be 
accessed in two steps via phthalimide protection of glucosamine•HCl (4.11) followed a 
two-step, one-pot, BF3•OEt2-catalysed peracetylation and thioglycoside formation. 
TMSOTf-promoted glycosylation between glucosamine acceptor 4.30 galactose donor 
4.1856 yielded disaccharide thioglycoside donor 4.32 in 77% yield (Scheme 4.20B). 
 
 
 
 
 
 
 Benzoylated lactose acceptor 4.31 was synthesized in an analogous fashion to 
that of benzoylated lactose derivative 4.34 reported previously by the Abbas and Nifantiev 
laboratories (Scheme 4.21);61, 62 in the Chen synthesis, a 3-azido propyl appendage was 
used as opposed to a 2-azido ethyl appendage. First, treatment of lactose (2.1) with 
Scheme 4.20. Synthesis of LNB donor 4.32. (A) Synthesis of glucosamine acceptor 4.30. 
(B) Glycosylation to yield LNB donor 4.32. 
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pTsOH and 2,2-dimethoxypropane (2,2-DMP) gave the 3’,4’-acetonide (not pictured) in 
45% yield along with 21% of the 4’,6’-acetonide (not pictured). Benzoylation of the 3’,4’-
acetonide then furnished 4.35. Treatment of 4.35 with aqueous acid facilitated acetonide 
removal to reveal the 3’,4’-diol (not pictured)61 which was subsequently treated with 
triethylorthobenzoate.62 The resulting 3’,4’-orthobenzoate was then opened 
regioselectively to furnish C4’ O-benzoylated 4.36. The free C3’ alcohol of 4.36 was 
acetylated and the resulting glycoside was converted to the corresponding anomeric 
bromide and glycosylated with 2-chloroethanol to yield 2-chloroethyl lactoside 4.37. 
Finally, chloride displacement with sodium azide (NaN3) followed by deacetylation 
furnished lactose derivative 4.34.62 
  
 
 With LNB thioglycoside 4.32 and benzoylated lactose acceptor 4.31 in hand, NIS 
and TfOH-promoted glycosylation between 4.32 and 4.31 gave fully protected LNT-ProN3 
4.38 in 64% yield (Scheme 4.22). A four-step deprotection sequence furnished the 
desired LNT-ProN3 4.29 in 54% over 4 steps.  
Scheme 4.21. Synthesis of lactose derivative 4.34. 
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4.4.5 Wong et al. Linker-Attached Lc4 Synthesis (Chemical)13 
 
 
 
 
 
 
 
 
 In 2012, the Wong group synthesized linker-attached derivatives of the lacto-series 
GSLs lactosyltetraosyl (Lc4) and 2’’’-O-fucosyl Lc4 (IV2Fuc-Lc4) ceramide (4.39) and 
(4.40), respectively (Figure 4.6). Notably, these syntheses featured a one-pot, two-
glycosylation reaction which showcased the influence of donor protecting group patterns 
on donor reactivity. In their initial attempt to synthesize linker-attached Lc4 4.41, Wong et 
al. attempted an NIS/TMSOTf-promoted glycosylation between known thiogalactoside 
Scheme 4.22. Chen’s synthesis of LNT-ProN3 4.29. 
Figure 4.6. Structures of Lc4 ceramide (4.39), IV2Fuc-Lc4 ceramide (4.40), and          
linker-attached Lc4, 4.41. 
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donor 4.42,63 and known glucosamine acceptor 4.43 (Scheme 4.23A).47 However, these 
conditions resulted in a mere 30% yield of the desired disaccharide 4.44. Moreover, a 
significant amount of unreacted acceptor was recovered. As an alternative, donor 4.42 
was replaced with known 3-O-silylated thiogalactoside 4.45; thiogalactoside 4.45 had 
previously been determined to be more reactive than 4.42 based on relative reactivity rate 
(RRV) calculations.64 Substitution of the 3-O-benzyl for a 3-O-TBS ether did indeed 
provide a more reactive donor as glycosylation between sialylated donor 4.45 and 
acceptor 4.43 yielded disaccharide 4.46 in 78% yield (Scheme 4.23B).  
 
  
 
 
 
 
  
 With the first glycosylation optimized, Wong et al. moved to implement the one-pot, 
two-glycosylation procedure using known lactose diol acceptor 4.47 (Scheme 4.24).65 
While initial attempts were unsuccessful, it was discovered that addition of 
tripropargylamine after completion of the first coupling followed by NIS/AgOTf-promoted 
glycosylation between newly formed LNB donor 4.46 and lactose acceptor 4.47 furnished 
tetrasaccharide 4.48 in 40% yield; conversely, glycosylation of LNB donor 4.44 with 
lactose acceptor 4.47 yielded only 18% of the corresponding tetrasaccharide (not 
Scheme 4.23. Synthesis of LNB donors 4.44 and 4.46. (A) Synthesis of LNB donor 4.44. 
(B) Synthesis of LNB donor 4.46. 
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pictured). From 4.48, a 5-step deprotection sequence afforded linker-attached Lc4 4.41 in 
50% yield over 5 steps. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.6 Albermann et al. LNT Synthesis (Enzymatic)49  
 In 2014, the Albermann group developed a method for the enzymatic production 
of LNT using metabolically engineered, plasmid-free E. coli. Important to this method 
development was a 2009 report from the Wang laboratory wherein they identified and 
characterized a novel b1-3-galactosyltransferase (b1-3-GalT) in E. coli 055:H7.66 This 
Scheme 4.24. Wong’s one-pot, two-glycosylation approach to linker-attached                                 
Lc4 4.41. 
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GalT, termed WbgO, was capable of transferring galactose to GlcNAc and/or 
oligosaccharides with a non-reducing end GlcNAc. Moreover, Wang et al. used this 
enzyme, overexpressed in E. coli BL21, in the in vitro enzymatic synthesis of benzyl b-
lacto-N-tetraoside (LNT-b-OBn) 4.49 (Scheme 4.25).  
 
 For their study, Albermann et al. selected E. coli strain K-12 LJ110 as the parent. 
To construct an LNT-producing strain, the lacZ gene, which encodes the LacZ b-
galactosidase, was removed; LacZ b-galactosidase hydrolyzes lactose into glucose and 
galactose. The strain was next equipped with LgtA, the b1-3-N-
acetylglucosaminyltransferase from N. meningitidis. The resulting strain was 
supplemented with the wbgO gene, which encodes the b1-3-Gal WbgO. Importantly, the 
modified strain, termed strain LJ-AYO-cat, retained the lacY gene, which encodes the 
lactose permease (LacY) transporter. This allowed for continued lactose uptake despite 
the lack of intracellular LacZ. Finally, the necessary nucleotide-sugars that serve as 
Scheme 4.25. Wang’s enzymatic synthesis of benzyl b-lacto-N-tetraoside 4.49 using 
recombinant LgtA and WbgO. Abbreviations: UDP-GlcNAc, uridine 5’-diphosphate-N-
acetylglucosamine; LgtA, b1-3 GlcNAc-transferase from Neisseria meningitidis; MnCl2, 
manganese(II) chloride; GST-WbgO, glutathione S-transferase-WbgO (b1-3 
galactosyltransferase in E. coli 055:H7) fused protein. 
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donors for the glycosyltransferases were derived endogenously from the intracellular pool 
of nucleotide-activated sugars (produced for use by host Leloir glycosyltransferases).  
 Starting with a combination of lactose and glucose or lactose and glycerol, strain 
LJ-AYO-cat was able to produce both lacto-N-triose (LNT II, 4.51) and LNT (2.4) 
(Scheme 4.26). Notably, it was found that the use of glycerol resulted in higher yields of 
LNT II than LNT; the use of glucose reversed this trend. Specifically, medium with glucose 
had 219.1 ± 3.5 mg/L LNT 24 h after induction whereas medium with glycerol had only 
162.1 ± 6.2 mg/L. These concentrations corresponded to LNT yields of 66.2 ± 1.6 
mg/gCDW (CDW, cell dry weight) for glucose-supplemented medium and 58.5 ± 2.0 
mg/gCDW for glycerol-supplemented medium. While LNT II was not fully converted to LNT 
by strain LJ-AYO-cat using either glycerol or glucose, this report nevertheless represents 
the first report of LNT being synthesized using recombinant E. coli cells.49 
 
 
   
   
 
Scheme 4.26. Albermann’s in vivo synthesis of lacto-N-triose (LNT II, 4.51) and lacto-N-
tetraose (LNT, 2.4) in recombinant E. coli cells using Leloir glycosyltransferases and 
intracellular nucleotide sugars. Dashed arrows indicate that the majority of these 
compounds are found in the extracellular environment (culture supernatant). 
Abbreviations: LacY, lactose permease from E. coli strain K-12; LacZ, b1-3 galactosidase 
from E. coli strain K-12; LgtA, b1-3 GlcNAc-transferase from N. meningitidis; WbgO, b1-
3-galactosyltransferase from E. coli O55:H7. 
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4.5 Synthesis of Lacto-N-Tetraose67 
4.5.1 Synthetic Strategy 
 
 
 
 
 
 
 
 
 
 
 Similar to the previously described Tejima and Schmidt LNT syntheses, our 
approach to LNT (2.4) featured a two-glycosylation approach wherein the tetrasaccharide 
could be assembled from known galactose donor 4.18,56 glucosamine acceptor 4.52, and 
known lactose acceptor 4.53 (Scheme 4.27).57 Importantly, galactose donor 4.18 
possessed a C2 functionality capable of neighboring group participation to facilitate b-
glycoside formation. Similarly, the C2 amine of glucosamine acceptor 4.52 was protected 
as the trichloroethyl (Troc) carbamate which is also capable of neighboring group 
participation; this participation would be key in the second glycosylation between LNB 
donor 4.54 and lactose acceptor 4.53 to form the desired b-linkage. Finally, in addition to 
providing an expeditious route to LNT, use of building blocks 4.52 and 4.53 would allow 
for potential installation of branching or other modification at the C6 and/or C4 alcohols 
of glucosamine as well as the C4’ of lactose, respectively.  
Scheme 4.27. Retrosynthetic analysis of LNT (2.4). 
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4.5.2 Synthesis of Glucosamine Acceptor 4.52 
 Synthesis of glucosamine acceptor 4.52 commenced with protection of the C2 
amine as the Troc carbamate via treatment of glucosamine•HCl (4.11) with saturated 
aqueous NaHCO3 solution followed by addition of 2,2,2-trichloroethyl chloroformate 
(Troc-Cl) (Scheme 4.28). Following peracetylation, selective removal of the anomeric 
acetate was accomplished using 3-(dimethylamino)-1-propylamine (DMAPA) to afford 
known lactol 4.55.68 Originally, this selective anomeric deacetylation was accomplished 
via treatment of the peracetylated compound with hydrazine acetate in DMF as reported 
by Schmidt et al.68 During the course of the synthesis, however, the Jensen group 
introduced DMAPA as a cheaper and safer alternative to hydrazine acetate.69 Moreover, 
the bifunctional nature of DMAPA allows it to be removed from the reaction by a simple 
acidic workup. Conversely, byproducts of hydrazine acetate-mediated deacetylation 
require chromatographic separation. As a final point of advantage, anomeric 
deacetylation with DMAPA can be performed in THF rather than DMF. 
 Lactol 4.55 was next converted to its triisopropylsilyl (TIPS) ether using standard 
Corey conditions (imidazole and DMF)70 to yield b-silyl ether 4.56 as a single anomer in 
54% yield for the 4-step sequence (Scheme 4.28). Deacetylation of 4.56 to furnish triol 
4.57 was initially attempted using sodium methoxide in methanol. Unfortunately, NaOMe 
treatment proved incompatible with the Troc carbamate. NMR analysis of the reaction 
product suggested that deacetylation was accompanied by deprotonation of the Troc 
methylene and subsequent elimination of a chloride atom from the Troc trichloromethyl 
group (effectively elimination of HCl). Fortunately, previous reports had identified 
guanidine as a milder deacetylating agent capable of sparing the Troc functionality.71-73  
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 Consistent with these reports, deacetylation of 4.56 using guanidinium chloride in 
the presence of ammonia gave triol 4.57 cleanly in 76% yield. Finally, triol 4.57 was 
converted to the corresponding 4,6-benzylidene acetal upon treatment with BDMA and 
catalytic 10-camphorsulfonic acid (CSA) to yield glucosamine acceptor 4.52 in 91% yield 
(Scheme 4.28). Notably, acceptor 4.52 is closely related to a compound synthesized 
previously by the Boons laboratory; rather than converting lactol 4.55 to its b-TIPS ether, 
Boons et al. converted the lactol to the corresponding b-dimethylthexylsilyl (TDS) ether.73   
 
 
 
 
 
 
4.5.3 Synthesis of Lacto-N-Biose Donor 4.54 
 
 
 
 
 Formation of LNB donor 4.54 first required union of glucosamine acceptor 4.52 
with known galactose trichloroacetimidate donor 4.18.56 Donor 4.18 is accessible in two 
steps from galactose pentaacetate 4.58 via anomeric deacetylation followed by treatment 
of the resulting lactol with trichloroacetonitrile and DBU in acetonitrile.56 For our synthesis 
of 4.18, we once again elected to use DMAPA for selective anomeric deacetylation as 
Scheme 4.28. Synthesis of glucosamine acceptor 4.52. 
Scheme 4.29. Synthesis of galactose donor 4.18. 
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opposed to hydrazine acetate as was previously reported.56, 58 Subsequent treatment of 
the crude lactol with trichloroacetonitrile and DBU in acetonitrile furnished galactose 
donor 4.18 in 64% over 2 steps (Scheme 4.29).  
 
 
 
 
  
 For glycosylation between donor 4.18 and acceptor 4.52, although donor 4.18 
possessed a C2 O-acetyl protecting group capable of NGP, we hypothesized we could 
further promote b-glycoside formation by using acetonitrile, a known b-director (as 
described in section 4.3.4 of this chapter), as the reaction solvent. In the initial attempt, 
TMSOTf was used as the promoter, acetonitrile as the solvent, and -40 oC as the reaction 
temperature. Under these conditions, the desired LNB disaccharide 4.59 was formed in 
60% yield (Table 4.1). It should be noted though that glycoside 4.59 was co-isolated with 
around 6% of rearranged galactose donor 4.18 (rearrangement from the 
trichloroacetimidate to the trichloroacetamide). Interestingly, in a second attempt using 
Entry Promoter Solvent Temp (o C) % Yield 4.59 % Yield 4.60 
1 TMSOTf CH3CN -40 18-60 0-50 
2 BF3•OEt2 CH3CN -40 0 23 
3 TMSOTf CH3CN -10 28-76 0-40 
4 TMSOTf CH3CN 0 0-44 26-49 
5 TMSOTf CH3CN r.t 30-70 0 
6 TMSOTf CH2Cl2 -78 0 22 
7 TMSOTf CH2Cl2 -10 to 0 70-85 0 
Table 4.1. Synthesis of Lacto-N-Biose Disaccharide 4.59 and Orthoacetate 4.60 
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the same reaction conditions, disaccharide 4.59 was obtained in only 18% yield while 
orthoacetate disaccharide 4.60 was isolated as the major product in 50% yield.  
 
 Formation of orthoacetate 4.60 results from nucleophilic attack of acceptor 4.52 at 
the C2 position of the dioxolane ring of the acyloxonium ion intermediate 4.61 (Path B) 
rather than at the anomeric center of intermediate 4.61 (Path A) (Scheme 4.30). 
Importantly, not only was 4.60 the undesired product, but its formation complicated 
chromatographic isolation of the desired disaccharide as the desired and undesired 
disaccharide products were extremely close in polarity. In an attempt to alleviate 
orthoacetate formation, TMSOTf was substituted for the milder BF3•OEt2 while keeping 
all other reaction parameters consistent (Table 4.1). However, this change proved only 
Scheme 4.30. Mechanistic explanation for the formation of undesired orthoacetate 4.60 
and desired b-linked disaccharide 4.59 glycosylation products. 
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to promote orthoacetate isolation as under these conditions orthoacetate 4.60 was the 
sole glycosylation product isolated, albeit in a meager 23% yield. 
 We next hypothesized that orthoacetate formation could be mitigated by raising 
the temperature of the reaction and retaining TMSOTf as the promoter (Table 4.1). In the 
first attempt, raising the reaction temperature to -10 oC resulted in formation of the desired 
disaccharide 4.59 in 76% yield without any contaminant orthoacetate formation. 
Unfortunately, once again, this result was not reproducible in a second attempt. The 
second attempt at -10 oC yielded the disaccharide in only 28% yield while orthoacetate 
4.60 was isolated as the major product in 40% yield. Similarly, inconsistent desired to 
undesired disaccharide product ratios were seen at 0 oC. Notably, it was found that 
orthoacetate 4.60 could be rearranged to the desired disaccharide via treatment with an 
equimolar quantity of acceptor 4.52 and catalytic TMSOTf in acetonitrile at 0 oC. However, 
the yield of disaccharide 4.59 was low. Finally, the reaction temperature was raised to 
room temperature. While at this temperature no orthoacetate product was isolated, the 
yield of disaccharide 4.59 was highly inconsistent and was accompanied by the formation 
of several unidentifiable by-products. 
  Due to significant quantities of orthoacetate formation as well as the consistent 
lack of any a-glycoside formation, it became clear that the C2 acetate of donor 4.18 was 
sufficient to promote b-glycoside formation, i.e. the use of b-directing acetonitrile was 
unnecessary. Thus, we elected to change the reaction solvent from acetonitrile to 
dichloromethane; dichloromethane is a non-participating solvent commonly used in 
glycosylation reactions. Moreover, it appeared that lower reaction temperatures and 
milder promoters facilitated preferential orthoacetate formation. Consequently, TMSOTf 
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was again selected as the promoter and the reaction temperature was raised to 0 oC. 
Satisfyingly, using these reaction parameters, the desired disaccharide was isolated 
consistently in yields exceeding 70% without the accompanying formation of any 
orthoacetate (Table 4.1). Moreover, this glycosylation was performed on gram scale 
without any decrease in yield. As expected, lowering of the reaction temperature to                  
-78 oC resulted in exclusive orthoacetate formation (again, albeit in low yield) despite the 
use of TMSOTf and dichloromethane. 
 After obtaining gram quantities of disaccharide 4.59, the b-silyl ether was removed 
via treatment with a 70% solution of HF in pyridine to yield lactol 4.63 in 77% yield 
(Scheme 4.31). It should be noted that silyl deprotection was also attempted using TBAF, 
both neat and with acetic acid, but this method resulted in low yields of the corresponding 
lactol. Finally, lactol 4.63 was treated with trichloroacetonitrile and DBU to afford a-imidate 
donor 4.54 in 89% yield. 
 
 
 
 
4.5.4 Synthesis of Lactose Acceptor 4.53 
 Synthesis of acceptor 4.53 commenced with conversion of LOA 4.8 (in the form of 
an a/b mixture of the reducing end acetate) to the corresponding anomeric b-benzyl ether 
4.64 (Scheme 4.32). In a first-generation approach, this transformation was 
accomplished by activating the anomeric acetate of 4.8 with BF3•OEt2 followed by 
treatment with benzyl alcohol. However, this approach proved problematic. First, the a-
Scheme 4.31. Synthesis of lacto-N-biose donor 4.54. 
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acetate of 4.8 was found to be unreactive towards activation with BF3•OEt2 and 
subsequent displacement by benzyl alcohol. This lack of reactivity was largely 
accountable for the low yields of benzyl ether 4.64. Second, chromatographic separation 
of the desired benzyl ether from unreacted a-acetate starting material proved to be 
extremely difficult. Third, formation of the desired benzyl glycoside was accompanied by 
formation of the undesired lactol 4.65, which also proved difficult to separate from the 
desired product. 
 
 In the second-generation approach, acetylated b-benzyl lactoside 4.64 was 
synthesized via Koenigs-Knorr glycosylation of known acetylated lactosyl bromide 4.23 
with benzyl alcohol (Scheme 4.33A).59 Bromide 4.23 was synthesized in one step from 
LOA 4.8 by treatment with a 33% HBr in acetic acid solution. The crude bromide was then 
treated with silver carbonate and benzyl alcohol to yield the desired b-benzyl lactoside 
4.64 in 58% yield over 2 steps. Unlike the first-generation approach, chromatographic 
separation of 4.64 from any reaction by-product(s) proved facile. Reaction of 4.64 with 
NaOMe in methanol followed by reaction with excess 2,2-DMP and catalytic pTsOH in 
acetone furnished the 3’,4’-acetonide 4.66 in 76% over the 2-step sequence;74 the 4’,6’-
Scheme 4.32. First-generation approach to acetylated b-benzyl lactoside 4.64. 
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acetonide (not pictured) was rarely observed. Interestingly, use of an extreme excess of 
2,2-DMP (≥ 10 eq.) resulted in very low yields of 4.66 (< 10%). Instead, the major products 
were suspected (based on NMR analysis) to be the 3’,4’-acetonide wherein a molecule 
of 2,2-DMP was appended to the C6 alcohol (4.67), C6’ alcohol (4.68), or both alcohols 
(4.69) (Scheme 4.33B). From 3’,4’-acetonide 4.66, lactose acceptor 4.53 could be 
accessed via perbenzylation of 4.66 followed by acid-mediated acetonide removal to 
reveal the diol (Scheme 4.33A). 
 
 It is important to note that although the C3’ and C4’ alcohols of acceptor 4.53 were 
both free, we hypothesized that glycosylation would occur selectively at the equatorial C3’ 
alcohol over the axial C4’ alcohol. Indeed, this selectively had been demonstrated in 
previous reports from the Danishefsky and Schmidt laboratories.68, 74, 75 
 
 
Scheme 4.33. Synthesis of lactose acceptor 4.53. (A) Reaction sequence to 4.53.             
(B) Suspected side-products in formation of 3’,4’-acetonide 4.66 when using ≥ 10 eq. of 
2,2-dimethoxypropane (2,2-DMP). 
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4.5.5 Synthesis of Lacto-N-Tetraose 
 For the initial attempt at uniting LNB donor 4.54 and lactose acceptor 4.53 to yield 
tetrasaccharide 4.70, we elected to use catalytic TMSOTf as the promoter, 
dichloromethane as the reaction solvent, and a reaction temperature of 0 oC due to the 
success of these conditions in the first glycosylation between galactose 
trichloroacetimidate donor 4.18 and glucosamine acceptor 4.52. Surprisingly, these 
conditions gave rise to a complex product mixture (Table 4.2). Attempts to lower the 
reaction temperature to -65 oC and further dilute the reaction did not remedy the situation 
as complex product mixtures were again observed.  
 
 
 
 Due to the failure of TMSOTf to promote a clean reaction at a range of 
temperatures, more mild promoters were tested including BF3•OEt2, AgOTf, and MeOTf 
(Table 4.2). Unfortunately, glycosylation with these promoters largely suffered from an 
Entry Promoter Conc. (M) Temp (oC) Result 
1 TMSOTf (cat.) 0.2 -5 complex mixture 
2 TMSOTf (cat.) 0.05 -65 complex mixture 
3 BF3•OEt2 (cat.) 0.05 -20 low reactivity 
4 BF3•OEt2 (xs) 0.05 -20 decomposition 
5 AgOTf (xs) 0.1 r.t. no reactivity 
6 MeOTf (cat.) 0.05 -35 low reactivity 
7 MeOTf (xs) 0.05 -15 to r.t. decomposition 
8 TfOH (cat.) 0.05 -65 complex mixture 
9 TfOH (cat.) 0.025 -20 decomposition 
Table 4.2. Attempted Glycosylations to Yield LNT Tetrasaccharide 4.70 
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apparent lack of donor activation, and increasing the amount of promoter did not improve 
glycosylation outcome. Subsequent attempts at uniting donor 4.54 and acceptor 4.53 
relied on TfOH as the promoter. As a stronger promoter than BF3•OEt2, AgOTf, and 
MeOTf, we reasoned that TfOH-mediated glycosylations would not suffer from a lack of 
donor activation. While TMSOTf is a similarly strong activator, the difficulties encountered 
in storing this Lewis acid and the continued need for distillation of the reagent prompted 
the switch to TfOH. Once again, however, complex product mixtures were observed in 
TfOH-promoted glycosylations between 4.54 and 4.53 at reaction temperatures ranging 
from -70 to  -20 oC.  
 Though NMR analysis of the product mixtures did not allow for a definite judgment 
of whether or not the desired tetrasaccharide was formed, there was evidence that we 
had united the LNB and lactose components. However, the configuration of this union 
remained unknown. Indeed, the LNB component could have been added to either the C3’ 
or C4’ alcohol of lactose acceptor 4.53, or both. Moreover, though it was hypothesized 
that any newly formed glycosidic linkage would be b-oriented due to the Troc protecting 
group at the C2 amine of donor 4.54, NMR analysis did not allow us to rule out the 
possibility that an a-linkage had formed. Finally, although we observed no compatibility 
issues with the benzylidene acetal in glycosylations between glucosamine acceptor 4.52 
and galactose donor 4.18, we nevertheless hypothesized that this acetal might not be 
compatible in the current glycosylation and that this lack of compatibility could be 
contributing to the observed glycosylation product mixture. 
  In an attempt to deconvolute the product mixtures resulting from TfOH-promoted 
glycosylations, we treated the mixtures with acetic anhydride to “cap” any remaining free 
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alcohols. Unfortunately, while this step did separate some byproducts from others, it 
never facilitated isolation and characterization of single compounds or characterization of 
single compounds within in a mixture. Moreover, attempts to carry the various acetylated 
glycosylation product mixtures through to the Troc removal step were similarly unfruitful.  
 
4.5.6 Second-Generation Approach to Lacto-N-Tetraose 
 As discussed previously in section 4.3.3, cyclic protecting groups like the 
benzylidene acetal are known to have a disarming effect on glycosyl donors. Indeed, this 
class of donor rigidifies the ring which serves to restrict formation of the oxocarbenium 
ion intermediate.33, 34, 76 We therefore hypothesized that the benzylidene acetal of donor 
4.54 was responsible for the low donor reactivity observed in several of the 
aforementioned glycosylation attempts. We further hypothesized that due to this lowered 
reactivity, the glycosylation promoters employed might be engaging the oxygens of the 
acetal and consequently facilitating various levels of acetal cleavage. Importantly, this 
result would be at least partially responsible for the mixture of products observed. 
 
 To circumvent the poor reactivity of acetal donor 4.54, the acetal was first removed 
via treatment of 4.59 with 80% aqueous acetic acid at 80 oC (Scheme 4.34). The resulting 
crude diol was then acetylated followed by HF-mediated removal of the b-silyl ether to 
Scheme 4.34. Synthesis of second-generation, peracetylated LNB donor 4.72. 
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yield lactol 4.71 in 78% over the 3-step sequence. Finally, lactol 4.71 was converted to  
a-trichloroacetimidate donor 4.72 in 77% yield by treatment with potassium carbonate 
and trichloroacetonitrile; although this method is characteristic of b-trichloroacetimidate 
formation, prolonged reaction times allow for equilibration to the more stable a-imidate. It 
is important to note that initial attempts to form a-imidate 4.72 did rely on typical DBU and 
trichloroacetonitrile conditions. Surprisingly however, these conditions proved unreliable 
as frequent decomposition was observed. Thus, in an attempt to lessen this degradation, 
potassium carbonate and prolonged reaction times were used to generate the desired 
imidate.  
 With new LNB donor 4.72 in hand, we once again attempted to glycosylate with 
lactose diol acceptor 4.53 to form the final glycosidic linkage to furnish LNT 
tetrasaccharide 4.73. Due to the strong electron-withdrawing nature of donor 4.72, TfOH 
was again selected as the glycosylation promoter. While TMSOTf is a similarly strong 
activator, TfOH was once again selected owing to its increased ease of continued use 
and storage compared to TMSOTf. Unfortunately, glycosylation between donor 4.72 and 
acceptor 4.53 did not proceed as smoothly as expected as once again multiple 
glycosylation products were obtained (Scheme 4.35). 
 Notably, the product mixture obtained for the current glycosylation was much 
simpler than that seen in the first-generation approach to LNT. Indeed, although we were 
unable to fully characterize and thus confirm formation of the desired tetrasaccharide 4.73, 
extensive NMR analysis and low-resolution mass spectral data suggested that 4.73 had 
in fact been formed. However, similar analyses suggested that this tetrasaccharide was 
not the major product formed. Rather, it appeared as if hexasaccharide 4.74, resulting 
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from glycosylation at both the C3’ and C4’ alcohols of acceptor 4.53, was the prime 
glycosylation product (Scheme 4.35). The recovery of significant quantities of unreacted 
acceptor 4.53 further supported this conclusion  
 
 
 
 
 
 
 
 
 
 
 
   
 In an attempt to better exploit the hypothesized increased reactivity of the 
equatorial C3’ alcohol over the axial C4’ alcohol and consequently mitigate formation of 
the suspected di-glycosylated 4.74, donor 4.72 was added dropwise to a solution of 
acceptor 4.53 and TfOH in dichloromethane. Despite numerous attempts at this order of 
addition, hexasaccharide 4.74 remained the suspected major glycosylation product. The 
lack of selective reactivity at the C3’ over C4’ alcohols was later found to be consistent 
with prior reports of glycosylations using extensively benzylated, electron-rich acceptors 
like 4.53.68 We therefore hypothesized that glycosylation would be improved by protecting 
Scheme 4.35. Hypothesized result of second-generation glycosylation towards              
LNT tetrasaccharide 4.73. 
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the C4’ alcohol of diol acceptor 4.53. Notably, the aforementioned chemical syntheses of 
LNT by the Tejumia and Schmidt laboratories as well as the chemical synthesis of LNT-
Pro3 reported by the Chen laboratory featured lactose acceptors with only the C3’ alcohol 
free. 
 Selective C4’ alcohol protection of lactose diol 4.53 was accomplished using a 
simple two-step, one-pot procedure reported previously by Nicolaou et al.77 Treatment of 
diol 4.53 with trimethyl orthoacetate and pTsOH followed by treatment with 90% aqueous 
trifluoroacetic acid (TFA) furnished known C4’ acetate 4.75 in 93% yield (Scheme 4.36).78 
With new lactose acceptor in hand, we once again attempted glycosylation with 
peracetylated, trichloroacetimidate LNB donor 4.72. Satisfyingly, use of TfOH, 
dichloromethane, and a reaction temperature of -10 oC cleanly yielded the desired 
tetrasaccharide 4.76 in 88% on the first attempt to give 73 mg of 4.76. Notably, with these 
conditions, glycosylation with 4.72 and 4.75 was performed to yield 850 mg of 
tetrasaccharide 4.76 in a single glycosylation event which corresponded to an improved 
yield of 94%.  
 
 
 
 
 
 
 
Scheme 4.36. Synthesis of fully protected LNT tetrasaccharide 4.76. (A) Synthesis of 
second-generation axially-acetylated lactose acceptor 4.75. (B) Glycosylation between 
peracetylated LNB trichloroacetimidate donor 4.72 and lactose acceptor 4.45 to yield 
tetrasaccharide 4.76. 
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 From fully protected tetrasaccharide 4.76, a three-step deprotection sequence was 
envisioned to yield LNT (2.4). Prior to deprotection attempts, however, we attempted to 
improve the route to 4.76 by revisiting the first glycosylation to yield an LNB disaccharide. 
 
4.5.7 Second-Generation Approach to Lacto-N-Biose Donor 4.72 
 In the first-generation route to donor 4.72, the benzylidene acetal of the 
glucosamine residue was removed after glycosylation between glucosamine acceptor 
4.52 and galactose donor 4.18 (see Scheme 4.34). As previously described, this 
manipulation proved particularly advantageous in the campaign to access a protected 
LNT-derivative cleanly and in high yields. While the two-step conversion of LNB acetal 
4.59 to the corresponding diacetate was high yielding, we noted that it would be 
preferential to perform these manipulations on a simpler substrate, i.e. remove the 
glucosamine acetal from monosaccharide 4.52 as opposed to LNB disaccharide 4.59, 
which was obtained through glycosylation.  
 
 Synthesis of second-generation, peracetylated glucosamine acceptor 4.77 began 
with protection of the free C3 alcohol of glucosamine acceptor 4.52 as the corresponding 
levulinic (Lev) ester (Scheme 4.37). This transformation was accomplished by 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (EDC)-mediated coupling of glucosamine alcohol 
4.52 with levulinic acid to yield Lev ester 4.78 in 77% yield. The benzylidene acetal of 
4.78 was then cleaved through treatment with 80% aqueous acetic acid at 80 oC and the 
Scheme 4.37. Synthesis of second-generation, acetylated glucosamine acceptor 4.77. 
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corresponding diol treated with acetic anhydride in pyridine to yield the diacetate 
(structure not pictured). Lev deprotection using hydrazine acetate then furnished second-
generation, acetylated glucosamine acceptor 4.77 in 65% over the three-step sequence. 
 
 
 
 
 Glycosylation of new glucosamine acceptor 4.77 with galactose donor 4.18 to yield 
LNB disaccharide 4.79 initially employed the conditions used for the first-generation 
approach to LNB disaccharide 4.59:  TMSOTf (cat.) as the promoter, dichloromethane as 
the solvent, and a reaction temperature between -10 and 0 oC (specifically -5 oC in the 
present glycosylation) (Table 4.3). Notably, under these conditions, a lack of product 
Entry Donor Promoter Solvent Conc. (M) % Yield a:b % R.A.a 
1 a; 1.3 eq. TMSOTf (cat.) CH2Cl2 0.08 39 1:2.5 0 
2 a; 2.0 eq. BF3•OEt2 (cat.) CH2Cl2 0.08 trace -- ≥ 50 
3 a; 1.5 eq. TfOH (cat.) CH2Cl2 0.08 72 1:7 14 
4 a; 2.0 eq. TfOH (cat.) CH2Cl2 0.08 72 1:2.8 15 
5 a/b, 1.5 eq. TfOH (cat.) CH2Cl2 0.08 70 1:2.3 16 
6 a; 2.0 eq. TfOH (xs) CH2Cl2 0.08 83 1:2.8 9 
7 a; 1.5 eq. TfOH (cat.) PhCH3/CH2Cl2 (1.2:1) 0.05 76 1:4.4 6 
8 a; 2.0 eq. TfOH (cat.) PhCH3/CH2Cl2 (3.7:1) 0.05 74 1:4.3 12 
9 a; 1.5 eq. TfOH (xs) PhCH3/CH2Cl2 (1.9:1) 0.08 71 1:2 0 
10 a; 2.0 eq. TfOH (xs) PhCH3/CH2Cl2 (2.8:1) 0.08 85 1:3.2 trace 
aR.A. = recovered acceptor 
Table 4.3. Attempted Glycosylations to Yield LNB Disaccharide 4.79 
4.18
O
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formation was observed and unreacted acceptor 4.77 remained. Thus, additional 
TMSOTf was added to push the reaction to completion. Although the reaction proceeded 
to completion, an unexpected result emerged.  
 Although donor 4.18 featured a C2 acetate capable of NGP that facilitates b-
glycoside formation, a mixture of the a and b isomers of disaccharide 4.79 was isolated. 
The desired b-anomer was the major product isolated in 28% yield while the a-anomer 
was isolated in only 11% yield (Table 4.3); the diminished overall yield is hypothesized to 
be due to product decomposition resulting from treatment with an excess of TMSOTf. It 
is important to note, that due to similar polarities, the a and b products proved difficult to 
separate from one another. Moreover, attempts to carry the anomeric mixture through to 
the next reaction in the hopes that this would facilitate separation were unfruitful. 
 A lack of reactivity and corresponding product formation was again seen when 
BF3•OEt2 was used as the promoter (Table 4.3). Despite the use of excess BF3•OEt2, 
and excess donor, only a trace amount of either the a or b disaccharide was isolated. In 
agreement with this result, a significant amount of unreacted acceptor was recovered. 
Interestingly, based on NMR analysis, it was suspected that the acetylated galactosyl a-
fluoride was a minor byproduct of the reaction. This result would agree with previous 
reports of glycosyl trichloroacetimidates being transformed into their corresponding 
fluorides upon treatment with BF3•OEt2.45, 79, 80 It has been proposed that this conversion 
is caused by reaction of the trichloroacetimidate donor with HF present in the BF3•OEt2. 
Moreover, literature precedent suggests that conversion to the fluoride is more likely to 
occur when using a significantly disarmed donor or a weakly nucleophilic acceptor.  
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 Due to the obvious need for a strong activator, we next elected to test TfOH as the 
glycosylation promoter. Unfortunately, although activation with catalytic TfOH increased 
overall yield, it did not prevent formation of the a-linked disaccharide (Table 4.3). The 
highest a/b product ratio that could be obtained was 1:7. This result was accomplished 
using catalytic TfOH in dichloromethane with 1.5 equivalencies of donor. It is important to 
note, however, that this result proved highly variable. Indeed, in a later attempt on a larger 
scale, these conditions gave a comparable overall yield of 78%, but the a/b ratio was a 
mere 1:2.1. Finally, use of an a/b imidate donor 4.18 mixture (1:6, a/b) did little to improve 
reaction selectivity. This donor mixture also failed to solve another shortcoming of the 
reaction: recovered unreacted acceptor. 
 In all cases, treatment with catalytic TfOH was accompanied by the recovery of 
unreacted acceptor. Although this material could be recycled, its presence further 
complicated purification of the desired b-glycoside. Surprisingly, increasing the amount 
of donor did little to mitigate recovery of unreacted acceptor (Table 4.3). As a final note, 
increasing the equivalences of TfOH did little to improve a/b product ratios or to decrease 
the amount of acceptor recovered.  
  
 Formation of the unexpected a-anomer is hypothesized to be a result of the 
decreased nucleophilicity of acceptor 4.77; nucleophilicity is decreased due to the 
Scheme 4.38. Proposed mechanistic explanation for the formation of both a and b 
glycosides despite a C2 participating functionality on galactose donor 4.18. 
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addition of electron-withdrawing acetate protecting groups at the C4 and C6 alcohols. As 
illustrated generically in Scheme 4.4 in section 4.5.3 and recapitulated specifically for the 
present reaction conditions in Scheme 4.38, glycosylation with peracetylated 
trichloroacetimidate donor 4.18 proceeds through acyloxonium ion intermediate 4.61 
(generated by NGP by the C2 acetate). Subsequent SN2-like attack of a glycosyl acceptor 
at the anomeric center of intermediate 4.61 generates the b-glycoside. Importantly, 
acyloxonium ion intermediate 4.61 is in equilibrium with oxocarbenium ion intermediate 
4.62. Thus, it is possible that the in the presence of a particularly unreactive acceptor, a 
portion of intermediate 4.61 has ample time to convert back to 4.62. Unlike attack at the 
anomeric center of acyloxonium ion 4.61, attack at the anomeric center of oxocarbenium 
ion 4.62 can generate either the a or b glycoside (Scheme 4.38). 
 Due to the previously encountered issues with orthoacetate formation when using 
the participating, highly-polar acetonitrile as the glycosylation solvent, we decided to 
investigate the effect of toluene, a solvent with a lower polarity than dichloromethane, on 
the outcome of the current glycosylation. Low solubilities of 4.18 and 4.77 in toluene, 
however, precluded exclusive use of toluene as the sole reaction solvent. Therefore, 
reactions were run in a mixture of toluene and dichloromethane. Unfortunately, this did 
little to improve the a/b product ratios or the amount of unreacted acceptor recovered 
(Table 4.3). 
 As a result of the inability to prevent a-glycoside formation as well as the difficulties 
encountered in separating the a and b products from one another, the second-generation 
route to LNB donor 4.72 was abandoned in favor of the first-generation route.  
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4.5.8 Deprotection of Tetrasaccharide 4.76 to Afford Lacto-N-Tetraose 
 As previously mentioned, a three-step deprotection sequence was hypothesized 
to yield LNT (2.4) from fully protected LNT tetrasaccharide 4.76. The first step of this 
deprotection sequence consisted of Troc cleavage with in situ acetamide formation. For 
this transformation, we initially employed standard Zn/AcOH/Ac2O in THF conditions.81-85 
While these conditions did yield the desired acetamide (not pictured), the reactions 
generally failed to proceed to completion even when using an extreme excess of activated 
Zn and extended reaction times (≥ 24 h). Moreover, formation of the desired product was 
often accompanied by the formation of unknown side-products, which forced 
chromatographic purification of the desired acetamide.  Importantly, this purification 
proved difficult and contributed to low yields of the desired acetamide.  
 In an attempt to improve reaction outcome, several reaction parameters were 
altered; in all cases, an extreme excess of activated zinc was used. First, different ratios 
of THF/AcOH/Ac2O were investigated. Unfortunately, deviation from the original 3:2:1 
THF/AcOH/Ac2O, including removal of THF altogether, had little effect on reaction 
outcome. Second, we investigated the effect of delayed addition of Ac2O.68 Once again, 
this change did little to improve reaction outcome. Finally, various zinc activation methods 
were employed including activation with 2% and 5% HCl solutions, elemental iodine (I2), 
and a combination of HCl and I2 activation. While zinc activated by these various methods 
proved effective on simpler substrates, they did not improve the outcome of Troc 
deprotection and acetamide formation on tetrasaccharide 4.76. 
 While Zn/AcOH is a standard method for Troc deprotection, it has been shown that 
this method often results in only partial cleavage of the carbamate.84, 85 Reexamination of 
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the literature, however, revealed a less conventional Zn-mediated cleavage method that 
was shown to have success. In separate reports from the Overman and Boger 
laboratories, a 10% Zn/Pb couple in THF and AcOH was found to effect efficient and high-
yielding conversions of Troc-protected amines into the corresponding free amines.86, 87 
Satisfyingly, treatment of tetrasaccharide 4.76 with 10% Zn/Pb couple in 3:2:1 THF/ 
AcOH/Ac2O resulted in full conversion to the corresponding amide without the formation 
of detectable side-products (Scheme 4.39). It has been hypothesized that formation of a 
Zn/metal couple serves to increase the surface area of the reactive zinc thus facilitating 
Zn-mediated reduction. Notably, use of a 10% Cd/Pb couple gave comparable results.88 
 Following clean Troc deprotection and acetamide formation, deacetylation of the 
crude acetamide was affected by treatment with NaOMe. Finally, hydrogenation using 
Pearlman’s catalyst facilitated cleavage of the benzyl ethers to yield fully deprotected, 
crude LNT (2.4). Purification of the crude tetrasaccharide using size exclusion 
chromatography ultimately furnished LNT in 64% over the three-step deprotection 
sequence (Scheme 4.39). 
 
 
 
 
 
 
 
Scheme 4.39. Deprotection of fully protected LNT tetrasaccharide 4.76 to yield               
LNT (2.4).   
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4.6 Conclusion 
 In summary, LNT was synthesized from three readily accessible building blocks 
using a two-glycosylation approach. Notably, both glycosylations relied on the use of 
trichloroacetimidate donors to yield the desired b-glycosides reliably and in high yields. In 
these glycosylations, the protecting group strategies of the glucosamine and lactose 
moieties proved to be particularly impactful. In the first glycosylation between galactose 
donor and glucosamine acceptor, the 4,6-benzylidene acetal-protected glucosamine 
acceptor was superior to the corresponding 4,6-diacetate variant in generating the 
desired b-linked LNB disaccharide selectively and in high yield. The 4,6-benzylidene 
acetal-protected LNB disaccharide was then readily converted to the corresponding 
trichloroacetimidate donor for glycosylation with a lactose diol acceptor.  
In this second glycosylation, both the 4,6-benzylidene acetal of the LNB donor and 
the presence of two free alcohols on the lactose acceptor proved problematic. Initial 
attempts demonstrated that the LNB acetal was incompatible with the glycosylation 
conditions employed. While conversion of the acetal to the corresponding diacetate 
improved glycosylation outcome, selective glycosylation at the equatorial C3’ alcohol over 
the axial C4’ alcohol the of the lactose acceptor was never achieved.  This selectivity 
issue was easily remedied by selectively acetylating the axial alcohol to generate a 
lactose acceptor featuring only the free C3’ alcohol. Indeed, use of this second-generation 
lactose acceptor with the 4,6-diacetate LNB donor produced a fully-protected LNT 
derivative reliably and in high yield. Of note is the fact that this reaction was conducted to 
produce ca. 1 g of fully-protected LNT in a single glycosylation event.  
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From the fully-protected LNT derivative, a three-step deprotection sequence 
furnished LNT. The first step of this sequence, the Troc carbamate removal with in situ 
acetamide formation, was originally attempted using activated Zn. Unfortunately, this 
method proved to be slow, unreliable, and often resulted in incomplete conversion to the 
desired acetamide. However, substitution of the Zn for either a 10% Zn/Pb or 10% Cd/Pd 
couple resulted in faster, more reliable, and complete conversion to the acetamide. 
Subsequent deacetylation and debenzylation proceeded smoothly to generate LNT in 
consistent yields of over 50% (after final purification) for the three-step deprotection 
sequence. To date, our synthetic efforts towards LNT using the route described herein 
have yielded around 150 mg of fully deprotected LNT.  
 
4.7 Experimental Methods 
General Methods 
Commercial reagents were used as received. Anhydrous solvents were taken from an 
MBRAUN solvent purification system (MB SPS) and stored over 4 Å or 3 Å molecular 
sieves. All moisture-sensitive reactions were performed in flame- or oven-dried round 
bottom flasks under an argon atmosphere. All air- or moisture-sensitive liquids were 
transferred via oven-dried stainless-steel syringes or cannula. Reaction temperatures 
were monitored and controlled via thermocouple thermometer and corresponding hot 
plate stirrer. Flash column chromatography was performed as described by Still et. al. 
using silica gel 230-400 mesh. Analytical thin-layer chromatography (TLC) was performed 
on glass-backed Silica gel 60 F254 plates (EMD/Merck KGaA) and visualized using UV, 
cerium ammonium molybdate stain, and anisaldehyde stain.  
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Instrumentation 
1H NMR spectra were obtained on a Bruker 400 or 600 MHz spectrometer with reporting 
relative to deuterated solvent signals. 1H NMR spectral data are presented as follows: 
chemical shifts (δ ppm), multiplicity (s=singlet, d=doublet, dd=doublet of doublets, 
t=triplet, q=quartet, p=pentet, m=multiplet, br=broad, app=apparent), coupling constants 
(J in Hz), integration, proton assignment. Deuterated chloroform was calibrated to 7.26 
ppm. Deuterated methanol was calibrated to 3.31 ppm. Deuterium oxide was calibrated 
to 4.79 ppm. 13C NMR spectra were obtained on a Bruker 100 MHz or 150 MHz 
spectrometer with reporting relative to deuterated solvent signals. 13C NMR spectral data 
are presented as follows: chemical shifts (δ ppm), carbon assignment. Deuterated 
chloroform was calibrated to 77.16 ppm. Deuterated methanol was calibrated to 49.0 
ppm. Proton and carbon assignments were made with the aid of 2D NMR techniques 
(COSY, HSQC, and HMBC). High resolution mass spectra were recorded on a high 
resolution Thermo Electron Corporation MAT 95XP-Trap by use of electro-spray 
ionization (ESI) by the Indiana University Mass Spectrometry facility and a SYNAPT G2 
or SYNAPT G2-S spectrometer (Waters, for TOF-MS) by the McLean lab of Vanderbilt 
University. Low resolution mass spectra were recorded on a Thermo Scientific Dionex 
Ultimate 3000 HPLC system with MSQ Plus Mass Detector. Optical rotations were 
obtained using a Perkin Elmer 341 polarimeter.  
 
 
 
 
 310 
Compound preparation 
 
(2R,3S,4R,5R,6S)-2-(acetoxymethyl)-5-(((2,2,2-trichloroethoxy)carbonyl) amino)-6-
((triisopropylsilyl)oxy)tetrahydro-2H-pyran-3,4-diyl diacetate (4.56). To a suspension 
of D-(+)-glucosamine hydrochloride (4.11) (1.0 eq, 3.0 g, 14 mmol) in H2O (30 mL) was 
added NaHCO3 (3.0 eq, 3.5 g, 42 mmol) at room temperature and the resulting mixture 
was stirred 1 H. 2,2,2-trichloroethyl chloroformate (5.0 eq, 9.4 mL, 70 mmol) was then 
added dropwise over 20 minutes. The reaction was stirred an additional 3 H after which 
a white solid had formed. The reaction was filtered, washed with additional H2O (250 mL), 
and allowed to dry overnight. The crude Troc-protected glucosamine was coevaporated 
with benzene (3x) then dissolved in pyridine (130 mL) and acetic anhydride (5.0 eq, 6.6 
mL, 70 mol) was added dropwise over 5 minutes. The resulting solution was stirred 6 H 
then was diluted with EtOAc (250 mL), washed with 2 N HCl (6 x 90 mL), brine (1 x 90 
mL), dried (MgSO4), filtered, and concentrated in vacuo to yield a pale-yellow foam. The 
crude tetraacetate was dissolved in THF (70 mL) and 3-(dimethylamino)-1-propylamine 
(DMAPA) (5.0 eq, 8.8 mL, 70 mmol) was added. The reaction was stirred 1 H and 15 
minutes then was diluted with CH2Cl2 (130 mL), washed with 2 N HCl (2 x 60 mL), dried 
(MgSO4), filtered, and concentrated in vacuo to yield a white foam. The crude lactol was 
dissolved in DMF (90 mL) and imidazole (2.0 eq, 1.9 g, 28 mmol), DMAP (cat), and 
chlorotriisopropylsilane (1.2 eq, 3.6 mL, 17 mmol) were added sequentially.  The resulting 
solution was stirred 16 H then additional chlorotriisopropylsilane was added (1.5 mL). The 
reaction stirred an additional 22 H then was diluted with EtOAc (180 mL), washed with 
O
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H2O (3 x 80 mL), 2N HCl (1 x 80 mL), brine (1 x 80 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. The crude product was purified via flash column chromatography 
(2:1 hexanes/EtOAc) to yield anomeric silyl ether 4.56 (4.87 g, 7.65 mmol, 55% over 4 
steps) as a white solid: Rf 0.48 (2:1 hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) d 5.23 
(t, J=10.1 Hz , 1H, H-3), 5.06 (d, J=8.6 Hz, 1H, NH), 5.04 (t, J=9.6 Hz, 1H, H-4), 4.89 (d, 
J=7.8 Hz, 1H, H-1), 4.75 (d, J=12.0 Hz, 1H, Troc CH), 4.61 (d, J=12.0 Hz, 1H, Troc CH), 
4.15 (d, J=4.2 Hz, 2H, H-6a, H-6b), 3.72-3.61 (m, 2H, H-2, H-5), 2.06 (s, 3H, COCH3), 
2.03 (s, 3H, COCH3), 2.02 (s, 3H, COCH3), 1.12-1.01 (m, 21H, TIPS), 1.60 (s, H2O); 13C 
(100 MHz, CDCl3) d 170.9 (COCH3), 170.8 (COCH3), 169.7 (COCH3), 154.1 (Troc CO), 
96.1 (C-1), 95.4 (Troc CCl3), 74.8 (Troc CH2), 72.1 (C-3), 71.9 (C-5), 69.1 (C-4), 62.6 (C-
6), 58.7 (C-2), 20.8 (COCH3), 17.9 (TIPS), 17.8 (TIPS), 12.3 (TIPS). HRMS (ESI) calcd 
for C24H40Cl3NO10Si [M+Na]+ 658.1385, found 658.1356.  
 
 
2,2,2-trichloroethyl((2S,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-((triisopr 
opylsilyl)oxy)tetrahydro-2H-pyran-3-yl)carbamate (4.57). To a solution of 4.56 (1.0 eq, 
4.0 g, 6.3 mmol) in CH2Cl2 (60 mL) and MeOH (60 mL), was added guanidine 
hydrochloride (5.0 eq, 3.0 g, 31 mmol) and 7 N NH3/MeOH (12.0 eq, 8.4 mL, 75 mmol) 
sequentially. The resulting solution was stirred 21 H then was neutralized with AcOH and 
concentrated in vacuo. The crude product was purified via flash column chromatography 
(10:1 CHCl3/MeOH) to yield triol 4.57 (2.45 g, 4.80 mmol, 76%) as a white solid: Rf  0.41 
(10:1 CH2Cl2/MeOH); 1H NMR (400 MHz, MeOD) d 4.73 (d, J=7.7 Hz, 1H, H-1), 4.70 (s, 
O
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AcO
OAc
OTIPS
4.56
Gnd•Cl, NH3/MeOH
3:2 MeOH/CH2Cl2
(61-78%)
O
NHTroc
HO
HO
OH
OTIPS
4.57
 312 
2H, Troc CH, Troc CH), 3.84 (dd, J=2.6, 11.8 Hz, 1H, H-6a), 3.72 (dd, J=5.0, 11.8 Hz, 1H, 
H-6b), 3.47-3.33 (m, 3H, H-2, H-3, H-4), 3.23 (ddd, J=2.6, 5.0, 9.0 Hz, 1H, H-5), 1.16-
1.07 (m, 21 H, TIPS), 1.98 (s, AcOH); 13C (100 MHz, MeOD) d 156.9 (Troc CO), 97.7 (C-
1), 97.0 (Troc CCl3), 77.7 (C-5), 75.8 (Troc CH2), 75.7 (C-3), 72.3 (C-4), 62.8 (C-6), 61.5 
(C-2), 18.4 (TIPS), 18.4 (TIPS), 13.5 (TIPS). HRMS (ESI) calcd for C18H34Cl3NO7Si 
[M+Na]+ 532.1068, found 532.1059.  
 
 
2,2,2-trichloroethyl((2R,4aR,6S,7R,8R,8aS)-8-hydroxy-2-phenyl-6-((triisopropylsilyl) 
oxy)hexahydropyrano[3,2-d][1,3]dioxin-7-yl)carbamate (4.52). To a solution of 4.57 
(1.0 eq, 1.5 g, 2.9 mmol) in CH3CN (30 mL) was added benzaldehyde dimethyl acetal 
(2.0 eq, 0.88 mL, 5.9 mmol). The reaction pH was adjusted between 2-4 using DL-10-
camphorsulfonic acid and the reaction heated to 60oC. The reaction was stirred 2 H then 
was neutralized with Et3N, diluted with EtOAc (70 mL), washed with water (2 x 30 mL), 
brine (1 x 30 mL), dried (MgSO4), filtered, and concentrated in vacuo. The crude product 
was purified via flash column chromatography (6:1 hexanes/EtOAc) to yield benzylidene 
acetal 4.52 (1.6 g, 3.0 mmol, 91%) as a white foam: Rf 0.60 (1:1 hexanes/EtOAc); 1H 
NMR (400 MHz, CDCl3) d 7.50-7.48 (m, 2H, aromatic), 7.40-7.36 (m, 3H, aromatic), 5.55 
(s, 1H, benzylidene CH), 5.15 (d, J=5.9 Hz, 1H, NH), 4.92 (d, J=7.5 Hz, 1H, H-1), 4.74 
(app d, J=12.0 Hz, 1H, Troc CH), 4.66 (app d, J=11.9 Hz, 1H, Troc CH), 4.29 (dd, J=10.5, 
4.9 Hz, 1H, H-6a), 4.06-4.02 (m, 1H, H-3), 3.78 (t, J=10.2 Hz, 1H, H-6b), 3.58 (t, J=9.2 
Hz, 1H, H-4), 3.49-3.36 (m, 2H, H-5, H-2), 1.15-1.03 (m, 21H, TIPS); 13C (100 MHz, CDCl3) 
O
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d 154.6 (Troc CO), 137.2 (aromatic), 129.5 (aromatic), 128.5 (aromatic), 126.5 (aromatic), 
102.1 (benzylidene CH), 96.2 (C-1), 95.3 (Troc CCl3), 81.7 (C-4), 75.0 (Troc CH2), 71.0 
(C-3), 68.7 (C-6), 66.3 (C-5), 61.3 (C-2), 17.9 (TIPS), 12.3 (TIPS). HRMS (ESI) calcd 
C25H38Cl3NO7Si [M+Na]+ 620.1381, found 620.1367.  
 
 
(2R,3S,4S,5R,6R)-2-(acetoxymethyl)-6-(2,2,2-trichloro-1-iminoethoxy)tetrahydro-
2H-pyran-3,4,5-triyl triacetate (4.18). To a solution of 4.58 (1.0 eq, 1.0 g, 2.6 mmol) in 
THF (13 mL) was added 3-(dimethylamino)-1-propylamine (DMAPA) (5.0 eq, 1.6 mL, 12.8 
mmol). The reaction was stirred 1.5 H then was diluted with CH2Cl2 (20 mL), washed with 
2 N HCl (2 x 10 mL), dried (MgSO4), filtered, and concentrated in vacuo. The crude lactol 
was dissolved in CH2Cl2 (18 mL) and cooled to 0 oC. To the cooled solution was added 
trichloroacetonitrile (5.0 eq, 1.3 mL, 13 mmol) followed by 1,8-diazabicyclo[5.4.0]undec-
7-ene (DBU) (0.25 eq, 0.96 mL, 0.64 mmol). After 30 minutes, the reaction was allowed 
to warm to room temperature and stir an additional 5.5 H. The reaction was then filtered 
and concentrated in vacuo. The crude product was purified via flash column 
chromatography (1:1 hexanes/EtOAc) to yield a-trichloroacetimidate 4.18 (0.81 g, 1.6 
mmol, 64% over 2 steps) as a pale-yellow foam: Rf 0.50 (1:1 hexanes/EtOAc). 1H and 
13C spectroscopy data were in accordance with literature data.56 
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(2R,3S,4S,5R,6R)-2-(acetoxymethyl)-6-(((2R,4aR,6S,7R,8R,8aS)-2-phenyl-7-(((2,2,2-
trichloroethoxy)carbonyl)amino)-6-((triisopropylsilyl)oxy)hexahydro pyrano[3,2-
d][1,3]dioxin-8-yl)oxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (4.59). Donor 4.18 
(1.4 eq, 1.46 g, 3.0 mmol) and acceptor 4.52 (1.0 eq, 1.27 g, 2.1 mmol) were 
coevaporated with benzene (2 x 8 mL) and placed in a vacuum desiccator containing 
P2O5 overnight. The donor/acceptor mixture was dissolved in CH2Cl2 (14 mL) and the 
resulting solution was cannulated into a reaction flask containing 4Å powdered molecular 
sieves (2.7 g). The mixture was stirred under argon 1 H then cooled to -10 oC and TMSOTf 
(0.1 eq, 0.038 mL in 0.2 mL CH2Cl2) was added. The reaction was stirred 10 minutes then 
quenched with Et3N. The reaction was diluted with CH2Cl2, filtered through celite, dried 
(MgSO4), filtered, and concentrated in vacuo. The crude residue was purified via flash 
column chromatography (2:1 hexanes/EtOAc) to yield disaccharide 4.59 (1.59 g, 1.71 
mmol, 81%) as a white foam: Rf 0.35 (1:1 hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) d 
7.49-7.45 (m, 2H, aromatic), 7.40-7.34 (m, 3H, aromatic), 5.54 (s, 1H, benzylidene CH), 
5.29 (d, J=2.8 Hz, 1H, H-4’), 5.19 (dd, J=8.4, 10.4 Hz, 1H, H-2’), 5.18 (d, J=8.0 Hz, NH), 
5.11 (d, J=7.8 Hz, H-1), 4.92 (dd, J=3.4, 10.4 Hz, 1H, H-3’), 4.69 (s, 2H, Troc CH, Troc 
CH), 4.68 (d, J=8.6 Hz, H-1’), 4.32 (t, J=9.2 Hz, H-3), 4.27 (dd, J=5.0, 10.6 Hz, 1H, H-6a), 
4.11 (q, EtOAc), 4.06 (dd, J=8.4, 10.6 Hz, 1H, H-6’a), 3.83 (dd, J=5.4, 10.7 Hz, 1H, H-
6’b), 3.78 (t, J=10.4 Hz, H-6b), 3.72 (t, J=9.2 Hz, 1H, H-4), 3.64 (t, J=6.7 Hz, 1H, H-5’), 
3.50-3.44 (ddd, J=4.9, 9.7, 9.7 Hz, 1H, H-5), 3.28 (q, J=8.0 Hz, 1H, H-2), 2.11 (s, 3H, 
COCH3), 2.04 (s, EtOAc), 2.03 (s, 3H, COCH3), 1.95 (s, 3H, COCH3), 1.93 (s, 3H, COCH3), 
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1.62 (s, H2O), 1.25 (t, EtOAc), 1.12-1.00 (m, 21H, TIPS), 0.06 (s, silicone grease); 13C 
(100 MHz, CDCl3) d 170.4 (COCH3), 170.3 (COCH3), 170.2 (COCH3), 169.6 (COCH3), 
153.9 (Troc CO), 137.2 (aromatic), 129.4 (aromatic), 128.5 (aromatic), 126.2 (aromatic), 
101.5 (benzylidene CH), 101.0 (C-1’), 95.3 (C-1), 95.2 (Troc CCl3), 80.4 (C-4), 78.2 (C-
3), 74.9 (Troc CH2), 71.1 (C-3’), 70.6 (C-5’), 69.4 (C-2’), 68.8 (C-6), 67.0 (C-4’), 66.2 (C-
5), 61.0 (C-6’), 60.7 (C-2), 20.9 (COCH3), 20.8 (COCH3), 20.7 (COCH3), 20.7 (COCH3), 
17.9 (TIPS), 17.9 (TIPS), 12.3 (TIPS). HRMS (ESI) calcd for C39H56Cl3NO16Si [M+Na]+ 
950.2332, found 950.2311.  
 
 
(3aR,5R,6S,7S,7aR)-5-(acetoxymethyl)-2-methyl-2-(((2R,4aR,6S,7R,8R,8aS)-2-phen 
yl-7-(((2,2,2-trichloroethoxy)carbonyl)amino)-6-((triisopropylsilyl)oxy) hexahydro 
pyrano[3,2-d][1,3]dioxin-8-yl)oxy)tetrahydro-5H-[1,3]dioxolo[4,5-b]pyran-6,7-diyl 
diacetate (4.60). Donor 4.18 (1.3 eq, 0.16 g, 0.33 mmol) and acceptor 4.52 (1.0 eq, 0.15 
g, 0.25 mmol) were coevaporated with benzene (2 x 4 mL) and placed in a vacuum 
desiccator containing P2O5 overnight. The donor/acceptor mixture was dissolved in 
CH3CN (1.25 mL) and the resulting solution was cannulated into a reaction flask 
containing 4Å powdered molecular sieves (0.4 g). The mixture was stirred under argon 1 
H then cooled to -40 oC and TMSOTf (1 drop) was added. The reaction was stirred 1 H 
then quenched with Et3N. The reaction was diluted with EtOAc (25 mL), filtered through 
celite, washed with water (3 x 10 mL), brine (1 x 10 mL), dried (MgSO4), filtered, and 
+
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concentrated in vacuo. The crude residue was purified via flash column chromotography 
(2:1 hexanes/EtOAc) to yield orthoacetate 4.60 (0.115 g, 0.124 mmol, 50%) as a white 
foam: Rf  0.48 (2:1 hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) d 7.45-7.43 (m, 2H, 
aromatic), 7.35-7.33 (m, 3H, aromatic), 5.82 (d, J=4.8 Hz, 1H, H-1’), 5.51 (s, 1H, 
benzylidene CH), 5.33 (dd, J=1.5, 3.2 Hz, 1H, H-4’), 5.26 (d, J=8.7 Hz, 1H, NH), 4.94 (d, 
J=7.2 Hz, 1H, H-3’), 4.93 (d, J=7.1 Hz, 1H, H-1), 4.83 (d, J=11.9 Hz, 1H, Troc CH), 4.55 
(d, J=12.0 Hz, 1H, Troc CH), 4.30-4.23 (m, 3H, H-6a, H-2’, H-5’), 4.11-4.05 (m, 3H, H-6’a, 
H-3, H-6’b), 3.76 (t, J=10.2 Hz, 1H, H-6b), 3.60 (t, J=9.3 Hz, 1H, H-4), 3.45-3.36 (m, 2H, 
H-5, H-2), 2.08 (s, 3H, COCH3), 2.04 (s, 3H, COCH3), 2.01 (s, 3H, COCH3), 1.65 
(orthoacetate CH3), 1.25 (m, grease), 0.06 (s, silcone grease), 1.11-1.02 (m, 21H, TIPS); 
13C (100 MHz, CDCl3) d 170.6 (COCH3), 170.1 (COCH3), 170.0 (COCH3), 154.0 (Troc 
CO), 137.2 (aromatic), 129.2 (aromatic), 128.3 (aromatic), 126.2 (aromatic), 120.5 
(orthoacetate C), 101.7 (benzylidene CH), 98.4 (C-1’), 96.6 (C-1), 95.2 (Troc CCl3), 80.5 
(C-4), 75.0 (Troc CH2), 72.5 (C-2’), 71.6 (C-3’), 71.6 (C-3), 69.0 (C-5’), 68.7 (C-6), 66.5 
(C-5), 65.8 (C-4’), 61.6 (C-6’), 60.3 (C-2), 25.1 (orthoacetate CH3), 20.9 (COCH3), 20.8 
(COCH3), 20.8 (COCH3), 17.9 (TIPS), 17.8 (TIPS), 12.3 (TIPS). HRMS (TOF) calcd for 
C39H56Cl3NO16Si [M+Na]+ 950.2326, found 950.2365.  
 
 
(2R,3S,4S,5R,6R)-2-(acetoxymethyl)-6-(((2R,4aR,6R,7R,8R,8aS)-6-hydroxy-2-phen 
yl-7-(((2,2,2-trichloroethoxy)carbonyl)amino)hexahydropyrano[3,2-d][1,3]dioxin-8-
yl)oxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (4.63). To a solution 4.59 (1.0 eq, 1.0 
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g, 1.1 mmol) in pyridine (11 mL) cooled to 0 oC was added 70% HF in pyridine (5.4 mL) 
dropwise over 5 minutes. The solution was stirred 30 minutes then was allowed to warm 
to room temperature and stir an additional 4.5 H. The reaction was diluted with water (40 
mL) and extracted with EtOAc (4 x 15 mL). The combined organics were quenched with 
solid NaHCO3, and saturated NaHCO3 solution, washed with 2 N HCl (3 x 20 mL), brine 
(1 x 20 mL), dried (MgSO4), filtered, and concentrated in vacuo. The crude residue was 
purified via flash column chromatography (2:3 hexanes/EtOAc) to yield lactol 4.63 (0.64 
g, 0.83 mmol, 77%) (a/b 2.2:1) as a white foam: Rf 0.38 (1:1 hexanes/EtOAc); 1H NMR 
(400 MHz, CDCl3) d (a anomer) 7.48-7.45 (m, 2H, aromatic), 7.38-7.35 (m, 3H, aromatic), 
5.55 (s, 1H, benzylidene CH), 5.54 (s, 0.45 H, minor anomer), 5.30-5.25 (m, 2H, H-1, H-
4’), 5.19 (dd, J=8.0, 10.4 Hz, minor anomer), 5.17 (dd, J=8.0, 10.4 Hz, H-2’), 4.96 (d, 
J=12.0 Hz, 1H, Troc CH), 4.92 (dd, J=3.4, 10.5 Hz, 1H, H-3’), 4.80 (d, J=11.9 Hz, 0.45 H, 
minor anomer), 4.71 (m, 0.45 H, minor anomer), 4.69 (d, J=8.0 Hz, 1H, H-1’), 4.59 (d, 
J=12.1 Hz, 1H, Troc CH), 4.43 (m, 0.45 H, minor anomer), 4.33 (dd, J=4.9, 10.5 Hz, 0.45 
H, minor anomer), 4.24 (dd, J=4.8, 10.3 Hz, 1H, H-6a), 4.14-3.98 (m, 4H, H-5, H-2, H-3, 
H-6’a), 3.83-3.71 (m, 3H, H-6’b, H-6b, H-4), 3.57 (t, J=6.7 Hz, 1H, H-5’), 3.52 (d, J=3.2 
Hz, 1H, OH), 3.53-3.47 (m, 0.9 H, minor anomer), 2.11 (s, 1.35 H, minor anomer), 2.10 
(s, 3H, COCH3), 2.06 (s, 3H, COCH3), 1.97 (s, 1.35 H, minor anomer), 1.95 (s, 1.35 H, 
minor anomer), 1.95 (s, 3H, COCH3), 1.91 (s, 3H, COCH3), 1.75 (br s, 0.45 H, minor 
anomer OH), 1.25 (m, grease), 0.06 (s, silicone grease); 13C (100 MHz, CDCl3) d 170.5 
(COCH3), 170.4 (minor anomer), 170.4 (COCH3), 170.3 (COCH3), 169.7 (COCH3), 154.2 
(Troc CO), 137.2 (aromatic), 137.0 (minor anomer), 129.5 (minor anomer), 129.4 
(aromatic), 128.5 (aromatic), 126.2 (minor anomer), 126.1 (aromatic), 126.1 (aromatic), 
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101.6 (minor anomer), 101.6 (benzylidene CH), 101.2 (C-1’), 95.5 (Troc CCl3), 95.3 
(minor anomer), 92.5 (C-1), 80.8 (C-4), 77.3 (C-3), 75.0 (Troc CH2), 71.1 (C-3’), 71.0 
(minor anomer), 70.8 (minor anomer), 70.6 (C-5’), 69.6 (C-2’), 69.4 (minor anomer), 69.0 
(C-6), 68.7 (minor anomer), 66.9 (C-4’), 66.5 (minor anomer), 62.7 (C-5), 60.9 (C-6’), 54.8 
(C-2), 20.8 (COCH3), 20.8 (COCH3), 20.7 (COCH3).   HRMS (ESI) calcd for 
C30H36Cl3NO16 [M+Na]+ 794.0997, found 794.1010.  
 
 
(2R,3S,4S,5R,6R)-2-(acetoxymethyl)-6-(((2R,4aR,6R,7R,8R,8aS)-2-phenyl-6-(2,2,2-
trichloro-1-iminoethoxy)-7-(((2,2,2trichloroethoxy)carbonyl)amino) hexahydro 
pyrano [3,2-d][1,3]dioxin-8-yl)oxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (4.54). 
To a solution of 4.63 (1.0 eq, 0.35 g, 0.45 mmol) in CH2Cl2 (6.2 mL) cooled to 0 oC was 
added trichloroacetonitrile (10 eq, 0.45 mL, 4.5 mmol) followed by 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) (cat.). The reaction was stirred 1 H then was 
allowed to warm to room temperature and stir an additional 1 H. The reaction was 
concentrated and the crude residue purified via flash column chromatography (1:1 
hexanes/EtOAc) to yield a-trichloroacetimidate 4.54 (0.36 g, 0.40 mmol, 89%) as a pale 
yellow powder: Rf 0.71 (1:1 hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) d 8.78 (s, 1H, 
imidate NH), 7.52-7.45 (m, 2H, aromatic), 7.40-7.35 (m, 3H, aromatic), 6.40 (d, J=3.8 Hz, 
H-1), 5.60 (s, 1H, benzylidene CH), 5.32 (d, J=3.0 Hz, 1H, H-4’), 5.21 (dd, J=7.9, 10.4 Hz, 
H-2’), 5.12 (d, J=8.6 Hz, 1H, NH), 4.97 (dd, J=3.4, 10.5 Hz, H-3’), 4.94 (d, J=11.9 Hz, 1H, 
Troc CH), 4.80 (d, J=7.9 Hz, 1H, H-1’), 4.56 (d, J=12.0 Hz, 1H, Troc CH), 4.34 (dd, J=4.6, 
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10.3 Hz, 1H, H-6a), 4.25 (ddd, J=3.8, 10.2, 10.2 Hz, 1H, H-2), 4.12-4.04 (m, 2H, H-3, H-
6’a), 3.98 (ddd, J=4.7, 9.7, 9.7 Hz, H-5), 3.92-3.84 (m, 2H, H-6’b, H-4), 3.82 (t, J=10.3 Hz, 
1H, H-6b), 3.72 (t, J=6.7 Hz, H-5’), 2.12 (s, 3H, COCH3), 2.01 (s, 3H, COCH3), 1.96 (s, 
3H, COCH3), 1.95 (s, 3H, COCH3), 1.56 (s, H2O), 1.25 (m, grease); 13C (100 MHz, CDCl3) 
d 170.4 (COCH3), 170.3 (COCH3), 169.6 (COCH3), 160.5 (imidate CNH), 154.1 (Troc CO), 
136.9 (aromatic), 129.5 (aromatic), 128.5 (aromatic), 126.1 (aromatic), 101.6 
(benzylidene CH), 100.9 (C-1’), 95.4 (Troc CCl3), 95.3 (C-1), 90.9 (imidate CCl3), 79.8 (C-
4), 76.8 (C-3), 74.9 (Troc CH2), 71.0 (C-3’), 70.9 (C-5’), 69.8 (C-2’), 68.6 (C-6), 66.8 (C-
4’), 65.2 (C-5), 61.0 (C-6’), 54.4 (C-2), 20.8 (COCH3), 20.7 (COCH3), 20.7 (COCH3). 
HRMS (ESI) calcd for C32H36Cl6N2O16 [M+Na]+ 937.0094, found 937.0067.  
 
 
(2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(((2R,3R,4S,5R,6R)-4,5-diacetoxy-2-(acetoxy 
methyl)-6-(benzyloxy)tetrahydro-2H-pyran-3-yl)oxy)tetrahydro-2H-pyran-3,4,5-triyl 
triacetate (4.64). To a solution of lactose octaacetate (4.8) (1.0 eq, 4.0 g, 5.9 mmol) in 
CH2Cl2 (4.5 mL) cooled to 0oC was added HBr/AcOH (33 wt%) (2.7 eq, 4.5 mL, 16 mmol) 
dropwise over 30 minutes. The reaction was slowly allowed to warm to room temperature 
and stir 2.5 H. The reaction was diluted with CH2Cl2 and water, quenched with saturated 
NaHCO3 solution, and extracted with additional CH2Cl2 (4 x 10 mL). The combined 
organics were washed with saturated NaHCO3 solution (3 x 20 mL), water (1 x 20 mL), 
brine (1 x 20 mL), dried (MgSO4), filtered, and concentrated in vacuo to yield a white foam. 
The crude anomeric bromide was dissolved in CH2Cl2 (20 mL) and added to a suspension 
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of Ag2CO3 (2.6 eq, 4.1 g, 15 mmol), 4Å molecular sieves (3.0 g), and a crystal of I2 in 
CH2Cl2 (10 mL). Benzyl alcohol (5.0 eq, 3.0 mL 29 mmol) was added and the resulting 
mixture stirred in the dark for 17.5 H then was filtered through a plug of celite and 
concentrated in vacuo. The crude residue was purified via flash column chromatography 
(1:1 hexanes/EtOAc) to yield anomeric benzyl ether 4.64 (2.5 g, 3.4 mmol, 58% over 2 
steps) as a white foam: Rf 0.40 (1:1 hexanes/EtOAc); 1H (400 MHz, CDCl3) d 7.37-7.25 
(m, 5H, aromatic), 5.34 (dd, J=1.1, 3.5 Hz, 1H, H-4’), 5.15 (dd, J=9.3, 9.2 Hz, 1H, H-3), 
5.10 (dd, J=7.9, 10.4 Hz, 1H, H-2’), 4.97 (dd, J=7.8, 9.8 Hz, 1H, H-2), 4.95 (dd, J=3.3, 9.8 
Hz, 1H, H-3’), 4.86 (d, J=12.3 Hz, PhCH), 4.59 (d, J=12.3 Hz, PhCH), 4.53 (dd, J=2.0, 
12.8 Hz, 1H, H-6a), 4.52 (d, J=8.0 Hz, 1H, H-1), 4.48 (d, J=7.9 Hz, 1H, H-1’), 4.15-4.05 
(m, 3H, H-6’a, H-6b, H-6’b), 3.88-3.84 (ddd, J=2.0, 4.9, 7.0 Hz, 1H, H-5), 2.14 (s, 3H, 
COCH3), 2.14 (s, 3H, COCH3), 2.05 (s, 3H, COCH3), 2.04 (s, 3H, COCH3), 2.03 (s, 3H, 
COCH3), 2.00 (s, 3H, COCH3), 1.96 (s, 3H, COCH3), 1.59 (s, H2O), 1.25 (m, grease); 13C 
(100 MHz, CDCl3) d 170.5 (COCH3), 170.5 (COCH3), 170.3 (COCH3), 170.2 (COCH3), 
169.9 (COCH3), 169.8 (COCH3), 169.2 (COCH3), 136.8 (aromatic), 128.6 (aromatic), 
128.2 (aromatic), 127.9 (aromatic), 101.2 (C-1’), 99.2 (C-1), 76.4 (C-4), 72.9 (C-3), 72.8 
(C-5), 71.8 (C-2), 71.1 (C-3’), 70.9 (C-5’), 70.8 (PhCH2), 69.3 (C-2’), 66.7 (C-4’), 62.1 (C-
6), 61.0 (C-6’), 21.0 (COCH3), 21.0 (COCH3), 20.8 (COCH3), 20.8 (COCH3), 20.7 
(COCH3). LRMS calcd for C33H42O18 [M+Na]+ 749.23, found 749.44.   
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(2R,3R,4R,5S,6R)-2-(benzyloxy)-5-(((3aS,4R,6S,7R,7aR)-7-hydroxy-4-(hydroxymeth 
yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-6-yl)oxy)-6-(hydroxymethyl) 
tetrahydro-2H-pyran-3,4-diol (4.66).74 To a solution of 4.64 (1.0 eq, 1.8 g, 2.5 mmol) in 
MeOH was added a concentrated NaOMe solution. The reaction was stirred 15 H then 
neutralized with Dowex 50Wx8, filtered, and concentrated in vacuo to yield a white solid. 
The crude deacetylated anomeric benzyl ether (1.0 eq, 1.0 g, 2.3 mmol) was suspended 
in acetone (18 mL) and 2,2-dimethoxypropane (8.5 eq, 2.4 mL, 20 mmol) and p-
toluenesulfonic acid (0.1 eq, 0.04 g, 0.23 mmol) were added sequentially. The resulting 
mixture was stirred 16 H. The reaction was concentrated in vacuo and purified via flash 
column chromatography (13:1 EtOAc/MeOH) to yield 3’,4’-acetonide 4.66 (0.89 g, 1.9 
mmol, 76%) as a white solid: Rf 0.35 (9:1 EtOAc/MeoH); 1H (400 MHz, CDCl3) d 7.43-
7.41 (m, 2H, aromatic), 7.35-7.27 (m, 3H, aromatic), 4.92 (d, J=11.8 Hz, 1H, PhCH), 4.67 
(d, J=11.8 Hz, 1H, PhCH), 4.39 (d, J=7.7 Hz, 1H, H-1), 4.37 (d, J=8.0 Hz, 1H, H-1’), 4.19 
(dd, J=2.0, 5.5 Hz, 1H, H-4’), 4.05 (dd, J=5.6, 7.2 Hz, 1H, H-3’), 3.95-3.92 (m, 1H, H-5’), 
3.90 (dd, J=2.4, 12.1 Hz, 1H-H-6a), 3.86-3.73 (m, 3H, H-6a, H-6’a, H-6’b), 3.59 (dd, J=8.8, 
9.3 Hz, 1H, H-4), 3.53 (t, J=8.9 Hz, 1H, H-3), 3.45 (dd, J=7.5, 8.0 Hz, 1H, H-2), 3.43-3.38 
(m, 1H, H-5), 1.47 (s, 3H, CCH3), 1.32 (s, 3H, CCH3); 13C (100 MHz, CDCl3) d 139.0 
(aromatic), 129.3 (aromatic), 129.2 (aromatic), 128.7 (aromatic),  111.1 (C(CH3)2), 104.2 
(C-1’), 103.1 (C-1), 81.0 (C-4), 80.9 (C-3’), 76.5 (C-5), 76.4 (C-3), 75.4 (C-5’), 75.1 (C-4’), 
74.9 (C-2), 74.5 (C-2’), 71.8 (PhCH2), 62.4 (C-6’), 61.9 (C-6), 28.4 (CCH3), 26.5 (CCH3). 
LRMS calcd for C22H32O11 [M+H]+ 473.20, found 473.28.  
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(3aS,4R,6S,7R,7aS)-7-(benzyloxy)-4-((benzyloxy)methyl)-2,2-dimethyl-6-(((2R,3R, 
4S,5R,6R)-4,5,6-tris(benzyloxy)-2-((benzyloxy)methyl)tetrahydro-2H-pyran-3-yl)oxy) 
tetrahydro-4H-[1,3]dioxolo[4,5-c]pyran (A1).74 To a solution of 4.66 (1.0 eq, 0.60 g, 1.3 
mmol) in DMF (13 mL) cooled to 0 oC was added benzyl bromide (10 eq, 1.5 mL, 13 mmol) 
followed by solid NaH (60 wt%) (7.5 eq, 0.38 g, 9.5 mmol) and 15-crown-5 (cat.). The 
reaction was slowly allowed to warm to room temperature and stir 4.5 H. The reaction 
was poured onto ice water (40 mL) and extracted with EtOAc (4 x 15 mL). The combined 
organics were washed with water (1 x 20 mL), brine (1 x 20 mL), dried (MgSO4), filtered, 
and concentrated in vacuo. The crude residue was purified via flash column 
chromatography (4:1 hexanes/EtOAc) to yield benzylated acetonide A1 (0.95 g, 1.0 mmol, 
81%) as a clear, sticky oil: Rf 0.72 (2:1 hexanes/EtOAc); 1H (400 MHz, CDCl3) d 7.39-
7.21 (m, 30H, aromatic), 4.96 (d, J=12.2 Hz, 1H, PhCH), 4.94 (d, J=11.2 Hz, 1H, PhCH), 
4.91 (d, J=11.2 Hz, 1H, PhCH), 4.80 (d, J=11.8 Hz, 1H, PhCH), 4.74 (d, J=10.5 Hz, 1H, 
PhCH), 4.73 (d, J=10.8 Hz, 1H, PhCH), 4.68 (d, J=11.8 Hz, 1H, PhCH), 4.67 (d, J=12.1 
Hz, 1H, PhCH), 4.60 (d, J=12.1 Hz, 1H, PhCH), 4.52 (d, J=12.1 Hz, 1H, PhCH), 4.51 (d, 
J=7.7 Hz, 1H, H-1), 4.45 (d, J=12.0 Hz, 1H, PhCH), 4.43 (d, J=8.0 Hz, 1H, H-1’), 4.32 (d, 
J=12.1 Hz, 1H, PhCH), 4.12 (dd, J=1.6, 5.6 Hz, 1H, H-4’), 4.04 (dd, J=5.8, 6.5 Hz, 1H, H-
3’), 3.99 (dd, J=9.3, 9.4, 1H, H-4), 3.84 (dd, J=4.2, 11.0 Hz, 1H, H-6a), 3.76 (dd, J=1.6, 
10.9 Hz, 1H, H-6b), 3.71-3.66 (m, 2H, H-6’a, H-5’), 3.59-3.33 (m, 5H, H-2’, H-6’b, H-3, H-
5, H-2), 1.36 (s, 3H, CCH3), 1.40 (s, 3H, CCH3); 13C (100 MHz, CDCl3) d 139.1 (aromatic), 
138.7 (aromatic), 138.7 (aromatic), 138.6 (aromatic), 138.4 (aromatic), 137.7 (aromatic), 
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128.5 (aromatic), 128.5 (aromatic), 128.4 (aromatic), 128.4 (aromatic), 128.3 (aromatic), 
128.3 (aromatic), 128.2 (aromatic), 128.0 (aromatic), 128.0 (aromatic), 127.8 (aromatic), 
127.7 (aromatic), 127.7 (aromatic), 127.6 (aromatic), 127.6 (aromatic), 127.6 (aromatic), 
127.4 (aromatic), 109.9 (C(CH3)2), 102.7 (C-1), 102.0 (C-1’), 83.2 (C-3), 82.0 (C-2), 80.8 
(C-2’), 79.5 (C-3’), 76.5 (C-4), 75.6 (PhCH2), 75.3 (C-5), 75.2 (PhCH2), 73.7 (C-4’), 73.5 
(PhCH2), 73.4 (PhCH2), 73.3 (PhCH2), 72.1 (C-5’), 71.1 (PhCH2), 69.0 (C-6’), 68.4 (C-6), 
28.1 (CCH3), 26.6 (CCH3). LRMS calcd for [M+H]+ 923.43, found 923.45.  
 
 
(2R,3R,4S,5R,6S)-5-(benzyloxy)-2-((benzyloxy)methyl)-6-(((2R,3R,4S,5R,6R)-4,5,6-
tris(benzyloxy)-2-((benzyloxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)tetrahydro-2H-
pyran-3,4-diol (4.53). A solution of A1 (1.0 eq, 1.5 g, 1.7 mmol) in 80% aqueous acetic 
acid (16 mL) was heated to 75 oC. The reaction was stirred 4 H then diluted with water 
(40 mL) and extracted with CH2Cl2 (4 x 15 mL) while solid NaHCO3 was added. The 
combined organics were washed with a saturated aqueous NaHCO3 solution (3 x 20 mL), 
brine (1 x 20 mL), dried (MgSO4), filtered, and concentrated in vacuo. The crude residue 
was purified via flash column chromatography (1:1 hexanes/EtOAc) to yield diol 4.53 (1.2 
g, 1.4 mmol, 82%) as a dense white solid: Rf  0.13 (2:1 hexanes/EtOAc); 1H (400 MHz, 
CDCl3) d 7.39-7.22 (m, 30H, aromatic), 4.98 (d, J=11.0 Hz, 1H, PhCH), 4.96 (d, J=12.1 
Hz, 1H, PhCH), 4.91 (d, J=10.8 Hz, 1H, PhCH), 4.81 (d, J=11.6 Hz, 1H, PhCH), 4.77 (d, 
J=11.0 Hz, 1H, PhCH), 4.73 (d, J=10.8 Hz, 1H, PhCH), 4.67 (d, J=11.6 Hz, 1H, PhCH), 
4.66 (d, J=12.1 Hz, 1H, PhCH), 4.62 (d, J=12.2 Hz, 1H, PhCH), 4.50 (d, J=7.8 Hz, 1H, H-
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1), 4.47 (d, J=12.2 Hz, 1H, PhCH), 4.45 (d, J=7.2 Hz, 1H, H-1’), 4.45 (d, J=11.8 Hz, 1H, 
PhCH), 4.39 (d, J=12.2 Hz, 1H, PhCH), 4.03 (t, J=9.3 Hz, 1H, H-3), 3.95 (d, J=1.7 Hz, H-
4’), 3.84 (dd, J=4.1, 11.1 Hz, 1H, H-6a), 3.77 (dd, J=1.8, 11.0 Hz, H-6b), 3.64-3.57 (m, 
2H, H-6’a, H-3), 3.52-3.48 (m, 2H, H-2, H-6’b), 3.44-3.39 (m, 3H, H-3’, H-2’, H-5), 3.37 (q, 
J=5.8 Hz, 1H, H-5’), 2.46 (br s, 1H, OH), 2.38 (br s, 1H, OH); 13C (100 MHz, CDCl3) d 
139.3 (aromatic), 138.7 (aromatic), 138.5 (aromatic), 138.4 (aromatic), 138.1 (aromatic), 
137.7 (aromatic), 128.7 (aromatic), 128.6 (aromatic), 128.5 (aromatic), 128.5 (aromatic), 
128.4 (aromatic), 128.2 (aromatic), 128.2 (aromatic), 128.1 (aromatic), 128.0 (aromatic), 
128.0 (aromatic), 127.9 (aromatic), 127.8 (aromatic), 127.7 (aromatic), 127.7 (aromatic), 
127.4 (aromatic), 102.7 (C-1’), 102.6 (C-1), 83.0 (C-3), 82.0 (C-2’), 76.7 (C-4), 75.4 
(PhCH2), 75.3 (C-5), 75.1 (PhCH2), 75.0 (PhCH2), 73.7 (PhCH2), 73.6 (C-3’), 73.4 
(PhCH2), 73.0 (PhCH2), 68.9 (C-4’), 68.8 (C-6’), 68.4 (C-6). LRMS calcd for [M+H]+ 883.41, 
found 883.79.  
 
 
(2R,3S,4S,5R,6R)-2-(acetoxymethyl)-6-(((2R,4aR,6R,7R,8R,8aS)-6-hydroxy-2-phen 
yl-7-(((2,2,2trichloroethoxy)carbonyl)amino)hexahydropyrano[3,2-d][1,3]dioxin-8-
yl)oxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (4.71). A solution of 4.59 (1.0 eq, 1.45 
g, 1.56 mmol) in 80% aqueous acetic acid (15 mL) was heated to 80 oC and stirred 5 H 
and 15 minutes. The reaction was diluted with water (40 mL) and extracted with EtOAc 
(4 x 15 mL) while solid NaHCO3 was added. The combined organics were washed with a 
saturated aqueous NaHCO3 solution (4 x 20 mL), brine (1 x 20 mL), dried (MgSO4), 
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filtered, and concentrated in vacuo to yield a white solid. The crude diol was dissolved in 
pyridine (16 mL) and acetic anhydride (2.5 eq, 0.37 mL, 3.9 mmol) and DMAP (cat.) were 
added. The reaction was stirred 1 H and 15 minutes then diluted with EtOAc (50 mL), 
washed with 2 N HCl (4 x 20 mL), brine (1 x 20 mL), dried (MgSO4), filtered, and 
concentrated in vacuo to yield a white foam. The crude diacetate was dissolved in pyridine 
(15 mL) and the resulting solution cooled to 0 oC. 70% HF in pyridine (8 mL) was added 
dropwise over 5 minutes. The reaction was stirred 1 H then allowed to warm to room 
temperature and stir an additional 5 H. The reaction was diluted with water (40 mL) and 
extracted with EtOAc (4 x 15 mL) while solid NaHCO3 was added. The combined organics 
were quenched with saturated NaHCO3 solution, washed with 2 N HCl (4 x 20 mL), brine 
(1 x 20 mL), dried (MgSO4), filtered, and concentrated in vacuo. The crude residue was 
purified via flash column chromatography (2:3 hexanes/EtOAc) to yield lactol 4.71 (0.94 
g, 1.2 mmol, 78% over 3 steps) (a/b 8:1) as a white foam: Rf 0.20 (1:1 hexanes/EtOAc); 
1H NMR (400 MHz, CDCl3) d (a anomer) 5.36 (m, 1H, NH), 5.35 (d, J=3.2 Hz, 1H, H-4’), 
5.25 (t, J=2.9 Hz, 1H, H-1), 5.05 (dd, J=7.8, 10.4 Hz, 1H, H-2’), 4.99 (t, J=8.8 Hz, H-4), 
4.92 (dd, J=3.4, 10.5 Hz, 1H, H-3’), 4.74 (s, 2H, Troc CH, Troc CH), 4.65 (d, J=7.8 Hz, H-
1’), 4.24-4.15 (m, 4H, H-6’a, H-5, H-6a, H-6b), 4.07-4.00 (m, 3H, H-3, H-6’b, H-2), 3.90 
(dd, J=7.0, 6.7 Hz, 1H, H-5’), 3.35 (d, J=3.0, 1H, OH), 2.14 (s, 3H, COCH3), 2.10 (s, 3H, 
COCH3), 2.07 (s, 3H, COCH3), 2.06 (s, 3H, COCH3), 2.06 (s, 3H, COCH3), 1.95 (s, 3H, 
COCH3); 13C (100 MHz, CDCl3) d (a anomer) 171.1 (COCH3), 170.6 (COCH3), 170.3 
(COCH3), 170.3 (COCH3), 169.8 (COCH3), 169.5 (COCH3), 154.1 (Troc CO), 100.7 (C-
1’), 95.3 (Troc CCl3), 92.1 (C-1), 75.4 (C-3), 74.9 (Troc CH2), 70.9 (C-3’), 70.6 (C-5’), 69.1 
(C-2’), 68.8 (C-4), 67.9 (C-5), 67.0 (C-4’), 62.5 (C-6), 61.0 (C-6’), 55.2 (C-2), 21.0 
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(COCH3), 20.9 (COCH3), 20.9 (COCH3), 20.8 (COCH3), 20.8 (COCH3), 20.7 (COCH3). 
HRMS (ESI) calcd for C27H36Cl3NO18 [M+Na]+ 790.0896, found 790.0905.  
 
 
(2R,3R,4S,5S,6R)-2-(((2R,3S,4R,5R,6R)-3-acetoxy-2-(acetoxymethyl)-6-(2,2,2-trichl 
oro-1-iminoethoxy)-5-(((2,2,2-trichloroethoxy)carbonyl)amino) tetrahydro-2H-
pyran-4-yl)oxy)-6-(acetoxymethyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (4.72). 
To a solution of 4.71 (1.0 eq, 0.30 g, 0.39 mmol) in CH2Cl2 (5.6 mL) was added potassium 
carbonate (3.0 eq, 1.6 g, 1.2 mmol) and trichloroacetonitrile (10 eq, 0.39 mL, 3.9 mmol) 
sequentially. The reaction was stirred 22 H then diluted with CH2Cl2, filtered through celite, 
and concentrated in vacuo. The crude residue was purified via flash column 
chromatography (1:1 hexanes/EtOAc) to yield a-trichloroacetimidate 4.72 (0.27 g, 0.30 
mmol, 77%) as a white foam: Rf 0.38 (1:1 hexanes/EtOAc); 1H (400 MHz, CDCl3) d 8.83 
(s, 1H, imidate NH), 6.31 (d, J=3.7 Hz, 1H, H-1), 5.37 (dd, J=0.8, 3.5 Hz, 1H, H-4’), 5.14-
5.05 (m, 3H, H-2’, H-4, NH), 4.96 (dd, J=3.4, 10.4 Hz, 1H, H-3’), 4.78 (d, J=12.0 Hz, 1H, 
Troc CH), 4.70 (d, J=7.5 Hz, 1H, H-1’), 4.69 (d, 12.2 Hz, 1H, Troc CH), 4.29 (td, J=3.8, 
10.1, 10.1 Hz, 1H, H-2), 4.23-4.17 (m, 2H, H-6’a, H-6a), 4.14-4.02 (m, 4H, H-6b, H-5, H-
3, H-6’b), 3.96 (t, J=6.7 Hz, 1H, H-5’), 2.15 (s, 3H, COCH3), 2.08 (s, 3H, COCH3), 2.07 (s, 
3H, COCH3), 2.06 (s, 3H, COCH3), 2.04 (s, 3H, COCH3), 1.96 (s, 3H, COCH3), 1.66 (s, 
H2O), 1.25 (m, grease), 0.06 (s, silicon grease); 13C (100 MHz, CDCl3) d 170.9 (COCH3), 
170.5 (COCH3), 170.2 (COCH3), 170.2 (COCH3), 169.5 (COCH3), 169.5 (COCH3), 160.4 
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(imidate CNH), 154.0 (Troc CO), 100.6 (C-1’), 95.2 (Troc CCl3), 90.9 (imidate CCl3), 75.8 
(C-3), 75.0 (Troc CH2), 70.9 (C-5’), 70.8 (C-3’), 70.3 (C-5), 69.3 (C-2’), 68.0 (C-4), 67.0 
(C-4’), 61.8 (C-6), 61.2 (C-6’), 54.7 (C-2), 20.9 (COCH3), 20.9 (COCH3), 20.8 (COCH3), 
20.8 (COCH3), 20.8 (COCH3), 20.7 (COCH3). HRMS (ESI) calcd for C29H36Cl6N2O18 
[M+Na]+ 932.9992, found 932.9962.  
 
 
 (2R,3R,4S,5R,6S)-5-(benzyloxy)-2-((benzyloxy)methyl)-4-hydroxy-6-(((2R,3R,4S,5R, 
6R)-4,5,6-tris(benzyloxy)-2-((benzyloxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)tetra 
hydro-2H-pyran-3-yl acetate (4.75).77, 89 To a solution of 4.53 (1.0 eq, 0.9 g, 1.0 mmol) 
in CH3CN (10 mL) was added trimethyl orthoacetate (3.0 eq, 0.38 mL, 3.0 mmol) and p-
toluenesulfonic acid (0.1 eq, 0.02 g, 0.1 mmol). The reaction was stirred 25 minutes then 
90% trifluoroacetic acid (0.36 mL) was added. The resulting solution was stirred 20 
minutes then diluted with water (15 mL) and extracted with EtOAc (4 x 5 mL). The 
combined organics were washed with a saturated NaHCO3 solution (2 x 7 mL), brine (1 
x 7 mL), dried (MgSO4), filtered, and concentrated in vacuo. The crude residue was 
purified via flash column chromatography (2:1 hexanes/EtOAc) to yield axial acetate 4.75 
(0.87 g, 0.94 mmol, 93%) as a white foam: Rf 0.32 (2:1 hexanes/EtOAc); 1H (600 MHz, 
CDCl3) d 7.34-7.13 (m, 30H, aromatic), 5.30 (d, J=3.2 Hz, 1H, H-4’), 4.93 (d, J=10.5 Hz, 
1H, PhCH), 4.91 (d, J=11.9 Hz, 1H, PhCH), 4.87 (d, J=10.9 Hz, 1H, PhCH), 4.76 (d, 
J=11.4 Hz, 1H, PhCH), 4.71 (d, J=10.6 Hz, 1H, PhCH), 4.69 (d, J=10.9 Hz, 1H, PhCH), 
4.63 (d, J=11.3 Hz, 1H, PhCH), 4.62 (d, J=12.1 Hz, 1H, PhCH), 4.59 (d, J=12.1 Hz, 1H, 
i. CH3C(OCH3)3
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PhCH), 4.45 (d, J=7.8 Hz, 1H, H-1), 4.44 (d, J=7.7 Hz, 1H, H-1’), 4.42 (d, J=11.4 Hz, 1H, 
PhCH), 4.41 (d, J=12.1 Hz, 1H, PhCH), 4.20 (d, J=12.0 Hz, 1H, PhCH), 3.99 (t, J=9.2 Hz, 
1H, H-4), 3.77 (dd, J=4.0, 11.0 Hz, 1H, H-6a), 3.71 (dd, J=1.2, 10.7 Hz, H-6b), 3.60 (dd, 
J=3.4, 9.6 Hz, 1H, H-3’), 3.53 (t, J=9.1 Hz, 1H, H-3), 3.48 (t, J=6.6 Hz, 1H, H-5’), 3.45 (dd, 
J=7.9, 8.9 Hz, 1H, H-2), 3.36 (dd, J=7.9, 9.4 Hz, 1H, H-2’), 3.33 (ddd, J=1.6, 3.8, 9.5 Hz, 
1H, H-5), 3.30 (d, J=6.7 Hz, 2H, H-6’a, H-6’b), 2.20 (br s, 1H, OH), 1.99 (s, 3H, COCH3), 
1.53 (s, H2O); 13C (100 MHz, CDCl3) d 171.1 (COCH3), 139.2 (aromatic), 138.7 (aromatic), 
128.4 (aromatic), 138.3 (aromatic), 138.1 (aromatic), 137.6 (aromatic), 128.6 (aromatic), 
128.5 (aromatic), 128.5 (aromatic), 128.4 (aromatic), 128.2 (aromatic), 128.1 (aromatic), 
128.0 (aromatic), 128.0 (aromatic), 127.9 (aromatic), 127.8 (aromatic), 127.8 (aromatic), 
127.8 (aromatic), 127.7 (aromatic), 127.5 (aromatic), 102.7 (C-1), 102.5 (C-1’), 82.9 (C-
3), 81.9 (C-2), 80.3 (C-2’), 76.5 (C-4), 75.4 (PhCH2), 75.2 (PhCH2), 75.2 (C-5), 73.6 
(PhCH2), 73.4 (PhCH2), 72.6 (C-3’), 72.1 (C-5’), 71.1 (PhCH2), 69.7 (C-4’), 68.3 (C-6), 
67.4 (C-6’), 20.9 (COCH3). LRMS calcd for C56H60O12 [M+NH4]+ 942.44, found 942.56. 
 
 
(2R,3R,4S,5S,6R)-2-(((2R,3S,4R,5R,6S)-3-acetoxy-6-(((2R,3S,4S,5R,6S)-3-acetoxy-
5-(benzyloxy)-2-((benzyloxy)methyl)-6-(((2R,3R,4S,5R,6R)-4,5,6-tris(benzyloxy)-2-
((benzyloxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)tetrahydro-2H-pyran-4-yl)oxy)-2-
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(acetoxymethyl)-5-(((2,2,2-trichloroethoxy)carbonyl)amino)tetrahydro-2H-pyran-4-
yl)oxy)-6-(acetoxymethyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (4.76). Donor 
4.72 (1.1 eq, 0.55 g, 0.60 mmol) and acceptor 4.75 (1.0 eq, 0.50 g, 0.54 mmol) were 
coevaporated with benzene (2 x 6 mL) and placed in a vacuum desiccator containing 
P2O5 overnight. The donor/acceptor mixture was dissolved in CH2Cl2 (18 mL) and the 
resulting solution was cannulated into a reaction flask containing 4Å powdered molecular 
sieves (1.1 g). The mixture was stirred under argon 1 H then cooled to -10 oC and TfOH 
(cat.) was added. The reaction was stirred 12 minutes then quenched with Et3N. The 
reaction was diluted with CH2Cl2, filtered through celite, dried (MgSO4), filtered, and 
concentrated in vacuo. The crude residue was purified via flash column chromatography 
(1:1 hexanes/EtOAc) to yield tetrasaccharide 4.76 (0.85 g, 0.51 mol, 94%) as a white 
foam: Rf 0.35 (1:1 hexanes/EtOAc); 1H (400 MHz, CDCl3) d 7.48-7.44 (m, 2H, aromatic), 
7.38-7.25 (m, 25H, aromatic), 7.23-7.16 (m, 3H, aromatic), 5.42 (d, J=3.6 Hz, 1H, H-4’), 
5.33 (d, J=3.0 Hz, H-4’’’), 5.01-4.82 (m, 7H, H-3’’’, H-2’’’, Troc CH, PhCH, PhCH, PhCH, 
PhCH), 4.77-4.69 (m, 5H, PhCH, PhCH, PhCH, H-1’’, H-4’’), 4.64 (d, J=12.3 Hz, 1H, 
PhCH), 4.61 (d, J=13.2 Hz, 1H, PhCH), 4.49-4.42 (m, 4H, PhCH, PhCH, H-1’, H-1), 4.32 
(d, J=12.1 Hz, 1H, Troc CH), 4.28 (d, J=11.8 Hz, PhCH), 4.23-4.14 (m, 4H, H-6’’’a, H-1’’’, 
H-6’’a, H-6’’b), 4.10-4.03 (m, 3H, H-6’’’b, H-4, NH), 3.81-3.77 (m, 2H, H-5’’’, H-6a), 3.71-
3.60 (m, 3H, H-5’’, H-3’, H-6b), 3.58-3.52 (m, 3H, H-5’, H-2’, H-3), 3.49-3.42 (m, 3H, H-
3’’, H-2’’, H-2), 3.36-3.31 (m, 3H, H-6a, H-6b, H-5), 2.13 (s, 3H, COCH3), 2.12 (s, 3H, 
COCH3), 2.07 (s, 3H, COCH3), 2.02 (s, 3H, COCH3), 1.99 (s, 3H, COCH3), 1.96 (s, 3H, 
COCH3), 1.95 (s, 3H, COCH3), 1.64 (s, H2O), 1.26 (m, grease); 13C (100 MHz, CDCl3) d 
171.0 (COCH3), 170.5 (COCH3), 170.3 (COCH3), 170.3 (COCH3), 169.8 (COCH3), 169.3 
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(COCH3), 169.3 (COCH3), 153.9 (Troc CO), 139.3 (aromatic), 139.1 (aromatic), 138.7 
(aromatic), 138.2 (aromatic), 138.1 (aromatic), 137.6 (aromatic), 128.9 (aromatic), 128.6 
(aromatic), 128.5 (aromatic), 128.4 (aromatic), 128.3 (aromatic), 128.2 (aromatic), 128.2 
(aromatic), 128.1 (aromatic), 128.0 (aromatic), 128.0 (aromatic), 127.9 (aromatic), 127.9 
(aromatic), 127.8 (aromatic), 127.7 (aromatic), 127.5 (aromatic), 126.9 (aromatic), 102.6 
(C-1), 102.0 (C-1’), 100.9 (C-1’’’), 100.7 (C-1’’), 95.6 (Troc CCl3), 82.8 (C-3), 81.9 (C-2’), 
81.7 (C-2), 77.2 (C-3’’), 76.7 (C-3’), 76.0 (C-4), 75.5 (PhCH2), 75.2 (PhCH2), 75.1 (C-5), 
74.6 (PhCH2), 74.3 (Troc CH2), 73.7 (PhCH2), 73.7 (PhCH2), 72.8 (C-5’), 71.7 (C-5’’), 71.0 
(PhCH2), 70.9 (C-3’’’), 70.5 (C-5’’’), 69.4 (C-4’), 69.4 (C-4’’), 68.8 (C-2’’’), 68.1 (C-6), 68.0 
(C-6’), 66.9 (C-4’’’), 62.5 (C-6’’), 61.1 (C-6’’’), 57.5 (C-2’’), 21.0 (COCH3), 21.0 (COCH3), 
20.8 (COCH3), 20.8 (COCH3), 20.8 (COCH3), 20.7 (COCH3), 20.7 (COCH3). HRMS (ESI) 
calcd for C83H94Cl3NO29 [M+Na]+ 1696.4875, found 1696.4839. 
 
 
(2R,4aR,6S,7R,8R,8aS)-2-phenyl-7-(((2,2,2-trichloroethoxy)carbonyl)amino)-6-((tri 
isopropylsilyl)oxy)hexahydropyrano[3,2-d][1,3]dioxin-8-yl 4-oxopentanoate (4.78). 
To a solution of 4.52 (1.0 eq, 1.45 g, 2.43 mmol) in CH2Cl2 (25 mL) cooled to 0 oC was 
added levulinic acid (3.0 eq, 0.746 mL, 7.29 mmol), Et3N (4.5 eq, 1.5 mL, 11 mmol), 
DMAP (cat.), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (3.0 eq, 1.46 g, 
7.29 mmol) sequentially. After 1 H, the reaction was allowed to warm to room temperature 
and stir an additional 20 H. The reaction was diluted with CH2Cl2 (50 mL), washed with 
water (3 x 20 mL), saturated aq. NaHCO3 solution (1 x 20 mL), brine (1 x 20 mL), dried 
O
NHTroc
HO OTIPS
O
OPh
4.52
Et3N, CH2Cl2
LevOH, EDC, DMAP
(63-77%)
O
NHTroc
LevO OTIPS
O
OPh
4.78
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(MgSO4), filtered, and concentrated in vacuo. The crude product was purified via flash 
column chromatography (4:5 hexanes/EtOAc) to yield levulinic ester 4.78 (1.31 g, 1.88 
mmol, 77%) as a white foam: Rf 0.35 (1:1 hexanes/EtOAc); 1H (400 MHz, CDCl3) d 7.46-
7.43 (m, 2H, aromatic), 7.37-7.33 (m, 3H, aromatic), 5.51 (s, 1H, benzylidene CH), 5.30 
(t, J=10.0 Hz, 1H, H-3), 4.73 (m, 2H, Troc CH, Troc CH), 4.93 (d, J=7.8 Hz, 1H, H-1), 4.30 
(dd, J=5.0, 10.5 Hz, 1H, H-6a), 3.80 (t, J=10.2 Hz, 1H, H-6b), 3.72 (t, J=9.4 Hz, 1H, H-4), 
3.67 (q, J=9.0 Hz, 1H, H-2), 3.50 (td, J=5.0, 9.8 Hz, H-5), 2.84-2.51 (m, 4H, Lev CH, Lev 
CH, Lev CH, Lev CH), 1,56 (s, H2O) 1.12-1.03 (m, 21H, TIPS); 13C (100 MHz, CDCl3) d 
206.2 (Lev CO), 172.8 (Lev COO), 154.3 (Troc CO), 137.1 (aromatic), 129.3 (aromatic), 
128.4 (aromatic), 126.4 (aromatic), 101.3 (benzylidene CH), 96.8 (C-1), 95.5 (Troc CCl3), 
79.0 (C-4), 74.9 (Troc CH2), 71.5 (C-3), 68.6 (C-6), 66.6 (C-5), 59.5 (C-2), 38.1 (Lev CH2), 
29.9 (Lev CH3), 28.1 (Lev CH2), 17.9 (TIPS), 17.8 (TIPS), 12.2 (TIPS). HRMS (ESI) calcd 
for C30H44Cl3NO9Si [M+Na]+ 718,1749, found 718.1725. 
 
 
((2R,3S,4R,5R,6S)-3-acetoxy-4-hydroxy-5-(((2,2,2-trichloroethoxy)carbonyl)amino)-
6-((triisopropylsilyl)oxy)tetrahydro-2H-pyran-2-yl)methyl acetate (4.77). A solution of 
4.78 (1.0 eq, 1.7 g, 2.4 mmol) in 80% aqueous acetic acid (20 mL) was heated to 80 oC 
and stirred 5 H. The reaction was diluted with water (40 mL) and extracted with EtOAc (4 
x 15 mL) while solid NaHCO3 was added. The combined organics were washed with a 
saturated aqueous NaHCO3 solution (5 x 20 mL), brine (1 x 20 mL), dried (MgSO4), 
filtered, and concentrated in vacuo to yield a white solid. The crude diol was dissolved in 
O
NHTroc
LevO OTIPS
O
OPh
4.78
3) NH2NH2·AcOH
    CH2Cl2/MeOH
1) 80% aq. AcOH, 80 oC
2) Ac2O, DMAP, pyr
(51-65%, 3 steps)
O
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pyridine and DMAP and acetic anhydride were added sequentially. The reaction was 
stirred 5.5 H then was diluted with EtOAc (50 mL), washed with 2 N HCl (5 x 20 mL), brine 
(1 x 20 mL), dried (MgSO4), filtered, and concentrated in vacuo to yield a dense, off-white 
solid. The crude diacetate was dissolved in a mixture of CH2Cl2 (24 mL) and MeOH (4.8 
mL) and hydrazine acetate was added. The reaction was stirred 7 H then was diluted with 
CH2Cl2 (50 mL), washed with water (3 x 20 mL), brine (1 x 20 mL), dried (MgSO4), filtered, 
and concentrated in vacuo. The crude product was purified via flash column 
chromatography (3:2 hexanes/EtOAc) to yield alcohol 4.77 (1.0 g, 1.7 mmol, 65% over 3 
steps) as a light, white solid: Rf  0.46 (1:1 hexanes/EtOAc) ; 1H (400 MHz, CDCl3) d 5.26 
(br s, 1H, NH), 4.88 (d, J=4.88 Hz, 1H, H-1), 4.88 (t, J=9.3 Hz, 1H, H-4), 4.69 (m, 2H, 
Troc CH, Troc CH), 4.16 (m, 2H, H-6a, H-6b), 3.95 (t, J=8.5 Hz, 1H, H-3), 3.66 (m, 1H, 
H-5), 3.34 (q, J=7.4, 7.4 Hz, H-2), 2.12 (s, 3H, COCH3), 2.05 (s, 3H, COCH3), 1.17-1.04 
(m, 21H, TIPS); 13C (100 MHz, CDCl3) d 170.9 (COCH3), 170.8 (COCH3), 154.9 (COCH3), 
95.4 (Troc CO), 95.3 (C-1), 75.0 (Troc CH2), 72.5 (C-3), 72.0 (C-5), 71.9 (C-4), 62.9 (C-
6), 61.4 (C-2), 21.0 (COCH3), 20.8 (COCH3), 18.0 (TIPS), 17.9 (TIPS), 12.3 (TIPS). 
HRMS (ESI) calcd for C22H38Cl3NO9Si [M+Na]+ 616.1279, found 616.1277. 
 
 
(2R,3R,4S,5S,6R)-2-(((2R,3S,4R,5R,6S)-3-acetoxy-2-(acetoxymethyl)-5-(((2,2,2-tri 
chloroethoxy)carbonyl)amino)-6-((triisopropylsilyl)oxy)tetrahydro-2H-pyran-4-yl) 
oxy)-6-(acetoxymethyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (4.79). Donor 4.18 
4.18
O
AcO
AcO
AcO
OAc
O
CCl3
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+ O
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HO OTIPS
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(71-78% α/β  1:7-2.1)
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(1.5 eq, 1.24 g, 2.52 mmol) and acceptor 4.77 (1.0 eq, 1.00 g, 1.68 mmol) were 
coevaporated with benzene (2 x 7 mL) and placed in a vacuum desiccator containing 
P2O5 overnight. The donor/acceptor mixture was dissolved in CH2Cl2 (17 mL) and the 
resulting solution was cannulated into a reaction flask containing 4Å powdered molecular 
sieves (1.5 g). The mixture was stirred under argon 1 H then cooled to -5 oC and TfOH 
(cat.) was added. The reaction was stirred 15 minutes then quenched with Et3N. The 
reaction was diluted with CH2Cl2, filtered through celite, dried (MgSO4), filtered, and 
concentrated in vacuo. The crude residue was purified via flash column chromatography 
(3:2 to 1:1 hexanes/EtOAc) to yield disaccharide 4.79 (1.20 g, 1.30 mmol, 78%) (a/b 1:2.1) 
as a white foam: Rf 0.60 (a), 0.40 (b) (1:1 hexanes/EtOAc); 1H (400 MHz, CDCl3) d (b 
anomer) 5.33 (dd, J=0.8, 3.5 Hz, 1H, H-4’), 5.11-5.05 (m, 2H, H-2’, NH), 4.96 (d, J=8.2 
Hz, 1H, H-1), 4.94-4.88 (m, 2H, H-3’, H-4), 4.71 (q, J=12.0 Hz, 2H, Troc CH, Troc CH), 
4.62 (d, J=7.8 Hz, 1H, H-1’), 4.22 (t, J=9.6 Hz, H-3), 4.19-4.04 (m, 4H, H-6a, H-6b, H-6a, 
H-6b), 3.85 (td, J=0.5, 6.8 Hz, 1H, H-5’), 3.68 (m, 1H, H-5), 3.33 (d, J=8.2, 10.2 Hz, 1H, 
H-2), 2.14 (s, 3H, COCH3), 2.08 (s, 3H, COCH3), 2.07 (s, 3H, COCH3), 2.06 (s, 3H, 
COCH3), 2.04 (s, 3H, COCH3), 1.96 (s, 3H, COCH3), 1.58 (s, H2O), 1.12-1.02 (m, 21 H, 
TIPS); 13C (100 MHz, CDCl3) d (b anomer) 170.8 (COCH3), 170.5 (COCH3), 170.3 
(COCH3), 170.2 (COCH3), 169.6 (COCH3), 169.5 (COCH3), 154.0 (Troc CO), 101.0 (C-
1’), 95.3 (Troc CCl3), 95.1 (C-1), 77.4 (C-3), 74.8 (Troc CH2), 71.8 (C-5), 71.0 (C-3’), 70.7 
(C-5’), 69.6 (C-4), 69.2 (C-2’), 67.0 (C-4’), 62.9 (C-6), 61.2 (C-6’), 60.5 (C-2), 21.0 
(COCH3), 21.0 (COCH3), 20.8 (COCH3), 20.8 (COCH3), 20.8 (COCH3), 20.7 (COCH3), 
17.9 (TIPS), 17.9 (TIPS), 14.3 (TIPS), 12.3 (TIPS). HRMS (ESI) calcd for 
C36H56Cl3NO18Si [M+Na]+ 946.2230, found 946.2243. 
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N-((2S,3R,4R,5S,6R)-2-(((2R,3S,4S,5R,6S)-3,5-dihydroxy-2-(hydroxymethyl)-6-(((2R, 
3S,4S,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)oxy) 
tetrahydro-2H-pyran-4-yl)oxy)-5-hydroxy-6-(hydroxymethyl)-4-(((2R,3R,4S,5R,6R)-
3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-
pyran-3-yl)acetamide (2.4). To a solution of 4.76 (1.0 eq, 0.10 g, 0.06 mmol) in THF (1.5 
mL) was added acetic acid (1.0 mL) and acetic anhydride (0.5 mL) followed by 10% Zn/Pb 
couple solid (0.24 g).87, 88 The resulting mixture was stirred 6 H and 15 min then was 
diluted with CH2Cl2 (20 mL), filtered through celite, washed with saturated NaHCO3 
solution (3 x 7 mL), brine (1 x 7 mL), dried (MgSO4), filtered, concentrated in vacuo, and 
coevaprotated with toluene to yield a white foam. The crude acetamide was suspended 
in MeOH (2 mL) and a concentrated NaOMe solution was added. The reaction was stirred 
2 H then neutralized with Dowex 50Wx8, filtered, and concentrated in vacuo to yield a 
white solid. The crude heptanol was suspended in MeOH (2 mL) and H2O (1 mL) and 
Pd(OH)2 was added (2.0 eq, 0.083 g, 0.119 mmol). The reaction was stirred under H2 for 
3 days then was diluted with H2O and MeOH, filtered through celite, concentrated in vacuo, 
coevaporated with toluene, and lyophilized to yield lacto-N-tetraose (2.4) (0.027 g, 0.038 
mmol, 64% over 3 steps) as a white solid: [a]20D +13.5 (c 0.26, DMSO); 1H and 13C 
spectroscopy data were in accordance with literature data.90 HRMS (TOF) calcd for 
C26H45NO21 [M+Na]+ 730.2382, found 730.3188.  
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Appendix A2:  
 
Spectra Relevant to Chapter 4 
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Figure A2.1. 1H NMR (400 MHz, CDCl3) and 13C (100 MHz, CDCl3) spectra of 4.56. 
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Figure A2.2. 1H NMR (400 MHz, MeOD) and 13C (100 MHz, MeOD) spectra of 4.57. 
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Figure A2.3. 1H NMR (400 MHz, CDCl3) and 13C (100 MHz, CDCl3) spectra of 4.52. 
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Figure A2.4. 1H NMR (400 MHz, CDCl3) and 13C (100 MHz, CDCl3) spectra of 4.59. 
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Figure A2.5. 1H NMR (400 MHz, CDCl3) and 13C (100 MHz, CDCl3) spectra of 4.60. 
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Figure A2.6. 1H NMR (400 MHz, CDCl3) and 13C (100 MHz, CDCl3) spectra of 4.63. 
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Figure A2.7. 1H NMR (400 MHz, CDCl3) and 13C (100 MHz, CDCl3) spectra of 4.54.  
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Figure A2.8. 1H NMR (400 MHz, CDCl3) and 13C (100 MHz, CDCl3) spectra of 4.64. 
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Figure A2.9. 1H NMR (400 MHz, CDCl3) and 13C (100 MHz, CDCl3) spectra of 4.66. 
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Figure A2.10. 1H NMR (400 MHz, CDCl3) and 13C (100 MHz, CDCl3) spectra of A1. 
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Figure A2.11. 1H NMR (400 MHz, CDCl3) and 13C (100 MHz, CDCl3) spectra of 
4.53. 
O
O
OH OBn
HO
OBn
O
OBn
OBn
BnO
4.53
OBn
 356 
 
 
 
 
 
 
Figure A2.12. 1H NMR (400 MHz, CDCl3) and 13C (100 MHz, CDCl3) spectra of 
4.71. 
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Figure A2.13. 1H NMR (400 MHz, CDCl3) and 13C (100 MHz, CDCl3) spectra of 
4.72. 
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Figure A2.14. 1H NMR (600 MHz, CDCl3) and 13C (100 MHz, CDCl3) spectra of 
4.75. 
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Figure A2.15. 1H NMR (400 MHz, CDCl3) and 13C (100 MHz, CDCl3) spectra of 
4.76. 
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Figure A2.16. 1H NMR (400 MHz, CDCl3) and 13C (100 MHz, CDCl3) spectra of 
4.78. 
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Figure A2.17. 1H NMR (400 MHz, CDCl3) and 13C (100 MHz, CDCl3) spectra of 
4.77. 
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Figure A2.18. 1H NMR (400 MHz, CDCl3) and 13C (150 MHz, CDCl3) spectra of  
4.79 (b). 
4.79 (β)
O
AcO
AcO
OAc
OAc
O
NHTroc
O OTIPS
AcO
OAc
 363 
 
 
 
 
 
 
 
 
 
 
Figure A2.19. 1H NMR (400 MHz, D2O) and 13C (100 MHz, D2O) spectra of (2.4). 
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Table A2.1. Synthetic and Natural Lacto-N-Tetraose (LNT, 2.4) in D2O 
 
 
 
 
Literature (400 MHz, D2O)a  Synthetic (400 MHz, D2O) 
dH dC  dH (multiplicity, J / Hz) dC 
5.128 176.13  5.23 (d, J=3.8 Hz) 174.9 
4.736 104.70  4.74 (d, J=8.4 Hz) 103.4 
4.732 104.15  4.74 (d, J=8.4 Hz) 102.8 
4.655 104.12  4.67 (d, J=8.0 Hz) 102.8 
4.436 103.73  4.45 (d, J=7.8 Hz) 102.5 
4.436 96.98  4.45 (d, J=7.8 Hz) 95.6 
4.146 93.04  4.16 (d, J=3.2 Hz) 91.7 
3.94 83.38  3.98-3.46 (m) 82.0 
3.92 83.21  3.29 (m) 81.9 
3.912 79.73  2.04 (s) 81.9 
3.898 79.63   78.3 
3.88 76.51   78.2 
3.87 76.44   76.2 
3.829 76.13   75.2 
3.816 76.02   75.1 
3.79 75.60   74.8 
3.76 75.50   74.7 
3.76 73.73   74.2 
3.732 72.64   73.7 
3.71 72.40   72.4 
3.70 71.94   71.3 
3.64 71.36   71.0 
3.64 71.27   70.6 
3.64 71.25   70.5 
3.636 69.78   70.0 
3.596 69.72   69.9 
3.595 69.58   69.9 
3.573 69.55   68.4 
3.56 62.28   68.3 
3.526 62.21   68.2 
3.477 61.80   68.2 
3.278 61.38   60.9 
2.025 61.26   60.9 
 55.95   60.4 
 23.54   60.0 
    59.8 
    54.6 
    22.1 
aStrecker, G.; Wieruszeski, J-M.; Michalski, J-C.; Montreuil, J., Glycoconj. J.  
1989, 6, 67-83. 
(2.4)
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CHAPTER 5 
 
Evaluation of the Antibacterial Properties of Homogeneous Human Milk 
Oligosaccharides Against Streptococcus agalactiae 
 
5.1 Introduction 
 In Chapter 3, our efforts to decipher the antibacterial properties of heterogenous 
HMOs were presented. Briefly, we demonstrated that HMOs possess antimicrobial and/or 
antibiofilm activity against several pathogens, and that the antimicrobial activity was a 
result of increased cell membrane permeability. As noted in the concluding remarks of 
Chapter 3, while these studies demonstrated the therapeutic utility of HMOs, they lacked 
descriptions of the activities of homogenous, single-entity compounds. Moreover, though 
an antimicrobial mechanism of action was identified, the specific HMO cellular targets 
remained unknown. To address these limitations, the work presented herein describes 
our efforts to identify the antibacterial activities of numerous single-entity HMOs against 
Streptococcus agalactiae (Group B Strep, GBS). These include neutral, non-fucosylated; 
neutral, fucosylated; and acidic, sialylated HMOs. Importantly, these studies were 
enabled by our synthetic efforts towards lacto-N-tetraose (LNT, 2.4) (detailed in Chapter 
4) as well as the donation of numerous HMOs by the Danish biotech company, Glycom. 
Additionally, this work was completed with the help of Harrison C. Thomas. 
 
5.2 Rationale for Inclusion of Acidic, Sialylated HMOs 
 As previously mentioned in section 2.2.3 of Chapter 2, HMOs can be divided into 
two groups: neutral and acidic. The acidic fraction accounts for around 10-20% of total 
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HMO concentration and is comprised of HMOs that feature one or more sialic acid 
residues (specifically N-acetylneuraminic acid, Neu5Ac) linked to a core carbohydrate 
chain via a2-3 and/or a2-6 glycosidic linkages.1, 2  
 In terms of biological activity, sialylated HMOs are of particular interest as a number 
of microbial pathogens, including Escherichia coli and Helicobacter pylori, are known to 
bind this class of oligosaccharide (see section 2.5.2 of Chapter 2).3, 4 Additionally, a study 
by Angeloni et al. provided evidence that sialylated HMOs may also directly modulate 
host intestinal epithelial cell responses to microbes5. In their study, Angeloni and co-
workers found that incubation of cultured human intestinal epithelial cell lines with 3’-
sialyllactose (3’-SL, 2.28) led to decreased sialylation levels of cell surface glycans due 
to lowered gene expression of numerous sialyltransferases. They further demonstrated 
that the decreased prevalence of sialylated cell surface glycans significantly lowered 
adhesion levels of enteropathogenic E. coli (EPEC).  
 It has also been shown that sialylated HMOs decrease the binding of leukocytes 
to endothelial cells.6 This is thought to be due to the similarity of some sialylated HMO 
structures to sialyl-Lewis X (sLex, 5.1), the binding determinant for selectins (Figure 5.1); 
leukocyte rolling, which is needed for the attachment of leukocytes to endothelial cells, is 
mediated by the interaction between selectins and their carbohydrate ligands. Moreover, 
it has been postulated that this decrease in leukocyte binding is one of the reasons for 
the lower rates of necrotizing enterocolitis (NEC) seen in breastfed infants compared to 
formula-fed infants. NEC, one of the most common and often fatal disorders in preterm 
infants, is a disease where the intestinal walls are invaded by bacteria which leads to 
infection and inflammation that can ultimately lead to destruction of the intestinal wall.7 As 
 367 
a result of this destruction, stool and bacteria can enter the bloodstream and cause life-
threatening infections. A link between NEC and sialylated HMOs was also detailed in a 
series of studies by the Bode and Chen laboratories. In these studies, it was shown that 
disiallacto-N-tetraose (DSLNT, 5.2; Figure 5.2) contributed to the ability of HMO extracts 
to prevent NEC in a neonatal rat model.8-10 Concurrently, a clinical cohort study found this 
molecule to be associated with a lower risk of NEC.11 Finally, sialylated HMOs are thought 
to be important for proper postnatal brain development as they serve as a rich source of 
sialic acid, which is an essential nutrient for brain development and cognition.12-14 
 
 
  
 
 
 
 While there exist studies such as those from the Angeloni, Bode, and Chen 
laboratories that describe the biological effects of single-entity sialylated HMOs, it remains 
that the benefits conferred by this class of carbohydrate are largely restricted to broad 
descriptions of the class as a whole.15 This lack of specificity is due in large part to the 
difficulties of obtaining single-entity HMOs through isolation from milk or through total 
synthesis. Indeed, we found this reality to be the case concerning the relationship 
between sialylated HMOs and GBS.  Despite the high structural similarity of numerous 
sialylated HMOs to GBS capsular polysaccharides (CPS) (see section 3.1.4 of chapter 3), 
prior to initiation of our studies, we were unable to find any reports detailing structure 
activity relationships for this class of HMO with regard to GBS antibacterial activity. There 
Figure 5.1. Structure of sialyl-Lewis X (sLeX, 5.1). 
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was, however, a report from the Bode laboratory detailing the antimicrobial activity of 
heterogenous sialylated HMO extracts against GBS. 
 In their report, Bode et al. found that the acidic, sialylated portion of HMO extracts 
dosed at 10 mg/mL was devoid of antimicrobial activity against a GBS serotype III strain 
over 6 h.16 Despite this seemingly bleak outlook for the potential of sialylated HMOs to 
protect against GBS, we hypothesized that the use of single-entity compounds might 
uncover activity that would otherwise be lost when evaluating a complex mixture. In a 
similar vein, we hypothesized that screening against multiple GBS strains of varying 
serotypes might reveal previously undisclosed activity. As a final note, the Bode study did 
not address any HMO antibiofilm activity. Thus, in addition to accessing sialylated HMOs 
for antimicrobial activity, we also elected to assay for antibiofilm activity. 
 The acidic, sialylated HMOs used in the present study are shown in Figure 5.2. 3’-
SL 2.28 and 6’-sialyllactose (6’-SL, 2.27) are sialylated lactose trisaccharides that have 
both been shown to possess anti-inflammatory and prebiotic activities.17 3’-SL tends to 
be slightly less abundant in human milk with concentrations typically ranging from 0.1 to 
0.3 g/L while 6’-SL is typically found between 0.3 and 0.5 g/L.18 The remaining three 
compounds are of increased complexity. Disialyllacto-N-tetraose (DSLNT, 5.2) is a 
hexasaccharide that, as previously mentioned, has been shown to protect against NEC. 
DSLNT has been reported to occur in human milk between 0.2 and 0.6 g/L.18 LS-
tetrasaccharide a (LST a, 3.1), like DSLNT, is a sialylated lacto-N-tetraose (LNT, 2.4) 
derivative, while LS-tetrasaccharide c (LST c, 5.3) is a sialylated lacto-N-neotetraose 
(LNnT, 2.5) derivative. LST a and c have previously been shown to play a role in the 
modulation of intestinal epithelial cell maturation.19 Additionally, it was recently shown that 
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sialyllacto-N-tetraose (corresponding to three structural isomers) could be consumed by 
the infant-associated commensal Bifidobacterium longum subsp. infantis.20 LST a is 
typically found in lower concentrations than LST c as these isomers have been reported 
to occur in human milk between 0.03 to 0.2 g/L and 0.1 to 0.6 g/L, respectively.18 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 5.2. Structures of sialylated HMOs evaluated for antibacterial activity against 
GBS. (A) Structures of sialylated lactose (Lac, 2.1) HMOs 3’-sialyllactose (3’-SL, 2.28) 
and 6’-sialyllactose (6’-SL, 2.27). (B) Structures of sialylated lacto-N-tetraose (LNT, 2.4) 
HMOs LS-tetrasaccharide a (LST a, 3.1) and disialyllacto-N-tetraose (DSLNT, 5.2). (C) 
Structure of sialylated lacto-N-neotetraose (LNnT, 2.5) HMO LS-tetrasaccharide c (LST 
c, 5.3). Lac, LNT, and LNnT core structures are in black, sialic acid residues are 
highlighted in green. 
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5.3 Antimicrobial and Antibiofilm Activities of Homogenous Acidic, Sialylated HMOs15 
 To determine whether any observed antibacterial effects were strain-specific, we 
elected to assay against two strains of GBS of differing serotypes. As detailed in section 
3.1.4 of Chapter 3, GBS strains can be classified into one of ten serotype classes (Ia, Ib, 
II-IX) based on the structure of their capsular polysaccharides (see Figure 3.2, section 
3.1.4 of chapter 3).21, 22 For the presently described study, we selected GBS strains 
GB590 and GB2 which are serotype III and Ia strains, respectively. GB590 was selected 
due to the global relevance of serotype III strains to GBS disease; serotype III strains 
account for the greatest number of GBS infections of any serotype.22 GB2 was selected 
for two reasons. One, GB2 is a serotype Ia strain, and this serotype is one of the five 
types that account for more than 85% of the global GBS disease burden.22 Two, in our 
earlier studies investigating the antibacterial activities of heterogenous HMO mixtures, 
GB2 was the strain most susceptible to HMO supplementation.21, 23 
 Antimicrobial activity was evaluated by monitoring GBS growth and viability over 
24 h. Growth was quantified spectrophotometrically at OD600 while viability was assessed 
by serial dilution of bacterial cultures and plating onto blood agar plates followed by 
enumeration of colony forming units (CFUs) the following day. GBS was grown in media 
alone (Todd-Hewitt Broth, THB) or THB supplemented with ca. 5 mg/mL HMO. This HMO 
concentration was selected for numerous reasons. First, in the course of our studies 
investigating the use of HMOs in antibiotic combination therapies (see section 3.3.1 of 
Chapter 3), we found the IC50 of heterogenous HMO extracts against GB590 and GB2 to 
be around 5 mg/mL.24 Thus, we hypothesized that dosing HMOs at this concentration 
would allow us to observe potential antibacterial activity without obliterating bacterial 
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growth. Furthermore, this concentration is physiologically relevant as HMOs are typically 
found in milk between 5 and 25 mg/mL. Finally, given the “irreplaceable” nature of the 
HMOs evaluated for this study, testing at the low end of physiological concentration 
enabled a thorough evaluation of antibacterial activity. 
 In addition to the five sialylated HMOs shown in Figure 5.2, the core carbohydrate 
structures lactose, LNT, and LNnT were included in the present evaluation. As previously 
mentioned, lactose serves as the core structure for 3’-SL and 6’-SL, LNT serves as the 
core structure for LST a and DSLNT, and LNnT serves as the core structure for LST c. 
Thus, inclusion of these neutral structures allowed for determination of whether any 
observed antibacterial activity of the sialylated HMOs was in fact contingent on the 
presence of sialic acid. Finally, as multiple laboratories including our own have found that 
HMO mixtures possess stronger antimicrobial activity than single HMOs, we also elected 
to assay against an HMO mixture composed of whole HMO extracts from multiple donor 
samples.10 This allowed for evaluation of whether any single compound was more 
effective than a heterogeneous HMO mixture. 
 Against both GB590 and GB2, the HMO mixture proved to be the most effective at 
reducing bacterial growth and viability (Figures 5.3 and 5.4). Compared to bacteria grown 
in media alone, the mixture was able to reduce GB590 growth by up to 99% and viability 
by up to 38% (Figure 5.3). Against GB2, growth reductions reached as high as 96% while 
viability was reduced by upwards of 36% (Figure 5.4). While impressive in its magnitude, 
this strong activity was not observed over the entire 24 h time frame. Indeed, by 24 h, 
bacterial growth had begun to recover; at 24 h, growth had rebounded to around 70% that 
of bacteria grown in media alone. This result was, however, in agreement with previous 
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findings from both our laboratory and the Bode laboratory that HMOs serve as 
bacteriostatic rather than bactericidal agents against GBS when they are dosed at the low 
end of physiological concentration.16, 23-25 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 5.3. Effects of homogenous and heterogenous HMOs dosed at ca. 5 mg/mL on 
the growth and viability of GB590 in Todd-Hewitt Broth. (A) OD600 readings were taken at 
0, 2, 4, 6, 8, and 24 h. Mean OD600 for each HMO source and time point is indicated by 
the respective symbols. (B) Enumeration of CFU/mL was performed at 0, 2, 4, 6, 8, and 
24 h corresponding to the OD values graphed in (A). Mean log10CFU/mL for each HMO 
source and time point is indicated by the respective symbols. Data displayed represent 
the mean OD600 or log10CFU/mL ± SEM of at least three independent experiments, each 
with 3 technical replicates. **** represents p < 0.0001 by 2-way ANOVA with posthoc 
Dunnett’s multiple comparison test comparing the growth and viability of GB590 in each 
HMO supplementation condition to the growth and viability of GB590 in media alone.  
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Figure 5.4. Effects of homogenous and heterogenous HMOs dosed at ca. 5 mg/mL on 
the growth and viability of GB2 in Todd-Hewitt Broth. (A) OD600 readings were taken at 0, 
2, 4, 6, 8, and 24 h. Mean OD600 for each HMO source and time point is indicated by the 
respective symbols. (B) Enumeration of CFU/mL was performed at 0, 2, 4, 6, 8, and 24 h 
corresponding to the OD values graphed in (A). Mean log10CFU/mL for each HMO source 
and time point is indicated by the respective symbols. Data displayed represent the mean 
OD600 or log10CFU/mL ± SEM of at least three independent experiments, each with 3 
technical replicates. **** represents p < 0.0001 by two-way ANOVA with posthoc 
Dunnett’s multiple comparison test comparing the growth and viability of GBS in each 
HMO supplementation condition to the growth and viability of GBS in media alone. 
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 Another notable finding was the difference in activity observed for LST a and 
DSLNT compared to their core neutral structure LNT as well as the difference between 
LST c and its core neutral structure LNnT (Figures 5.3 and 5.4). For the LNT-derived 
HMOs, as a general trend, LST a and DSLNT proved more effective at reducing growth 
and viability for both GB590 and GB2 than LNT. This trend was particularly pronounced 
for GB2. Against GB2, LNT did not significantly decrease growth or viability at any time 
point while LST a and DSLNT significantly reduced both growth and viability over several 
hours. Similarly, LST c was significantly more effective at reducing GB2 growth and 
viability than LNnT; LNnT did not reduce GB2 growth or viability at any point during the 
24 h time frame. However, a different trend was seen against GB590 for LNnT and LST 
c. Against this strain, LNnT significantly decreased growth over several hours while LST 
c failed to significantly decrease GB590 growth at any time point. Interestingly, LNnT and 
its monosialylated derivative did cause comparable decreases in GB590 viability. Taken 
together, these results demonstrate that the sialic acid residue(s) of LST a, DSLNT, and 
LST c are indeed largely important for antimicrobial activity.  
 In addition to being generally more effective antimicrobial agents than their 
respective neutral core counterparts, LST a, DSLNT, and LST c proved much more 
effective than the monosialylated lactose-derivative 3’-SL and 6’-SL (Figures 5.3 and 5.4). 
Aside from 3’-SL and 6’-SL significantly reducing GB590 growth at 6 h, neither of these 
compounds showed any antimicrobial activity against either GBS strain. In fact, both 3’-
SL and 6’-SL were found to significantly increase GB590 viability by 8 h. Importantly, we 
hypothesize that this lack of antimicrobial activity seen for 3’-SL and 6’-SL might be 
responsible for the lack of activity observed by Bode and co-workers for the acidic fraction 
 375 
of HMOs against a serotype III strain.16 Given the results of the presently described study, 
it is possible that LST a, DSLNT, and LST c, which are strongly antimicrobial, did not 
constitute large enough portions of the acidic fraction to significantly alter bacterial growth 
in the original Bode study. This possibility is made more likely if 3’-SL and 6’-SL, which 
are largely devoid of antimicrobial activity, constituted a large portion of the acidic HMO 
fraction.  
 Notably, our findings represent the first report of single-entity sialylated HMOs 
possessing antimicrobial activity against GBS. Moreover, we showed that this 
antimicrobial activity was not limited to a single strain. Finally, the findings disclosed 
herein support our original hypothesis that testing single-entity sialylated compounds can 
uncover activity that would otherwise be lost when evaluating a complex mixture.  
 As a final point of study, we investigated the effects of single-entity HMO 
supplementation on GBS biofilm production (Figure 5.5). Biofilm production was 
assessed after 24 h of growth using the plate-based biofilm assay previously introduced 
in section 3.2.2 of Chapter 3. Again, this assay allows for quantification of bacterial growth 
via spectrophotometric reading at OD600 followed by crystal violet staining of adherent 
bacteria and subsequent spectrophotometric reading at OD560 to quantify biofilm 
production. As before, to account for any accompanying antimicrobial activity, results are 
expressed as a ratio of biofilm produced to the number of bacterial cells present (biomass).  
 Of the compounds tested, LNT, LST a, and LNnT were the only compounds found 
to significantly alter bacterial biofilm production (Figure 5.5). Against GB590, LNT and 
LNnT both increased biofilm production. Against GB2, LST a increased production while 
LNT decreased production. 
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Fig. 5.5 Effects of homogeneous HMOs dosed at ca. 5 mg/mL on GBS biofilm production 
after 24 h of growth in Todd-Hewitt Broth. (A) Biofilm production, denoted by the ratio of 
biofilm/biomass (OD560/OD600), by GB590 in the presence of homogeneous HMOs 
relative to biofilm production in media alone. Data displayed represent the relative mean 
biofilm/biomass ratio ± SEM of at least three independent experiments, each with 3 
technical replicates, wherein biofilm production of GB590 in media alone is assigned a 
value of 100%. ** represents p = 0.0020 by one-way ANOVA, F = 3.536 with posthoc 
Dunnett’s multiple comparison test comparing biofilm production of GB590 in each HMO 
supplementation condition to biofilm production of GB590 in media alone.  (B) Biofilm 
production, denoted by the ratio of biofilm/biomass (OD560/OD600), by GB2 in the 
presence of homogeneous HMOs relative to biofilm production in media alone. Data 
displayed represent the relative mean biofilm/biomass ratio ± SEM of at least three 
independent experiments, each with 3 technical replicates, wherein biofilm production of 
GB2 in media alone is assigned a value of 100%. **** represents p < 0.0001 by one-way 
ANOVA, F = 4.955 with posthoc Dunnett’s multiple comparison test comparing biofilm 
production of GB2 in each HMO supplementation condition to biofilm production of GB2 
in media alone. Mean GBS biofilm production levels in media alone are marked with a 
dotted line.  
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 The promotion of biofilm production by LST a-supplementation was not wholly 
unexpected. Biofilm production, as detailed in section 3.1.4 of Chapter 3, is a well-known 
and common strategy used by bacterial pathogens to evade the action of antimicrobial 
agents, like antibiotics. Indeed, the ESKAPE pathogens (first discussed in section 1.4 of 
Chapter 1), which are notorious for their abilities to resist antimicrobial action, are also 
prolific biofilm producers.26, 27 Thus, it is possible that when challenged by a strong 
antimicrobial agent like LST a, GBS increases biofilm production in an attempt to protect 
itself against antimicrobial action. This line of reasoning could also be used to explain the 
patterns of altered biofilm production observed for LNT and LNnT. It remains unclear, 
however, why LST c and DSLNT, both of which showcased stronger antimicrobial activity 
than LNT, did not significantly increase biofilm formation. 
 
5.4 Rationale for Inclusion of Neutral, Fucosylated and Non-Fucosylated HMOs 
 The neutral HMO fraction comprises around 80-90% of total HMO concentration. 
Moreover, over half of neutral HMOs are fucosylated.1, 28 As detailed previously in section 
2.5.2 of Chapter 2, several neutral fucosylated HMOs are well-known for their ability to 
protect infants from pathogenic colonization.29 Briefly, fucosylated HMOs share structural 
homology with host epithelial cell surface glycans and thus can serve as soluble receptor 
analogs that compete for bacterial binding with intestinal mucosa (see Figure 2.18 in 
section 2.5.2 of chapter 2). For example, 2’-fucosyllactose (2’-FL, 2.8) inhibits the binding 
of Campylobacter jejuni to intestinal cells and the binding of noroviruses to histo-blood 
group antigens (HBGAs).30, 31 2’-FL as well as 3-fucosyllactose (3’-FL, 2.9) inhibit 
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adhesion of Pseudomonas aeruginosa to epithelial cells.32 Furthermore, 3-FL and 
difucosyllactose (DFL, 2.12) inhibit the adhesion of Escherichia coli to epithelial cells.33, 34 
 Neutral HMOs, both fucosylated and non-fucosylated, have also been previously 
shown by the Le Doare and Bode laboratories to protect against GBS infection (briefly 
introduced in section 3.1.6 of chapter 3).16, 35 Using both in vivo and in vitro experiments, 
Le Doare and co-workers found that the presence of lacto-N-difucohexaose I (LNDFH I, 
2.26; Figure 5.6) correlated to reduced GBS growth; the presence of HMOs like LNDFH 
I and 2’-FL in various milk samples was determined using 1H NMR spectroscopy.35 While 
this study supports the protective effect of fucosylated HMOs against GBS, no evaluations 
were performed using single compounds, and the concentrations of individual HMOs in 
the milk extracts that were used were known. Indeed, the authors were aware of these 
and other limitations of their report and thus expressed the need for further studies not 
only to validate their findings but also to more clearly define the HMOs involved in 
protecting against GBS.  
 In contrast to the Le Doare study, Bode and co-workers assayed both HMO 
mixtures and several single-entity neutral, fucosylated and neutral, non-fucosylated 
HMOs against GBS.16 Initial screens showed that the neutral HMO portion of HMO 
extracts significantly slowed the growth of serotype III, Ia, and V GBS strains over 6 h. In 
an attempt to identity the HMO(s) responsible for this activity, Bode et al. next assayed 
the following HMOs for activity against GBS (serotype not specified): lacto-N-tetraose 
(LNT, 2.4), lacto-N-neotetraose (LNnT, 2.5), lacto-N-neohexaose (LNnH, 2.14), lacto-N-
fucopentaose I (LNFP I, 2.10), lacto-N-difucohexaose II (LNDFH II, 5.4), lacto-N-
neooctaose (LNnO, 5.5), lacto-N-neodifucohexaose (LNnDFH, 5.6), lacto-N-
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neofucopentaose (LNnFP, 5.7), and lacto-N-fucopentaose V (LNFP V, 5.8) (Figures 5.6 
and 5.7). Treatment with LNT and LNFP I dosed at 5 mg/mL resulted in significantly 
reduced GBS growth at 2 h. Once again, while this study provided evidence for the 
protective effects of neutral HMOs, it was limited in its scope. For example, bacterial 
growth was only evaluated after a very short growth period (2-6 h), the lone GBS serotype 
used for single-compound evaluation was not specified, and no fucosylated lactose-
derived HMOs were tested for activity despite their prevalence in milk.  
 
Figure 5.6. Structures of neutral HMOs previously assayed for antimicrobial activity 
against GBS. HMO core structures are in black, fucose residues are highlighted in red, 
non-fucosylated elongations of HMO core structures are highlighted in purple. 
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Figure 5.7. Structures of neutral HMOs assayed for antibacterial activity against GBS. (A) 
(B) Structures of elongated lactose-derived HMOs 2’-fucosyllactose (2’-FL, 2.8), 3-
fucosyllactose (3-FL, 2.9), difucosyllactose (DFL, 2.12), and lacto-N-triose II (LNT II, 4.51). 
(B) Structures of lacto-N-tetraose (LNT, 2.4) and fucosylated LNT-derived HMOs lacto-N-
fucopentaose I (LNFP I, 2.10),  and lacto-N-fucopentaose II (LNFP II, 2.11). (C)  Structures 
of elongated lacto-N-neotetraose (LNnT, 2.5) and LNnT-derived HMOs lacto-N-
fucopentaose III (LNFP III, 2.13), lacto-N-neohexaose (LNnH, 2.14), and para-lacto-N-
neohexaose (para-LNnH, 5.9),  HMO core structures are in black. Fucose residues are 
highlighted in red. Non-fucosylated elongations of core structures are highlighted in purple. 
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 To expand on the findings of the Le Doare and Bode laboratories and to address 
some limitations of their respective studies, we elected to screen a variety of neutral 
fucosylated and non-fucosylated HMOs, including several fucosylated-lactose derivatives, 
against two GBS strains (Figure 5.7). We hypothesized that increasing the time frame of 
the activity screens would provide a more comprehensive and useful account of HMO-
mediated protection against GBS. Thus, growth and viability were monitored over 24 h. 
Finally, as HMO antibiofilm activity was not addressed in any prior study, we also elected 
to evaluate GBS biofilm production when grown in the presence of the various single-
entity HMOs. 
 
5.5 Antimicrobial and Antibiofilm Activities of Homogenous Neutral, Fucosylated and Non-
Fucosylated HMOs36 
 Analogous to our studies with sialylated single-entity HMOs, for the present study, 
we assayed the neutral HMOs shown in Figure 5.7 for antibacterial activity against GBS 
strains GB590 and GB2; as before, HMOs were dosed at ca. 5 mg/mL (see section 5.3 
for further explanation). Once again, antimicrobial activity was assessed by examining 
GBS growth and viability in THB over 24 h, while antibiofilm activity was assessed at 24 
h of growth (see section 5.3 for more detail).  
 The antimicrobial activities of HMOs against GB590, as determined by changes in 
GBS growth and viability compared to GBS grown in media alone, are shown in Figures 
5.8 and 5.9. As was observed with the sialylated HMOs, while numerous neutral single-
entity HMOs were found to significantly reduce bacterial growth and viability, no single 
compound had as profound an effect as the heterogenous HMO mixture. As previously 
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described (see section 5.3), the mixture decreased GB590 growth by over 80% for the 
entirety of the first 8 h and significantly reduced viability for the first 8 h with reductions 
reaching almost 40%.  
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Figure 5.8. Effects of single-entity, neutral HMOs dosed at ca. 5 mg/mL on the growth of 
GB590 in Todd-Hewitt Broth. Growth was measured via OD600 readings taken at 0, 2, 4, 
6, 8, and 24 h. Mean OD600 for each HMO source and time point is indicated by the 
respective symbols. (A) Growth of GB590 (OD600) in the presence of neutral, fucosylated 
HMOs and an HMO mixture. (B) Growth of GB590 (OD600) in the presence of neutral, 
nonfucosylated HMOs, lactose, and an HMO mixture. Data displayed represent the mean 
OD600 ± SEM of at least three independent experiments, each with three technical 
replicates. **** represents p < 0.0001 by two-way ANOVA with posthoc Dunnett’s multiple 
comparison test comparing the growth and viability of GBS in each HMO supplementation 
condition to the growth and viability of GBS in media alone. 
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Figure 5.9. Effects of single-entity, neutral HMOs dosed at ca. 5 mg/mL on the viability of 
GB590 in Todd-Hewitt Broth. Viability was assessed via enumeration of CFU/mL 
performed at 0, 2, 4, 6, 8, and 24 h. Log10CFU/mL for each HMO source and time point is 
indicated by the respective symbols. (A) Viability of GB590 (CFU/mL) corresponding to 
the OD values graphed in Figure 5.8A. (B) Viability of GB590 (CFU/mL) corresponding to 
the OD values graphed in Figure 5.8B. Data displayed represent the mean OD600 or 
log10CFU/mL ± SEM of at least three independent experiments, each with three technical 
replicates. **** represents p < 0.0001 by two-way ANOVA with posthoc Dunnett’s multiple 
comparison test comparing the growth and viability of GBS in each HMO supplementation 
condition to the growth and viability of GBS in media alone. 
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 For individual compounds, the presence or absence of fucose on a molecule was 
not a predictor of antimicrobial activity against GB590. For example, LNFP II and III 
displayed similar levels and patterns of growth and viability depressions as their 
nonfucosylated counterparts LNT and LNnT, respectively (Figures 5.8 and 5.9). Likewise, 
aside from significant growth reductions at 6 h, 2’-FL and 3-FL showed no more 
antimicrobial activity than lactose (which was inactive). Furthermore, the nonfucosylated 
HMOs LNT II and LNnH showed fairly similar levels of antimicrobial activity to LNFP II 
and LNFP III. In fact, these nonfucosylated compounds tended to suppress growth to a 
greater extent on average than LNFP II and III.  
 Although the absence of fucose did not correlate to lessened antimicrobial activity, 
the location and number of fucose residues did appear to have an effect. For instance, 
while LNFP II significantly reduced GB590 growth between 6 and 24 h, LNFP I did not 
significantly reduce growth at any point in the 24 h time frame (Figure 5.8); LNFP I and 
LNFP II are each monofucosylated LNT derivatives that differ only in the location of the 
fucose residue (see Figure 5.7). Interestingly, despite not significantly decreasing growth, 
LNFP I treatment did significantly reduce viability between 2 and 24 h with reductions 
reaching as high as 30% (Figure 5.9). Additionally, it was the only HMO source, including 
the HMO mixture, to significantly decrease viability at 24 h. Conversely, LNFP II only 
significantly decreased viability between 2 and 6 h. It is important to note, however, that 
between 2 and 6 h, both fucosylated LNT derivatives showed comparable viability 
reductions. 
 Comparison of the effects of DFL on GB590 growth and viability with those of 2’-
FL and 3-FL further highlighted the importance of location and number of fucose residues. 
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As mentioned, aside from significant growth reductions at 6 h, 2’-FL and 3-FL were devoid 
of antimicrobial activity. DFL on the other hand significantly reduced growth between 4 
and 24 h and significantly reduced viability at 2 and 6 h; growth reductions ranged from 
around 30-50%, while viability reductions were around 20% (Figures 5.8 and 5.9). As 
shown in Figure 5.7, DFL incorporates the functional aspects of both 2’-FL and 3-FL. That 
is, DFL features a1-2-linked fucose residues at both the C2’ and C3 positions of lactose. 
Based on these results, it appears as though both fucose residues are necessary for 
antimicrobial activity of fucosylated lactose derivatives against GB590. 
 For the activities of non-fucosylated HMOs against GB590, a few notable trends 
emerged. First, LNT and LNnT, structural isomers differing only by the glycosidic linkage 
between the terminal Gal and subterminal GlcNAc residues (see Figure 5.7), had fairly 
similar levels and patterns of antimicrobial activity (Figures 5.8 and 5.9). Conversely, 
LNnH and para-LNnH, structural isomers differing only by the location of one LacNAc (N-
acetyllactosamine) unit (see Figure 5.7), did showcase noticeable differences in 
antimicrobial activity. Although neither compound was able to significantly reduce viability 
past 4 h, LNnH did significantly reduce growth between 4 and 24 h, while para-LNnH 
failed to significantly reduce growth at any point. 
 Moving from GB590, the antimicrobial activities of HMOs against GB2 are shown 
in Figures 5.10 and 5.11. The HMO mixture was again the most operative antimicrobial 
agent against GB2. As first described in section 5.3, treatment with the HMO mixture 
resulted in GB2 growth and viability reductions of up to 95% and 36%, respectively. As 
for the specific effects of single-entity compounds, as expected based on previous work, 
the effects of homogenous HMOs were indeed found to be strain-specific.   
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Figure 5.10. Effects of single-entity, neutral HMOs dosed at ca. 5 mg/mL on the growth 
of GB2 in Todd-Hewitt Broth. Growth was measured via OD600 readings taken at 0, 2, 4, 
6, 8, and 24 h. Mean OD600 for each HMO source and time point is indicated by the 
respective symbols. (A) Growth of GB2 (OD600) in the presence of neutral, fucosylated 
HMOs and an HMO mixture. (B) Growth of GB2 (OD600) in the presence of neutral, 
nonfucosylated HMOs, lactose, and an HMO mixture. Data displayed represent the mean 
OD600 ± SEM of at least three independent experiments, each with three technical 
replicates. **** represents p < 0.0001 by two-way ANOVA with posthoc Dunnett’s multiple 
comparison test comparing the growth and viability of GBS in each HMO supplementation 
condition to the growth and viability of GBS in media alone. 
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 Although LNT and LNnT significantly reduced GB590 growth and viability at 
several time points, neither of these compounds had any effect on the growth or viability 
of GB2 (Figures 5.10 and 5.11). Similarly, LNFP I, II, and III all saw reduced antimicrobial 
Figure 5.11. Effects of single-entity, neutral HMOs dosed at ca. 5 mg/mL on the viability 
of GB2 in Todd-Hewitt Broth. Viability was assessed via enumeration of CFU/mL 
performed at 0, 2, 4, 6, 8, and 24 h. Log10CFU/mL for each HMO source and time point is 
indicated by the respective symbols. (A) Viability of GB2 (CFU/mL) corresponding to the 
OD values graphed in Figure 5.10A. (B) Viability of GB2 (CFU/mL) corresponding to the 
OD values graphed in Figure 5.10B. Data displayed represent the mean OD600 or 
log10CFU/mL ± SEM of at least three independent experiments, each with three technical 
replicates.  **** represents p < 0.0001 by two-way ANOVA with posthoc Dunnett’s multiple 
comparison test comparing the growth and viability of GBS in each HMO supplementation 
condition to the growth and viability of GBS in media alone. 
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activity against GB2. In fact, generally speaking, GB2 was found to be less susceptible to 
individual HMO supplementation than GB590. Indeed, LNT II and LNnH were the only 
single compounds to significantly reduce growth during the 24 h window. Interestingly, 
LNFP III was even found to significantly increase growth from 6 to 8 h. Impressively and 
uniquely, LNnH decreased growth from 4 to 24 h with reductions ranging on average 
around 20-50%. 
 In contrast to the minimal effect on GB2 growth, numerous individual HMOs did 
significantly reduce GB2 viability (Figure 5.11). As with growth, LNnH was the most 
effective at reducing cellular viability. LNnH decreased GB2 viability by around 15% over 
the entire 24 h period. Aside from 3-FL, all fucosylated compounds significantly reduced 
viability over several hours. Additionally, while LNT and LNnT did not reduce viability at 
any point, LNT II, LNnH, and para-LNnH did significantly reduce cellular viability over 
several hours. Although numerous compounds significantly decreased viability, it is 
important to note that the magnitudes of these reductions were universally smaller than 
those observed for GB590. This trend also held true for the magnitudes of growth 
reductions seen for the two strains.  
 Comparison of the antimicrobial activities of lactose, LNT, and LNnT against GB2 
with their respective fucosylated derivatives showed that fucose generally appeared to 
increase antimicrobial activity. However, in some cases, such as with LNFP III, 
improvements in antimicrobial activity were minimal. Furthermore, it is notable that LNT 
II, a lactose-derived HMO lacking a fucose residue, significantly reduced GB2 growth and 
viability. Nevertheless, despite the general significance of fucose, it is not clear what 
effects fucose location and number of residues have on antimicrobial activity.  
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Figure 5.12. Effects of single-entity, neutral HMOs dosed at ca. 5 mg/mL on GBS biofilm 
production after 24 h of growth in Todd-Hewitt Broth. (A) Biofilm production, denoted by 
the ratio of biofilm/biomass (OD560/OD600), by GB590 in the presence of single-entity 
HMOs relative to biofilm production in media alone. Data displayed represent the relative 
mean biofilm/biomass ratio ± SEM of at least three independent experiments, each with 
three technical replicates, wherein biofilm production of GB590 in media alone is assigned 
a value of 100%. **** represents p < 0.0001 by one-way ANOVA, F = 9.811 with posthoc 
Dunnett’s multiple comparison test comparing biofilm production of GB590 in each HMO 
supplementation condition to biofilm production of GB590 in media alone.  (B) Biofilm 
production, denoted by the ratio of biofilm/biomass (OD560/OD600), by GB2 in the presence 
of homogeneous HMOs relative to biofilm production in media alone. Data displayed 
represent the relative mean biofilm/biomass ratio ± SEM of at least three independent 
experiments, each with three technical replicates, wherein biofilm production of GB2 in 
media alone is assigned a value of 100%. ** represents p < 0.005 by one-way ANOVA, F 
= 2.527 with posthoc Dunnett’s multiple comparison test comparing biofilm production of 
GB2 in each HMO supplementation condition to biofilm production of GB2 in media alone. 
Mean GBS biofilm production levels in media alone are marked with a dotted line.  
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 As a final evaluation of antibacterial activity, we evaluated the effects of individual 
neutral HMOs on GBS biofilm production (Figure 5.12). As detailed in section 5.3, 
antibiofilm activity was evaluated at 24 h using a plate-based assay that enables 
quantification of bacterial growth and biofilm production. For the neutral HMOs tested, no 
compound was found to significantly decrease biofilm formation for either GBS strain. 
Conversely, DFL, LNnT, LNT II, and LNnH significantly increased biofilm formation in 
GB590. Notably, these compounds also showcased some of the largest and most 
prolonged growth repressions. Given this result, we once again hypothesize that when 
challenged by strong antimicrobial agents, GBS increases biofilm production in order to 
evade antimicrobial action. 
 
5.6 Summary of Homogenous HMO Evaluation Results37 
 A summary of the antimicrobial and anti-biofilm activities of all single-entity HMOs 
tested is provided in Table 5.1 (see Appendix A3 for more detail). While varying levels of 
activity were observed for the compounds, several general trends emerged. First and 
foremost, while numerous single compounds were potent antimicrobials, overall, no 
single compound was as effective of an antimicrobial as the heterogenous HMO mixture. 
Second, as was observed in previous studies using HMO mixtures, we found that different 
GBS strains had different susceptibilities to single-entity HMO-supplementation, i.e. HMO 
antimicrobial activity is strain-dependent. Overall, GB590 appeared to be more 
susceptible to treatment with single compounds, both neutral and acidic, than GB2.  
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 S. agalactiae GB590 S. agalactiae GB2 
Human Milk 
Oligosaccharide 
Average 
Growth 
Reductionb 
Average 
Viability 
Reductionb 
Average 
Biofilm 
Reductionc 
Average 
Growth 
Reductionb 
Average 
Viability 
Reductionb 
Average 
Biofilm 
Reductionc 
Lactose (Lac) 3% 0% 0% 0% 2% 0% 
2’-Fucosyllactose (2’-FL) 8% 0% 0% 9% 9% 0% 
3-Fucosyllactose (3-FL) 15% 0% 0% 0% 4% 0% 
Difucosyllactose (DFL) 51% 17% 0%d 0% 11% 0% 
Lacto-N-triose II (LNT II) 54% 12% 0%d 22% 8% 0% 
3’-Sialyllactose (3’-SL) 13% 0% 0% 0% 5% 0% 
6’-Sialyllactose (6’-SL) 18% 0% 0% 0% 4% 0% 
Lacto-N-tetraose (LNT) 24% 11% 0%d 0% 0% 28% 
Lacto-N-fucopentaose I 
(LNFP I) 1% 24% 35% 0% 10% 0% 
Lacto-N-fucopentaose II 
(LNFP II) 31% 15% 0% 0% 9% 0% 
LS-tetrasaccharide a 
(LST a) 38% 23% 0%
d 42% 25% 0%d 
Disialyllacto-N-tetraose 
(DSLNT) 28% 18% 0% 18% 21% 0% 
Lacto-N-neotetraose 
(LNnT) 42% 13% 0%
d 5% 4% 0% 
Lacto-N-fucopentaose III 
(LNFP III) 26% 14% 0%
 0% 9% 0% 
Lacto-N-neohexaose 
(LNnH) 48% 12% 0%
d 39% 15% 0% 
para-Lacto-N-neo 
hexaose (para-LNnH) 23% 9% 0% 0% 8% 0% 
LS-tetrasaccharide c 
(LST c) 15% 16% 0% 35% 18% 0% 
Heterogeneous HMO 
extract 82% 23% N/A 73% 24% N/A 
astrongest activity is bolded and highlighted in blue. baverage over 24 h of growth. caverage at 24 h of growth. 
dsignificantly increased biofilm formation. 
 
Table 5.1. Summary of Antimicrobial and Antibiofilm Activities of Single-Entity HMOs 
Against Two Strains of GBSa 
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 In a similar vein, while neutral and acidic HMOs tended to have generally 
comparable levels of antimicrobial activity against GB590, against GB2, the larger acidic 
HMOs (LST a, DSLNT, and LST c) were superior antimicrobials than the neutral 
compounds. For example, against GB2, LST a, DSLNT, and LST c were all significantly 
better antimicrobials than LNT and LNnT; LST a and DSLNT are mono and disialylated 
LNT derivatives, respectively, while LST c is a monosialylated LNnT derivative. We 
hypothesize that the stronger antimicrobial activity of LST a, DSLNT, and LST c is related 
the high structural similarity seen between these compounds and the CPS of G590 
(serotype III) and GB2 (serotype Ib) (see Figure 3.2, section 3.1.4 of Chapter 3). The 
mechanism underlying this hypothesized activity, however, is currently unclear. As a final 
note, the strain-specificity observed for HMO treatment supports the possibility of 
developing narrow-spectrum antimicrobial compounds.  
 These studies also demonstrated that, as is characteristic of HMO antimicrobial 
activity in vivo, HMO antimicrobial activity in vitro is highly dependent on HMO structure. 
Indeed, we found that small differences in HMO structure could drastically alter 
antimicrobial activity. For example, we observed against GB590 that DFL possessed 
strong antimicrobial activity while the structurally similar 2’-FL and 3-FL were generally 
devoid of activity. Additionally, the isomeric LST a and LST c possessed varying levels of 
activity against GB590 both in terms of growth and viability. We also found that the simpler, 
monosialylated and monofucosylated lactose derivatives were significantly less effective 
antimicrobials than the larger HMOs derived from LNT and/or LNnT.  
 Initially, the lack of 2’-FL antimicrobial activity was surprising. However, a review 
of the extensive literature detailing the protective effects of 2’-FL against pathogenic 
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colonization offers a potential explanation for the lack of observed activity.29 As previously 
described, 2’-FL is particularly well-known for its ability to protect infants from infection. 
This ability is attributable to the structural similarly of 2’-FL to numerous epithelial cell 
surface glycans that serve as sites for pathogen binding. This allows 2’-FL to serve as a 
soluble decoy receptor and inhibit initial pathogen binging; the binding of pathogens to 
epithelial cells is the first step towards pathogen colonization and proliferation. This 
knowledge in combination with the results of our studies suggests that the environment 
wherein 2’-FL encounters a pathogen is perhaps as important to the antimicrobial 
capabilities of this HMO as its molecular structure. Thus, we hypothesize that any 
antimicrobial activity of 2’-FL against GBS would likely be attributable to an ability to 
prevent bacterial adhesion to epithelial cells. This mechanism of action would not, 
however, have been assessable with the assays employed in our studies thus far. 
 Finally, in contrast to the often high levels of antimicrobial activity observed, the 
vast majority of HMOs did not reduce GBS biofilm production for either strain tested. In 
fact, numerous compounds actually increased biofilm production. As previously 
mentioned, this result is hypothesized to be the result of a high level of antimicrobial 
activity as biofilm production is a common pathogen defense mechanism. 
 
5.7 Antimicrobial and Antibiofilm Activities of Simple HMO Mixtures36 
 Given the strong antimicrobial activity of several single-entity HMOs, we 
hypothesized that challenging GBS with an HMO mixture consisting of the most active 
compounds would yield antimicrobial activity equal or superior to that of whole HMO 
extracts. Importantly, as HMO antimicrobial activity was found to be strain-specific, 
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different combinations of HMOs were used for GB590 and GB2. The GB590-specific 
mixture consisted of the following HMOs in equal quantities: LNFP I, LNFP II, LNFP III, 
LNnT, and LST a; this mixture is denoted as GB590 HMO mixture in Figures 5.13 and 
5.15. The GB2-specific mixture consisted of the following HMOs is equal quantities: 
DSLNT, LST a, LST c, LNT II, and DFL; this mixture is denoted as GB2 HMO mixture in 
Figure 5.14 and 5.15. 
 In addition to mixtures consisting of the five most potent antimicrobial HMOs for 
each strain, we also screened an HMO mixture that attempted to mimic the general 
composition of whole HMO extracts; this mixture is denoted as HMO extract mimic in 
Figures 5.13, 5.14, and 5.15.2, 18, 28 The goal of this simplified mixture was to duplicate, 
to the best of our abilities, concentrations of the various classes of HMOs present in 
human milk. While whole milk extracts can contain over 100 different HMOs, the HMO 
extract mimic contained only 10 (Table 5.2).  
 
General HMO Classes and 
Concentrations 
Individual HMO Components 
and Concentrations 
Neutral, Fucosylated HMOs (60%) 
2’-FL (20%) 
LNFP I (20%) 
DFL (20%) 
LNT (15%) LNT (15%) 
Neutral, Nonfucosylated HMOs 
(excluding LNT) (15%) 
LNnT (5%) 
LNT II (5%) 
Para-LNnH (5%) 
Acidic, Sialylated HMOs (10%) 
3’-SL (3.3%) 
6’-SL (3.3%) 
DSLNT (3.3%) 
Table 5.2. HMO Extract Mimic Composition 
 395 
 
0 4 8 12 16 20 24
0.0
0.1
0.2
0.3
0.4
0.5
Time (h)
O
D
60
0
Media
GB590 HMO Mixture
HMO Extract Mimic
Whole HMO Extract
****
****
****
*
** *
0 4 8 12 16 20 24
4
6
8
10
Time (h)
Lo
g 1
0 
C
FU
/m
L
Media
GB590 HMO Mixture
HMO Extract Mimic
Whole HMO Extract
****
****
**
*
****
****
A.
B.
Figure 5.13. Effects of heterogeneous HMO mixtures dosed at ca. 5 mg/mL on the growth 
and viability of GB590 in Todd-Hewitt Broth. (A) OD600 readings were taken at 0, 2, 4, 6, 
8, and 24 h. Mean OD600 for each HMO source and time point is indicated by the 
respective symbols. (B) Enumeration of CFU/mL was performed at 0, 2, 4, 6, 8, and 24 h 
corresponding to the OD values graphed in (A). Mean log10CFU/mL for each HMO source 
and time point is indicated by the respective symbols. Data displayed represent the mean 
OD600 or log10CFU/mL ± SEM of at least three independent experiments, each with 3 
technical replicates. **** represents p < 0.0001 by two-way ANOVA with posthoc 
Dunnett’s multiple comparison test comparing the growth and viability of GBS in each 
HMO supplementation condition to the growth and viability of GBS in media alone. 
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Figure 5.14 Effects of heterogenous HMO mixtures dosed at ca. 5 mg/mL on the growth 
and viability of GB2 in Todd-Hewitt Broth. (A) OD600 readings were taken at 0, 2, 4, 6, 8, 
and 24 h. Mean OD600 for each HMO source and time point is indicated by the respective 
symbols. (B) Enumeration of CFU/mL was performed at 0, 2, 4, 6, 8, and 24 h 
corresponding to the OD values graphed in (A). Mean log10CFU/mL for each HMO source 
and time point is indicated by the respective symbols. Data displayed represent the mean 
OD600 or log10CFU/mL ± SEM of at least three independent experiments, each with 3 
technical replicates. **** represents p < 0.0001 by two-way ANOVA with posthoc 
Dunnett’s multiple comparison test comparing the growth and viability of GBS in each 
HMO supplementation condition to the growth and viability of GBS in media alone. 
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Figure 5.15. Effects of heterogeneous HMO mixtures dosed at ca. 5 mg/mL on GBS 
biofilm production after 24 h of growth in Todd-Hewitt Broth. (A) Biofilm production, 
denoted by the ratio of biofilm/biomass (OD560/OD600), by GB590 in the presence of single-
entity HMOs relative to biofilm production in media alone. Data displayed represent the 
relative mean biofilm/biomass ratio ± SEM of at least three independent experiments, 
each with 3 technical replicates, wherein biofilm production of GB590 in media alone is 
assigned a value of 100%. **** represents p < 0.0001 by one-way ANOVA, F = 14.47 with 
posthoc Dunnett’s multiple comparison test comparing biofilm production of GB590 in 
each HMO supplementation condition to biofilm production of GB590 in media alone.  (B) 
Biofilm production, denoted by the ratio of biofilm/biomass (OD560/OD600), by GB2 in the 
presence of homogeneous HMOs relative to biofilm production in media alone. Data 
displayed represent the relative mean biofilm/biomass ratio ± SEM of at least three 
independent experiments, each with 3 technical replicates, wherein biofilm production of 
GB2 in media alone is assigned a value of 100%. **** represents p < 0.0001 by one-way 
ANOVA, F = 14.4 with posthoc Dunnett’s multiple comparison test comparing biofilm 
production of GB2 in each HMO supplementation condition to biofilm production of GB2 
in media alone. Mean GBS biofilm production levels in media alone are marked with a 
dotted line.  
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 Analogous to prior experiments, each HMO mixture was dosed at ca. 5 mg/mL. 
Surprisingly, while each custom mixture significantly reduced GB590 or GB2 growth and 
viability, none of these mixtures displayed comparable antimicrobial activity to that of the 
whole HMO extract; the custom mixtures possessed similar levels and patterns of activity 
to one another (Figures 5.13 and 5.14). Interestingly, against GB2, the HMO extract 
mimic and the GB2 HMO mixture actually significantly increased GB2 viability from 6 to 
24 h (Figure 5.14). In terms of antibiofilm activity, for both GB590 and GB2, the HMO 
mimic extract was the only mixture capable of significantly decreasing biofilm production 
(Figure 5.15). On average, this mixture decreased biofilm formation by over 50%. Given 
the similar magnitudes and patterns of antimicrobial activity for the HMO extract mimic 
and the GBS strain-specific HMO mixtures, it is unclear why only the HMO extract mimic 
reduced biofilm formation. This result is made even more interesting considering the fact 
that no individual compound in the HMO extract mimic was previously found to reduce 
biofilm formation.15, 36 Contrarily, several of these HMOs were found to increase GB590 
biofilm formation. 
 
5.8 Antimicrobial and Antibiofilm Activities of 1-Amino-2’-Fucosyllactose38 
 Intrigued by the general lack of antibiofilm activity observed for the homogenous 
HMOs, we elected to investigate whether the natural structures could be minimally 
modified to yield superior antibiofilm compounds. Due to its widespread availability, we 
selected 2’-FL (2.8) as our HMO scaffold to modify. This selection was also favorable for 
the current investigation given the inability of 2’-FL to significantly increase or decrease 
GBS biofilm formation. We hypothesized that 2’-FL could be converted to an effective 
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antibiofilm compound by incorporating a positive charge into the structure. This 
hypothesis was founded on the premise that biofilm matrices are largely composed of 
anionic polymeric substances and negatively charged extracellular DNA. Given this 
characteristic, cationic small molecules are known to disrupt the biofilm matrix.39-47  
 The most facile method to incorporate a positive charge into the structure of 2’-FL 
(or the reducing end of any saccharide) is to convert the anomeric alcohol to an amine 
using the Kochetkov amination.48 To achieve this conversion, 2’-FL was exposed to 
ammonium carbonate and heated for 72 hours to generate amine 5.10 in near quantitative 
yield as the b-anomer exclusively (Scheme 5.1); this work was completed by Prof. 
Townsend. 
 
 
 
 
 
 
 Gratifyingly, while the effects of amino 2’-FL derivative 5.10 on GB590 and GB2 
growth and viability were generally comparable to those of 2’-FL (Figures 5.16 and 5.17), 
compound 5.10 was a significantly more effective antibiofilm compound than the parent 
2’-FL (Figure 5.18). Impressively, exposure of GBS to ca. 5 mg/mL of amine 5.10 resulted 
in an average biofilm production decrease of 37% and 46% for strains GB590 and GB2, 
respectively. It is important to note that compound 5.10 does not decompose under the 
assay conditions used. As a final note, although assays to confirm the mechanism behind 
Scheme 5.1. Synthesis of 1-amino-2’-fucosyllactose (amino 2’-FL, 5.10). 
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the observed antibiofilm activity have not yet been initiated, we hypothesize that the 
positively charged carbohydrate could serve as a surfactant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16. Effects lactose (2.1), 2’-FL (2.8), and amino 2’-FL (5.10) dosed at ca. 5 
mg/mL on the growth and viability of GB590 in Todd-Hewitt Broth. (A) OD600 readings 
were taken at 0, 2, 4, 6, 8, and 24 h. Mean OD600 for each HMO source and time point is 
indicated by the respective symbols. (B) Enumeration of CFU/mL was performed at 0, 2, 
4, 6, 8, and 24 h corresponding to the OD values graphed in (A). Mean log10CFU/mL for 
each HMO source and time point is indicated by the respective symbols. Data displayed 
represent the mean OD600 or log10CFU/mL ± SEM of at least three independent 
experiments, each with 3 technical replicates. **, ***, and **** represent p = 0.0037, p = 
0.0005, and p < 0.0001 respectively in (A), and *** and **** represent p = 0.0007 and p < 
0.0001 respectively in (B) by 2-way ANOVA with posthoc Dunnett’s multiple comparison 
test comparing the growth and viability of GB590 in each HMO supplementation condition 
to the growth and viability of GB590 in media alone.  
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Figure 5.17. Effects of lactose (2.1), 2’-FL (2.8), and amino 2’-FL (5.10) dosed at ca. 5 
mg/mL on the growth and viability of GB2 in Todd-Hewitt Broth. (A) OD600 readings were 
taken at 0, 2, 4, 6, 8, and 24 h. Mean OD600 for each HMO source and time point is 
indicated by the respective symbols. (B) Enumeration of CFU/mL was performed at 0, 2, 
4, 6, 8, and 24 h corresponding to the OD values graphed in (A). Mean log10CFU/mL for 
each HMO source and time point is indicated by the respective symbols. Data displayed 
represent the mean OD600 or log10CFU/mL ± SEM of at least three independent 
experiments, each with 3 technical replicates. * and **** represent p = 0.0142 and p < 
0.0001 respectively in (A), and *** and **** represent p = 0.0005 and p < 0.0001 
respectively in (B) by 2-way ANOVA with posthoc Dunnett’s multiple comparison test 
comparing the growth and viability of GB2 in each HMO supplementation condition to the 
growth and viability of GB2 in media alone.  
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Figure 5.18. Effects of lactose (2.1), 2’-FL (2.8), and amino 2’-FL (5.10) dosed at ca. 5 
mg/mL on GBS biofilm production after 24 h of growth in Todd-Hewitt Broth. (A) Biofilm 
production, denoted by the ratio of biofilm/biomass (OD560/OD600), by GB590 in the 
presence of various carbohydrates relative to biofilm production in media alone. Data 
displayed represent the relative mean biofilm/biomass ratio ± SEM of at least three 
independent experiments, each with 3 technical replicates, wherein biofilm production of 
GB590 in media alone is assigned a value of 100%. *** represents p = 0.0004 by one-
way ANOVA, F = 7.562 with posthoc Dunnett’s multiple comparison test comparing biofilm 
production of GB590 in each carbohydrate supplementation condition to biofilm 
production of GB590 in media alone.  (B) Biofilm production, denoted by the ratio of 
biofilm/biomass (OD560/OD600), by GB2 in the presence of various carbohydrates relative 
to biofilm production in media alone. Data displayed represent the relative mean 
biofilm/biomass ratio ± SEM of at least three independent experiments, each with 3 
technical replicates, wherein biofilm production of GB2 in media alone is assigned a value 
of 100%. **** represents p < 0.0001 by one-way ANOVA, F = 9.961 with posthoc Dunnett’s 
multiple comparison test comparing biofilm production of GB2 in each carbohydrate 
supplementation condition to biofilm production of GB2 in media alone. Mean GBS biofilm 
production levels in media alone are marked with a dotted line.  
.  
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5.9 Conclusions and Future Outlook 
 The work with neutral and acidic homogenous HMOs presented in this chapter has 
revealed that several single-entity HMOs possess strong antimicrobial activity against 
Group B Streptococcus (Streptococcus agalactiae, GBS). In agreement with previous 
reports from our laboratory and several others, the antimicrobial activity of single 
compounds was generally found to be lesser than that of whole heterogenous HMO 
extracts. Moreover, as with heterogenous HMO mixtures, the activity of homogenous 
HMOs was found to be strain-specific.  
 Having identified several active HMOs, the next goal will be to use these 
compounds as tools to identify specific HMO cellular targets. Indeed, although we have 
uncovered the mechanism of action of HMO antimicrobial activity, we have yet to uncover 
the targets engaged by HMOs to affect this activity. To address this void, future work will 
be focused on the synthesis of minimally-modified HMO-based chemoproteomic tools to 
identify the interacting partners of HMOs.  
 
5.10 Experimental Methods 
Materials 
2'-fucosyllactose (2’-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-
fucopentaose I (LNFP I), lacto-N-fucopentaose II (LNFP II), lacto-N-fucopentaose III 
(LNFP III), lacto-N-neohexaose (LNnH), para-lacto-N-hexaose (para-LNnH), LS-
tetrasaccharide a (LST a) sodium salt, LS-tetrasaccharide c (LST c) sodium salt, and 
disialyllacto-N-tetraose (DSLNT) disodium salt were generously donated by Glycom. 
Lacto-N-triose II (LNT II), lacto-N-neotetraose (LNnT), 3’-sialyllactose (3’-SL) sodium salt 
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and 6’-sialyllactose (6’-SL) sodium salt were purchased from Carbosynth. D-lactose 
monohydrate was purchased from Sigma Aldrich. Lacto-N-tetraose was synthesized 
previously (see Chapter 4).49  
 
Instrumentation 
1H NMR spectra were obtained on a Bruker 400 MHz spectrometer with reporting relative 
to deuterated solvent signals. 1H NMR spectral data are presented as follows: chemical 
shifts (δ ppm), multiplicity (s=singlet, d=doublet, dd=doublet of doublets, t=triplet, 
q=quartet, p=pentet, m=multiplet, br=broad, app=apparent), coupling constants (Hz), 
integration, proton assignment. Deuterium oxide was calibrated to 4.79 ppm. 13C NMR 
spectra were obtained on a Bruker 100 MHz spectrometer with reporting relative to 
deuterated solvent signals. 13C NMR spectral data are presented as follows: chemical 
shifts (δ ppm). Proton assignments were made with the aid of 2D COSY NMR. Mass 
spectral data were recorded on an Ultraflex TOF MS in reflectron positive mode.  
 
Compound Preparation 
 
 
 
 
(2S,3S,4R,5S,6S)-2-(((2S,3R,4S,5R,6R)-2-(((2R,3S,4R,5R,6R)-6-amino-4,5-dihydroxy 
-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)oxy)-4,5-dihydroxy-6-(hydroxymethyl) 
tetrahydro-2H-pyran-3-yl)oxy)-6-methyltetrahydro-2H-pyran-3,4,5-triol (5.10). 
O O
OH OH
HO
O
O
OH
OH
OH
HO
O
HO
OH
OH
H2O, 40 oC
(94%, β-only)
NH4HCO3
O O
OH OH
HO
O
O
OH
NH2
OH
HO
O
HO
OH
OH
(2.8) 5.10
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2’-FL (2.8) (1.0 eq, 0.49 g, 1.00 mmol) was dissolved in water (10 mL) and (NH4)HCO3 
(10.0 eq, 0.79 g, 10.0 mmol) was added. The resultant slurry was warmed to 40 °C and 
stirred for three days. The clear supernatant was filtered through a plug of cotton, frozen, 
and lyophilized. Lyophilization was determined to be complete when the mass of the 
product remained constant. Glycosyl amine 5.10 (0.46 g, 0.94 mmol, 94%, 9:1 ratio of 
product to starting material) was obtained as a white solid: Rf 0.15 (60:30:3:5 
CHCl3:CH3OH:AcOH:H2O); 1H NMR (400 MHz, D2O) δ 5.31 (d, J = 2.2 Hz, 1H, H-1’’), 
4.55 (dd, J = 26.6, 8.5 Hz, 1H, H-1), 4.40 (d, J = 7.7 Hz, 1H, H-1’), 4.18 – 4.06 (m, 1H), 
3.90 – 3.14 (m, 15H), 1.12 (t, J = 7.4 Hz, 3H); 13C NMR (100 MHz, D2O) δ 100.1, 99.2, 
84.9, 82.9, 76.1, 75.9, 75.1, 74.9, 73.9, 73.5, 71.5, 69.5, 69.0, 68.0, 66.76, 61.0, 60.2, 
15.2. (M + Na)+ calcd for C18H32NNaO14 510.179, found 510.170. 
 
Bacterial Strains and Culture Conditions 
Clinical strains of S. agalactiae (GB590 and GB2) were generously provided by Dr. 
Shannon Manning at Michigan State University. All strains were grown on tryptic soy agar 
plates supplemented with 5% sheep blood (blood agar plates) at 37°C in ambient air 
overnight. All strains were subcultured from blood agar plates into 5 mL of Todd-Hewitt 
broth (THB) and incubated under shaking conditions at 180 RPM at 37°C overnight. 
Following overnight incubation, bacterial density was quantified through absorbance 
readings at 600 nm (OD600) using a Promega GloMax-Multi Detection System plate 
reader. Bacterial numbers were determined using the predetermined coefficient of 1 
OD600= 109 CFU/mL. 
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HMO isolation  
Human milk was obtained from 21 healthy, lactating women between 3 days and 3 
months postnatal and stored between −80 and −20 °C. Deidentified milk was provided by 
Dr. Jörn-Hendrik Weitkamp from the Vanderbilt Department of Pediatrics, under a 
collection protocol approved by the Vanderbilt University Institutional Review Board 
(IRB#100897), and Medolac. Milk samples were thawed then centrifuged for 45 min. 
Following centrifugation, the resultant top lipid layer was removed. The proteins were then 
removed by diluting the remaining sample with roughly 1:1 v/v 180 or 200 proof ethanol, 
chilling the sample briefly, and centrifuging for 45 min followed by removal of the resulting 
HMO- containing supernatant. Following concentration of the supernatant in vacuo, the 
HMO-containing extract was dissolved in phosphate buffer (pH 6.5, 0.2 M) and heated to 
37 °C.50, 51 β-galactosidase from Kluyveromyces lactis was added, and the reaction was 
stirred until lactose hydrolysis was complete. The reaction mixture was diluted with 
roughly 1:0.5 v/v 180 or 200 proof ethanol, chilled briefly, then centrifuged for 30 min. The 
supernatant was removed and concentrated in vacuo, and the remaining salts, glucose, 
and galactose were separated from the oligosaccharides using P-2 Gel (H2O elutant). 
The oligosaccharides were then dried by lyophilization. HMO extracts from the 21 donor 
samples were pooled together to create an HMO cocktail.24 
 
Bacterial strains and culture conditions 
Clinical strains of S. agalactiae (GB590 and GB2) were generously provided by Dr. 
Shannon Manning at Michigan State University. All strains were grown on tryptic soy agar 
plates supplemented with 5% sheep blood (blood agar plates) at 37 °C in ambient air 
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overnight. All strains were subcultured from blood agar plates into 5 mL of Todd-Hewitt 
broth (THB) and incubated under shaking conditions at 180 RPM at 37 °C overnight. 
Following overnight incubation, bacterial density was quantified through absorbance 
readings at 600 nm (OD600) using a Promega GloMax-Multi Detection System plate 
reader. Bacterial numbers were determined using the predetermined coefficient of 1 
OD600= 109 CFU/mL. 
 
Bacterial growth and viability assays  
S. agalactiae strains GB590 and GB2 were grown overnight as described above and used 
to inoculate fresh THB or THB supplemented with ca. 5 mg/mL HMO. Inoculation was 
performed at a multiplicity of infection (MOI) of 106 colony forming units per 200 µL of 
growth medium in 96 well tissue culture treated, sterile polystyrene plates (Corning, Inc.). 
Cultures were grown under static conditions at 37 oC in ambient air. Bacterial growth was 
quantified through spectrophotometric readings at OD600. Bacterial viability was evaluated 
by serial dilution and plating onto blood agar plates followed by quantification of viable 
colony forming units per mL of culture (CFU/mL). 
 
Bacterial biofilm assay 
S. agalactiae strains GB590 and GB2 were grown overnight as described and used to 
inoculate fresh THB or THB supplemented with ca. 5 mg/mL HMO. Inoculation was 
performed at a multiplicity of infection (MOI) of 106 colony forming units per 200 µL of 
growth medium in 96 well tissue culture treated, sterile polystyrene plates (Corning, Inc.). 
Cultures were incubated under static conditions at 37 oC in ambient air for 24 h. Following 
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spectrophotometric reading at OD600, culture media was removed and the wells were 
gently washed once with phosphate-buffered saline (PBS, pH 7.4) to removed non-
adherent cells. Adherent cells were next stained with a 10% crystal violet solution for 10 
minutes. Excess stain was removed and the wells were gently washed once with PBS 
then allowed to dry at room temperature for at least 30 minutes. The crystal violet stain 
was solubilized with an 80% ethanol/20% acetone solution and biofilm formation was 
quantified through spectrophotometric reading at OD560.25  
 
Statistical analysis 
All data shown represent at least 3 independent experiments each with 3 technical 
replicates. Data are expressed as the mean ± SEM. Statistical analyses were performed 
in GraphPad Prism Software v. 7.0c. Statistical significance for growth and viability 
measurements were determined using two-way ANOVA with posthoc Dunnett’s multiple 
comparison test comparing growth and viability in the presence of HMOs to growth and 
viability in media alone. Statistical significance for biofilm production was determined 
using one-way ANOVA with posthoc Dunnett’s multiple comparison test comparing 
biofilm production in the presence of HMOs to biofilm production in media alone.  
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Appendix A3: 
 
Data and Spectra Relevant to Chapter 5 
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Table A3.19. Effects of HMO Mixtures on GB590 Growth Over 24 ha,b 
 
 
 
 
 
Table A3.20. Effects of HMO Mixtures on GB590 Viability Over 24 ha,b 
 Media (Control) GB590 HMO Mixture HMO Extract Mimic Whole HMO Extract 
Time 
(h) Difference from Control (%) ± SEM 
0 0 ± 53.26 435.37 ± 320.79 326.07 ± 345.94 605.46 ± 363.47 
2 0 ± 10.76 -34.25 ± 23.89 -43.73 ± 35.22 -56.22 ± 13.26 
4 0 ± 14.00 -35.54 ± 18.84 -38.07 ± 29.03 -92.10 ± 2.46 
6 0 ± 1.21 -29.48 ± 7.37 -35.85 ± 12.01 -99.22 ± 0.41 
8 0 ± 1.67 -15.49 ± 6.75 -19.38 ± 9.86 -99.17 ± 0.50 
24 0 ± 1.32 -9.57 ± 6.73 -16.34 ± 9.23 -3.69 ± 6.99 
aSignificant reductions from control are bolded and highlighted in blue (P < 0.05, by two-way ANOVA with posthoc 
Dunnett’s multiple comparison test). bSignificant increases from control are highlighted in red (P < 0.05, by two-way 
ANOVA with posthoc Dunnett’s multiple comparison test). 
 Media (Control) GB590 HMO Mixture HMO Extract Mimic Whole HMO Extract 
Time 
(h) Difference from Control (%) ± SEM 
0 0 ± 2.90 -2.09 ± 4.16 -12.49 ± 4.79 -5.99 ± 3.83 
2 0 ± 2.72 -11.73 ± 2.43 -17.33 ± 3.16 -20.64 ± 2.37 
4 0 ± 2.21 -22.18 ± 3.08 -19.84 ± 2.51 -30.55 ± 1.49 
6 0 ± 1.49 -6.17 ± 2.73 -4.93 ± 1.95 -35.11 ± 1.56 
8 0 ± 2.71 -3.43 ± 2.52 5.60 ± 2.51 -33.67 ± 1.60 
24 0 ± 2.93 -13.35 ± 2.21 -5.78 ± 2.49 37.52 ± 3.08 
aSignificant reductions from control are bolded and highlighted in blue (P < 0.05, by two-way ANOVA with posthoc 
Dunnett’s multiple comparison test). bSignificant increases from control are highlighted in red (P < 0.05, by two-
way ANOVA with posthoc Dunnett’s multiple comparison test). 
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Table A3.21. Effects of HMO Mixtures on GB2 Growth Over 24 ha,b 
 
 
 
 
 
Table A3.22. Effects of HMO Mixtures on GB2 Viability Over 24 ha,b 
 Media (Control) GB2 HMO Mixture HMO Extract Mimic Whole HMO Extract 
Time 
(h) Difference from Control (%) ± SEM 
0 0 ± 68.10 511.18 ± 361.67 575.82 ± 493.49 1078.82 ± 657.40 
2 0 ± 6.04 -20.09 ± 23.47 -4.61 ± 36.12 -20.15 ± 18.34 
4 0 ± 4.66 -31.69 ± 16.50 -17.98 ± 21.37 -89.92 ± 2.16 
6 0 ± 1.60 -22.94 ± 9.58 -14.87 ± 10.22 -97.22 ± 0.77 
8 0 ± 0.87 -13.43 ± 9.73 -5.76 ± 9.00 -94.84 ± 0.77 
24 0 ± 0.81 -14.52 ± 8.26 -9.78 ± 9.20 13.28 ± 2.50 
aSignificant reductions from control are bolded and highlighted in blue (P < 0.05, by two-way ANOVA with posthoc 
Dunnett’s multiple comparison test). bSignificant increases from control are highlighted in red (P < 0.05, by two-way 
ANOVA with posthoc Dunnett’s multiple comparison test). 
 Media (Control) GB2 HMO Mixture HMO Extract Mimic Whole HMO Extract 
Time 
(h) Difference from Control (%) ± SEM 
0 0 ± 2.57 -10.38 ± 3.76 -9.13 ± 3.96 -12.73 ± 4.41 
2 0 ± 1.94 -16.27 ± 1.97 -15.10 ± 1.68 -23.29 ± 1.76 
4 0 ± 2.36 -16.21 ± 3.44 -8.17 ± 1.65 -27.35 ± 1.59 
6 0 ± 1.33 6.85 ± 1.43 7.25 ± 1.24 -30.03 ± 1.04 
8 0 ± 1.04 6.66 ± 2.10 7.90 ± 2.11 -24.97 ± 1.17 
24 0 ± 1.09 8.77 ± 1.80 8.18 ± 1.58 49.65 ± 1.76 
aSignificant reductions from control are bolded and highlighted in blue (P < 0.05, by two-way ANOVA with posthoc 
Dunnett’s multiple comparison test). bSignificant increases from control are highlighted in red (P < 0.05, by two-way 
ANOVA with posthoc Dunnett’s multiple comparison test). 
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Table A3.23. Effects of HMO Mixtures on GB590 Biofilm Production at 24 ha,b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A3.24. Effects of HMO Mixtures on GB2 Biofilm Production at 24 ha,b 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Media (Control) GB590 HMO Mixture HMO Extract Mimic Whole HMO Extract 
Difference from Control (%) ± SEM 
0.00 ± 7.52 -11.76 ± 8.90 -54.65 ± 7.31 16.98 ± 12.61 
aSignificant reductions from control are bolded and highlighted in blue (P < 0.05, by one-way ANOVA with 
posthoc Dunnett’s multiple comparison test). bSignificant increases from control are highlighted in red             
(P < 0.05, by one-way ANOVA with posthoc Dunnett’s multiple comparison test). 
Media (Control) GB590 HMO Mixture HMO Extract Mimic Whole HMO Extract 
Difference from Control (%) ± SEM 
0.00 ± 9.03 24.12 ± 15.80 -64.72 ± 4.50 19.68 ± 17.16 
aSignificant reductions from control are bolded and highlighted in blue (P < 0.05, by one-way ANOVA with 
posthoc Dunnett’s multiple comparison test). bSignificant increases from control are highlighted in red             
(P < 0.05, by one-way ANOVA with posthoc Dunnett’s multiple comparison test). 
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Table A3.25. Effects of 1-Amino-2’-Fucosyllactose (Amino-2’-FL) on GB590 Growth 
Over 24 ha,b 
 
 
 
Table A3.26. Effects of 1-Amino-2’-Fucosyllactose (Amino-2’-FL) on GB590 Viability 
Over 24 ha,b 
 Media (Control) Lactose 2'-FL Amino-2'-FL 
Time 
(h) Difference from Control (%) ± SEM 
0 0 ± 36.75 -98.91 ± 1.12 -63.77 ± 37.43 -100.00 ± 0.00 
2 0 ± 13.85 -42.01 ± 17.65 2.06 ± 18.38 -27.84 ± 15.30 
4 0 ± 10.66 -17.11 ± 14.45 -19.44 ± 12.82 -11.85 ± 15.75 
6 0 ± 5.64 -8.51 ± 11.03 -14.28 ± 8.69 -5.66 ± 9.48 
8 0 ± 1.62 6.36 ± 3.00 -7.18 ± 4.14 -7.53 ± 3.43 
24 0 ± 1.83 11.85 ± 3.50 -10.88 ± 3.72 -8.81 ± 3.36 
aSignificant reductions from control are bolded and highlighted in blue (P < 0.05, by two-way ANOVA with posthoc 
Dunnett’s multiple comparison test). bSignificant increases from control are highlighted in red (P < 0.05, by two-way 
ANOVA with posthoc Dunnett’s multiple comparison test). 
 Media Lactose 2'-FL Amino-2'-FL 
Time 
(h) Difference from Control (%) ± SEM 
0 0 ± 4.80 7.55 ± 9.61 -1.64 ± 8.57 -9.19 ± 7.93 
2 0 ± 6.36 -15.13 ± 5.61 -9.34 ± 10.03 -7.77 ± 6.44 
4 0 ± 3.69 1.91 ± 3.75 4.06 ± 5.57 -5.08 ± 5.56 
6 0 ± 8.55 -9.74 ± 5.90 0.88 ± 9.15 -10.72 ± 6.15 
8 0 ± 2.53 6.29 ± 4.44 13.35 ± 3.83 19.76 ± 4.12 
24 0 ± 3.79 21.46 ± 8.85 14.13 ± 5.14 27.20 ± 6.27 
aSignificant reductions from control are bolded and highlighted in blue (P < 0.05, by two-way ANOVA with posthoc 
Dunnett’s multiple comparison test). bSignificant increases from control are highlighted in red (P < 0.05, by two-
way ANOVA with posthoc Dunnett’s multiple comparison test). 
 434 
Table A3.27. Effects of 1-Amino-2’-Fucosyllactose (Amino-2’-FL) on GB2 Growth Over 
24 ha,b 
 
 
 
Table A3.28. Effects of 1-Amino-2’-Fucosyllactose (Amino-2’-FL) on GB2 Viability Over 
24 ha,b 
 Media Lactose 2'-FL Amino 2'-FL 
Time 
(h) Difference from Control (%) ± SEM 
0 0 ± 35.56 91.90 ± 63.02 7.47 ± 59.56 116.09 ± 77.58 
2 0 ± 18.97 30.06 ± 27.95 -4.66 ± 31.50 30.25 ± 32.91 
4 0 ± 18.69 26.48 ± 27.77 -19.23 ± 18.56 1.39 ± 22.08 
6 0 ± 5.24 34.86 ± 7.65 2.77 ± 6.60 17.55 ± 7.34 
8 0 ± 3.18 38.82 ± 3.50 5.99 ± 7.26 17.21 ± 6.10 
24 0 ± 2.70 33.78 ± 4.48 -2.72 ± 6.78 9.03 ± 4.24 
aSignificant reductions from control are bolded and highlighted in blue (P < 0.05, by two-way ANOVA with posthoc 
Dunnett’s multiple comparison test). bSignificant increases from control are highlighted in red (P < 0.05, by two-
way ANOVA with posthoc Dunnett’s multiple comparison test). 
 Media Lactose 2'-FL Amino 2'-FL 
Time 
(h) Difference from Control (%) ± SEM 
0 0 ± 2.65 6.55 ± 4.38 0.75 ± 7.17 4.75 ± 4.67 
2 0 ± 4.26 -3.40 ± 5.72 -4.12 ± 10.58 -7.33 ± 7.86 
4 0 ± 4.42 -1.40 ± 6.09 -10.50 ± 6.23 0.33 ± 9.73 
6 0 ± 2.98 -9.36 ± 3.45 -14.58 ± 3.74 -7.27 ± 4.02 
8 0 ± 2.71 -5.50 ± 2.76 -9.90 ± 4.76 -1.50 ± 5.83 
24 0 ± 3.01 -2.04 ± 3.04 -15.81 ± 2.61 5.90 ± 3.48 
aSignificant reductions from control are bolded and highlighted in blue (P < 0.05, by two-way ANOVA with posthoc 
Dunnett’s multiple comparison test). bSignificant increases from control are highlighted in red (P < 0.05, by two-
way ANOVA with posthoc Dunnett’s multiple comparison test). 
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Table A3.29. Effects of 1-Amino-2’-Fucosyllactose (Amino-2’-FL) on GB590 Biofilm 
Production at 24 ha,b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A3.30. Effects of 1-Amino-2’-Fucosyllactose (Amino-2’-FL) on GB2 Biofilm 
Production at 24 ha,b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Media Lactose 2'-FL Amino 2'-FL 
Difference from Control (%) ± SEM 
0 ± 10.47 25.38 ± 14.61 11.61 ± 12.89 -37.57 ± 7.61 
aSignificant reductions from control are bolded and highlighted in blue (P < 0.05, by one-way ANOVA with 
posthoc Dunnett’s multiple comparison test). bSignificant increases from control are highlighted in red             
(P < 0.05, by one-way ANOVA with posthoc Dunnett’s multiple comparison test). 
Media Lactose 2'-FL Amino 2'-FL 
Difference from Control (%) ± SEM 
0 ± 4.16 -10.89 ± 9.20 7.62 ± 13.20 -46.01 ± 5.82 
aSignificant reductions from control are bolded and highlighted in blue (P < 0.05, by one-way ANOVA with 
posthoc Dunnett’s multiple comparison test). bSignificant increases from control are highlighted in red             
(P < 0.05, by one-way ANOVA with posthoc Dunnett’s multiple comparison test). 
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Figure A3.1. 1H NMR (400 MHz, D2O) comparison of 2’-FL (2.8) and 1-amino-2’-FL, 
5.10. 
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Figure A3.2 13C NMR (100 MHz, D2O) comparison of 2’-FL (2.8) and 1-amino-2’-FL, 
5.10. 
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